
<html lang="en"     class="pb-page"  data-request-id="5f6b0e7f-8883-4b76-a76a-37e276acc67b"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/acs.jmedchem.0c01059;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2020.63.issue-21"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Design, Synthesis, and Biological Evaluation of Covalent Inhibitors of Focal Adhesion Kinase (FAK) against Human Malignant Glioblastoma" /></meta><meta name="dc.Creator" content="Bo  Li" /></meta><meta name="dc.Creator" content="Yongliang  Li" /></meta><meta name="dc.Creator" content="Céline  Tomkiewicz-Raulet" /></meta><meta name="dc.Creator" content="Pascal  Dao" /></meta><meta name="dc.Creator" content="Daniel  Lietha" /></meta><meta name="dc.Creator" content="Expédite  Yen-Pon" /></meta><meta name="dc.Creator" content="Zhiyun  Du" /></meta><meta name="dc.Creator" content="Xavier  Coumoul" /></meta><meta name="dc.Creator" content="Christiane  Garbay" /></meta><meta name="dc.Creator" content="Mélanie  Etheve-Quelquejeu" /></meta><meta name="dc.Creator" content="Huixiong  Chen" /></meta><meta name="dc.Description" content="Human malignant glioblastoma (GBM) is a highly invasive and lethal brain tumor. Targeting of integrin downstream signaling mediators in GBM such as focal adhesion kinase (FAK) seems reasonable and ..." /></meta><meta name="Description" content="Human malignant glioblastoma (GBM) is a highly invasive and lethal brain tumor. Targeting of integrin downstream signaling mediators in GBM such as focal adhesion kinase (FAK) seems reasonable and ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="October 29, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01059" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01059" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01059" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01059" /></link>
        
    
    

<title>Design, Synthesis, and Biological Evaluation of Covalent Inhibitors of Focal Adhesion Kinase (FAK) against Human Malignant Glioblastoma | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01059" /></meta><meta property="og:title" content="Design, Synthesis, and Biological Evaluation of Covalent Inhibitors of Focal Adhesion Kinase (FAK) against Human Malignant Glioblastoma" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/large/jm0c01059_0014.jpeg" /></meta><meta property="og:description" content="Human malignant glioblastoma (GBM) is a highly invasive and lethal brain tumor. Targeting of integrin downstream signaling mediators in GBM such as focal adhesion kinase (FAK) seems reasonable and recently demonstrated promising results in early clinical studies. Herein, we report the structure-guided development of a series of covalent inhibitors of FAK. These new compounds displayed highly potent inhibitory potency against FAK enzymatic activity with IC50 values in the nanomolar range. Several inhibitors retarded tumor cell growth as assessed by a cell viability assay in multiple human glioblastoma cell lines. They also significantly reduced the rate of U-87 cell migration and delayed the cell cycle progression by stopping cells in the G2/M phase. Furthermore, these inhibitors showed a potent decrease of autophosphorylation of FAK in glioblastoma cells and its downstream effectors Akt and Erk as well as nuclear factor-κB. These data demonstrated that these inhibitors may have the potential to offer a promising new targeted therapy for human glioblastomas." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01059"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01059">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01059&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01059&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01059&amp;href=/doi/10.1021/acs.jmedchem.0c01059" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 21</span><span class="cit-fg-pageRange">, 12707-12724</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/21" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c00997" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c01063" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Design, Synthesis, and Biological Evaluation of Covalent Inhibitors of Focal Adhesion Kinase (FAK) against Human Malignant Glioblastoma</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Bo Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bo Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemistry of RNA, Nucleosides, Peptides and Heterocycles, CNRS UMR8601, Université de Paris, 45 rue des Saints-Pères, 75006 Paris, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bo++Li">Bo Li</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yongliang Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yongliang Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Chemical Engineering and Light Industry, Guangdong University of Technology, No. 100 Waihuan Xi Road, Education Mega Center, Guangzhou 510006, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yongliang++Li">Yongliang Li</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Céline Tomkiewicz-Raulet</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Céline Tomkiewicz-Raulet</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Toxicologie, Pharmacologie et Signalisation Cellulaire, INSERM, UMR S 1124, Université de Paris, 45 rue des Saints-Pères, 75006 Paris, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=C%C3%A9line++Tomkiewicz-Raulet">Céline Tomkiewicz-Raulet</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Pascal Dao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Pascal Dao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Université Côte d’Azur, CNRS, Institut de Chimie de Nice UMR7272, 06108 Nice, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Pascal++Dao">Pascal Dao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Daniel Lietha</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Daniel Lietha</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Cell Signalling and Adhesion Group, Structural and Chemical Biology, Biological Research Center (CIB), Spanish National Research Council (CSIC), Calle Ramiro de Maeztu, Madrid 28040, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Daniel++Lietha">Daniel Lietha</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Expédite Yen-Pon</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Expédite Yen-Pon</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemistry of RNA, Nucleosides, Peptides and Heterocycles, CNRS UMR8601, Université de Paris, 45 rue des Saints-Pères, 75006 Paris, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Exp%C3%A9dite++Yen-Pon">Expédite Yen-Pon</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhiyun Du</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhiyun Du</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Chemical Engineering and Light Industry, Guangdong University of Technology, No. 100 Waihuan Xi Road, Education Mega Center, Guangzhou 510006, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhiyun++Du">Zhiyun Du</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xavier Coumoul</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xavier Coumoul</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Toxicologie, Pharmacologie et Signalisation Cellulaire, INSERM, UMR S 1124, Université de Paris, 45 rue des Saints-Pères, 75006 Paris, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xavier++Coumoul">Xavier Coumoul</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Christiane Garbay</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christiane Garbay</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemistry of RNA, Nucleosides, Peptides and Heterocycles, CNRS UMR8601, Université de Paris, 45 rue des Saints-Pères, 75006 Paris, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christiane++Garbay">Christiane Garbay</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mélanie Etheve-Quelquejeu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mélanie Etheve-Quelquejeu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemistry of RNA, Nucleosides, Peptides and Heterocycles, CNRS UMR8601, Université de Paris, 45 rue des Saints-Pères, 75006 Paris, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=M%C3%A9lanie++Etheve-Quelquejeu">Mélanie Etheve-Quelquejeu</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Huixiong Chen</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Huixiong Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemistry of RNA, Nucleosides, Peptides and Heterocycles, CNRS UMR8601, Université de Paris, 45 rue des Saints-Pères, 75006 Paris, France</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#0c647965746563626b226f6469624c2c7c6d7e657f68697f6f6d7e78697f226a7e"><span class="__cf_email__" data-cfemail="7d150814051412131a531e1518133d">[email protected]</span> parisdescartes.fr</a>. Tel: +33 1-428-640-85. Fax: +33 1-428-640-82.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Huixiong++Chen">Huixiong Chen</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7676-1584" title="Orcid link">http://orcid.org/0000-0001-7676-1584</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01059&amp;href=/doi/10.1021%2Facs.jmedchem.0c01059" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 21</span><span class="cit-pageRange">, 12707–12724</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">October 29, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>19 June 2020</li><li><span class="item_label"><b>Published</b> online</span>29 October 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 12 November 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01059" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01059</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D12707%26pageCount%3D18%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DBo%2BLi%252C%2BYongliang%2BLi%252C%2BC%25C3%25A9line%2BTomkiewicz-Raulet%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D21%26contentID%3Dacs.jmedchem.0c01059%26title%3DDesign%252C%2BSynthesis%252C%2Band%2BBiological%2BEvaluation%2Bof%2BCovalent%2BInhibitors%2Bof%2BFocal%2BAdhesion%2BKinase%2B%2528FAK%2529%2Bagainst%2BHuman%2BMalignant%2BGlioblastoma%26numPages%3D18%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D12724%26publicationDate%3DNovember%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01059"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1536</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">3</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01059" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Design, Synthesis, and Biological Evaluation of Covalent Inhibitors of Focal Adhesion Kinase (FAK) against Human Malignant Glioblastoma&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Bo&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Yongliang&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Céline&quot;,&quot;last_name&quot;:&quot;Tomkiewicz-Raulet&quot;},{&quot;first_name&quot;:&quot;Pascal&quot;,&quot;last_name&quot;:&quot;Dao&quot;},{&quot;first_name&quot;:&quot;Daniel&quot;,&quot;last_name&quot;:&quot;Lietha&quot;},{&quot;first_name&quot;:&quot;Expédite&quot;,&quot;last_name&quot;:&quot;Yen-Pon&quot;},{&quot;first_name&quot;:&quot;Zhiyun&quot;,&quot;last_name&quot;:&quot;Du&quot;},{&quot;first_name&quot;:&quot;Xavier&quot;,&quot;last_name&quot;:&quot;Coumoul&quot;},{&quot;first_name&quot;:&quot;Christiane&quot;,&quot;last_name&quot;:&quot;Garbay&quot;},{&quot;first_name&quot;:&quot;Mélanie&quot;,&quot;last_name&quot;:&quot;Etheve-Quelquejeu&quot;},{&quot;first_name&quot;:&quot;Huixiong&quot;,&quot;last_name&quot;:&quot;Chen&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;10&quot;,&quot;day&quot;:&quot;29&quot;,&quot;issue&quot;:&quot;21&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;12707-12724&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01059&quot;},&quot;abstract&quot;:&quot;Human malignant glioblastoma (GBM) is a highly invasive and lethal brain tumor. Targeting of integrin downstream signaling mediators in GBM such as focal adhesion kinase (FAK) seems reasonable and recently demonstrated promising results in early clinical studies. Herein, we report the structure-guided development of a series of covalent inhibitors of FAK. These new compounds displayed highly potent inhibitory potency against FAK enzymatic activity with IC50 values in the nanomolar range. Several inhibitors retarded tumor cell growth as assessed by a cell viability assay in multiple human glioblastoma cell lines. They also significantly reduced the rate of U-87 cell migration and delayed the cell cycle progression by stopping cells in the G2/M phase. Furthermore, these inhibitors showed a potent decrease of autophosphorylation of FAK in glioblastoma cells and its downstream effectors Akt and Erk as well as nuclear factor-κB. These data demonstrated that these inhibitors may have the potential to offer a promis&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01059&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01059" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01059&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01059" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01059&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01059" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01059&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01059&amp;href=/doi/10.1021/acs.jmedchem.0c01059" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01059" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01059" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01059%26sid%3Dliteratum%253Aachs%26pmid%3D33119295%26genre%3Darticle%26aulast%3DLi%26date%3D2020%26atitle%3DDesign%252C%2BSynthesis%252C%2Band%2BBiological%2BEvaluation%2Bof%2BCovalent%2BInhibitors%2Bof%2BFocal%2BAdhesion%2BKinase%2B%2528FAK%2529%2Bagainst%2BHuman%2BMalignant%2BGlioblastoma%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D21%26spage%3D12707%26epage%3D12724%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291305" title="Cell physiology">Cell physiology</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/21" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/jmcmar.2020.63.issue-21/20201112/jmcmar.2020.63.issue-21.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/medium/jm0c01059_0014.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/large/jm0c01059_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01059&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Human malignant glioblastoma (GBM) is a highly invasive and lethal brain tumor. Targeting of integrin downstream signaling mediators in GBM such as focal adhesion kinase (FAK) seems reasonable and recently demonstrated promising results in early clinical studies. Herein, we report the structure-guided development of a series of covalent inhibitors of FAK. These new compounds displayed highly potent inhibitory potency against FAK enzymatic activity with IC<sub>50</sub> values in the nanomolar range. Several inhibitors retarded tumor cell growth as assessed by a cell viability assay in multiple human glioblastoma cell lines. They also significantly reduced the rate of U-87 cell migration and delayed the cell cycle progression by stopping cells in the G2/M phase. Furthermore, these inhibitors showed a potent decrease of autophosphorylation of FAK in glioblastoma cells and its downstream effectors Akt and Erk as well as nuclear factor-κB. These data demonstrated that these inhibitors may have the potential to offer a promising new targeted therapy for human glioblastomas.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64124" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64124" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">More than 30% primary brain tumor patients were diagnosed with gliomas, and among these, more than 50% are glioblastomas (GBMs), the most aggressive and malignant form of glioma in adults.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> GBM is characterized by poorly differentiated neoplastic astrocytes and a great invasiveness and infiltration of surrounding normal brain.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> The poor prognosis of patients with GBM has not been obviously improved over the past few decades. The difficulties in the treatment of these lethal cancers are their highly infiltrative feature, particularly resistant to conventional treatments and high recurrence rate. Extensive infiltration of the central nervous system by neoplastic cells in patients with GBM prevents complete and safe removal of the tumor through surgical resections.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> The intrinsic apoptosis resistance of residual human malignant GBM cells and increased survival signaling hinder tumor elimination, resulting in tumor recurrence.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> The resistance of GBM to conventional therapies is mainly due to a subpopulation of GBM stem cells (GSCs)<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> and a highly mutated genome, which also results in significant tumor genetic heterogeneity and upregulation of cellular signaling pathways involved in cell proliferation, angiogenesis, apoptosis, migration, and invasion.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a></div><div class="NLM_p">Currently available treatment options for patients with GBM have limited efficacy. Despite the use of aggressive multimodal treatment strategies including maximum surgical resection, radiation, and temozolomide chemotherapy, the median survival of patients with diagnosed GBM is generally less than 15 months.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Thus, new therapeutic approaches are of utmost importance. With an increased understanding of GBM biology and the complex networks of mechanisms involved in GBM tumors, current research efforts have mainly focused on innovative targeted therapies to accurately treat GBM with maximal efficacy and minimized side effects. Among them, targeting of integrin downstream signaling mediators in GBM such as focal adhesion kinase (FAK) seems reasonable and demonstrated promising results in early clinical studies.<a onclick="showRef(event, 'ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10">(8−10)</a></div><div class="NLM_p">FAK, a nonreceptor protein tyrosine kinase localized to focal adhesions, is uniquely positioned at the convergence point of integrins, which transmits signals from cell-surface receptors such as integrins, cytokines, and growth factors and triggers subsequent signaling cascades leading to various functions in normal and cancer cells.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Extensive research has elucidated that FAK signaling pathways can stimulate tumor progression and metastasis formation through their regulation of the epithelial–mesenchymal transition (ECM), angiogenesis, cell migration, and cell invasion.<a onclick="showRef(event, 'ref12 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14">(12−14)</a> Other studies have shown the significant relationships between FAK and proliferation, survival and migration, as well as angiogenesis and grade of malignancy of gliomas in vitro and in vivo.<a onclick="showRef(event, 'ref15 ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref15 ref16 ref17">(15−17)</a> In addition, FAK stimulates cancer stem cell (CSC) renewal and promotes drug resistance through functioning in survival signaling pathways.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></div><div class="NLM_p">Previous studies have indicated that targeting FAK expression with antisense oligonucleotide treatment may increase GBM cell sensitivity to chemotherapy.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Therefore, several ATP-competitive inhibitors of FAK have been successfully developed and entered into preclinical and clinical trials (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>),<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20,21)</a> and among them, TAE-226 showed a wide variety of effects on human GBM cells including inhibition of cell proliferation, migration, and invasion as well as G0/G1 cell cycle arrest.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Moreover, TAE-226 treatment significantly prolonged the survival rate of nude mice in an intracranial glioblastoma xenograft model.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> The therapeutic efficacy of TAE-226 may be a result of its ability to potently inhibit both tumor growth and tumor-associated angiogenesis. However, there is a poor correlation between enzymatic and cellular activity for the ATP-competitive inhibitors due to the cellular efficacy, which can be considerably affected by the high physiological ATP concentration.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/medium/jm0c01059_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/large/jm0c01059_0002.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of FAK inhibitors in preclinical and clinical trials.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/large/jm0c01059_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01059&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Covalent targeting of noncatalytic cysteine residues in dysregulated protein kinases is a powerful approach for enhancing pharmacological potency and selectivity and provides distinct advantages over conventional ATP-competitive inhibition.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Covalent inhibitors behave noncompetitively with ATP, once covalently bound to enzymes, which is advantageous in a pharmacokinetic manner in the presence of high intracellular ATP concentrations. Furthermore, they could increase their residence time on the kinase to obtain durable inhibition despite a decrease in the plasma concentrations of covalent drugs and avoid drug resistance during the development of mutations.<a onclick="showRef(event, 'ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref25 ref26">(25,26)</a></div><div class="NLM_p">In general, covalent inhibitors affect through a two-step binding mode (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01059/suppl_file/jm0c01059_si_001.pdf" class="ext-link">Figure S1</a>). First, they form a reversible complex with the enzyme. This step is driven by the affinity of inhibitors to the enzyme. Then, in the second step, the electrophilic group of the inhibitors attacks the targeted residue in the enzyme, forming a covalent bond. Based on the two-step process for kinase inhibition and kinome-wide sequence analysis in connection with the three-dimensional (3D) structure of the ATP site, we have recently designed and characterized the first covalent inhibitor of FAK <b>7a</b><sub><b>1</b></sub> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) and solved its cocrystal structure with the FAK kinase domain, in which it binds covalently to Cys427 from the glycine-rich loop closer to the ATP site, whereas this residue is not conserved in most of the other human kinases.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> However, <b>7a1</b> was also highly active against some other protein tyrosine kinases (see <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). These off-target inhibitions are probably due to the extremely high affinity of the pyrimidine scaffold, which is similar to the purine ring of ATP and well located in the ATP-binding site for these kinases. To better understand the underlying mechanism of the FAK signaling pathway in GBM progression, it is desirable to discover more selective FAK inhibitors. Previous studies demonstrated that VS-6062 (PF 562 271), an ATP-competitive inhibitor of FAK with an arylaminopyridylmethylaminopyrimidine motif, had a good kinase selectivity profile on a panel of 42 kinases.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> The good selectivity resulted from a helical conformation of “DFG” induced by this motif. Thus, we tried to modify an arylamino group in the diarylaminopyrimidine scaffold with benzylamino or pyridylmethylamino groups to increase the selectivity of our inhibitors.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. In Vitro Kinase Assay IC<sub>50</sub> Values of Novel 2,4-Diarylaminopyrimidines and 2-Arylamino-4-arylmethylaminopyrimidines Compared with That of TAE-226</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/medium/jm0c01059_0013.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">No.</th><th class="colsep0 rowsep0" align="center"><i>n</i></th><th class="colsep0 rowsep0" align="center">X</th><th class="colsep0 rowsep0" align="center">R<sub>1</sub></th><th class="colsep0 rowsep0" align="center">R<sub>2</sub></th><th class="colsep0 rowsep0" align="center">R<sub>3</sub></th><th class="colsep0 rowsep0" align="center" char="±">IC<sub>50</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7a</b><sub><b>1</b></sub></td><td class="colsep0 rowsep0" align="left">0</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">2-CONHCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">CH═CH<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char="±">0.6 ± 0.04</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7a</b><sub><b>2</b></sub></td><td class="colsep0 rowsep0" align="left">0</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">2-CONHCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>Cl</td><td class="colsep0 rowsep0" align="char" char="±">5.6 ± 0.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7b</b></td><td class="colsep0 rowsep0" align="left">0</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">2-CONHOCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">CH═CH<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char="±">3.7 ± 0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7c</b></td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">2-N(CH<sub>3</sub>)SO<sub>2</sub>CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">CH═CH<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char="±">4.6 ± 0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7d</b></td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">3-N(CH<sub>3</sub>)SO<sub>2</sub>CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">CH═CH<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char="±">4.9 ± 0.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7e</b></td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">3-SO<sub>2</sub>CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">CH═CH<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char="±">16.3 ± 1.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7f</b></td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">2-N(CH<sub>3</sub>)SO<sub>2</sub>CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">CH═CH<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char="±">5.5 ± 0.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7g</b></td><td class="colsep0 rowsep0" align="left">0</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">2-CONHCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">CH═CH<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char="±">6.8 ± 0.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9a</b></td><td class="colsep0 rowsep0" align="left">0</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">2-CONHCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">C(CN)═CHEt</td><td class="colsep0 rowsep0" align="char" char="±">2.5 ± 0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9b</b></td><td class="colsep0 rowsep0" align="left">0</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">2-CONHCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">C(CN)═CHCH(CH<sub>3</sub>)<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char="±">1.2 ± 0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9c</b></td><td class="colsep0 rowsep0" align="left">0</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">2-CONHCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">C(CN)═CHCH(CH<sub>2</sub>)<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char="±">1.0 ± 0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TAE-226</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="±">5.8 ± 0.6</td></tr></tbody></table></div></div><div class="NLM_p">On the other hand, it has been previously shown that α-cyanoacrylamide-based Michael acceptors could be applied to design reversible covalent kinase inhibitors with improved pharmacological properties.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> The reversible nature of this modification, which still maintains the prolonged residence time of the inhibitor on the kinase of interest, is likely to lower the risk of forming a permanent covalent adduct with off-target cysteine. Therefore, several α-cyanoacrylamide-based warheads were introduced into our 2,4-diarylaminopyrimidine scaffold. We sought to explore the contribution of the binding affinity and the rate of covalent bond formation of these reversible covalent inhibitors. We expected this novel mechanism to hold promise for the development of FAK inhibitors with better therapeutic efficacy against human malignant GBM.</div><div class="NLM_p">These compounds were designed based on the crystal structure of the covalent inhibitor <b>7a</b><sub><b>1</b></sub> (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6GCR">6GCR</a>) to fit the proposed binding mode with the FAK kinase domain. One set of compounds contains modifications in the high-affinity region inside the ATP-binding pocket (<b>7b–g</b>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A), and another set is modified in the electrophilic warheads for covalent bonding with Cys427 (<b>7a</b><sub><b>2</b></sub>, <b>9a–c</b>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B). Since compounds <b>9a–c</b> contain relatively large substituents in the Michael group, we ensured the stereochemical compatibility of covalent bond formation with maintaining all high-affinity interactions by molecular modeling. For this, the positions of the high-affinity binding regions were fixed and the linker positions were adjusted for covalent binding with Cys427. Stereochemical geometries were enforced using restraints calculated with PRODRG<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> and the covalent linkage defined in JLigand.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> As shown in <a href="/doi/suppl/10.1021/acs.jmedchem.0c01059/suppl_file/jm0c01059_si_001.pdf" class="ext-link">Figure S2</a>, cyanoacrylamide electrophiles attached to the 2,4-diarylaminopyrimidine scaffold targeting FAK kinase were able to form a covalent bond with Cys427 in a similar manner to the covalent inhibitor of FAK <b>7a</b><sub><b>1</b></sub> and the substituted groups in the electrophilic warheads pointed away from Cys427 and the ATP-binding cleft.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/medium/jm0c01059_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/large/jm0c01059_0003.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Design strategy of FAK covalent inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/large/jm0c01059_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01059&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Herein, we present the structure-guided design of pyrimidine-based derivatives to covalently target FAK. The synthesis and biological evaluations provided a series of new analogues as covalent inhibitors of FAK based on our previously reported scaffold. These inhibitors showed a potent inhibition of FAK with IC<sub>50</sub> values in the nanomolar range. They also strongly suppressed the proliferation of several human malignant glioma cell lines in which FAK expression was at high levels. Furthermore, these new inhibitors decreased the phosphorylation of Akt, Erk, and NF-κB, induced glioma cell cycle arrest at the G2/M phase, and inhibited the migration of U-87 MG cells, indicating their therapeutic potential to treat human malignant glioblastomas.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41057" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41057" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Starting from commercially available 2,4,5-trichloropyrimidine, the first chlorine atom at position 4 of 2,4,5-trichloropyrimidine was substituted by 2-amino-<i>N</i>-methylbenzamide or 2-amino-<i>N</i>-methoxybenzamide in the presence of NaHCO<sub>3</sub> in EtOH at reflux to provide monosubstituted intermediates <b>1a–b</b> in a yield of 93% (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). Compounds <b>1c–f</b> were obtained in mild conditions at room temperature in the presence of <i>N</i>,<i>N</i>-diisopropylethylamine (DIPEA) in tetrahydrofuran (THF) from the appropriate benzylamine derivatives. The subsequent nucleophilic substitution at position 2 of the pyrimidine ring of compounds <b>1</b> proceeded well with allyl(4-aminobenzyl)carbamate under acidic conditions to give intermediates <b>2a</b> and <b>2c–f</b>, except for <b>2b</b>, which was prepared using a Pd-catalyzed Buchwald–Hartwig reaction with XantPhos as the ligand. In contrast to 2,4,5-trichloropyrimidine, 2,4-dichloro-5-trifluoromethyl-pyrimidine yielded a 1/1 mixture of the two isomers for the first substitution. Thus, the expected isomer <b>3</b> was prepared using a selective substitution of allyl(4-aminobenzyl)carbamate to 5-trifluoromethyl-2,4-dichloropyrimidine in the presence of zinc chloride, as described previously.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Then, under the catalysis of hydrochloric acid, intermediate <b>2g</b> was obtained from <b>3</b> and 2-amino-<i>N</i>-methylbenzamide in a good yield.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/medium/jm0c01059_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/large/jm0c01059_0010.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Reagents and conditions<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/large/jm0c01059_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01059&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) Substituted aniline, NaHCO<sub>3</sub>, EtOH, reflux, overnight (for <b>1a–b</b>); (b) benzylamine derivatives (or pyridin-3-ylmethanamine derivative for <b>1f</b>), DIPEA, THF, rt, overnight (for <b>1c–f</b>); (c) allyl(4-aminobenzyl)carbamate, HCl in dioxane, <i>n</i>-BuOH, 100 °C, overnight (for <b>2a</b>, <b>2c</b>–<b>2f</b>); (d) <i>tert</i>-butyl(4-aminobenzyl)carbamate, Pd<sub>2</sub>(dba)<sub>3</sub>, XantPhos, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, reflux, 24 h (for <b>2b</b>); (e) allyl(4-aminobenzyl)carbamate, zinc chloride, Et<sub>3</sub>N, <i>t</i>-BuOH/dichloromethane (DCM) (1/1), 0 °C—rt, 6 h; (f) 2-amino-<i>N</i>-methylbenzamide, HCl in dioxane, DMF, 90 °C, 7 h.</p></p></figure><div class="NLM_p">The Alloc- or Boc-protecting group (PG) of compounds <b>2a–g</b> were removed using typical methods, affording <b>4a–g</b>, respectively. The primary amines of <b>4a–g</b> were further condensed with <i>tert</i>-butyl(2-((2-methoxyl-3,4-dioxacyclobut-1-en-1-yl)amino)ethyl)carbamate (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01059/suppl_file/jm0c01059_si_001.pdf" class="ext-link">Scheme S1</a>) in the presence of DIPEA at 75 °C, followed by deprotection of the Boc group to afford compounds <b>6a–g</b> in good yields. Subsequently, acylation of the primary amine with acryloyl chloride or 2-chloroacetyl chloride gave the expected, targeted inhibitors <b>7a–g</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>).</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/medium/jm0c01059_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/large/jm0c01059_0011.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Reagents and Conditions<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/large/jm0c01059_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01059&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) Morpholine, Pd(PPh<sub>3</sub>)<sub>4</sub>, THF or DMF, rt, 3 h (for <b>2a</b>, <b>2c–g</b>), or TFA/DCM (v/v = 1/1), rt, 30 min (for <b>2b</b>); (b) DIPEA, <i>tert</i>-butyl(2-((2-methoxyl-3,4-dioxacyclobut-1-en-1-yl)amino)ethyl)carbamate, DMF, 75 °C, overnight; (c) TFA/DCM (v/v = 1/1), rt, 30 min; (d) appropriate chloride (acryloyl chloride for <b>7a<sub>1</sub>–g</b>, 2-chloroacetyl chloride for <b>7a<sub>2</sub></b>), 0 °C—rt, 12 h.</p></p></figure><div class="NLM_p">For the synthesis of reversible covalent inhibitors, cyanoacetic acid was coupled to the primary amine of <b>6a</b> using EDCI and HOBT, affording <b>8</b>, which was subsequently condensed with appropriate aldehydes through Knoevenagel condensation, yielding inhibitors <b>9a–c</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>).</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/medium/jm0c01059_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/large/jm0c01059_0012.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Reagents and Conditions<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/large/jm0c01059_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01059&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) Cyanoacetic acid, EDCI, HOBT, DIPEA, DMF, 0 °C—rt, overnight; (b) appropriate aldehyde, AcOH, piperidine, DMF, 100 °C, 2 h.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82145" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82145" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> <i>In Vitro</i> Inhibition of FAK Enzymatic Activity and Kinetic Study and Reversibility of Thiol Addition</h3><div class="NLM_p">The inhibitory activity of the newly synthesized inhibitors against FAK was first evaluated using an ADP-Glo kinase assay, as reported previously.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> A known ATP-competitive and reversible inhibitor of FAK, TAE-226, was included as a control in this assay.</div><div class="NLM_p">As shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, potency differences were observed among these compounds and most of them showed more potent inhibitory activity toward FAK kinase than TAE-226. Turning the warhead from acrylamide (compound <b>7a</b><sub><b>1</b></sub>) to chloromethylketone led to compound <b>7a</b><sub><b>2</b></sub> with decreased inhibitory potency. Replacing the amide group on the arylamine (ring B for compound <b>7a</b><sub><b>1</b></sub>) with an <i>N</i>-methoxy-amide moiety (compound <b>7b</b>) or switching the chloro atom on the arylamine (ring A for compound <b>7a</b><sub><b>1</b></sub>) to the CF<sub>3</sub> group (compound <b>7g</b>) was not well tolerated and resulted in a decreased potency toward FAK activity. The replacement of the NH group between phenyl ring B and pyrimidine group (ring A) by a NHCH<sub>2</sub> moiety leading to compounds <b>7c–f</b> did not demonstrate improved activity against FAK. Among them, the displacement of the <i>N</i>-methylmethanesulfonamide group from the ortho (compound <b>7c</b>) to the meta position in phenyl ring B (compound <b>7d</b>) or replacing phenyl ring B with pyridine (compound <b>7f</b>) displayed similar inhibitory potency on FAK kinase activity. However, the replacement of the <i>N</i>-methylmethanesulfonamide group by the methanesulfonyl group (compound <b>7e</b>) was not favorable and led to a decreased inhibitory effect toward FAK. Finally, replacing the acrylamide (compound <b>7a</b><sub><b>1</b></sub>) with several more reactive warheads, α-cyanoacrylamide-based groups leading to compounds <b>9a–c</b> were well tolerated and resulted in only a marginal loss in potency.</div><div class="NLM_p">To analyze quantitatively the contribution of the reversible binding affinity and the rate of covalent bond formation to our covalent inhibitors, we evaluated <i>K</i><sub>i</sub> and <i>k</i><sub>inact</sub> parameters of our best compounds, which were realized by measuring IC<sub>50</sub> values in a time-dependent manner. Interestingly, compounds <b>9b–c</b> demonstrated the fastest rates of covalent formation among the tested compounds. Indeed, as shown in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, compounds <b>9b–c</b> showed <i>k</i><sub>inact</sub> values of 0.25 ± 0.03 and 0.24 ± 0.04 min<sup>–1</sup>, respectively, while compounds <b>7a</b><sub><b>1</b></sub> and <b>7g</b> displayed vales of 0.16 ± 0.02 and 0.047 ± 0.01 min<sup>–1</sup>.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Kinetic Study</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compounds</th><th class="colsep0 rowsep0" align="center" char="±"><i>K</i><sub>i</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char="±"><i>k</i><sub>inact</sub> (min<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center" char="±"><i>k</i><sub>inact</sub>/<i>K</i><sub>i</sub> (μM<sup>–1</sup> s<sup>–1</sup>)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7a</b><sub><b>1</b></sub></td><td class="colsep0 rowsep0" align="char" char="±">0.23 ± 0.03</td><td class="colsep0 rowsep0" align="char" char="±">0.16 ± 0.02</td><td class="colsep0 rowsep0" align="char" char="±">11.6 ± 3.40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7g</b></td><td class="colsep0 rowsep0" align="char" char="±">2.64 ± 0.40</td><td class="colsep0 rowsep0" align="char" char="±">0.047 ± 0.01</td><td class="colsep0 rowsep0" align="char" char="±">0.30 ± 0.12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9b</b></td><td class="colsep0 rowsep0" align="char" char="±">0.47 ± 0.06</td><td class="colsep0 rowsep0" align="char" char="±">0.25 ± 0.03</td><td class="colsep0 rowsep0" align="char" char="±">8.87 ± 2.51</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9c</b></td><td class="colsep0 rowsep0" align="char" char="±">0.40 ± 0.05</td><td class="colsep0 rowsep0" align="char" char="±">0.24 ± 0.04</td><td class="colsep0 rowsep0" align="char" char="±">10.0 ± 3.33</td></tr></tbody></table></div></div><div class="NLM_p">Then, to confirm the reversible nature of compounds <b>9b–c</b> and compare with that of compound <b>7a</b><sub><b>1</b></sub>, a β-mercaptoethanol addition to compound <b>9c</b> or <b>7a</b><sub><b>1</b></sub> was performed and monitored by the LC–MS/MS technique. As shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, when <b>9c</b> was treated with β-mercaptoethanol, adduct <b>11c</b> was detected by LC–MS/MS (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01059/suppl_file/jm0c01059_si_001.pdf" class="ext-link">Figure S3 and Table S1</a>), indicating a 17/83 ratio of the adduct <b>11c</b> to the starting compound <b>9c</b> after 24 h treatment. A tenfold dilution in buffer showed that the reaction was reversible because the <b>11c</b>/<b>9c</b> ratio decreased to 2/98. These results showed that an amide and a nitrile group increased the acidity of its neighbor αH in <b>11c</b> and facilitated the elimination of the thiol group of adduct <b>11c</b> to recover <b>9c</b>. These data are also consistent with the previously reported results that the addition of a thiol to 2-cyanoacrylate at the physiological pH is a rapid-equilibrium reaction.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Conversely, the reaction of <b>7a</b><sub><b>1</b></sub> with β-mercaptoethanol produced the stable adduct <b>10a</b><sub><b>1</b></sub> with a ratio of 62/38 after 24 h and the tenfold dilution experiment showed an increase of the ratio (<b>10a</b><sub><b>1</b></sub>/<b>7a</b><sub><b>1</b></sub>) to 81/19, in accordance with the irreversibility of this addition reaction.</div><figure id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/medium/jm0c01059_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/large/jm0c01059_0004.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. β-Mercaptoethanol addition to compounds <b>7a</b><sub><b>1</b></sub> and <b>9c</b> monitored by LC–MS/MS.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/large/jm0c01059_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01059&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Kinase Selectivity Profile</h3><div class="NLM_p">To investigate the selectivity of these covalent inhibitors, we evaluated the selected compounds <b>7a</b><sub><b>1</b></sub>, <b>7f</b>, <b>7g</b>, and <b>9b</b> in vitro against a panel of ten kinases (c-Src, FGFR1, c-kit, EGFR, IGF1R, PDGFR, IR, Akt, Erk, and Pyk2). The assay was performed with human recombinant protein in the presence of each compound at 100 nM by Eurofins Cerep, France, using a radiometric kinase activity assay protocol. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>, the results indicate that these inhibitors did not show any inhibition of c-kit at 100 nM among the tested kinases. Otherwise, compound <b>7f</b> only strongly inhibited two kinases, FAK and Pyk2, showing a good selectivity profile against the other tested kinases. In contrast, compounds <b>7a</b><sub><b>1</b></sub>, <b>7g</b> and <b>9b</b> were active against the majority of kinases tested, such as FGFR1, IGF1R, PDGFRA, and EGFR, which are also involved in the pathogenesis of GBM.<a onclick="showRef(event, 'ref34 ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref34 ref35 ref36">(34−36)</a> These off-target inhibitions are probably due to the extremely high affinity of the diarylaminopyrimidine scaffold for these kinases.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. In Vitro Profile of Compounds <b>7a</b><sub><b>1</b></sub>, <b>7f</b>, <b>7g</b>, and <b>9b</b> against a Panel of Kinases<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinases</th><th class="colsep0 rowsep0" align="center" char="."><b>7a</b><sub>1</sub> (%)</th><th class="colsep0 rowsep0" align="center" char="."><b>7f</b> (%)</th><th class="colsep0 rowsep0" align="center" char="."><b>7g</b> (%)</th><th class="colsep0 rowsep0" align="center" char="."><b>9b</b> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Src</td><td class="colsep0 rowsep0" align="char" char=".">52.1</td><td class="colsep0 rowsep0" align="char" char=".">17.9</td><td class="colsep0 rowsep0" align="char" char=".">55.6</td><td class="colsep0 rowsep0" align="char" char=".">31.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FGFR1</td><td class="colsep0 rowsep0" align="char" char=".">87.1</td><td class="colsep0 rowsep0" align="char" char=".">32.5</td><td class="colsep0 rowsep0" align="char" char=".">88.3</td><td class="colsep0 rowsep0" align="char" char=".">83.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">c-kit</td><td class="colsep0 rowsep0" align="char" char=".">0.2</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char=".">0.1</td><td class="colsep0 rowsep0" align="char" char=".">0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EGFR</td><td class="colsep0 rowsep0" align="char" char=".">47.2</td><td class="colsep0 rowsep0" align="char" char=".">1.2</td><td class="colsep0 rowsep0" align="char" char=".">29.0</td><td class="colsep0 rowsep0" align="char" char=".">25.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IGF1R</td><td class="colsep0 rowsep0" align="char" char=".">91.5</td><td class="colsep0 rowsep0" align="char" char=".">28.1</td><td class="colsep0 rowsep0" align="char" char=".">94.4</td><td class="colsep0 rowsep0" align="char" char=".">71.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDGFRA</td><td class="colsep0 rowsep0" align="char" char=".">91.0</td><td class="colsep0 rowsep0" align="char" char=".">12.5</td><td class="colsep0 rowsep0" align="char" char=".">78.4</td><td class="colsep0 rowsep0" align="char" char=".">67.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IR</td><td class="colsep0 rowsep0" align="char" char=".">57.6</td><td class="colsep0 rowsep0" align="char" char=".">15.1</td><td class="colsep0 rowsep0" align="char" char=".">82.5</td><td class="colsep0 rowsep0" align="char" char=".">32.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Akt</td><td class="colsep0 rowsep0" align="char" char=".">3.7</td><td class="colsep0 rowsep0" align="char" char=".">2.5</td><td class="colsep0 rowsep0" align="char" char=".">25.1</td><td class="colsep0 rowsep0" align="char" char=".">19.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Erk</td><td class="colsep0 rowsep0" align="char" char=".">14.2</td><td class="colsep0 rowsep0" align="char" char=".">4.1</td><td class="colsep0 rowsep0" align="char" char=".">21.8</td><td class="colsep0 rowsep0" align="char" char=".">4.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Pyk2</td><td class="colsep0 rowsep0" align="char" char=".">97.6</td><td class="colsep0 rowsep0" align="char" char=".">68.3</td><td class="colsep0 rowsep0" align="char" char=".">99.8</td><td class="colsep0 rowsep0" align="char" char=".">97.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FAK</td><td class="colsep0 rowsep0" align="char" char=".">98.1</td><td class="colsep0 rowsep0" align="char" char=".">92.2</td><td class="colsep0 rowsep0" align="char" char=".">98.6</td><td class="colsep0 rowsep0" align="char" char=".">94.1</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Inhibition at the dose of 100 nM.</p></div></div></div><div class="NLM_p last">It is well known that most of the kinase inhibitors as anticancer drugs in clinical use or in late development stages are multitarget kinase inhibitors (MTKIs). They could exert effective antitumor effects through modulating several different signaling pathways, minimize resistance from the inhibition of only one of oncogenic signaling pathways, and give greater clinical efficacy and benefit. In fact, TAE-226 inhibited not only FAK enzymatic activity (IC<sub>50</sub> = 0.0054 μM) but also several other protein tyrosine kinases including IGF1R (IC<sub>50</sub> = 0.081 μM), Ins-R (IC<sub>50</sub> = 0.043 μM), FGFR1 (IC<sub>50</sub> = 0.75 μM), HER-1 (IC<sub>50</sub> = 0.55 μM), HER-2 (IC<sub>50</sub> = 0.71 μM), and PDGFR-β (IC<sub>50</sub> = 2.6 μM).<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> However, this inhibitor efficiently suppressed glioma proliferation in vitro and in vivo,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> probably due to its ability to inhibit several aberrant signaling pathways in glioma. Thus, compounds <b>7a</b><sub><b>1</b></sub>, <b>7g</b>, and <b>9b</b> were selected in this study for further evaluation of their biological properties against human glioblastoma cell lines.</div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Inhibition of FAK Autophosphorylation and Covalent Inhibition of FAK in U-87 MG Cells</h3><div class="NLM_p">A previous study showed that the autophosphorylation site Tyr397 of FAK is important for the FAK-mediated signaling pathway and a key event for FAK biological functions. Thus, we investigated whether our selected compounds could affect FAK autophosphorylation in U-87 MG cells compared to TAE-226 as previously described.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> As shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A, the autophosphorylation of FAK was significantly inhibited by treatment with inhibitors <b>7a</b><sub><b>1</b></sub>, <b>7g</b>, <b>9b</b>, and <b>9c</b> at low concentrations. In addition, these compounds could block Tyr397 phosphorylation in an obvious dose-dependent manner and most of them were more potent than TAE-226. This is consistent with their inhibitory activity against the FAK kinase in vitro. Furthermore, the inhibition of FAK autophosphorylation in U-87 MG with inhibitors <b>7a</b><sub><b>1</b></sub>, <b>9b</b>, and <b>9c</b> was confirmed by Western blotting (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B).</div><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/medium/jm0c01059_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/large/jm0c01059_0005.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Inhibition of FAK autophosphorylation in U-87 MG cells. (A) Cells were treated for 48 h with compounds <b>7a</b><sub><b>1</b></sub>, <b>9b</b>, <b>9c</b> or TAE-226 as control at 0.6 and 3 μM. (B) TAE-226 and compounds <b>7a</b><sub><b>1</b></sub>, <b>9b</b>, and <b>9c</b> inhibited FAK autophosphorylation in a dose-dependent manner. (C) Compounds <b>7a</b><sub><b>1</b></sub>, <b>9b</b>, and <b>9c</b> sustained inhibition of FAK autophosphorylation after washout experiments, which is not the case for TAE-226. Data obtained represent the mean of triplicate readings of three independent experiments. *<i>p</i> < 0.05 and **<i>p</i> < 0.01 compared with the control group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/large/jm0c01059_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01059&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Then, we performed washout experiments to investigate the reversibility of the inhibition of FAK autophosphorylation at Tyr397. After a washing step with PBS to remove the drug from the medium, the FAK autophosphorylation process was recovered in the case of TAE-226 (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>C), in accordance with its reversible characteristic. Conversely, under these conditions, U-87 MG cells treated with inhibitors <b>7a</b><sub><b>1</b></sub>, <b>9b</b>, and <b>9c</b> maintained potent inhibition of FAK phosphorylation (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>C). The sustained inhibitory effects are likely due to the covalent attachment of these compounds to FAK.</div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Effects of Compounds <b>7a</b><sub>1</sub>, <b>7g</b>, <b>9b</b>, and <b>9c</b> on Glioma Cell Proliferation, Cell Morphology, Apoptosis, and Cell Cycle</h3><div class="NLM_p">To explore the antiproliferative effects of several selected compounds on glioblastoma cell lines, we used the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and chose three human glioblastoma cell lines (U-87 MG, A172, and U251). As shown in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>, the IC<sub>50</sub> values of these inhibitors against the different tumor cells ranged between 0.13 and 9.8 μM. Among them, our compounds were more effective on A172 and U251 cell lines with IC<sub>50</sub> values significantly lower than that of TAE-226, except for <b>9b</b> that exhibited less cytotoxicity on U251 cells. On the contrary, TAE-226 was more efficient on U-87 MG cells than our compounds <b>9b</b> and <b>9c</b> in terms of survival decrease, except for <b>7a</b><sub><b>1</b></sub>, which displayed an IC<sub>50</sub> value of 2.2 μM, slightly lower than that of TAE-226.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Antiproliferative Activity, IC<sub>50</sub> (μM)</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compounds</th><th class="colsep0 rowsep0" align="center" char="±">U-87 MG</th><th class="colsep0 rowsep0" align="center" char="±">A172</th><th class="colsep0 rowsep0" align="center" char="±">U251</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7a</b><sub><b>1</b></sub></td><td class="colsep0 rowsep0" align="char" char="±">2.2 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">0.65 ± 0.05</td><td class="colsep0 rowsep0" align="char" char="±">0.22 ± 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7g</b></td><td class="colsep0 rowsep0" align="char" char="±">3.3 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">0.13 ± 0.01</td><td class="colsep0 rowsep0" align="char" char="±">0.15 ± 0.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9b</b></td><td class="colsep0 rowsep0" align="char" char="±">7.1 ± 0.6</td><td class="colsep0 rowsep0" align="char" char="±">1.3 ± 0.02</td><td class="colsep0 rowsep0" align="char" char="±">9.8 ± 0.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9c</b></td><td class="colsep0 rowsep0" align="char" char="±">7.2 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">0.89 ± 0.07</td><td class="colsep0 rowsep0" align="char" char="±">1.2 ± 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TAE-226</td><td class="colsep0 rowsep0" align="char" char="±">2.9 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">8.3 ± 0.6</td><td class="colsep0 rowsep0" align="char" char="±">6.3 ± 0.5</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">All data represent mean ± standard deviation (SD) from different experiments performed in triplicate.</p></div></div></div><div class="NLM_p">To decipher further the mechanism by which these compounds inhibit U-87 MG cellular proliferation, we first evaluated apoptosis by FACS analysis using Annexin V staining in the presence or absence of compounds <b>7a</b><sub><b>1</b></sub>, <b>7g</b>, <b>9b</b>, and <b>9c</b>, as compared with TAE-226. As shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A, we noted that there was no change in apoptosis in U-87 cells treated by the compounds up to 10 μM concentration. This finding is consistent with previous results obtained in the case of an imidazo[1,2-<i>a</i>][1,3,5]triazine series.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a></div><figure id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/medium/jm0c01059_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/large/jm0c01059_0006.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) U-87 MG cells were plated at 10<sup>5</sup> cells/well in a six-well culture dish, incubated overnight, and then treated with <b>7a</b><sub><b>1</b></sub>, <b>7g</b>, <b>9b</b>, <b>9c</b>, or TAE-226 at 10 μM for 48 h. Cells were stained with annexin V-FITC and propidium iodide and analyzed by FACS Calibur. Cells were then classified as alive with no apoptosis (i.e., PE negative, annexin V negative), dead (i.e., PE positive), or apoptotic (i.e., annexin V positive). One representative experiment is shown. (B) Immunofluorescence staining of U-87 MG cells treated with <b>7a</b><sub><b>1</b></sub>, <b>7g</b>, <b>9b</b>, <b>9c</b>, or TAE-226 at 1 μM for 48 h. Nuclei were stained with TO-PRO-3. The organization of filamentous actin and paxillin was detected after staining with FITC-conjugated phalloidin and paxillin antibodies. Pictures were taken to depict actin in green and paxillin in red using a Zeiss microscope equipped with appropriate filters. Scale bar = 20 μm.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/large/jm0c01059_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01059&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">On the other hand, cell fluorescence imaging of paxillin and actin was performed using U-87 MG cells treated with our inhibitors <b>7a</b><sub><b>1</b></sub>, <b>7g</b>, <b>9b</b>, <b>9c</b>, or TAE-226 at 1 μM for 48 h. As shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B, we observed the presence of multinucleated giant cells, which may be the result of nuclear division not being followed by cytokinesis, suggesting that these compounds would likely induce a cell cycle arrest. Previous studies had also reported that FAK inhibitors could induce cell multinucleation by suppressing furrowing and cytokinesis, which caused enhanced phagocytosis activity and significant changes in cyto/chemokine production.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> In addition, U-87 MG cells treated with our compounds had flat and enlarged morphology, which resembled a state of cellular senescence. FAK is a scaffold protein localized to focal adhesions that link the extracellular matrix to the actin cytoskeleton and ensure the proper communication between the cell and the epithelial–mesenchymal transition (ECM) during adhesion and migration. Focal adhesions are often connected to stress fibers, which are composed of bundles of 10–30 actin filaments and essential for cancer cell invasion and migration.<a onclick="showRef(event, 'ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref40 ref41">(40,41)</a> It is worth noting that our inhibitors could stimulate the appearance of stress fibers in a similar manner to TAE-226 compared with untreated cells. Previous studies also showed that primary GBM cell lines treated with a MEK inhibitor, PD0325901, which displayed in vitro and in vivo efficacy of inhibiting tumor growth in an orthotopic mouse model of GBM, led to decreased motility and a significant change in the cell shape and reorganization of actin from cortical to stress fibers.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a></div><div class="NLM_p">Then, cell cycle distribution was analyzed using flow cytometry and compounds <b>7a</b><sub><b>1</b></sub>, <b>7g</b>, <b>9b</b>, and <b>9c</b> were used for the investigation compared with TAE-226 (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.0c01059/suppl_file/jm0c01059_si_001.pdf" class="ext-link">S4</a>). U-87 MG cells were treated either with or without the inhibitors at 1 and 10 μM for 48 h, and it was observed that the cell cycle was blocked in the G2/M phase compared with the dimethyl sulfoxide (DMSO) control. Indeed, for untreated cells, the live populations of DNA contents in G0/G1 and G2/M were 51.6 ± 4.3% and 28.9 ± 2.1%, respectively. When U-87 MG cells were exposed to compounds <b>7a1</b>, <b>7g</b>, <b>9b</b>, and <b>9c</b> at 1 μM for 48 h, the population of cells in the G2-M phase markedly increased from 28.9 ± 2.1% to 80.8 ± 6.7%, 75.1 ± 5.2%, 79.1 ± 6.4%, and 83.1 ± 7.9%, respectively, while the population of cells in the G0/G1 phase decreased from 51.6 ± 4.3% to 9.2 ± 1.2%, 13.7 ± 1.9%, 12.7 ± 1.3%, and 8.1 ± 0.9%, respectively. In addition, when U-87 MG cells were treated with TAE-226 at the same concentration for 48 h, we found that the live populations of the DNA contents in G0/G1 and G2/M were 16.2 ± 1.1% and 66.1 ± 3.7%, suggesting that our inhibitors <b>7a1</b>, <b>7g</b>, <b>9b</b>, and <b>9c</b> could disrupt the cell cycle progression and had more potent effect than TAE-226 on the G2/M phase of the cell cycle.</div><figure id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/medium/jm0c01059_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/large/jm0c01059_0007.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Cell cycle distribution in each phase was studied by flow cytometry: (A) U-87 MG cells were plated at 10<sup>5</sup>/well in a six-well culture dish, incubated overnight, and then exposed to <b>7a</b><sub><b>1</b></sub>, <b>7g</b>, <b>9b</b>, <b>9c</b>, or TAE-226 along with DMSO control for 24 h. After incubation in 10% serum, cells were collected and stained with propidium iodide for cell cycle analysis. (B) Representative histograms of glioblastoma cells treated with 1 μM inhibitor show an increased G2 cell cycle fraction.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/large/jm0c01059_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01059&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Effects of Inhibitors on Migration and Inhibition of FAK Suppresses Downstream Signaling in U-87 MG Cells</h3><div class="NLM_p">Cancer metastasis remains a major clinical problem in cancer diagnosis and treatment. Elevated levels of FAK, which play a key role in integrin-mediated cell adhesion and migration as well as in advancing signaling from integrin to its downstream signaling partners, have been associated with the progression of multiple malignant tumors. We first determined the inhibitory effect on U-87 MG cell migration by our inhibitors using a scratch assay. As shown in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>, upon creation of a new artificial gap on a confluent U-87 MG cell monolayer, certain sections within the scratched area were occupied by migrated cells with DMSO treatment after 24 h incubation, whereas the cells treated by our inhibitors moved more slowly toward the opening to close the newly created gap. Thus, the reduced rate of cell migration to the scratched defect suggests that our FAK inhibitors have a negative impact on cell mobility, which is in accordance with that observed in the stress fibers. In addition, these inhibitors, especially <b>7a</b><sub><b>1</b></sub> and <b>9c</b>, demonstrated a stronger inhibitory activity than TAE-226 (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>).</div><figure id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/medium/jm0c01059_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/large/jm0c01059_0008.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Effects of compounds <b>7a</b><sub><b>1</b></sub>, <b>7g</b>, <b>9b</b>, and <b>9c</b> at 0.2 and 1 μM on U-87 MG cell migration in a scratch-wound assay. Top, images of control and treatments at 0.2 μM, with time 0 and 24 h scratch positions marked. Scale bar = 250 μm. Bottom, quantification of migration. Representative data from three independent experiments. *<i>p</i> <0.05 and **<i>p</i> <0.01 compared with the control group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/large/jm0c01059_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01059&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Next, we explored downstream signaling proteins of FAK in U-87 MG cells when treated with inhibitors <b>7a</b><sub><b>1</b></sub>, <b>9b</b>, and <b>9c</b> to understand which signaling pathways are involved in the growth of U-87 MG cells. As shown in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a> by western blot analysis, these inhibitors suppressed the phosphorylation of FAK in a dose-dependent manner, which resulted in a decrease of Akt and Erk activities. Phosphorylation of Akt and Erk is a key modulator for cell survival and proliferation. There was little or no effect of inhibitors <b>7a</b><sub><b>1</b></sub> and <b>9b</b> on the activation of Akt and Erk (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>), suggesting that suppression of FAK activity by these inhibitors caused an inhibition in Akt and Erk phosphorylation. We focused further on the activation of nuclear factor-kappaB (NF-κB), a family of transcription factors. Evidence indicated that the degree of overexpression and activation of NF-κB is associated with glioma grade and NF-κB activation could play a crucial role in the tumorigenesis and progression of high-grade gliomas by promoting growth, proliferation, invasiveness, and angiogenesis.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Western blot analysis was also used in this study to examine the activation status of NF-κB in GBM cells. Indeed, the strong positive immunostaining for activated diffuse cytoplasmic and scattered nuclear <i>p</i>-NF-κB was detected in untreated U-87 MG cells, and there was a significant correlation of the phosphorylation levels among <i>p</i>397FAK, <i>p</i>-NF-κB, and <i>p</i>-Akt (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). Treatment of U-87 MG cells with our inhibitors resulted in a dose-dependent decrease in the levels of <i>p</i>397FAK, leading to a concomitant dose-dependent decrease of Akt and NF-κB levels, especially in the case of <b>7a</b><sub><b>1</b></sub>. Thus, these data displayed that these inhibitors may suppress in part the proliferation of human malignant glioma cell lines through the inactivation of Akt/NF-κB signaling pathways in GBM cells. Moreover, Akt is considered as the main mediator of the resistance to chemotherapy. Studies demonstrated that independent activation of Akt and NF-κB signaling pathways promoted the tumors resistant to chemotherapy.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Therefore, the capability of these inhibitors to concomitantly reduce Akt and NF-κB activities might offer an increased sensitivity of glioblastoma cells to chemotherapy and efficiently treat GBM.</div><figure id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/medium/jm0c01059_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/large/jm0c01059_0009.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Effects of compounds <b>7a</b><sub><b>1</b></sub>, <b>9b</b>, and <b>9c</b> produced by the inhibition of FAK on FAK-mediated signal pathways compared with an ATP-competitive FAK inhibitor, TAE-226.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/large/jm0c01059_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01059&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04472" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04472" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">GBMs are highly lethal brain cancers and extremely resistant to conventional radiation and chemotherapies. Current therapy of these malignant gliomas remains essentially palliative, and there is a great need for more efficient therapeutic strategies. In glioblastomas of patients, FAK is overexpressed and activated FAK promotes the tumor growth and invasion. Therefore, FAK kinase may offer a novel possibility for targeted therapy of glioblastomas. In this study, we developed a series of novel covalent inhibitors of the FAK kinase. These new compounds displayed highly potent inhibitory potency against FAK enzymatic activity with IC<sub>50</sub> values in the nanomolar range. Several inhibitors delayed tumor growth in multiple human glioblastomas cell lines including U-87 MG, U251, and A172. They also significantly reduced the rate of cell migration and delayed cell cycle progression by stopping U-87 cells in the G2/M phase. Furthermore, glioblastoma cells treated with these inhibitors showed a potent decrease of autophosphorylation of FAK and its downstream effectors Akt and Erk as well as nuclear factor-kappaB in a dose-dependent manner. These results exhibit the potential therapeutic benefits of covalent inhibitors of FAK for the treatment of human malignant gliomas and may offer a promising new targeted therapy for human glioblastomas.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11568" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11568" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> General Information</h3><div class="NLM_p">All reagents were purchased and used without further purification unless otherwise noted. Reactions were monitored with thin-layer chromatography (TLC) on a commercial silica gel plate (GF254). Visualization of the developed plates was performed under UV light (254 nm). Flash column chromatography was performed on silica gel (200–300 mesh). Melting points were determined on a Kofler apparatus as uncorrected values. <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on a 250 or 500 MHz NMR spectrometer at 25 °C. Chemical shifts (δ) are reported in ppm and referenced to an internal tetramethylsilane standard or to the residual peak DMSO-<i>d</i><sub>6</sub> (δ 2.50), MeOD (δ 3.31), or CDCl<sub>3</sub> (δ 7.26) for <sup>1</sup>H NMR. Chemical shifts of <sup>13</sup>C are reported relative to CDCl<sub>3</sub> (δ 77.0), MeOD (δ 49.0), or DMSO-<i>d</i><sub>6</sub> (δ 39.5). The following abbreviations were used to describe peak-splitting patterns when appropriate: br s, broad singlet; s, singlet; d, doublet; t, triplet; q, quartet; and m, multiplet. Coupling constants, <i>J</i>, were reported in hertz units (Hz). All compounds have purity >95% as determined by HPLC on a Shimadzu LC-10AD system (Shimadzu, Kyoto, Japan) using an InertSustain C18 Column (4.6 × 250 mm<sup>2</sup>, 5 μm) with a mobile phase of water (solvent A) and MeOH (solvent B) under isocratic conditions, 0 min (60% A and 40% B), 5 min (60% A and 40% B), 15 min (5% A and 95% B), and 20 min (5% A and 95% B), at a flow rate of 1 mL/min. The eluted peaks were monitored at 254 nm. High-resolution mass spectra (HRMS) were obtained using a Micromass Q-TOF Micro with positive ESI and APCI ion sources (CV = 30 V).</div><div class="NLM_p last">Human glioma (U-87 MG, A172, and U252) was purchased from American Type Culture Collection (ATCC). All cell lines were maintained as monolayer cultures at 37°C in a 5% CO<sub>2</sub> humidified incubator and in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum and 5% penicillin–streptomycin.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> General Procedure for the Synthesis of <b>1a–f</b></h3><div class="NLM_p">2,4,5-Trichloropyrimidine (1.0 equiv) was added to a stirred solution of appropriate aniline (1.1 equiv) and NaHCO<sub>3</sub> (1.2 equiv) in anhydrous EtOH at room temperature. The resulted mixture was heated to reflux and stirred overnight before being cooled to room temperature. The precipitate was filtered out and washed with water to obtain the desired product. In method B, appropriate amine (1.1 equiv) was added to a solution of 2,4,5-trichloropyrimidine (1 equiv) in THF at room temperature, followed by DIPEA (1.5 equiv), and the mixture was stirred for overnight. The solution was diluted with ethyl acetate and washed with water and brine. The organic phase was dried over MgSO<sub>4</sub> and concentrated under reduced pressure. The residue was purified by silica column chromatography to obtain the desired product.</div><div id="sec5_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> 2-((2,5-Dichloropyrimidin-4-yl)amino)-<i>N</i>-methylbenzamide (<b>1a</b>)</h4><div class="NLM_p last">Yellowish solid, yield 93%, mp 208 °C. <sup>1</sup>H NMR (250 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.18 (s, 1H), 8.86 (d, <i>J</i> = 4.2 Hz, 1H), 8.52 (d, <i>J</i> = 8.0 Hz, 1H), 8.48 (s, 1H), 7.80 (dd, <i>J</i> = 7.9, 1.3 Hz, 1H), 7.60 (t, <i>J</i> = 7.9 Hz, 1H), 7.23 (t, <i>J</i> = 7.2 Hz, 1H), 2.81 (d, <i>J</i> = 4.5 Hz, 3H). HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>12</sub>H<sub>11</sub>Cl<sub>2</sub>N<sub>4</sub>O [M + H]<sup>+</sup>: 297.0310, found: 297.0295.</div></div><div id="sec5_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> 2-((2,5-Dichloropyrimidin-4-yl)amino)-<i>N</i>-methoxybenzamide (<b>1b</b>)</h4><div class="NLM_p last">White solid, yield 77%, mp 222 °C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.05 (s, 1H), 11.34 (s, 1H), 8.47 (s, 1H), 8.40 (d, <i>J</i> = 8.4 Hz, 1H), 7.69–7.56 (m, 2H), 7.23 (td, <i>J</i> = 7.6, 1.2 Hz, 1H), 3.72 (s, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.53, 156.65, 156.33, 155.40, 137.82, 132.13, 127.95, 123.55, 121.72, 120.16, 114.76, 63.31. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>12</sub>H<sub>11</sub>Cl<sub>2</sub>N<sub>4</sub>O<sub>2</sub>[M + H]<sup>+</sup>: 313.02504, found: 313.02536.</div></div><div id="sec5_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> <i>N</i>-(3-(((2,5-Dichloropyrimidin-4-yl)amino)methyl)pyridin-2-yl)-<i>N</i>-methylmethanesulfonamide (<b>1c</b>)</h4><div class="NLM_p last">White solid, yield 92%, mp 190 °C. <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ 8.45 (dd, <i>J</i> = 4.7, 1.9 Hz, 1H), 8.00 (s, 1H), 7.96 (dd, <i>J</i> = 7.7, 1.9 Hz, 1H), 7.32 (dd, <i>J</i> = 7.7, 4.7 Hz, 1H), 4.87 (s, 2H), 3.31 (s, 3H), 3.06 (s, 3H).<sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 158.85, 158.34, 153.93, 153.21, 149.04, 140.59, 133.34, 124.69, 113.70, 40.37, 38.02, 35.51. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>12</sub>H<sub>14</sub>O<sub>2</sub>N<sub>5</sub>Cl<sub>2</sub>S [M + H]<sup>+:</sup> 362.02398, found: 362.02335.</div></div><div id="sec5_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> <i>N</i>-(2-(((2,5-Dichloropyrimidin-4-yl)amino)methyl)phenyl)-<i>N</i>-methylmethanesulfonamide (<b>1d</b>)</h4><div class="NLM_p last">White solid, yield 88%, mp 177 °C. <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ 7.97 (s, 1H), 7.60–7.57 (m, 1H), 7.38–7.35 (m, 2H), 7.30–7.27 (m, 1H), 4.51 (d, <i>J</i> = 15.7 Hz, 2H), 3.31 (s, 3H), 3.00 (s, 3H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 158.76, 158.34, 153.65, 140.14, 138.42, 131.73, 129.56, 129.45, 126.35, 113.56, 40.40, 39.61, 35.56. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>13</sub>H<sub>15</sub>O<sub>2</sub>N<sub>4</sub>Cl<sub>2</sub>S [M + H]<sup>+:</sup> 361.02873, found: 361.02857.</div></div><div id="sec5_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> <i>N</i>-(3-(((2,5-Dichloropyrimidin-4-yl)amino)methyl)phenyl)-<i>N</i>-methylmethanesulfonamide (<b>1e</b>)</h4><div class="NLM_p last">White solid, yield 76%, mp 154 °C. <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ 7.90 (s, 1H), 7.27–7.21 (m, 2H), 7.19–7.10 (m, 2H), 5.77 (t, <i>J</i> = 5.9 Hz, 1H), 4.56 (d, <i>J</i> = 5.9 Hz, 2H), 3.18 (s, 3H), 2.70 (s, 3H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 158.80, 158.52, 154.00, 142.01, 138.81, 129.92, 126.98, 126.21, 125.42, 113.43, 44.92, 38.19, 35.57. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>13</sub>H<sub>15</sub>O<sub>2</sub>N<sub>4</sub>Cl<sub>2</sub>S [M + H]<sup>+:</sup> 361.02873, found: 361.02863.</div></div><div id="sec5_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> 2,5-Dichloro-<i>N</i>-(3-(methylsulfonyl)benzyl)pyrimidin-4-amine (<b>1f</b>)</h4><div class="NLM_p last">White solid, yield 83%, mp 148 °C. <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ 8.03 (s, 1H), 7.91 (d, <i>J</i> = 1.7 Hz, 1H), 7.84 (dt, <i>J</i> = 7.9, 1.4 Hz, 1H), 7.65 (d, <i>J</i> = 7.7 Hz, 1H), 7.54 (t, <i>J</i> = 7.7 Hz, 1H), 4.78 (d, <i>J</i> = 6.0 Hz, 2H), 3.05 (s, 3H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 158.80, 158.41, 154.08, 141.03, 139.44, 133.39, 129.96, 126.85, 126.72, 113.47, 44.54, 44.47. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>12</sub>H<sub>12</sub>O<sub>2</sub>N<sub>3</sub>Cl<sub>2</sub>S [M + H]<sup>+:</sup> 332.00218, found: 332.00168.</div></div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> General Procedure for the Synthesis of <b>2a, 2c–f</b></h3><div class="NLM_p">To a solution of appropriate 4-aminosubstituted 2,5-dichloropyrimidine (1.0 equiv) in <i>n</i>-BuOH, allyl(4-aminobenzyl)carbamate (1.0 equiv) and HCl (4 M in dioxane, 1.0 equiv) were added. The mixtures were heated at 100 °C overnight. After being cooled to room temperature, the solution was diluted with DCM, washed with 1 M K<sub>2</sub>CO<sub>3</sub> and brine, and dried over MgSO<sub>4</sub>. The organic phase was concentrated under reduced pressure. The residue was purified through silica gel column chromatography to obtain the desired product.</div><div id="sec5_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> Allyl(4-((5-chloro-4-((2-(methylcarbamoyl)phenyl)amino)pyrimidin-2-yl)amino) benzyl)carbamate (<b>2a</b>)</h4><div class="NLM_p last">White solid, yield 44%, mp 229 °C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.60 (s, 1H), 9.42 (s, 1H), 8.79–8.68 (m, 2H), 8.21 (s, 1H), 7.76 (dd, <i>J</i> = 8.0, 1.6 Hz, 1H), 7.70 (t, <i>J</i> = 6.2 Hz, 1H), 7.62–7.57 (m, 2H), 7.48 (ddd, <i>J</i> = 8.7, 7.3, 1.6 Hz, 1H), 7.19–7.10 (m, 3H), 5.93 (ddt, <i>J</i> = 17.3, 10.6, 5.3 Hz, 1H), 5.34–5.13 (m, 2H), 4.50 (dt, <i>J</i> = 5.4, 1.6 Hz, 2H), 4.15 (d, <i>J</i> = 6.2 Hz, 2H), 2.81 (d, <i>J</i> = 4.5 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO) δ 168.88, 157.73, 156.12, 154.96, 154.58, 139.28, 138.90, 133.80, 133.06, 131.38, 127.94, 127.21, 121.88, 121.42, 120.73, 119.65, 116.85, 104.99, 64.28, 43.46, 26.28. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>24</sub>O<sub>3</sub>N<sub>6</sub>Cl [M + H]<sup>+:</sup> 467.15984, found: 467.16043.</div></div><div id="sec5_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> Allyl(4-((5-chloro-4-(((2-(<i>N</i>-methylmethylsulfonamido)pyridin-3-yl)methyl)amino)pyrimidin-2-yl)amino)benzyl)carbamate (<b>2c</b>)</h4><div class="NLM_p last">Pale foamy solid, yield 86%, mp 100 °C. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.40 (dd, <i>J</i> = 4.8, 1.8 Hz, 1H), 7.86 (s, 1H), 7.77 (dd, <i>J</i> = 7.7, 1.8 Hz, 1H), 7.35–7.28 (m, 3H), 7.05 (d, <i>J</i> = 8.2 Hz, 2H), 5.94 (ddd, <i>J</i> = 15.5, 10.5, 5.2 Hz, 1H), 5.34–5.25 (m, 1H), 5.21–5.13 (m, 1H), 4.84 (s, 2H), 4.58–4.52 (m, 2H), 4.18 (s, 2H), 3.18 (s, 3H), 3.12 (s, 3H). <sup>13</sup>C NMR (126 MHz, MeOD) δ 159.59, 158.79, 153.99, 153.87, 148.70, 140.47, 138.99, 135.87, 134.53, 134.06, 128.63, 125.33, 120.74, 117.48, 116.65, 105.56, 66.41, 45.06, 41.49, 37.94, 36.38. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>27</sub>O<sub>4</sub>N<sub>7</sub>ClS [M + H]<sup>+</sup>: 532.15283, found: 532.15167.</div></div><div id="sec5_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> Allyl(4-((5-chloro-4-((2-(<i>N</i>-methylmethylsulfonamido)benzyl)amino)pyrimidin-2-yl) amino)benzyl)carbamate (<b>2d</b>)</h4><div class="NLM_p last">Pale solid, yield 64%, mp 110 °C. <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ 7.88 (s, 1H), 7.55–7.47 (m, 3H), 7.38–7.27 (m, 3H), 7.22– 7.15 (m, 3H), 6.17 (t, <i>J</i> = 6.1 Hz, 1H), 5.92 (ddt, <i>J</i> = 16.3, 10.8, 5.6 Hz, 1H), 5.34–5.19 (m, 2H), 5.07 (t, <i>J</i> = 6.2 Hz, 2H), 4.64 (br, 1H), 4.59 (d, <i>J</i> = 5.7 Hz, 2H), 4.30 (d, <i>J</i> = 5.9 Hz, 2H), 3.27 (s, 3H), 2.99 (s, 3H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 158.07, 157.91, 156.35, 153.17, 139.92, 139.40, 139.37, 133.03, 132.08, 130.94, 129.42, 128.97, 128.34, 126.48, 119.54, 117.80, 105.27, 65.75, 44.87, 40.61, 39.47, 35.74. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>28</sub>O<sub>4</sub>N<sub>6</sub>ClS [M + H]<sup>+</sup>: 531.15758, found: 531.15652.</div></div><div id="sec5_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> Allyl(4-((5-chloro-4-((3-(<i>N</i>-methylmethylsulfonamido)benzyl)amino)pyrimidin-2-yl) amino)benzyl)- carbamate (<b>2e</b>)</h4><div class="NLM_p last">White solid, yield 62%, mp 177 °C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.96 (s, 1H), 7.81 (t, <i>J</i> = 6.2 Hz, 1H), 7.63 (s, 1H), 7.52 (d, <i>J</i> = 8.4 Hz, 2H), 7.41 (t, <i>J</i> = 2.0 Hz, 1H), 7.35 (t, <i>J</i> = 7.8 Hz, 1H), 7.26 (dt, <i>J</i> = 7.5, 2.1 Hz, 2H), 7.07 (d, <i>J</i> = 8.3 Hz, 2H), 5.91 (ddd, <i>J</i> = 16.1, 10.7, 5.3 Hz, 1H), 5.31–5.14 (m, 2H), 4.63 (d, <i>J</i> = 5.9 Hz, 2H), 4.49 (dt, <i>J</i> = 5.4, 1.7 Hz, 2H), 4.09 (d, <i>J</i> = 5.7 Hz, 2H), 3.16 (s, 3H), 2.86 (s, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 157.89, 157.34, 156.08, 153.22, 141.59, 140.74, 139.37, 133.78, 132.17, 128.90, 127.14, 125.64, 125.03, 124.61, 118.51, 116.87, 103.41, 64.26, 43.42, 43.30, 37.75, 34.86. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>28</sub>O<sub>4</sub>N<sub>6</sub>ClS [M + H]<sup>+</sup>: 531.15758, found: 531.15627.</div></div><div id="sec5_3_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> Allyl(4-((5-chloro-4-((3-(methylsulfonyl)benzyl)amino)pyrimidin-2-yl)amino)benzyl)carbamate (<b>2f</b>)</h4><div class="NLM_p last">White solid, yield 55%, mp 169 °C. <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ 7.93 (s, 1H), 7.92 (d, <i>J</i> = 1.8 Hz, 1H), 7.84 (dt, <i>J</i> = 7.8, 1.5 Hz, 1H), 7.62 (dt, <i>J</i> = 8.0, 1.3 Hz, 1H), 7.55 (t, <i>J</i> = 7.7 Hz, 1H), 7.44–7.37 (m, 2H), 7.18 (d, <i>J</i> = 8.1 Hz, 2H), 7.05 (s, 1H), 5.93 (ddt, <i>J</i> = 17.2, 10.4, 5.6 Hz, 1H), 5.80 (t, <i>J</i> = 6.1 Hz, 1H), 5.34–5.18 (m, 3H), 4.77 (d, <i>J</i> = 6.1 Hz, 2H), 4.59 (d, <i>J</i> = 5.6 Hz, 2H), 4.31 (d, <i>J</i> = 6.0 Hz, 2H), 2.96 (s, 3H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 158.04, 157.83, 156.43, 153.69, 141.08, 140.51, 138.92, 133.08, 132.69, 132.62, 129.93, 128.31, 126.55, 126.52, 119.63, 117.75, 105.05, 65.98, 44.80, 44.55, 44.50. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>25</sub>O<sub>4</sub>N<sub>5</sub>ClS [M + H]<sup>+</sup>: 502.13103, found: 502.13037.</div></div><div id="sec5_3_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> <i>tert</i>-Butyl(4-((5-chloro-4-((2-(methoxycarbamoyl)phenyl)amino)pyrimidin-2-yl) amino)benzyl)carbamate (<b>2b</b>)</h4><div class="NLM_p last">In an argon-charged sealed tube, to the solution of <b>1b</b> (337 mg, 1.08 mmol) in dioxane (6 mL) were added Pd<sub>2</sub>(dba)<sub>3</sub> (99 mg, 10% mmol), XantPhos (128 mg, 20% mmol), and Cs<sub>2</sub>CO<sub>3</sub> (420 mg, 1.29 mmol), followed by the addition of <i>tert</i>-butyl(4-aminobenzyl)carbamate (240 mg, 1.08 mmol). The mixture was stirred at room temperature for 10 min and then stirred at 105 °C for 24 h. Subsequently, the solvent was concentrated and the resulting residue was purified by silica gel chromatography (elution: DCM/MeOH = 100/1) to give the titled compound as a white solid (231 mg, 43%). Mp 216 °C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.98 (s, 1H), 10.89 (s, 1H), 9.42 (s, 1H), 8.68 (d, <i>J</i> = 8.4 Hz, 1H), 8.22 (s, 1H), 7.66–7.60 (m, 1H), 7.57 (d, <i>J</i> = 8.2 Hz, 2H), 7.54–7.47 (m, 1H), 7.30 (t, <i>J</i> = 6.3 Hz, 1H), 7.17–7.10 (m, 3H), 4.08 (d, <i>J</i> = 6.2 Hz, 2H), 3.74 (s, 3H), 1.40 (s, 9H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.97, 157.74, 155.75, 154.93, 154.71, 139.07, 138.69, 133.56, 131.79, 127.77, 127.08, 122.11, 121.87, 119.65, 119.14, 104.80, 77.64, 63.35, 43.01, 28.25. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>28</sub>O<sub>4</sub>N<sub>6</sub>Cl [M + H]<sup>+</sup>: 499.18551, found: 499.18489.</div></div><div id="sec5_3_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> Allyl(4-((4-chloro-5-(trifluoromethyl)pyrimidin-2-yl)amino)benzyl)carbamate (<b>3</b>)</h4><div class="NLM_p last">To a solution of 2,4-dichloro-5-(trifluromethyl)pyrimidine (200 μL, 1.48 mmol) in 10 mL of 1:1 mixture of <i>t</i>-BuOH/DCM was added at 0 °C zinc chloride (403 mg, 2.96 mmol). After 1 h, ally(4-aminobezyl)carbamate (305 mg, 1.48 mmol) was added followed by dropwise addition of triethylamine (207 μL, 1.48 mmol). After stirring for 6 h, the mixture was diluted with DCM and washed with water and brine. The organic layer was dried over MgSO<sub>4</sub>. After filtration, the organic solution was concentrated in vacuo, and the residue was purified through silica gel chromatography (elution: DCM/MeOH = 150/1) to give the titled compound as a white solid (477 mg, 83%). Mp 154 °C. <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ 8.53 (s, 1H), 7.65 (s, 1H), 7.55 (d, <i>J</i> = 8.3 Hz, 2H), 7.30 (d, <i>J</i> = 8.3 Hz, 2H), 5.99–5.89 (m, 1H), 5.31 (dq, <i>J</i> = 17.3, 1.7 Hz, 1H), 5.22 (dp, <i>J</i> = 10.5, 1.3 Hz, 1H), 5.09 (s, 1H), 4.61 (d, <i>J</i> = 5.6 Hz, 2H), 4.37 (d, <i>J</i> = 6.0 Hz, 2H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 160.63, 157.49, 156.45, 136.89, 134.91, 132.95, 128.48, 123.78, 122.90, 121.62, 120.85, 117.92, 65.91, 44.75. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>15</sub>O<sub>2</sub>N<sub>4</sub>ClF<sub>3</sub> [M + H]<sup>+</sup>: 387.08356, found: 387.08279.</div></div><div id="sec5_3_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> Allyl(4-((4-((2-(methylcarbamoyl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl) amino)benzyl)carbamate (<b>2g</b>)</h4><div class="NLM_p last">To a solution <b>3</b> (380 mg, 0.98 mmol) in DMF was added 2-amino-<i>N</i>-methylbenzamide (147 mg, 0.98 mmol) followed by addition of HCl (250 μL, 4 M in dioxane). The mixture was stirred at 90 °C for 7 h. Then, the solvent was removed in vacuo. To the residue, DCM was added, the product was precipitated, and through filtration the titled compound was obtained as a white solid (286 mg, 58%). Mp 251 °C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.35 (s, 1H), 9.81 (s, 1H), 8.79 (q, <i>J</i> = 4.6 Hz, 1H), 8.42 (s, 1H), 7.76–7.72 (m, 2H), 7.58 (d, <i>J</i> = 8.0 Hz, 2H), 7.45 (t, <i>J</i> = 8.0 Hz, 1H), 7.17–7.15 (m, 3H), 5.96–5.89 (m, 1H), 5.35–5.22 (m, 1H), 5.18 (d, <i>J</i> = 10.5 Hz, 1H), 4.50 (d, <i>J</i> = 5.0 Hz, 2H), 4.15 (d, <i>J</i> = 6.2 Hz, 2H), 2.78 (d, <i>J</i> = 4.4 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.77, 160.80, 156.13, 155.87, 138.63, 138.03, 134.05, 133.79, 131.10, 127.88, 127.20, 125.66, 123.51, 122.52, 120.52, 116.87, 64.30, 43.42, 26.20. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>24</sub>O<sub>3</sub>N<sub>6</sub>F<sub>3</sub> [M + H]<sup>+</sup>: 501.18620, found: 501.18442.</div></div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> General Procedure for the Synthesis of <b>4a–g</b></h3><div class="NLM_p">To a solution of corresponding Alloc-protected compounds (1.0 equiv) in anhydrous THF or DMF, morpholine (10 equiv) and Pd(PPh<sub>3</sub>)<sub>4</sub> (0.1–0.5 equiv) were added under an inert atmosphere. The mixture was stirred at room temperature without light for 3 h. After monitoring the completion with TLC, the solvent was concentrated under reduced pressure. The residue was purified through silica gel column chromatography to give the desired product. In method B, TFA and DCM (v/v = 1/1) were added to the Boc-protected compounds and the mixture was stirred at room temperature for 30 min. Then, the solvent was concentrated in vacuo and diethyl ether was added to the residue; after filtration, the desired product was obtained.</div><div id="sec5_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 2-((2-((4-(Aminomethyl)phenyl)amino)-5-chloropyrimidin-4-yl)amino)-<i>N</i>-methylbenzamide (<b>4a</b>)</h4><div class="NLM_p last">White solid, yield 85%, mp 205 °C. <sup>1</sup>H NMR (250 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.61 (s, 1H), 9.43 (s, 1H), 8.77 (d, <i>J</i> = 7.9 Hz, 2H), 8.22 (s, 1H), 7.77 (d, <i>J</i> = 7.9 Hz, 1H), 7.62 (d, <i>J</i> = 8.2 Hz, 2H), 7.52 (t, <i>J</i> = 7.9 Hz, 1H), 7.26 (d, J = 8.2 Hz, 2H), 7.16 (t, <i>J</i> = 7.4 Hz, 1H), 3.73 (s, 2H), 2.82 (d, <i>J</i> = 4.2 Hz, 3H). <sup>13</sup>C NMR (250 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.87, 157.74, 154.94, 154.57, 139.28, 138.56, 136.46, 131.43, 127.94, 127.24, 121.88, 121.38, 120.70, 119.46, 104.89, 44.88, 26.28. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>20</sub>ClN<sub>6</sub>O 383.1387, found 383.1380.</div></div><div id="sec5_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 2-((2-((4-(Aminomethyl)phenyl)amino)-5-chloropyrimidin-4-yl)amino)-<i>N</i>-methoxybenzamide trifluoroacetate (<b>4b</b>)</h4><div class="NLM_p last">White solid, yield 100%, mp 240 °C. <sup>1</sup>H NMR (250 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.57 (d, <i>J</i> = 8.4 Hz, 2H), 8.17 (s, 2H), 7.66 (dd, <i>J</i> = 8.6, 6.6 Hz, 6H), 7.64–7.49 (m, 1H), 7.40 (d, <i>J</i> = 8.5 Hz, 4H), 7.32–7.17 (m, 2H), 4.10 (s, 4H), 3.82 (s, 6H). HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>20</sub>ClN<sub>6</sub>O<sub>2</sub> 399.13308, found: 399.13248.</div></div><div id="sec5_4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> <i>N</i>-(3-(((2-((4-(Aminomethyl)phenyl)amino)-5-chloropyrimidin-4-yl)amino)methyl)pyridin-2-yl)-<i>N</i>-methylmethanesulfonamide (<b>4c</b>)</h4><div class="NLM_p last">White solid, yield 94%, mp 124 °C. <sup>1</sup>H NMR (250 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.43–8.41 (m, 1H), 7.93–7.87 (m, 1H), 7.81 (dd, <i>J</i> = 7.7, 1.9 Hz, 1H), 7.46–7.32 (m, 3H), 7.14 (d, <i>J</i> = 8.6 Hz, 2H), 4.87 (s, 2H), 3.74 (s, 2H), 3.22 (s, 3H), 3.13 (s, 3H). <sup>13</sup>C NMR (126 MHz, MeOD) δ 159.57, 154.04, 153.89, 148.77, 140.81, 139.18, 135.88, 135.11, 129.07, 125.35, 120.72, 116.57, 105.67, 45.80, 41.35, 37.93, 36.39. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>23</sub>O<sub>2</sub>N<sub>7</sub>ClS [M + H]<sup>+</sup>: 448.13170, found: 448.13054.</div></div><div id="sec5_4_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> <i>N</i>-(2-(((2-((4-(Aminomethyl)phenyl)amino)-5-chloropyrimidin-4-yl)amino)methyl)phenyl)-<i>N</i>-methylmethanesulfonamide (<b>4d</b>)</h4><div class="NLM_p last">White solid, yield 84%, mp 218 °C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.06 (s, 1H), 7.98 (s, 1H), 7.55 (dd, <i>J</i> = 7.0, 2.0 Hz, 1H), 7.47 (t, <i>J</i> = 6.0 Hz, 1H), 7.43 (d, <i>J</i> = 8.2 Hz, 2H), 7.38–7.30 (m, 3H), 7.06 (d, <i>J</i> = 8.2 Hz, 2H), 4.78 (d, <i>J</i> = 32.3 Hz, 2H), 3.59 (s, 2H), 3.19 (s, 3H), 3.11 (s, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 158.06, 157.60, 153.19, 139.61, 139.25, 138.81, 136.53, 128.34, 127.88, 127.81, 127.04, 127.02, 118.43, 103.33, 45.18, 40.06, 38.64, 35.98. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>24</sub>O<sub>2</sub>N<sub>6</sub>ClS [M + H]<sup>+</sup>: 447.13645, found: 447.13549.</div></div><div id="sec5_4_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> <i>N</i>-(3-(((2-((4-(Aminomethyl)phenyl)amino)-5-chloropyrimidin-4-yl)amino)methyl)phenyl)-<i>N</i>-methylmethanesulfonamide (<b>4e</b>)</h4><div class="NLM_p last">White solid, yield 81%, mp 176 °C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.11 (s, 1H), 7.97 (s, 1H), 7.81 (t, <i>J</i> = 6.2 Hz, 1H), 7.55–7.51 (m, 2H), 7.42 (m, 1H), 7.38 (t, <i>J</i> = 7.7 Hz, 1H), 7.30–7.26 (m, 2H), 7.17–7.12 (m, 2H), 4.64 (d, <i>J</i> = 6.1 Hz, 2H), 3.64 (s, 2H), 3.17 (s, 3H), 2.88 (s, 3H). <sup>13</sup>C NMR (126 MHz, DMSO) δ 157.95, 157.32, 153.22, 141.57, 140.76, 138.86, 136.36, 128.93, 127.01, 125.66, 125.14, 124.55, 118.50, 103.26, 45.08, 43.29, 37.76, 34.93. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>24</sub>O<sub>2</sub>N<sub>6</sub>ClS [M + H]<sup>+</sup>: 447.13645, found: 447.13558.</div></div><div id="sec5_4_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> <i>N</i><sup>2</sup>-(4-(Aminomethyl)phenyl)-5-chloro-<i>N</i><sup>4</sup>-(3-(methylsulfonyl)benzyl)pyrimidine-2,4-diamine (<b>4f</b>)</h4><div class="NLM_p last">White solid, yield 86.5%, mp 216 °C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.15 (s, 1H), 7.98 (s, 1H), 7.95–7.91 (m, 2H), 7.81 (d, <i>J</i> = 7.7 Hz, 1H), 7.69 (d, <i>J</i> = 7.7 Hz, 1H), 7.62 (t, <i>J</i> = 7.7 Hz, 1H), 7.48 (d, <i>J</i> = 8.1 Hz, 2H), 7.14 (d, <i>J</i> = 8.2 Hz, 2H), 4.71 (d, <i>J</i> = 6.0 Hz, 2H), 3.65 (s, 2H), 3.14 (s, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 157.94, 157.31, 153.36, 141.37, 140.81, 138.98, 135.39, 131.96, 129.43, 127.21, 125.32, 125.15, 118.49, 103.31, 44.78, 43.46, 43.28. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>21</sub>O<sub>2</sub>N<sub>5</sub>ClS [M + H]<sup>+</sup>: 418.10990, found: 418.10920.</div></div><div id="sec5_4_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 2-((2-((4-(Aminomethyl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)-<i>N</i>-methylbenzamide (<b>4g</b>)</h4><div class="NLM_p last">White solid, yield 68%, mp 180 °C. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.37 (d, <i>J</i> = 8.6 Hz, 1H), 8.30 (d, <i>J</i> = 1.1 Hz, 1H), 7.63 (dd, <i>J</i> = 7.9, 1.6 Hz, 1H), 7.56–7.51 (m, 2H), 7.45 (ddd, <i>J</i> = 8.6, 7.4, 1.7 Hz, 1H), 7.25 (d, <i>J</i> = 8.5 Hz, 2H), 7.18 (td, <i>J</i> = 7.6, 1.2 Hz, 1H), 3.80 (d, <i>J</i> = 3.0 Hz, 2H), 2.89 (d, <i>J</i> = 1.3 Hz, 3H). <sup>13</sup>C NMR (126 MHz, MeOD) δ 171.57, 162.26, 158.15, 156.54, 139.47, 139.32, 132.46, 129.03, 128.76, 126.91, 125.14, 125.01, 124.77, 124.54, 122.38, 68.43, 26.87. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>2</sub>ON<sub>6</sub>F<sub>3</sub> [M + H]<sup>+</sup>: 417.16507, found: 417.16470.</div></div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> General Procedure for the Synthesis of <b>5a–g</b></h3><div class="NLM_p">To a solution of appropriate amine (1.0 equiv) in dry DMF were added <i>tert</i>-butyl(2-((2-methoxy-3,4-dioxocyclobut-1-en-1- yl)amino)ethyl)carbamate (1.0 equiv) and DIPEA (1.0 equiv). The mixture was stirred at 75 °C for overnight. After removal of the solvent, the crude product was purified by flash silica gel chromatography to obtain the desired product as a solid.</div><div id="sec5_5_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> <i>tert</i>-Butyl(2-((2-((4-((5-chloro-4-((2-(methylcarbamoyl)phenyl)amino)pyrimidin- 2-yl)amino)benzyl)amino)-3,4-dioxocyclobut-1-en-1-yl)amino)ethyl)carbamate (<b>5a</b>)</h4><div class="NLM_p last">White solid, yield 77%, mp 226 °C. <sup>1</sup>H NMR (250 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.62 (s, 1H), 9.51 (s, 1H), 8.74 (d, <i>J</i> = 8.3 Hz, 2H), 8.23 (s, 1H), 7.77 (d, <i>J</i> = 7.8 Hz, 1H), 7.66 (d, <i>J</i> = 8.2 Hz, 2H), 7.47 (t, <i>J</i> = 7.9 Hz, 1H), 7.26 (d, <i>J</i> = 8.2 Hz, 2H), 7.14 (t, <i>J</i> = 7.5 Hz, 1H), 6.91 (s, 1H), 4.66 (d, <i>J</i> = 5.9 Hz, 2H), 3.52 (s, 2H), 3.10 (d, <i>J</i> = 6.1 Hz, 2H), 2.82 (d, <i>J</i> = 4.3 Hz, 3H), 1.36 (s, 9H). <sup>13</sup>C NMR (250 MHz, DMSO-<i>d</i><sub>6</sub>) δ 182.6, 182.4, 168.8 (2C), 162.2, 157.6, 155.7, 154.9, 154.5, 139.5, 139.2, 132.0, 131.3, 127.9, 127.8, 121.9, 121.4, 120.7, 119.8, 105.1, 77.8, 46.5, 43.2, 41.1, 28.1(3C), 26.2. HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>30</sub>H<sub>33</sub>ClN<sub>8</sub>O<sub>5</sub> 621.2341, found 621.2308.</div></div><div id="sec5_5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> <i>tert</i>-Butyl(2-((2-((4-((5-chloro-4-((2-(methoxycarbamoyl)phenyl)amino)pyrimidin-2-yl)amino)benzyl)amino)-3,4-dioxocyclobut-1-en-1-yl)amino)ethyl)carbamate (<b>5b</b>)</h4><div class="NLM_p last">White solid, yield 42%, mp 206 °C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.97 (s, 1H), 10.91 (s, 1H), 9.49 (s, 1H), 8.67 (d, <i>J</i> = 8.3 Hz, 1H), 8.23 (s, 1H), 7.63 (t, <i>J</i> = 8.4 Hz, 3H), 7.53–7.47 (m, 1H), 7.29–7.22 (m, 2H), 7.14 (td, <i>J</i> = 7.6, 1.2 Hz, 1H), 6.88 (t, <i>J</i> = 5.7 Hz, 1H), 4.71–4.57 (m, 2H), 3.73 (s, 3H), 3.51 (s, 2H), 3.09 (q, <i>J</i> = 5.9 Hz, 2H), 1.35 (s, 9H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 182.64, 182.45, 168.09, 167.38, 165.94, 157.64, 155.70, 154.94, 154.67, 139.44, 139.02, 132.11, 131.81, 127.81, 127.76, 122.20, 121.85, 119.79, 119.16, 105.02, 77.78, 63.34, 46.48, 43.22, 41.12, 28.16. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>30</sub>H<sub>34</sub>O<sub>6</sub>N<sub>8</sub>Cl [M + H]<sup>+</sup>: 637.22843 found: 637.22760.</div></div><div id="sec5_5_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> <i>tert</i>-Butyl(2-((2-((4-((5-chloro-4-(((2-(<i>N</i>-methylmethylsulfonamido)pyridin-3-yl)methyl)amino)pyrimidin-2-yl)amino)benzyl)amino)-3,4-dioxocyclobut-1-en-1-yl)amino)ethyl)carbamate (<b>5c</b>)</h4><div class="NLM_p last">Beige solid, yield 58%, mp 209 °C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.18 (s, 1H), 8.43 (dd, <i>J</i> = 4.7, 1.9 Hz, 1H), 8.01 (s, 1H), 7.73–7.68 (m, 1H), 7.66 (t, <i>J</i> = 6.0 Hz, 1H), 7.45–7.39 (m, 3H), 7.04 (d, <i>J</i> = 8.1 Hz, 2H), 6.87 (d, <i>J</i> = 5.8 Hz, 1H), 4.76 (d, <i>J</i> = 5.9 Hz, 2H), 4.63–4.52 (m, 2H), 3.51 (s, 2H), 3.15 (s, 6H), 3.09 (q, <i>J</i> = 6.0 Hz, 2H), 1.35 (s, 9H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 182.60, 182.44, 168.00, 167.35, 157.91, 157.66, 155.70, 153.32, 152.18, 147.26, 139.86, 137.11, 133.91, 131.18, 127.69, 124.03, 118.46, 103.66, 77.79, 46.42, 43.19, 41.12, 37.15, 35.98, 28.16. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>30</sub>H<sub>37</sub>O<sub>6</sub>N<sub>9</sub>ClS [M + H]<sup>+</sup>: 686.22705 found: 686.22590.</div></div><div id="sec5_5_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> <i>tert</i>-Butyl (2-((2-((4-((5-chloro-4-((2-(<i>N</i>-methylmethylsulfonamido)benzyl)amino)pyrimidin-2-yl)amino)benzyl)amino)-3,4-dioxocyclobut-1-en-1-yl)amino)ethyl)carbamate (<b>5d</b>)</h4><div class="NLM_p last">White solid, yield 86%, mp 237 °C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.19 (s, 1H), 8.00 (s, 1H), 7.53 (t, <i>J</i> = 4.5 Hz, 2H), 7.48 (d, <i>J</i> = 8.1 Hz, 2H), 7.37–7.32 (m, 2H), 7.30 (d, <i>J</i> = 5.4 Hz, 1H), 7.06 (d, <i>J</i> = 8.2 Hz, 2H), 6.89 (d, <i>J</i> = 5.9 Hz, 1H), 4.85–4.72 (m, 2H), 4.65–4.51 (m, 2H), 3.52 (s, 2H), 3.17 (s, 3H), 3.11–3.08 (m, 5H), 1.36 (s, 9H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 182.61, 182.44, 168.04, 167.37, 157.95, 157.67, 155.71, 153.21, 139.97, 139.56, 139.19, 131.10, 128.36, 127.86, 127.79, 127.67, 127.00, 118.48, 103.61, 77.80, 46.45, 43.22, 41.13, 38.58, 35.93, 28.17. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>31</sub>H<sub>38</sub>O<sub>6</sub>N<sub>8</sub>ClS [M + H]<sup>+</sup>: 685.23181, found: 685.23068.</div></div><div id="sec5_5_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> <i>tert</i>-Butyl(2-((2-((4-((5-chloro-4-((3-(<i>N</i>-methylmethylsulfonamido)benzyl)amino)pyrimidin-2-yl)amino)benzyl)amino)-3,4-dioxocyclobut-1-en-1-yl)amino)ethyl)carbamate (<b>5e</b>)</h4><div class="NLM_p last">White solid, yield 82%, mp 234 °C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.22 (s, 1H), 7.98 (s, 1H), 7.83 (t, <i>J</i> = 6.1 Hz, 1H), 7.59 (d, <i>J</i> = 8.4 Hz, 2H), 7.42 (t, <i>J</i> = 1.9 Hz, 1H), 7.37 (t, <i>J</i> = 7.8 Hz, 1H), 7.30–7.24 (m, 2H), 7.16 (d, <i>J</i> = 8.3 Hz, 2H), 6.88 (t, <i>J</i> = 5.7 Hz, 1H), 4.63 (m, 4H), 3.52 (s, 2H), 3.32 (s, 2H), 3.18 (s, 3H), 3.10 (q, <i>J</i> = 6.0 Hz, 2H), 2.88 (s, 3H), 1.37 (s, 9H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 182.61, 182.40, 168.03, 167.33, 157.84, 157.36, 155.70, 153.20, 141.61, 140.70, 139.98, 131.14, 128.91, 127.75, 125.67, 125.05, 124.53, 118.66, 103.59, 77.78, 46.48, 43.21, 41.12, 37.76, 34.89, 28.16. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>31</sub>H<sub>38</sub>O<sub>6</sub>N<sub>8</sub>ClS [M + H]<sup>+</sup>: 685.23181, found: 685.23092.</div></div><div id="sec5_5_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> <i>tert</i>-Butyl(2-((2-((4-((5-chloro-4-((3-(methylsulfonyl)benzyl)amino)pyrimidin-2-yl)amino)benzyl)amino)-3,4-dioxocyclobut-1-en-1-yl)amino)ethyl)carbamate (<b>5f</b>)</h4><div class="NLM_p last">White solid, yield 68%, mp 186 °C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.23 (s, 1H), 8.00 (s, 1H), 7.97–7.89 (m, 2H), 7.80 (d, <i>J</i> = 7.6 Hz, 1H), 7.69 (d, <i>J</i> = 7.7 Hz, 1H), 7.61 (t, <i>J</i> = 7.7 Hz, 1H), 7.55 (d, <i>J</i> = 8.2 Hz, 2H), 7.15 (d, <i>J</i> = 8.2 Hz, 2H), 6.88 (t, <i>J</i> = 5.7 Hz, 1H), 4.72 (d, <i>J</i> = 6.1 Hz, 2H), 4.61 (d, <i>J</i> = 5.9 Hz, 2H), 3.52 (s, 2H), 3.14 (s, 3H), 3.10 (q, <i>J</i> = 6.0 Hz, 2H), 1.36 (s, 9H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 182.61, 182.42, 168.05, 167.36, 157.86, 157.35, 155.70, 153.32, 141.32, 140.84, 139.88, 132.08, 131.22, 129.38, 127.73, 125.33, 125.10, 118.69, 103.59, 77.78, 46.48, 43.45, 43.28, 41.12, 28.16. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>30</sub>H<sub>35</sub>O<sub>6</sub>N<sub>7</sub>ClS [M + H]<sup>+</sup>: 656.20526, found: 656.20439.</div></div><div id="sec5_5_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> <i>tert</i>-Butyl(2-((2-((4-((4-((2-(methylcarbamoyl)phenyl)amino)-5-(trifluoromethyl) pyrimidin-2-yl)amino)benzyl)amino)-3,4-dioxocyclobut-1-en-1-yl)amino)ethyl)carbamate (<b>5g</b>)</h4><div class="NLM_p last">White solid, yield 89%, mp 258 °C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.34 (s, 1H), 9.84 (s, 1H), 8.71 (q, <i>J</i> = 4.6 Hz, 1H), 8.43 (s, 1H), 7.72 (dd, <i>J</i> = 7.9, 1.6 Hz, 1H), 7.63 (d, <i>J</i> = 8.1 Hz, 2H), 7.43 (t, <i>J</i> = 7.9 Hz, 1H), 7.36 (q, <i>J</i> = 5.0 Hz, 1H), 7.24 (d, <i>J</i> = 8.1 Hz, 2H), 7.15 (t, <i>J</i> = 7.6 Hz, 1H), 6.88 (t, <i>J</i> = 5.7 Hz, 1H), 4.66 (s, 2H), 3.58–3.45 (m, 2H), 3.10 (q, <i>J</i> = 6.0 Hz, 2H), 2.79 (d, <i>J</i> = 4.5 Hz, 3H), 1.35 (s, 9H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 182.65, 182.50, 168.74, 168.15, 167.40, 160.75, 156.12, 155.90, 155.73, 138.61, 133.12, 132.49, 131.07, 127.81, 125.62, 124.43, 123.47, 123.07, 122.59, 122.11, 120.71, 77.81, 46.44, 43.24, 41.13, 28.16, 26.20. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>31</sub>H<sub>34</sub>O<sub>5</sub>N<sub>8</sub>F<sub>3</sub> [M + H]<sup>+</sup>: 655.26043, found: 655.26227.</div></div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> General Procedure for the Synthesis of <b>6a–g</b></h3><div class="NLM_p">TFA and DCM (v/v = 1/1) were added to the Boc-protected compounds, and the mixture was stirred at room temperature for 30 min. Then, the solvent was concentrated in vacuo and diethyl ether was added to the residue; after filtration, the desired product was obtained, which was directly used for the next step without further purification.</div><div id="sec5_6_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 2-((2-((4-(((2-((2-Aminoethyl)amino)-3,4-dioxocyclobut-1-en-1-yl)amino)methyl)phenyl)amino)-5-chloropyrimidin-4-yl)amino)-<i>N</i>-methylbenzamide Trifluoroacetate Salt (<b>6a</b>)</h4><div class="NLM_p last">Solid, yield 100%. <sup>1</sup>H NMR (250 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.67 (s, 1H), 9.55 (s, 1H), 8.75 (d, <i>J</i> = 10.6 Hz, 2H), 8.24 (s, 1H), 7.87 (s, 2H), 7.77 (d, <i>J</i> = 7.8 Hz, 1H), 7.66 (d, <i>J</i> = 8.3 Hz, 3H), 7.48 (t, <i>J</i> = 7.8 Hz, 1H), 7.26 (d, <i>J</i> = 8.1 Hz, 2H), 7.14 (t, <i>J</i> = 7.6 Hz, 1H), 3.72 (d, <i>J</i> = 6.9 Hz, 2H), 3.03 (d, <i>J</i> = 6.1 Hz, 2H), 2.82 (d, <i>J</i> = 4.4 Hz, 3H). <sup>13</sup>C NMR (250 MHz, DMSO-<i>d</i><sub>6</sub>) δ 182.8, 182.3, 168.7, 168.2, 155.7, 155.6,155.4, 150.8, 138.5, 138.2, 133.5, 131.5, 128.0, 127.9, 122.8, 121.8, 121.2, 120.9, 105.3, 46.4, 40.8, 39.3,26.3. HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>26</sub>ClN<sub>8</sub>O<sub>3</sub>[M + H]<sup>+</sup>: 521.1816, found 521.1803.</div></div><div id="sec5_6_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 2-((2-((4-(((2-((2-Aminoethyl)amino)-3,4-dioxocyclobut-1-en-1-yl)amino)methyl)phenyl)amino)-5-chloropyrimidin-4-yl)amino)-<i>N</i>-methoxybenzamide Trifluoroacetate Salt (<b>6b</b>)</h4><div class="NLM_p last">Solid, yield 100%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.02 (s, 1H), 10.99 (s, 1H), 9.66 (s, 1H), 8.63 (d, <i>J</i> = 8.3 Hz, 1H), 8.26 (s, 1H), 8.15 (s, 1H), 7.92 (s, 3H), 7.77 (s, 1H), 7.63 (t, <i>J</i> = 7.7 Hz, 3H), 7.49 (t, <i>J</i> = 8.0 Hz, 1H), 7.26 (d, <i>J</i> = 8.2 Hz, 2H), 7.15 (t, <i>J</i> = 7.6 Hz, 1H), 4.67 (s, 2H), 3.73 (d, <i>J</i> = 10.5 Hz, 5H), 3.03 (q, <i>J</i> = 6.0 Hz, 2H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 182.95, 182.51, 168.02, 165.93, 157.05, 155.24, 153.46, 139.14, 138.81, 132.57, 131.85, 127.94, 127.86, 122.57, 122.10, 120.19, 119.47, 117.04, 114.72, 105.18, 63.37, 46.55, 40.99. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>26</sub>ClN<sub>8</sub>O<sub>4</sub> 537.17601, found 537.17561.</div></div><div id="sec5_6_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> <i>N</i>-(3-(((2-((4-(((2-((2-Aminoethyl)amino)-3,4-dioxocyclobut-1-en-1-yl)amino)methyl)phenyl)amino)-5-chloropyrimidin-4-yl)amino)methyl)pyridin-2-yl)-<i>N</i>-methylmethanesulfonamide Trifluoroacetate Salt (<b>6c</b>)</h4><div class="NLM_p last">Pale solid, yield 100%. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.44 (dd, <i>J</i> = 4.7, 1.8 Hz, 1H), 8.00 (s, 1H), 7.73 (dd, <i>J</i> = 7.8, 1.8 Hz, 1H), 7.36 (dd, <i>J</i> = 7.8, 5.0 Hz, 3H), 7.26 (d, <i>J</i> = 8.3 Hz, 2H), 4.90 (s, 2H), 4.74 (s, 2H), 3.88 (t, <i>J</i> = 6.0 Hz, 2H), 3.21 (t, <i>J</i> = 5.9 Hz, 2H), 3.12 (s, 3H), 3.10 (s, 3H). <sup>13</sup>C NMR (126 MHz, MeOD) δ 184.22, 184.03, 169.85, 169.25, 160.76, 154.07, 153.98, 149.27, 143.58, 139.07, 138.00, 134.05, 129.60, 125.40, 123.25, 119.23, 106.58, 44.64, 42.48, 42.43, 41.49, 37.89, 36.27. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>29</sub>O<sub>4</sub>N<sub>9</sub>ClS [M + H]<sup>+</sup>: 586.17463, found: 586.17391.</div></div><div id="sec5_6_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> <i>N</i>-(2-(((2-((4-(((2-((2-Aminoethyl)amino)-3,4-dioxocyclobut-1-en-1-yl)amino)methyl)phenyl)amino)-5-chloropyrimidin-4-yl)amino)methyl)phenyl)-<i>N</i>-methylmethanesulfonamide Trifluoroacetate Salt (<b>6d</b>)</h4><div class="NLM_p last">White solid, yield 100%. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.00 (s, 1H), 7.52 (d, <i>J</i> = 7.8 Hz, 1H), 7.42 (td, <i>J</i> = 7.6, 1.8 Hz, 1H), 7.39–7.30 (m, 4H), 7.26 (d, <i>J</i> = 8.2 Hz, 2H), 4.96 (d, <i>J</i> = 15.9 Hz, 2H), 4.74 (d, <i>J</i> = 8.7 Hz, 2H), 3.87 (t, <i>J</i> = 6.0 Hz, 2H), 3.20 (t, <i>J</i> = 6.0 Hz, 2H), 3.13 (s, 3H), 3.04 (s, 3H). <sup>13</sup>C NMR (126 MHz, MeOD) δ 184.21, 184.01, 169.84, 169.29, 160.67, 153.18, 142.07, 141.36, 138.65, 137.66, 130.04, 129.96, 129.72, 129.61, 128.26, 123.45, 119.19, 106.63, 48.25, 43.04, 42.48, 41.48, 39.37, 35.90. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>30</sub>O<sub>4</sub>N<sub>8</sub>ClS [M + H]<sup>+</sup>: 585.17938, found: 585.17836.</div></div><div id="sec5_6_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> <i>N</i>-(3-(((2-((4-(((2-((2-Aminoethyl)amino)-3,4-dioxocyclobut-1-en-1-yl)amino)methyl)phenyl)amino)-5-chloropyrimidin-4-yl)amino)methyl)phenyl)-<i>N</i>-methylmethanesulfonamide Trifluoroacetate Salt (<b>6e</b>)</h4><div class="NLM_p last">Pale solid, yield 100%. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.90 (s, 1H), 7.32–7.20 (m, 8H), 7.13 (dt, <i>J</i> = 7.6, 1.4 Hz, 1H), 4.68 (s, 2H), 4.62 (s, 2H), 3.77 (s, 2H), 3.70–3.66 (m, 1H), 3.12 (d, <i>J</i> = 5.4 Hz, 6H), 2.68 (s, 3H). HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>30</sub>O<sub>4</sub>N<sub>8</sub>ClS [M + H]<sup>+</sup>: 585.17938, found: 585.17886.</div></div><div id="sec5_6_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> 3-((2-Aminoethyl)amino)-4-((4-((5-chloro-4-((3-(methylsulfonyl)benzyl)amino)pyrimidin-2-yl)amino)benzyl)amino)cyclobut-3-ene-1,2-dione Trifluoroacetate Salt (<b>6f</b>)</h4><div class="NLM_p last">Pale solid, yield 100%. <sup>1</sup>H NMR (250 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.91–7.81 (m, 2H), 7.64–7.57 (m, 2H), 7.41–7.33 (m, 3H), 4.84–4.73 (m, 4H), 3.88 (t, <i>J</i> = 6.0 Hz, 2H), 3.20 (t, <i>J</i> = 6.0 Hz, 2H), 3.02 (s, 3H). HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>27</sub>O<sub>4</sub>N<sub>7</sub>ClS [M + H]<sup>+</sup>: 556.15283, found: 556.15204.</div></div><div id="sec5_6_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> 2-((2-((4-(((2-((2-Aminoethyl)amino)-3,4-dioxocyclobut-1-en-1-yl)amino)methyl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)-<i>N</i>-methylbenzamide Trifluoroacetate Salt (<b>6g</b>)</h4><div class="NLM_p last">White solid, yield 100%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.35 (s, 1H), 9.86 (s, 1H), 8.73 (q, <i>J</i> = 4.5 Hz, 1H), 8.43 (s, 1H), 8.13 (d, <i>J</i> = 7.2 Hz, 1H), 7.90 (s, 3H), 7.72 (dd, <i>J</i> = 7.9, 1.6 Hz, 2H), 7.63 (d, <i>J</i> = 8.1 Hz, 2H), 7.44 (t, <i>J</i> = 8.0 Hz, 1H), 7.24 (d, <i>J</i> = 8.2 Hz, 2H), 7.15 (td, <i>J</i> = 7.6, 1.2 Hz, 1H), 4.66 (s, 2H), 3.72 (q, <i>J</i> = 6.2 Hz, 2H), 3.02 (p, <i>J</i> = 5.9 Hz, 2H), 2.78 (d, <i>J</i> = 4.6 Hz, 3H).</div></div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> General Procedure for the Synthesis of Compounds <b>7a</b><sub><b>2</b></sub><b>–g</b></h3><div class="NLM_p">To an ice-cooled solution of appropriate amine trifluorocetate salt in dry DMF were added Et<sub>3</sub>N (or DIPEA) (5 equiv) and appropriate chloride (1.5 equiv) at 0°C. The mixture was stirred at room temperature for 12 h. The solvent was removed in vacuo, and the crude product was purified by column chromatography.</div><div id="sec5_7_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> 2-((5-Chloro-2-((4-(((2-((2-(2-chloroacetamido)ethyl)amino)-3,4-dioxocyclobut-1-en-1-yl)amino)methyl)phenyl)amino)pyrimidin-4-yl)amino)-<i>N</i>-methylbenzamide (<b>7a</b><sub><b>2</b></sub>)</h4><div class="NLM_p last">White solid, yield 32%, mp > 260 °C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.61 (s, 1H), 9.51 (s, 1H), 8.87–8.66 (m, 2H), 8.38 (t, <i>J</i> = 5.8 Hz, 1H), 8.22 (s, 1H), 7.75 (dd, <i>J</i> = 7.9, 1.6 Hz, 1H), 7.65 (d, <i>J</i> = 8.2 Hz, 2H), 7.46 (t, <i>J</i> = 7.9 Hz, 1H), 7.24 (dd, <i>J</i> = 8.6, 3.4 Hz, 2H), 7.13 (t, <i>J</i> = 7.5 Hz, 1H), 4.65 (s, 2H), 4.03 (s, 2H), 3.57 (s, 2H), 3.28 (p, <i>J</i> = 6.0, 5.5 Hz, 3H), 2.81 (d, <i>J</i> = 4.5 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 182.72, 182.47, 168.91, 168.13, 167.47, 166.35, 157.68, 155.00, 154.60, 139.53, 139.27, 131.45, 127.99, 127.89, 122.00, 121.47, 120.78, 119.86, 105.21, 46.53, 42.69, 42.60, 40.29, 26.34. HRMS (ESI) <i>m</i>/<i>z</i> calcd for [M + H]+ C<sub>27</sub>H<sub>27</sub>C<sub>l2</sub>N<sub>8</sub>O<sub>4</sub> 597.15323, found 597.15395.</div></div><div id="sec5_7_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> 2-((2-((4-(((2-((2-Acrylamidoethyl)amino)-3,4-dioxocyclobut-1-en-1-yl)amino)methyl)phenyl)amino)-5-chloropyrimidin-4-yl)amino)-<i>N</i>-methoxybenzamide (<b>7b</b>)</h4><div class="NLM_p last">White solid, yield 28%, mp 234 °C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.62 (d, <i>J</i> = 8.3 Hz, 1H), 8.20 (s, 1H), 7.60 (t, <i>J</i> = 7.0 Hz, 3H), 7.48 (t, <i>J</i> = 8.0 Hz, 1H), 7.23 (d, <i>J</i> = 8.1 Hz, 2H), 7.13 (t, <i>J</i> = 7.6 Hz, 1H), 6.23–6.04 (m, 2H), 5.59 (dd, <i>J</i> = 9.9, 2.2 Hz, 1H), 4.64 (s, 2H), 3.72 (s, 3H), 3.59 (s, 2H), 3.30 (t, <i>J</i> = 6.1 Hz, 2H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 182.77, 182.59, 168.24, 167.60, 166.18, 165.49, 157.82, 155.16, 154.95, 139.52, 138.98, 132.45, 132.15, 131.54, 128.09, 128.03, 125.88, 122.66, 122.19, 120.11, 119.48, 105.25, 63.67, 46.62, 42.96, 42.03. HRMS (ESI) <i>m</i>/<i>z</i> calcd for [M + H]<sup>+</sup>: C<sub>28</sub>H<sub>26</sub>ClN<sub>8</sub>O<sub>5</sub>, 589.17092, found: 589.17023.</div></div><div id="sec5_7_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> <i>N</i>-(2-((2-((4-((5-Chloro-4-((2-(<i>N</i>-methylmethylsulfonamido)benzyl)amino)pyrimidin-2-yl)amino)benzyl)amino)-3,4-dioxocyclobut-1-en-1-yl)amino)ethyl)acrylamide (<b>7c</b>)</h4><div class="NLM_p last">White solid, yield 56%, mp 219 °C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.22 (s, 1H), 8.26 (t, <i>J</i> = 5.6 Hz, 1H), 8.01 (s, 1H), 7.58 (t, <i>J</i> = 6.0 Hz, 1H), 7.55–7.51 (m, 1H), 7.46 (d, <i>J</i> = 8.1 Hz, 2H), 7.35 (dt, <i>J</i> = 5.5, 2.0 Hz, 2H), 7.30 (d, <i>J</i> = 5.5 Hz, 1H), 7.06 (d, <i>J</i> = 8.1 Hz, 2H), 6.19 (dd, <i>J</i> = 17.1, 10.1 Hz, 1H), 6.08 (dd, <i>J</i> = 17.1, 2.3 Hz, 1H), 5.59 (dd, <i>J</i> = 10.0, 2.3 Hz, 1H), 4.78 (t, <i>J</i> = 7.3 Hz, 2H), 4.58 (s, 2H), 3.73–3.53 (m, 2H), 3.31 (q, <i>J</i> = 5.8 Hz, 2H), 3.16 (s, 3H), 3.11 (s, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 182.61, 182.45, 167.94, 167.42, 164.98, 157.70, 152.82, 139.81, 139.55, 139.11, 131.54, 131.25, 128.36, 127.85, 127.79, 127.64, 127.00, 125.26, 118.56, 103.63, 46.42, 42.79, 40.27, 38.56, 35.92. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>29</sub>H<sub>32</sub>O<sub>5</sub>N<sub>8</sub>ClS [M + H]<sup>+</sup>: 639.18994, found: 639.18772.</div></div><div id="sec5_7_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> <i>N</i>-(2-((2-((4-((5-Chloro-4-((3-(<i>N</i>-methylmethylsulfonamido)benzyl)amino)pyrimidin-2-yl)amino)benzyl)amino)-3,4-dioxocyclobut-1-en-1-yl)amino)ethyl)acrylamide (<b>7d</b>)</h4><div class="NLM_p last">White solid, yield 61%, mp 153 °C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.22 (s, 1H), 8.26 (t, <i>J</i> = 6.0 Hz, 1H), 7.98 (s, 1H), 7.84 (t, <i>J</i> = 6.1 Hz, 1H), 7.59 (d, <i>J</i> = 8.2 Hz, 2H), 7.41 (s, 1H), 7.36 (t, <i>J</i> = 7.8 Hz, 1H), 7.30–7.25 (m, 2H), 7.16 (d, <i>J</i> = 8.2 Hz, 2H), 6.20 (dd, <i>J</i> = 17.1, 10.1 Hz, 1H), 6.09 (dd, <i>J</i> = 17.1, 2.3 Hz, 1H), 5.59 (dd, <i>J</i> = 10.0, 2.3 Hz, 1H), 4.63 (m, 4H), 3.59 (s, 2H), 3.32 (d, <i>J</i> = 6.2 Hz, 2H), 3.17 (s, 3H), 2.88 (s, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 182.65, 182.46, 168.00, 167.44, 165.05, 157.85, 157.40, 153.19, 141.64, 140.73, 139.98, 131.56, 131.23, 128.95, 127.79, 125.71, 125.31, 125.08, 124.56, 118.73, 103.64, 46.52, 43.34, 42.83, 37.79, 34.91. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>29</sub>H<sub>32</sub>O<sub>5</sub>N<sub>8</sub>ClS [M + H]<sup>+</sup>: 639.18994, found: 639.18925.</div></div><div id="sec5_7_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> <i>N</i>-(2-((2-((4-((5-Chloro-4-((3-(methylsulfonyl)benzyl)amino)pyrimidin-2-yl)amino)benzyl)amino)-3,4-dioxocyclobut-1-en-1-yl)amino)ethyl)acrylamide (<b>7e</b>)</h4><div class="NLM_p last">White solid, yield 65%, mp 198°C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.23 (s, 1H), 8.25 (t, <i>J</i> = 5.9 Hz, 1H), 7.99 (s, 1H), 7.94 (t, <i>J</i> = 6.2 Hz, 1H), 7.91 (s, 1H), 7.79 (d, <i>J</i> = 7.7 Hz, 1H), 7.68 (d, <i>J</i> = 7.7 Hz, 1H), 7.60 (t, <i>J</i> = 7.7 Hz, 1H), 7.54 (d, <i>J</i> = 8.1 Hz, 2H), 7.14 (d, <i>J</i> = 8.1 Hz, 2H), 6.24–6.03 (m, 2H), 5.58 (dd, <i>J</i> = 10.0, 2.3 Hz, 1H), 4.71 (d, <i>J</i> = 6.1 Hz, 2H), 4.66–4.54 (m, 2H), 3.58 (s, 2H), 3.31 (d, <i>J</i> = 6.0 Hz, 2H), 3.13 (s, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 182.63, 182.45, 167.99, 167.43, 165.00, 157.83, 157.36, 153.27, 141.32, 140.84, 139.87, 132.08, 131.55, 131.27, 129.38, 127.74, 125.33, 125.26, 125.10, 118.72, 103.60, 46.48, 43.44, 43.29, 42.80, 40.11. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>29</sub>O<sub>5</sub>N<sub>7</sub>ClS [M + H]<sup>+</sup>: 610.16449, found: 610.16272.</div></div><div id="sec5_7_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> <i>N</i>-(2-((2-((4-((5-Chloro-4-(((2-(<i>N</i>-methylmethylsulfonamido)pyridin-3-yl)methyl)amino)pyrimidin-2-yl)amino)benzyl)amino)-3,4-dioxocyclobut-1-en-1-yl)amino)ethyl)acrylamide (<b>7f</b>)</h4><div class="NLM_p last">White solid, yield 50%, mp 179 °C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.24 (s, 1H), 8.43 (d, <i>J</i> = 4.7 Hz, 1H), 8.26 (t, <i>J</i> = 5.8 Hz, 1H), 8.02 (s, 1H), 7.76–7.69 (m, 2H), 7.41 (dd, <i>J</i> = 12.6, 7.9 Hz, 3H), 7.04 (d, <i>J</i> = 8.2 Hz, 2H), 6.19 (dd, <i>J</i> = 17.1, 10.1 Hz, 1H), 6.08 (dd, <i>J</i> = 17.2, 2.3 Hz, 1H), 5.58 (dd, <i>J</i> = 10.0, 2.3 Hz, 1H), 4.76 (d, <i>J</i> = 5.9 Hz, 2H), 4.64–4.48 (m, 2H), 3.58 (s, 2H), 3.31 (q, <i>J</i> = 6.6, 6.2 Hz, 2H), 3.14 (s, 6H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 182.61, 182.46, 167.93, 167.41, 165.00, 157.74, 157.54, 152.68, 152.18, 147.30, 139.65, 137.13, 133.81, 131.54, 127.72, 125.27, 124.04, 118.64, 103.72, 46.40, 42.79, 40.11, 37.15, 35.98. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>29</sub>O<sub>5</sub>N<sub>9</sub>ClS [M – H]<sup>+</sup>: 638.16954, found: 638.16895.</div></div><div id="sec5_7_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> 2-((2-((4-(((2-((2-Acrylamidoethyl)amino)-3,4-dioxocyclobut-1-en-1-yl)amino)methyl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)-N-methylbenzamide (<b>7g</b>)</h4><div class="NLM_p last">White solid, yield 60%, mp 179 °C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.33 (s, 1H), 9.85 (s, 1H), 8.79–8.65 (m, 1H), 8.43 (s, 2H), 8.27 (s, 1H), 7.72 (d, <i>J</i> = 7.9 Hz, 1H), 7.63 (d, <i>J</i> = 8.1 Hz, 2H), 7.43 (t, <i>J</i> = 7.9 Hz, 1H), 7.24 (d, <i>J</i> = 8.1 Hz, 2H), 7.15 (t, <i>J</i> = 7.6 Hz, 1H), 6.27–6.00 (m, 2H), 5.58 (d, <i>J</i> = 10.2 Hz, 1H), 4.66 (s, 2H), 3.59 (s, 2H), 2.79 (d, <i>J</i> = 4.6 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 182.66, 182.52, 168.74, 168.06, 167.47, 165.02, 160.76, 156.12, 155.90, 138.58, 133.15, 131.54, 131.06, 127.80, 125.62, 125.27, 123.47, 123.09, 122.58, 122.08,120.74, 46.44, 42.81, 39.78, 26.20. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>29</sub>H<sub>28</sub>O<sub>4</sub>N<sub>8</sub>F<sub>3</sub> [M + H]<sup>+</sup>: 609.21856, found: 609.21967.</div></div><div id="sec5_7_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> 2-((5-Chloro-2-((4-(((2-((2-(2-cyanoacetamido)ethyl)amino)-3,4-dioxocyclobut-1-en-1-yl)amino)methyl)phenyl)amino)pyrimidin-4-yl)amino)-<i>N</i>-methylbenzamide (<b>8</b>)</h4><div class="NLM_p last">To an ice-cold solution of <b>6a</b> (500 mg, 0.67 mmol) in dry DMF (3 mL) was added DIPEA (700 μL, 4.01 mmol), EDCI (257 mg, 1.34 mmol), HOBt (181 mg, 1.34 mmol), followed by addition of cyanoacetic acid (114mg, 1.34 mmol). The mixture was continue stirred at 0 °C for 30 min, then stirred at room temperature overnight. The solvent was removed in vacuo, then the residue was purified though silica gel chromatography (elution: DCM/MeOH = 20/1–10/1) to give the final product as yellow solid (293 mg, 74%). Mp 258 °C, <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.61 (s, 1H), 9.49 (s, 1H), 8.74 (t, <i>J</i> = 5.9 Hz, 2H), 8.40 (t, <i>J</i> = 5.7 Hz, 1H), 8.22 (s, 1H), 7.76 (d, <i>J</i> = 7.8 Hz, 1H), 7.66 (d, <i>J</i> = 8.2 Hz, 2H), 7.47 (t, <i>J</i> = 7.9 Hz, 1H), 7.26 (d, <i>J</i> = 8.1 Hz, 2H), 7.14 (t, <i>J</i> = 7.6 Hz, 1H), 4.66 (s, 2H), 3.58 (s, 2H), 3.58–3.52 (m, 2H), 3.26 (q, <i>J</i> = 6.0 Hz, 2H), 2.82 (d, <i>J</i> = 4.4 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 182.71, 182.46, 168.87, 168.02, 167.49, 162.50, 157.66, 154.97, 154.58, 139.51, 139.25, 132.03, 131.40, 127.95, 127.88, 121.95, 121.44, 120.77, 119.85, 116.02, 105.18, 46.52, 42.63, 40.36, 26.30, 25.31. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>27</sub>O<sub>4</sub>N<sub>9</sub>Cl [M + H]<sup>+</sup>: 588.18745, found: 588.18890.</div></div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> General Procedure for the Synthesis of Compound <b>9a–c</b></h3><div class="NLM_p">To a solution of <b>8</b> (1 equiv) in a mixture of DMF and acetic acid (1:1) were added piperidine (1.5 equiv) and appropriate aldehyde (1.5 equiv). The solution was heated to 100 °C and stirred for 2 h. After being cooled to room temperature, the solvent was removed in vacuo. Subsequently, the residue was purified through silica gel chromatography to obtain the desired product as a solid.</div><div id="sec5_8_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> (<i>E</i>)-2-((5-Chloro-2-((4-(((2-((2-(2-cyanopent-2-enamido)ethyl)amino)-3,4-dioxocyclobut-1-en-1-yl)amino)methyl)phenyl)amino)pyrimidin-4-yl)amino)-<i>N</i>-methylbenzamide (<b>9a</b>)</h4><div class="NLM_p last">Beige solid, yield 34%, mp 194 °C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.61 (s, 1H), 9.49 (s, 1H), 8.80–8.68 (m, 2H), 8.46 (s, 1H), 8.22 (s, 1H), 7.76 (d, <i>J</i> = 7.9 Hz, 1H), 7.65 (d, <i>J</i> = 8.1 Hz, 2H), 7.47 (t, <i>J</i> = 7.9 Hz, 1H), 7.40 (t, <i>J</i> = 7.7 Hz, 1H), 7.25 (d, <i>J</i> = 8.1 Hz, 2H), 7.13 (t, <i>J</i> = 7.6 Hz, 1H), 4.66 (s, 2H), 3.61 (s, 2H), 3.38–3.34 (m, 2H), 2.82 (d, <i>J</i> = 4.5 Hz, 3H), 2.42 (q, <i>J</i> = 7.5 Hz, 2H), 1.24 (s, 1H), 1.06 (t, <i>J</i> = 7.5 Hz, 2H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 182.69, 182.45, 168.86, 168.14, 167.50, 160.68, 159.42, 157.66, 154.97, 154.57, 139.50, 139.24, 132.13, 131.38, 127.93, 127.81, 121.93, 121.42, 120.76, 119.83, 114.55, 111.26, 105.16, 46.50, 42.57, 40.67, 26.28, 24.77, 12.15. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>31</sub>H<sub>31</sub>O<sub>4</sub>N<sub>9</sub>Cl [M + H]<sup>+</sup>: 628.21875, found: 628.22015.</div></div><div id="sec5_8_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> (<i>E</i>)-2-((5-Chloro-2-((4-(((2-((2-(2-cyano-4-methylpent-2-enamido)ethyl)amino)-3,4-dioxocyclobut-1-en-1-yl)amino)methyl)phenyl)amino)pyrimidin-4-yl)amino)-<i>N</i>-methylbenzamide (<b>9b</b>)</h4><div class="NLM_p last">Beige solid, yield 63%, mp 236 °C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.60 (s, 1H), 9.47 (s, 1H), 8.87–8.65 (m, 2H), 8.46 (t, <i>J</i> = 5.8 Hz, 1H), 8.21 (s, 1H), 7.75 (d, <i>J</i> = 7.9 Hz, 1H), 7.65 (d, <i>J</i> = 8.1 Hz, 2H), 7.46 (t, <i>J</i> = 7.8 Hz, 1H), 7.25 (d, <i>J</i> = 7.9 Hz, 2H), 7.13 (t, <i>J</i> = 7.5 Hz, 1H), 4.66 (s, 2H), 3.60 (s, 2H), 3.37–3.33 (m, 2H), 2.81 (d, <i>J</i> = 4.5 Hz, 3H), 2.76 (dd, <i>J</i> = 8.2, 4.8 Hz, 1H), 1.68 (d, <i>J</i> = 19.8 Hz, 1H), 1.06 (d, <i>J</i> = 6.6 Hz, 5H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 182.69, 182.48, 168.87, 168.10, 167.52, 163.39, 160.78, 157.66, 154.97, 154.57, 139.51, 139.25, 132.10, 131.39, 127.94, 127.85, 127.81, 121.94, 121.43, 120.76, 119.83, 114.50, 109.75, 105.18, 46.51, 42.60, 40.70, 31.22, 26.29, 21.07. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>32</sub>H<sub>33</sub>O<sub>4</sub>N<sub>9</sub>Cl [M + H]<sup>+</sup>: 642.23440, found: 642.23553.</div></div><div id="sec5_8_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> (<i>E</i>)-2-((5-Chloro-2-((4-(((2-((2-(2-cyano-3-cyclopropylacrylamido)ethyl)amino)-3,4-dioxocyclobut-1-en-1-yl)amino)methyl)phenyl)amino)pyrimidin-4-yl)amino)-<i>N</i>-methylbenzamide (<b>9c</b>)</h4><div class="NLM_p last">Beige solid, yield 63%, mp 248 °C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.62 (s, 1H), 9.49 (s, 1H), 8.75 (q, <i>J</i> = 4.0 Hz, 2H), 8.28 (t, <i>J</i> = 5.7 Hz, 1H), 8.23 (s, 1H), 7.77 (dd, <i>J</i> = 8.0, 1.6 Hz, 1H), 7.66 (d, <i>J</i> = 8.1 Hz, 2H), 7.47 (t, <i>J</i> = 7.7 Hz, 1H), 7.26 (d, <i>J</i> = 8.3 Hz, 2H), 7.14 (t, <i>J</i> = 7.5 Hz, 1H), 6.90 (d, <i>J</i> = 11.1 Hz, 1H), 4.67 (s, 2H), 3.68–3.52 (m, 2H), 3.35 (d, <i>J</i> = 6.0 Hz, 2H), 2.82 (d, <i>J</i> = 4.5 Hz, 3H), 1.89 (dtt, <i>J</i> = 11.9, 7.9, 4.2 Hz, 1H), 1.22 (dt, <i>J</i> = 7.7, 3.7 Hz, 2H), 0.97–0.86 (m, 2H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 182.68, 182.47, 168.87, 168.12, 167.51, 163.97, 160.78, 157.66, 154.97, 154.57, 139.50, 139.24, 132.11, 131.38, 127.94, 127.81, 121.93, 121.43, 120.75, 119.83, 115.56, 107.48, 105.17, 46.50, 42.63, 40.63, 26.28, 15.37, 10.37. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>32</sub>H<sub>31</sub>O<sub>4</sub>N<sub>9</sub>Cl [M + H]<sup>+</sup>: 640.21875, found: 640.21960.</div></div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> In Vitro Kinase Assay and Kinetic Characterization and Reversibility of Thiol Addition</h3><div class="NLM_p">IC<sub>50</sub> determinations for FAK were carried out using an ADP-Glo kinase assay from Promega Corporation according to the manufacturer’s instructions and using GraphPad Prism (GraphPad Software, San Diego, CA). In this assay, FAK, FAK substrate, and ATP were set to 5 ng, 0.5 μg, and 8 μM, respectively, in each reaction well, which was mixed with different concentrations of the tested compounds in kinase reaction buffer (40 mM Tris, 20 mM MgCl<sub>2</sub>, 0.1 mg/mL BSA, 2 mM MnCl<sub>2</sub>, 2 μM DTT). After completion of the reaction for 1 h, the kinase reaction was stopped by the addition of ADP-Glo reagent (5 μL) and incubated at room temperature for 40 min. Finally, the luminescence signal was detected with an Enspire plate reader after the addition of kinase detection reagent (10 μL) and incubation at room temperature for 15–20 min.</div><div class="NLM_p">For kinetic characterization (<i>K</i><sub>i</sub>, <i>k</i><sub>inact</sub>), the selected compounds were preincubated with FAK during different periods of time (2–60 min). The duration of the incubation and stop reaction were kept constant as described above. IC<sub>50</sub> values were plotted versus incubation time, and data were calculated with XLfit (version 5.4.0.8; IDBS, Munich, Germany) as reported by Krippendorff et al. to obtain kinetic parameters.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a></div><div class="NLM_p last">For the reversibility of thiol addition, a solution of <b>7a</b><sub><b>1</b></sub> or <b>9c</b> (200 μM) and β-mercaptoethanol (100 mM) in ammonium acetate buffer (pH = 7.4) was incubated at 37 °C for 24 h. The reaction mixture was analyzed by LC–MS/MS. Then, it was diluted tenfold by the addition of ammonium acetate buffer and incubated at 37 °C. After 24 h, analysis of the solution was performed by LC–MS/MS.</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> FAK ELISA Assay</h3><div class="NLM_p last">U-87 MG cells were plated for each well in 24-well plates at 1 × 10<sup>4</sup> cells, incubated at 37 °C and 5% CO<sub>2</sub>, and treated with the inhibitors at different concentrations. After 48 h, cell lysates were prepared and adjusted to the same concentrations with extraction buffer (10 mM Tris (pH 7.4), 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM NaF, 20 mM Na<sub>4</sub>P<sub>2</sub>O<sub>7</sub>, 2 mM Na<sub>3</sub>VO<sub>4</sub>, 1% Triton X-100, 10% glycerol, 0.1% SDS, and 0.5% deoxycholate) with PMSF and protease inhibitor. According to the manufacturer’s instructions (Thermo Fisher Scientific), cell lysates and detection antibodies were added to each well except for the chromogen blanks and incubated for 3 h at room temperature. After washing four times with 1× wash buffer, the antirabbit IgG HRP-conjugated solution was added except for the chromogen blanks and incubated for 30 min at room temperature. We thoroughly aspirate the solution, washed the wells four times with 1× wash buffer, added 100 μL of stabilized Chromogen solution to each well, and read OD at 450 nm using a microplate reader. The levels of FAK phosphorylation were normalized by the levels of total FAK protein.</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> Cell Viability Assay</h3><div class="NLM_p last">Cell viability of glioblastomas cell lines (U-87 MG, A172, and U251) was evaluated by the MTT assay. Briefly, the cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM, 10567014, Gibco) containing 10% fetal bovine serum (FBS, Gibco). A total of 5000 cells were seeded for each well in 96-well culture plates, and the plates were kept in an incubator with 5% CO<sub>2</sub> at 37 °C for 12 h before the addition of 200 μL of medium containing different concentrations of compounds. After incubation for 48 h, the medium was replaced by 100 μL of fresh DMEM containing 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, 0.5 mg/mL at final concentration), and the cells were further incubated for 4 h. The optical density of each well was measured at 570 nm using a microplate reader. The data are expressed as the mean of three independent experiments. IC<sub>50</sub> values were calculated using GraphPad Prism (GraphPad Software, San Diego, CA).</div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> Apoptosis Determination</h3><div class="NLM_p last">U-87 MG cells were seeded in six-well culture plates at 2 × 10<sup>5</sup> cells. After 48 h incubation with the selected compounds, the adherent cells from each well were trypsinized, the collected cells were washed twice with PBS and centrifuged, and each pellet was resuspended. The treated cells were collected and incubated in Annexin V binding buffer with Annexin V-FITC and propidium iodide for 30 min at room temperature. The cells were then washed, resuspended in Annexin V binding buffer, and analyzed by flow cytometry on a BD LSR II (Becton Dickinson, San Jose, CA). Results were analyzed using FlowJo software (Treestar, Ashland, OR).</div></div><div id="sec5_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> Cell Cycle Analysis by Flow Cytometer</h3><div class="NLM_p last">U-87 MG cells were plated for each well in six-well culture plates at 2 × 10<sup>5</sup> cells, treated with the selected compounds, incubated for 48 h, and stained with 1 μg/mL propidium iodide. Cells were analyzed by a flow cytometer, and cell cycle distribution was determined using Dean–Jett–Fox methods on a FACS Calibur (Becton Dickinson, San Jose, CA).</div></div><div id="sec5_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> Scratch Assay</h3><div class="NLM_p last">U-87 MG cells were plated to confluence on six-well tissue culture dishes, and a single scratch was made in the confluent monolayer using a sterile 10 μL pipette tip. The monolayer was washed with PBS and added with medium containing either an inhibitor (0.2 and 1 μM) or DMSO. The images were captured during cell migration to close the scratch at the beginning and after 24 and 48 h.</div></div><div id="sec5_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> Immunocytochemistry and Confocal Microscopy</h3><div class="NLM_p last">U-87 MG cells were seeded at 2 × 10<sup>5</sup> cells on the coverslips. After 48 h incubation with the selected compounds, cells were fixed with 4% paraformaldehyde for 20 min, permeabilized with 0.2% Triton X-100 for 3 min at room temperature, and then washed with PBS. The cells were incubated in a blocking solution (PBS–glycine 0.3 M–bovine serum albumin 1%) for 1 h and then incubated with the primary antibody paxillin (Abcam Ab32084) in PBS for 1 h 30 min at room temperature. After washing with PBS-T (PBS containing 0.1% Tween-20), the cells were incubated with a second antibody conjugated with a fluorescent dye for 1 h at room temperature. For the staining of actin and nucleus, FITC-conjugated phalloidin and TO-PRO-3 (Invitrogen) were included during the incubation with the secondary antibody. The coverslips were sealed with Dako Faramount Aqueous Mounting Medium Ready-to-Use Medium (Invitrogen), and images recorded using a Zeiss LSM 510 confocal microscope (Carl Zeiss Meditec France SAS, Le Pecq, France) using a 40 Plan-Neofluar 1.3 NA oil objective and LSM Image Browser (Zeiss).</div></div><div id="sec5_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> Western Blot Analysis</h3><div class="NLM_p">U-87 MG cells were seeded in six-well plates at 1 × 10<sup>5</sup> cells/well and cultured in the incubator for 24 h before the culture medium was replaced by DMEM with 10% FBS containing compounds at 0,1 0.5, 1, 5, and 10 μM. The cells were incubated with different concentrations of compounds for 48 h. For washout experiments, PBS was used to wash the cells and then the cells were cultured for 3 h with a fresh culture medium.</div><div class="NLM_p last">Cells were collected, washed twice with ice-cold PBS, and lysed for 20 min in 100 μL of ice-cold cell lysis buffer (P0013B, Beyotime Biotechnology, China) containing 1 mM phenylmethanesulfonyl fluoride (ST506, Beyotime Biotechnology, China) and 2% phosphatase inhibitor (P1081, Beyotime Biotechnology, China). Cell lysates from the cytoplasm and nucleus were centrifuged at 12000<i>g</i> for 10 min, and the protein content was determined by the BCA Protein Assay Kit (23225, Thermo Fisher Scientific, China). After adding load buffer and incubating in a 95 °C water bath for 7 min, 10 mg of total protein from each sample was loaded to 8% polyacrylamide gels and transferred to PVDF membranes. The membranes were blocked with 5% BSA in TBS/0.05% Tween-20 (TBST) for 2 h and incubated with FAK (ab40794, Abcam), p-FAK (Tyr397) (ab81298, Abcam), Akt (4691, Cell Signaling Technology), p-Akt (Ser 473) (9271, Cell Signaling Technology), Erk1/2 (4695, Cell Signaling Technology), p-Erk1/2 (Thr202/Tyr204) (4377, Cell Signaling Technology), NF-κB (ab32536, Abcam), p-NF-κB (ab76032, Abcam), and β-actin (T0022, Affinity) primary antibodies overnight. Blots were washed with TBST and incubated with goat antirabbit IgG (H+L) HRP (S0001, Affinity) or goat antimouse IgG (H+L) HRP (IH-0031, Beijing DingGuo ChangSheng Biotechnology) secondary antibody. Finally, the blots were washed with TBST and visualized with the Immobilon Western Chemiluminescent HRP Substrate (WBKLS0100, Millipore) on a Chemiluminescence imaging system (P&Q Science and Technology, China).</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i81"><a href="/doi/suppl/10.1021/acs.jmedchem.0c01059" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03126" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03126" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c01059?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01059</a>.<ul class="NLM_list-list_type-label"><li><p class="inline">Kinetic mechanism for two-step covalent inhibition of FAK, molecular docking, intermediate synthesis, ion chromatograms obtained by QTRAP-MS, cell cycle distribution, HPLC purity of final compounds, and <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra of final compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01059/suppl_file/jm0c01059_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular string files for all of the final target compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01059/suppl_file/jm0c01059_si_002.csv" class="ext-link">CSV</a>)</p></li></ul><ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">(<a href="/doi/suppl/10.1021/acs.jmedchem.0c01059/suppl_file/jm0c01059_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">(<a href="/doi/suppl/10.1021/acs.jmedchem.0c01059/suppl_file/jm0c01059_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01059/suppl_file/jm0c01059_si_001.pdf">jm0c01059_si_001.pdf (1.22 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01059/suppl_file/jm0c01059_si_002.csv">jm0c01059_si_002.csv (1.66 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01059" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62381" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62381" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Huixiong Chen</span> - <span class="hlFld-Affiliation affiliation">Chemistry
of RNA, Nucleosides, Peptides and Heterocycles, CNRS UMR8601, Université
de Paris, 45 rue des
Saints-Pères, 75006 Paris, France</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7676-1584" title="Orcid link">http://orcid.org/0000-0001-7676-1584</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#b4dcc1ddccdddbdad39ad7dcd1daf494c4d5c6ddc7d0d1c7d7d5c6c0d1c79ad2c6"><span class="__cf_email__" data-cfemail="adc5d8c4d5c4c2c3ca83cec5c8c3ed">[email protected]</span> parisdescartes.fr</a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bo Li</span> - <span class="hlFld-Affiliation affiliation">Chemistry
of RNA, Nucleosides, Peptides and Heterocycles, CNRS UMR8601, Université
de Paris, 45 rue des
Saints-Pères, 75006 Paris, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yongliang Li</span> - <span class="hlFld-Affiliation affiliation">School
of Chemical Engineering and Light Industry, Guangdong University of Technology, No. 100 Waihuan Xi Road, Education Mega Center, Guangzhou 510006, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Céline Tomkiewicz-Raulet</span> - <span class="hlFld-Affiliation affiliation">Toxicologie,
Pharmacologie et Signalisation Cellulaire, INSERM, UMR S 1124, Université
de Paris, 45 rue des
Saints-Pères, 75006 Paris, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pascal Dao</span> - <span class="hlFld-Affiliation affiliation">Université
Côte d’Azur, CNRS, Institut de Chimie de Nice UMR7272, 06108 Nice, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniel Lietha</span> - <span class="hlFld-Affiliation affiliation">Cell
Signalling and Adhesion Group, Structural and Chemical Biology, Biological
Research Center (CIB), Spanish National
Research Council (CSIC), Calle Ramiro de Maeztu, Madrid 28040, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Expédite Yen-Pon</span> - <span class="hlFld-Affiliation affiliation">Chemistry
of RNA, Nucleosides, Peptides and Heterocycles, CNRS UMR8601, Université
de Paris, 45 rue des
Saints-Pères, 75006 Paris, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhiyun Du</span> - <span class="hlFld-Affiliation affiliation">School
of Chemical Engineering and Light Industry, Guangdong University of Technology, No. 100 Waihuan Xi Road, Education Mega Center, Guangzhou 510006, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xavier Coumoul</span> - <span class="hlFld-Affiliation affiliation">Toxicologie,
Pharmacologie et Signalisation Cellulaire, INSERM, UMR S 1124, Université
de Paris, 45 rue des
Saints-Pères, 75006 Paris, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christiane Garbay</span> - <span class="hlFld-Affiliation affiliation">Chemistry
of RNA, Nucleosides, Peptides and Heterocycles, CNRS UMR8601, Université
de Paris, 45 rue des
Saints-Pères, 75006 Paris, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mélanie Etheve-Quelquejeu</span> - <span class="hlFld-Affiliation affiliation">Chemistry
of RNA, Nucleosides, Peptides and Heterocycles, CNRS UMR8601, Université
de Paris, 45 rue des
Saints-Pères, 75006 Paris, France</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e5686-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i82">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64568" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64568" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We gratefully thank the support from La Ligue contre le cancer, Paris Ile-de-France. B.L. thanks to the China Scholarship Council (CSC) for financial support. Y.L. thanks the support from the National Natural Science Foundation of China (Grants 21672043). D.L. acknowledges support from the Spanish Ministry of Economy, Industry and Competitiveness for the Retos Grant BFU2016-77665-R and the Ministry of Science, Innovation and Universities for the Spanish State Research Agency Retos Grant RTI2018-099318-B-I00, both cofunded by the European Regional Development Fund (FEDER).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">GBM</td><td class="NLM_def"><p class="first last">glioblastoma</p></td></tr><tr><td class="NLM_term">FAK</td><td class="NLM_def"><p class="first last">focal adhesion kinase</p></td></tr><tr><td class="NLM_term">GSC</td><td class="NLM_def"><p class="first last">glioblastoma stem cell</p></td></tr><tr><td class="NLM_term">ECM</td><td class="NLM_def"><p class="first last">epithelial–mesenchymal transition</p></td></tr><tr><td class="NLM_term">CSC</td><td class="NLM_def"><p class="first last">cancer stem cell</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N,N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">PG</td><td class="NLM_def"><p class="first last">protecting group</p></td></tr><tr><td class="NLM_term">EDCI</td><td class="NLM_def"><p class="first last"><i>N</i>-(3-dimethylaminopropyl)-<i>N</i>′-ethylcarbodiimide hydrochloride</p></td></tr><tr><td class="NLM_term">HOBT</td><td class="NLM_def"><p class="first last">1-hydroxybenzotriazole hydrate</p></td></tr><tr><td class="NLM_term">c-Src</td><td class="NLM_def"><p class="first last">proto-oncogene tyrosine-protein kinase Src</p></td></tr><tr><td class="NLM_term">FGFR1</td><td class="NLM_def"><p class="first last">fibroblast growth factor receptor 1</p></td></tr><tr><td class="NLM_term">IGF1R</td><td class="NLM_def"><p class="first last">insulin-like growth factor 1 receptor</p></td></tr><tr><td class="NLM_term">PDGFR</td><td class="NLM_def"><p class="first last">platelet-derived growth factor receptor</p></td></tr><tr><td class="NLM_term">IR</td><td class="NLM_def"><p class="first last">insulin receptor</p></td></tr><tr><td class="NLM_term">Akt</td><td class="NLM_def"><p class="first last">protein kinase B</p></td></tr><tr><td class="NLM_term">Erk</td><td class="NLM_def"><p class="first last">extracellular signal-regulated kinase</p></td></tr><tr><td class="NLM_term">Pyk2</td><td class="NLM_def"><p class="first last">proline-rich tyrosine kinase 2</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i84">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33705" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33705" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 45 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butowski, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, S.</span></span> <span> </span><span class="NLM_article-title">Recent advances in therapy for glioblastoma</span>. <i>Arch. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">279</span>– <span class="NLM_lpage">283</span>, <span class="refDoi"> DOI: 10.1001/archneurol.2010.5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1001%2Farchneurol.2010.5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=20212224" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A280%3ADC%252BC3c7ms1yhsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2010&pages=279-283&author=J.+Clarkeauthor=N.+Butowskiauthor=S.+Chang&title=Recent+advances+in+therapy+for+glioblastoma&doi=10.1001%2Farchneurol.2010.5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in therapy for glioblastoma</span></div><div class="casAuthors">Clarke Jennifer; Butowski Nicholas; Chang Susan</div><div class="citationInfo"><span class="NLM_cas:title">Archives of neurology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">279-83</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Glioblastoma is the most common primary malignant brain tumor in adults and is a challenging disease to treat.  The current standard of care includes maximal safe surgical resection, followed by a combination of radiation and chemotherapy with temozolomide.  Despite that, recurrence is quite common, and so we continue to search for more effective treatments both for initial therapy and at the time of recurrence.  This article will review recent advances in therapy for glioblastoma, including surgery, radiotherapy, cytotoxic chemotherapies, molecularly targeted agents, and immunotherapy; the role of antiangiogenic agents in the treatment of glioblastoma is discussed in a separate article in this issue of the Archives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSGJ5vxZEjTdkwlCcfExbvbfW6udTcc2eZzQxLAZ0aznbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c7ms1yhsA%253D%253D&md5=ac2c3e292cb0f821f4a843235426b4c9</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1001%2Farchneurol.2010.5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchneurol.2010.5%26sid%3Dliteratum%253Aachs%26aulast%3DClarke%26aufirst%3DJ.%26aulast%3DButowski%26aufirst%3DN.%26aulast%3DChang%26aufirst%3DS.%26atitle%3DRecent%2520advances%2520in%2520therapy%2520for%2520glioblastoma%26jtitle%3DArch.%2520Neurol.%26date%3D2010%26volume%3D67%26spage%3D279%26epage%3D283%26doi%3D10.1001%2Farchneurol.2010.5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grobben, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Deyn, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slegers, H.</span></span> <span> </span><span class="NLM_article-title">Rat C6 glioma as experimental model system for the study of glioblastoma growth and invasion</span>. <i>Cell Tissue Res.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>310</i></span>,  <span class="NLM_fpage">257</span>– <span class="NLM_lpage">270</span>, <span class="refDoi"> DOI: 10.1007/s00441-002-0651-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1007%2Fs00441-002-0651-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=12457224" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BD3sXos1Cruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=310&publication_year=2002&pages=257-270&author=B.+Grobbenauthor=P.+P.+De+Deynauthor=H.+Slegers&title=Rat+C6+glioma+as+experimental+model+system+for+the+study+of+glioblastoma+growth+and+invasion&doi=10.1007%2Fs00441-002-0651-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Rat C6 glioma as experimental model system for the study of glioblastoma growth and invasion</span></div><div class="casAuthors">Grobben, Bert; De Deyn, Peter Paul; Slegers, Herman</div><div class="citationInfo"><span class="NLM_cas:title">Cell & Tissue Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">310</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">257-270</span>CODEN:
                <span class="NLM_cas:coden">CTSRCS</span>;
        ISSN:<span class="NLM_cas:issn">0302-766X</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">A review.  Infiltration of the central nervous system by neoplastic cells in patients with glioblastoma multiforme (GBM) leads to neurol. dysfunction and eventually to death.  The elucidation of the mechanisms underlying the aggressive nature of GBM aims at improving radio-, chemo- and gene therapy.  This review is focused on the use of rat C6 glioma as an exptl. model system for GBM and provides an overview of the exptl. data published in the literature using this cell line in elucidating the mechanism of tumor growth, angiogenesis and invasion, and in the design and evaluation of anticancer therapies.  Understanding the stages of malignant brain tumor progression requires a series of exptl. approaches with a varying degree of complexity.  Implantation of malignant cells into animal brain tissue closely resembles in vivo tumor growth and has the advantage over simplified models that inflammatory and vascular mechanisms are activated.  However, the complexity of these models makes it difficult to identify the individual processes involved in sustained tumor growth, angiogenesis and invasion.  In cell culture models, the effect of growth factors, extracellular matrix components, proteases and adhesion mols. can be investigated.  The secretion of tumor-derived factors into the medium can also be analyzed when simplified models are used.  This review is a compilation of exptl. data focused on the characterization of tumor-related processes and on the evaluation of new therapies for the treatment of malignant glial neoplasms using rat C6 glioma as a model system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVhBTbKj6JnbVg90H21EOLACvtfcHk0lg5sx8sk-MIGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXos1Cruw%253D%253D&md5=e3745b59b0a152ded9784a09647d47cb</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1007%2Fs00441-002-0651-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00441-002-0651-7%26sid%3Dliteratum%253Aachs%26aulast%3DGrobben%26aufirst%3DB.%26aulast%3DDe%2BDeyn%26aufirst%3DP.%2BP.%26aulast%3DSlegers%26aufirst%3DH.%26atitle%3DRat%2520C6%2520glioma%2520as%2520experimental%2520model%2520system%2520for%2520the%2520study%2520of%2520glioblastoma%2520growth%2520and%2520invasion%26jtitle%3DCell%2520Tissue%2520Res.%26date%3D2002%26volume%3D310%26spage%3D257%26epage%3D270%26doi%3D10.1007%2Fs00441-002-0651-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Furnari, F. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenton, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachoo, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukasa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stommel, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stegh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligon, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louis, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DePinho, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavenee, W. K.</span></span> <span> </span><span class="NLM_article-title">Malignant astrocytic glioma: genetics, biology, and paths to treatment</span>. <i>Genes Dev.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2683</span>– <span class="NLM_lpage">2710</span>, <span class="refDoi"> DOI: 10.1101/gad.1596707</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1101%2Fgad.1596707" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=17974913" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlSitLrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=2683-2710&author=F.+B.+Furnariauthor=T.+Fentonauthor=R.+M.+Bachooauthor=A.+Mukasaauthor=J.+M.+Stommelauthor=A.+Steghauthor=W.+C.+Hahnauthor=K.+L.+Ligonauthor=D.+N.+Louisauthor=C.+Brennanauthor=L.+Chinauthor=R.+A.+DePinhoauthor=W.+K.+Cavenee&title=Malignant+astrocytic+glioma%3A+genetics%2C+biology%2C+and+paths+to+treatment&doi=10.1101%2Fgad.1596707"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Malignant astrocytic glioma: genetics, biology, and paths to treatment</span></div><div class="casAuthors">Furnari, Frank B.; Fenton, Tim; Bachoo, Robert M.; Mukasa, Akitake; Stommel, Jayne M.; Stegh, Alexander; Hahn, William C.; Ligon, Keith L.; Louis, David N.; Brennan, Cameron; Chin, Lynda; DePinho, Ronald A.; Cavenee, Webster K.</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Development</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2683-2710</span>CODEN:
                <span class="NLM_cas:coden">GEDEEP</span>;
        ISSN:<span class="NLM_cas:issn">0890-9369</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">A review.  Malignant astrocytic gliomas such as glioblastoma are the most common and lethal intracranial tumors.  These cancers exhibit a relentless malignant progression characterized by widespread invasion throughout the brain, resistance to traditional and newer targeted therapeutic approaches, destruction of normal brain tissue, and certain death.  The recent confluence of advances in stem cell biol., cell signaling, genome and computational science and genetic model systems have revolutionized our understanding of the mechanisms underlying the genetics, biol. and clin. behavior of glioblastoma.  This progress is fueling new opportunities for understanding the fundamental basis for development of this devastating disease and also novel therapies that, for the first time, portend meaningful clin. responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDlfTN9OqeLLVg90H21EOLACvtfcHk0lg5sx8sk-MIGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlSitLrO&md5=5b89b311117f70e3708194afa9165414</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1101%2Fgad.1596707&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.1596707%26sid%3Dliteratum%253Aachs%26aulast%3DFurnari%26aufirst%3DF.%2BB.%26aulast%3DFenton%26aufirst%3DT.%26aulast%3DBachoo%26aufirst%3DR.%2BM.%26aulast%3DMukasa%26aufirst%3DA.%26aulast%3DStommel%26aufirst%3DJ.%2BM.%26aulast%3DStegh%26aufirst%3DA.%26aulast%3DHahn%26aufirst%3DW.%2BC.%26aulast%3DLigon%26aufirst%3DK.%2BL.%26aulast%3DLouis%26aufirst%3DD.%2BN.%26aulast%3DBrennan%26aufirst%3DC.%26aulast%3DChin%26aufirst%3DL.%26aulast%3DDePinho%26aufirst%3DR.%2BA.%26aulast%3DCavenee%26aufirst%3DW.%2BK.%26atitle%3DMalignant%2520astrocytic%2520glioma%253A%2520genetics%252C%2520biology%252C%2520and%2520paths%2520to%2520treatment%26jtitle%3DGenes%2520Dev.%26date%3D2007%26volume%3D21%26spage%3D2683%26epage%3D2710%26doi%3D10.1101%2Fgad.1596707" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ziegler, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kieran, M. W.</span></span> <span> </span><span class="NLM_article-title">Anti-apoptosis mechanisms inmalignant gliomas</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">493</span>– <span class="NLM_lpage">500</span>, <span class="refDoi"> DOI: 10.1200/JCO.2007.13.9717</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1200%2FJCO.2007.13.9717" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=18202424" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitVGnu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=493-500&author=D.+S.+Zieglerauthor=A.+L.+Kungauthor=M.+W.+Kieran&title=Anti-apoptosis+mechanisms+inmalignant+gliomas&doi=10.1200%2FJCO.2007.13.9717"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-apoptosis mechanisms in malignant gliomas</span></div><div class="casAuthors">Ziegler, David S.; Kung, Andrew L.; Kieran, Mark W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">493-500</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  Malignant gliomas are characterized by an intrinsic resistance to apoptosis.  Increasing evidence suggests that this is a fundamental mechanism by which gliomas evade elimination when treated with both conventional and targeted therapies.  In this review, we describe the multiple anti-apoptotic signals that have been demonstrated to be active in malignant gliomas.  We describe the preclin. evidence that suggests that targeting those signaling anomalies can increase tumor responsiveness and enhance the elimination of gliomas in preclin. models.  We discuss recent advances in translating pro-apoptotic compds. to clin. trial, and the potential for implementing agents that target the apoptotic pathway as a strategy for improving the outcomes for patients with high-grade gliomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqbiNBLFKEN7Vg90H21EOLACvtfcHk0ljAcPQJtthF_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitVGnu7w%253D&md5=5019f2250e3b46e1e969573d2dc34985</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1200%2FJCO.2007.13.9717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2007.13.9717%26sid%3Dliteratum%253Aachs%26aulast%3DZiegler%26aufirst%3DD.%2BS.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DKieran%26aufirst%3DM.%2BW.%26atitle%3DAnti-apoptosis%2520mechanisms%2520inmalignant%2520gliomas%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26spage%3D493%26epage%3D500%26doi%3D10.1200%2FJCO.2007.13.9717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garnier, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renoult, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alves-Guerra, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paris, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pecqueur, C.</span></span> <span> </span><span class="NLM_article-title">Glioblastoma stem-like cells, metabolic strategy to kill a challenging target</span>. <i>Front Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">118</span> <span class="refDoi"> DOI: 10.3389/fonc.2019.00118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.3389%2Ffonc.2019.00118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=30895167" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A280%3ADC%252BB3cbmsFSjuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&author=D.+Garnierauthor=O.+Renoultauthor=M.+C.+Alves-Guerraauthor=F.+Parisauthor=C.+Pecqueur&title=Glioblastoma+stem-like+cells%2C+metabolic+strategy+to+kill+a+challenging+target&doi=10.3389%2Ffonc.2019.00118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Glioblastoma Stem-Like Cells, Metabolic Strategy to Kill a Challenging Target</span></div><div class="casAuthors">Garnier Delphine; Renoult Ophelie; Paris Francois; Pecqueur Claire; Alves-Guerra Marie-Clotilde; Alves-Guerra Marie-Clotilde; Paris Francois; Pecqueur Claire</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">118</span>
        ISSN:<span class="NLM_cas:issn">2234-943X</span>.
    </div><div class="casAbstract">Over the years, substantial evidence has definitively confirmed the existence of cancer stem-like cells within tumors such as Glioblastoma (GBM).  The importance of Glioblastoma stem-like cells (GSCs) in tumor progression and relapse clearly highlights that cancer eradication requires killing of GSCs that are intrinsically resistant to conventional therapies as well as eradication of the non-GSCs cells since GSCs emergence relies on a dynamic process.  The past decade of research highlights that metabolism is a significant player in tumor progression and actually might orchestrate it.  The growing interest in cancer metabolism reprogrammation can lead to innovative approaches exploiting metabolic vulnerabilities of cancer cells.  These approaches are challenging since they require overcoming the compensatory and adaptive responses of GSCs.  In this review, we will summarize the current knowledge on GSCs with a particular focus on their metabolic complexity.  We will also discuss potential approaches targeting GSCs metabolism to potentially improve clinical care.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSAjc-w0X6rAQMthz5_Rx5rfW6udTcc2eYKj14lyg2es7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbmsFSjuw%253D%253D&md5=59b1174ee9c9111d87016d158f1ff0c1</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2019.00118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2019.00118%26sid%3Dliteratum%253Aachs%26aulast%3DGarnier%26aufirst%3DD.%26aulast%3DRenoult%26aufirst%3DO.%26aulast%3DAlves-Guerra%26aufirst%3DM.%2BC.%26aulast%3DParis%26aufirst%3DF.%26aulast%3DPecqueur%26aufirst%3DC.%26atitle%3DGlioblastoma%2520stem-like%2520cells%252C%2520metabolic%2520strategy%2520to%2520kill%2520a%2520challenging%2520target%26jtitle%3DFront%2520Oncol.%26date%3D2019%26volume%3D9%26doi%3D10.3389%2Ffonc.2019.00118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Djedid, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiss, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefranc, F.</span></span> <span> </span><span class="NLM_article-title">Targeted therapy of glioblastomas: a 5 year view</span>. <i>Therapy</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">351</span>– <span class="NLM_lpage">370</span>, <span class="refDoi"> DOI: 10.2217/thy.09.12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.2217%2Fthy.09.12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlvF2lsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2009&pages=351-370&author=R.+Djedidauthor=R.+Kissauthor=F.+Lefranc&title=Targeted+therapy+of+glioblastomas%3A+a+5+year+view&doi=10.2217%2Fthy.09.12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted therapy of glioblastomas: a 5-year view</span></div><div class="casAuthors">Djedid, Ryad; Kiss, Robert; Lefranc, Florence</div><div class="citationInfo"><span class="NLM_cas:title">Therapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">351-370</span>CODEN:
                <span class="NLM_cas:coden">THERCR</span>;
        ISSN:<span class="NLM_cas:issn">1475-0708</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  The treatment of glioblastomas requires a multidisciplinary approach that takes the presently incurable nature of the disease into consideration.  Treatments are multimodal and include surgery, radiotherapy and chemotherapy.  Current recommendations are that patients with glioblastoma should undergo max. surgical resection followed by concurrent radiation and chemotherapy with the novel alkylating drug temozolomide, followed subsequently by addnl. adjuvant temozolomide for a period of up to 6 mo.  We describe here the major signaling pathways that can be constitutively activated in migrating glioma cells, and which render these cells resistant to pro-apoptotic insults such as conventional chemotherapies.  In light of this resistance, we therefore describe the mol. therapies and local drug delivery systems that could be used to complement conventional treatments.  We have reviewed more than 400 ongoing clin. trials with respect to these new targeted therapy approaches alone or in combination for glioblastoma therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC0RlzsP6hxLVg90H21EOLACvtfcHk0ljAcPQJtthF_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlvF2lsL4%253D&md5=3f13563fc0e2d1bf80fdfc7b012b8039</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.2217%2Fthy.09.12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Fthy.09.12%26sid%3Dliteratum%253Aachs%26aulast%3DDjedid%26aufirst%3DR.%26aulast%3DKiss%26aufirst%3DR.%26aulast%3DLefranc%26aufirst%3DF.%26atitle%3DTargeted%2520therapy%2520of%2520glioblastomas%253A%2520a%25205%2520year%2520view%26jtitle%3DTherapy%26date%3D2009%26volume%3D6%26spage%3D351%26epage%3D370%26doi%3D10.2217%2Fthy.09.12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stupp, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Den Bent, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taphoorn, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belanger, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandes, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marosi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogdahn, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curschmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janzer, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwin, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorlia, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allgeier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacombe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cairncross, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenhauer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirimanoff, R. O.</span></span> <span> </span><span class="NLM_article-title">Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>352</i></span>,  <span class="NLM_fpage">987</span>– <span class="NLM_lpage">996</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa043330</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1056%2FNEJMoa043330" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=15758009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BD2MXit1Wksbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=987-996&author=R.+Stuppauthor=W.+P.+Masonauthor=M.+J.+Van+Den+Bentauthor=M.+Wellerauthor=B.+Fisherauthor=M.+J.+Taphoornauthor=K.+Belangerauthor=A.+A.+Brandesauthor=C.+Marosiauthor=U.+Bogdahnauthor=J.+Curschmannauthor=R.+C.+Janzerauthor=S.+K.+Ludwinauthor=T.+Gorliaauthor=A.+Allgeierauthor=D.+Lacombeauthor=J.+G.+Cairncrossauthor=E.+Eisenhauerauthor=R.+O.+Mirimanoff&title=Radiotherapy+plus+concomitant+and+adjuvant+temozolomide+for+glioblastoma&doi=10.1056%2FNEJMoa043330"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma</span></div><div class="casAuthors">Stupp, Roger; Mason, Warren P.; van den Bent, Martin J.; Weller, Michael; Fisher, Barbara; Taphoorn, Martin J. B.; Belanger, Karl; Brandes, Alba A.; Marosi, Christine; Bogdahn, Ulrich; Curschmann, Jurgen; Janzer, Robert C.; Ludwin, Samuel K.; Gorlia, Thierry; Allgeier, Anouk; Lacombe, Denis; Cairncross, J. Gregory; Eisenhauer, Elizabeth; Mirimanoff, Rene O.; Forsyth, P.; Fulton, D.; Kirby, S.; Wong, R.; Fenton, D.; Fisher, B.; Cairncross, G.; Whitlock, P.; Belanger, K.; Burdette-Radoux, S.; Gertler, S.; Saunders, S.; Laing, K.; Siddiqui, J.; Martin, L. A.; Gulavita, S.; Perry, J.; Mason, W.; Thiessen, B.; Pai, H.; Alam, Z. Y.; Eisenstat, D.; Mingrone, W.; Hofer, S.; Pesce, G.; Curschmann, J.; Dietrich, P. Y.; Stupp, R.; Mirimanoff, R. O.; Thum, P.; Baumert, B.; Ryan, G.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">987-996</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Glioblastoma, the most common primary brain tumor in adults, is usually rapidly fatal.  The current std. of care for newly diagnosed glioblastoma is surgical resection to the extent feasible, followed by adjuvant radiotherapy.  In this trial we compared radiotherapy alone with radiotherapy plus temozolomide, given concomitantly with and after radiotherapy, in terms of efficacy and safety.  METHODS Patients with newly diagnosed, histol. confirmed glioblastoma were randomly assigned to receive radiotherapy alone (fractionated focal irradn. in daily fractions of 2 Gy given 5 days per wk for 6 wk, for a total of 60 Gy) or radiotherapy plus continuous daily temozolomide (75 mg per square meter of body-surface area per day, 7 days per wk from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28-day cycle).  The primary end point was overall survival.  RESULTS A total of 573 patients from 85 centers underwent randomization.  The median age was 56 years, and 84 % of patients had undergone debulking surgery.  At a median follow-up of 28 mo, the median survival was 14.6 mo with radiotherapy plus temozolomide and 12.1 mo with radiotherapy alone.  The unadjusted hazard ratio for death in the radiotherapy-plus-temozolomide group was 0.63 (95 % confidence interval, 0.52 to 0.75; P<0.001 by the log-rank test).  The two-year survival rate was 26.5 % with radiotherapy plus temozolomide and 10.4 % with radiotherapy alone.  Concomitant treatment with radiotherapy plus temozolomide resulted in grade 3 or 4 hematol. toxic effects in 7 % of patients.  Conclusions The addn. of temozolomide to radiotherapy for newly diagnosed glioblastoma resulted in a clin. meaningful and statistically significant survival benefit with minimal addnl. toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdNLD2mISWE7Vg90H21EOLACvtfcHk0ljnzUvarYGgNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXit1Wksbk%253D&md5=28546eb2e78f7346974d7d029c9fa916</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa043330&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa043330%26sid%3Dliteratum%253Aachs%26aulast%3DStupp%26aufirst%3DR.%26aulast%3DMason%26aufirst%3DW.%2BP.%26aulast%3DVan%2BDen%2BBent%26aufirst%3DM.%2BJ.%26aulast%3DWeller%26aufirst%3DM.%26aulast%3DFisher%26aufirst%3DB.%26aulast%3DTaphoorn%26aufirst%3DM.%2BJ.%26aulast%3DBelanger%26aufirst%3DK.%26aulast%3DBrandes%26aufirst%3DA.%2BA.%26aulast%3DMarosi%26aufirst%3DC.%26aulast%3DBogdahn%26aufirst%3DU.%26aulast%3DCurschmann%26aufirst%3DJ.%26aulast%3DJanzer%26aufirst%3DR.%2BC.%26aulast%3DLudwin%26aufirst%3DS.%2BK.%26aulast%3DGorlia%26aufirst%3DT.%26aulast%3DAllgeier%26aufirst%3DA.%26aulast%3DLacombe%26aufirst%3DD.%26aulast%3DCairncross%26aufirst%3DJ.%2BG.%26aulast%3DEisenhauer%26aufirst%3DE.%26aulast%3DMirimanoff%26aufirst%3DR.%2BO.%26atitle%3DRadiotherapy%2520plus%2520concomitant%2520and%2520adjuvant%2520temozolomide%2520for%2520glioblastoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26spage%3D987%26epage%3D996%26doi%3D10.1056%2FNEJMoa043330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaFortune, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohmori, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatakeyama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Groot, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yung, W. K.</span></span> <span> </span><span class="NLM_article-title">Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1357</span>– <span class="NLM_lpage">1367</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-06-0476</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1158%2F1535-7163.MCT-06-0476" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=17431114" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BD2sXktFams7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=1357-1367&author=T.+J.+Liuauthor=T.+LaFortuneauthor=T.+Hondaauthor=O.+Ohmoriauthor=S.+Hatakeyamaauthor=T.+Meyerauthor=D.+Jacksonauthor=J.+de+Grootauthor=W.+K.+Yung&title=Inhibition+of+both+focal+adhesion+kinase+and+insulin-like+growth+factor-I+receptor+kinase+suppresses+glioma+proliferation+in+vitro+and+in+vivo&doi=10.1158%2F1535-7163.MCT-06-0476"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo</span></div><div class="casAuthors">Liu, Ta-Jen; LaFortune, Tiffany; Honda, Toshiyuki; Ohmori, Osamu; Hatakeyama, Shinji; Meyer, Thomas; Jackson, Dowdy; de Groot, John; Yung, W. K. Alfred</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1357-1367</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Multiple genetic aberrations in human gliomas contribute to their highly infiltrative and rapid growth characteristics.  Focal adhesion kinase (FAK) regulates tumor migration and invasion.  Insulin-like growth factor-I receptor (IGF-IR), whose expression correlates with tumor grade, is involved in proliferation and survival.  We hypothesized that inhibiting the phosphorylation of FAK and IGF-IR by NVP-TAE226 (hereafter called TAE226), a novel dual tyrosine kinase inhibitor of FAK and IGF-IR, would suppress the growth and invasion of glioma cells.  In culture, TAE226 inhibited extracellular matrix-induced autophosphorylation of FAK (Tyr397).  TAE226 also inhibited IGF-I-induced phosphorylation of IGF-IR and activity of its downstream target genes such as MAPK and Akt.  TAE226 retarded tumor cell growth as assessed by a cell viability assay and attenuated G2-M cell cycle progression assocd. with a decrease in cyclin B1 and phosphorylated cdc2 (Tyr15) protein expression.  TAE226 treatment inhibited tumor cell invasion by at least 50% compared with the control in an in vitro Matrigel invasion assay.  Interestingly, TAE226 treatment of tumor cells contg. wild-type p53 mainly exhibited G2-M arrest, whereas tumor cells bearing mutant p53 underwent apoptosis.  Induction of apoptosis by TAE226 was substantiated by detection of caspase-3/7 activation and poly(ADP-ribose) polymerase cleavage and by an Annexin V apoptosis assay.  More importantly, TAE226 treatment significantly increased the survival rate of animals in an intracranial glioma xenograft model.  Collectively, these data show that blocking the signaling pathways of FAK and IGF-IR with TAE226 has the potential to be an efficacious treatment for human gliomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQMIquqcQABrVg90H21EOLACvtfcHk0ljnzUvarYGgNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXktFams7o%253D&md5=1659c50e987e8bbb24c998e0aae14861</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-06-0476&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-06-0476%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DT.%2BJ.%26aulast%3DLaFortune%26aufirst%3DT.%26aulast%3DHonda%26aufirst%3DT.%26aulast%3DOhmori%26aufirst%3DO.%26aulast%3DHatakeyama%26aufirst%3DS.%26aulast%3DMeyer%26aufirst%3DT.%26aulast%3DJackson%26aufirst%3DD.%26aulast%3Dde%2BGroot%26aufirst%3DJ.%26aulast%3DYung%26aufirst%3DW.%2BK.%26atitle%3DInhibition%2520of%2520both%2520focal%2520adhesion%2520kinase%2520and%2520insulin-like%2520growth%2520factor-I%2520receptor%2520kinase%2520suppresses%2520glioma%2520proliferation%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D1357%26epage%3D1367%26doi%3D10.1158%2F1535-7163.MCT-06-0476" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hjelmeland, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keir, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wickman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohmori, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigner, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rich, J. N.</span></span> <span> </span><span class="NLM_article-title">A novel low molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth</span>. <i>Mol. Carcinog.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">488</span>– <span class="NLM_lpage">496</span>, <span class="refDoi"> DOI: 10.1002/mc.20297</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1002%2Fmc.20297" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=17219439" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BD2sXms1Olsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2007&pages=488-496&author=Q.+Shiauthor=A.+B.+Hjelmelandauthor=S.+T.+Keirauthor=L.+Songauthor=S.+Wickmanauthor=D.+Jacksonauthor=O.+Ohmoriauthor=D.+D.+Bignerauthor=H.+S.+Friedmanauthor=J.+N.+Rich&title=A+novel+low+molecular+weight+inhibitor+of+focal+adhesion+kinase%2C+TAE226%2C+inhibits+glioma+growth&doi=10.1002%2Fmc.20297"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth</span></div><div class="casAuthors">Shi, Qing; Hjelmeland, Anita B.; Keir, Stephen T.; Song, Linhua; Wickman, Sarah; Jackson, Dowdy; Ohmori, Osamu; Bigner, Darell D.; Friedman, Henry S.; Rich, Jeremy N.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Carcinogenesis</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">488-496</span>CODEN:
                <span class="NLM_cas:coden">MOCAE8</span>;
        ISSN:<span class="NLM_cas:issn">0899-1987</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Glioblastomas are highly lethal cancers that resist current therapies.  Novel therapies under development target mol. mechanisms that promote glioblastoma growth.  In glioblastoma patient specimens, the non-receptor tyrosine kinase focal adhesion kinase (FAK) is overexpressed.  Upon growth factor receptor stimulation or integrin engagement, FAK is activated by phosphorylation on crit. tyrosine residues.  Activated FAK initiates a signal transduction cascade which promotes glioma growth and invasion by increasing cellular adhesion, migration, invasion, and proliferation.  We find that human glioma cell lines express different levels of total FAK protein and activating phosphorylation of tyrosine residues Tyr397, Tyr861, and Tyr925.  As all glioma cell lines examd. expressed phosphorylated FAK, we examd. the efficacy of a novel low-mol. wt. inhibitor of FAK, TAE226, against human glioma cell lines.  TAE226 inhibited the phosphorylation of FAK as well as the downstream effectors AKT, extracellular signal-related kinase, and S6 ribosomal protein in multiple glioma cell lines.  TAE226 induced a concn.-dependent decrease in cellular proliferation with an assocd. G2 cell cycle arrest in every cell line and an increase in apoptosis in a cell-line-specific manner.  TAE226 also decreased glioma cell adhesion, migration, and invasion through an artificial extracellular matrix.  Together, these data demonstrate the potential benefit of TAE226 for glioma therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXL0wEDuHo9bVg90H21EOLACvtfcHk0ljnzUvarYGgNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXms1Olsrg%253D&md5=83711a44fe2472eae4baf568ee4332a4</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1002%2Fmc.20297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmc.20297%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DHjelmeland%26aufirst%3DA.%2BB.%26aulast%3DKeir%26aufirst%3DS.%2BT.%26aulast%3DSong%26aufirst%3DL.%26aulast%3DWickman%26aufirst%3DS.%26aulast%3DJackson%26aufirst%3DD.%26aulast%3DOhmori%26aufirst%3DO.%26aulast%3DBigner%26aufirst%3DD.%2BD.%26aulast%3DFriedman%26aufirst%3DH.%2BS.%26aulast%3DRich%26aufirst%3DJ.%2BN.%26atitle%3DA%2520novel%2520low%2520molecular%2520weight%2520inhibitor%2520of%2520focal%2520adhesion%2520kinase%252C%2520TAE226%252C%2520inhibits%2520glioma%2520growth%26jtitle%3DMol.%2520Carcinog.%26date%3D2007%26volume%3D46%26spage%3D488%26epage%3D496%26doi%3D10.1002%2Fmc.20297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chilukuri, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brady, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulos, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kappes, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galileo, D. S.</span></span> <span> </span><span class="NLM_article-title">L1 stimulation of human glioma cell motility correlates with FAK activation</span>. <i>J Neurooncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">44</span>, <span class="refDoi"> DOI: 10.1007/s11060-011-0557-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1007%2Fs11060-011-0557-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=21373966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A280%3ADC%252BC3MfjsFensw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2011&pages=27-44&author=M.+Yangauthor=Y.+Liauthor=K.+Chilukuriauthor=O.+A.+Bradyauthor=M.+I.+Boulosauthor=J.+C.+Kappesauthor=D.+S.+Galileo&title=L1+stimulation+of+human+glioma+cell+motility+correlates+with+FAK+activation&doi=10.1007%2Fs11060-011-0557-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">L1 stimulation of human glioma cell motility correlates with FAK activation</span></div><div class="casAuthors">Yang Muhua; Li Yupei; Chilukuri Kalyani; Brady Owen A; Boulos Magdy I; Kappes John C; Galileo Deni S</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neuro-oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-44</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The neural adhesion/recognition protein L1 (L1CAM; CD171) has been shown or implicated to function in stimulation of cell motility in several cancer types, including high-grade gliomas.  Our previous work demonstrated the expression and function of L1 protein in stimulation of cell motility in rat glioma cells.  However, the mechanism of this stimulation is still unclear.  This study further investigated the function of L1 and L1 proteolysis in human glioblastoma multiforme (GBM) cell migration and invasion, as well as the mechanism of this stimulation.  L1 mRNA was found to be present in human T98G GBM cell line but not in U-118 MG grade III human glioma cell line.  L1 protein expression, proteolysis, and release were found in T98G cells and human surgical GBM cells by Western blotting.  Exosome-like vesicles released by T98G cells were purified and contained full-length L1.  In a scratch assay, T98G cells that migrated into the denuded scratch area exhibited upregulation of ADAM10 protease expression coincident with loss of surface L1.  GBM surgical specimen cells exhibited a similar loss of cell surface L1 when xenografted into the chick embryo brain.  When lentivirally introduced shRNA was used to attenuate L1 expression, such T98G/shL1 cells exhibited significantly decreased cell motility by time lapse microscopy in our quantitative Super Scratch assay.  These cells also showed a decrease in FAK activity and exhibited increased focal complexes.  L1 binding integrins which activate FAK were found in T98G and U-118 MG cells.  Addition of L1 ectodomain-containing media (1) rescued the decreased cell motility of T98G/shL1 cells and (2) increased cell motility of U-118 MG cells but (3) did not further increase T98G cell motility.  Injection of L1-attenuated T98G/shL1 cells into embryonic chick brains resulted in the absence of detectable invasion compared to control cells which invaded brain tissue.  These studies support a mechanism where glioma cells at the edge of a cell mass upregulate ADAM10 to proteolyze surface L1 and the resultant ectodomain increases human glioma cell migration and invasion by binding to integrin receptors, activating FAK, and increasing turnover of focal complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRUFN-7xleI5xJ5E29YNGvQfW6udTcc2ebu8oIcAHcuXLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MfjsFensw%253D%253D&md5=d8e05ff5761c0576f0c48e9c5ea26657</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1007%2Fs11060-011-0557-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11060-011-0557-x%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DChilukuri%26aufirst%3DK.%26aulast%3DBrady%26aufirst%3DO.%2BA.%26aulast%3DBoulos%26aufirst%3DM.%2BI.%26aulast%3DKappes%26aufirst%3DJ.%2BC.%26aulast%3DGalileo%26aufirst%3DD.%2BS.%26atitle%3DL1%2520stimulation%2520of%2520human%2520glioma%2520cell%2520motility%2520correlates%2520with%2520FAK%2520activation%26jtitle%3DJ%2520Neurooncol.%26date%3D2011%26volume%3D105%26spage%3D27%26epage%3D44%26doi%3D10.1007%2Fs11060-011-0557-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cornillon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campos, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guyotat, D.</span></span> <span> </span><span class="NLM_article-title">Focal adhesion kinase (FAK), une protéine aux fonctions multiples</span>. <i>Med. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">743</span>– <span class="NLM_lpage">752</span>, <span class="refDoi"> DOI: 10.1051/medsci/20031967743</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1051%2Fmedsci%2F20031967743" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A280%3ADC%252BD3svgtlKisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2003&pages=743-752&author=J.+Cornillonauthor=L.+Camposauthor=D.+Guyotat&title=Focal+adhesion+kinase+%28FAK%29%2C+une+prot%C3%A9ine+aux+fonctions+multiples&doi=10.1051%2Fmedsci%2F20031967743"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Focal adhesion kinase (FAK), a multifunctional protein</span></div><div class="casAuthors">Cornillon Jerome; Campos Lydia; Guyotat Denis</div><div class="citationInfo"><span class="NLM_cas:title">Medecine sciences : M/S</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6-7</span>),
    <span class="NLM_cas:pages">743-52</span>
        ISSN:<span class="NLM_cas:issn">0767-0974</span>.
    </div><div class="casAbstract">Focal adhesion kinase (FAK) is a cytoplasmic protein tyrosine kinase localized to regions called focal adhesions.  Many stimuli can induce tyrosine phosphorylation and activation of FAK, including integrins and growth factors.  The major site of autophosphorylation, tyrosine 397, is a docking site for the SH2 domains of Src family proteins.  The other sites of phosphorylation are phosphorylated by Src kinases.  Phosphorylated FAK binds proteins of focal adhesion and can activate them directly or indirectly by phosphorylation.  These activated proteins forming the FAK complex facilitate the generation of downstream signals necessary to regulate cell functions, like motility, survival and proliferation.  Dysregulation of FAK could participate in the development of cancer.  This review will focus upon the mechanisms by which FAK transmits biochemical signals and elicits biological effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ649HwIg5BIf69nzq6467DfW6udTcc2ebu8oIcAHcuXLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3svgtlKisg%253D%253D&md5=d0da696545b44f37f28ec55e93f4b643</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1051%2Fmedsci%2F20031967743&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1051%252Fmedsci%252F20031967743%26sid%3Dliteratum%253Aachs%26aulast%3DCornillon%26aufirst%3DJ.%26aulast%3DCampos%26aufirst%3DL.%26aulast%3DGuyotat%26aufirst%3DD.%26atitle%3DFocal%2520adhesion%2520kinase%2520%2528FAK%2529%252C%2520une%2520prot%25C3%25A9ine%2520aux%2520fonctions%2520multiples%26jtitle%3DMed.%2520Sci.%26date%3D2003%26volume%3D19%26spage%3D743%26epage%3D752%26doi%3D10.1051%2Fmedsci%2F20031967743" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochwald, S. N.</span></span> <span> </span><span class="NLM_article-title">The role of FAK in tumor metabolism and therapy</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">154</span>– <span class="NLM_lpage">163</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2013.12.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1016%2Fj.pharmthera.2013.12.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=24333503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktFyiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2014&pages=154-163&author=J.+Zhangauthor=S.+N.+Hochwald&title=The+role+of+FAK+in+tumor+metabolism+and+therapy&doi=10.1016%2Fj.pharmthera.2013.12.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">The role of FAK in tumor metabolism and therapy</span></div><div class="casAuthors">Zhang, Jianliang; Hochwald, Steven N.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">154-163</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Focal adhesion kinase (FAK) plays a vital role in tumor cell proliferation, survival and migration.  Altered metabolic pathways fuel rapid tumor growth by accelerating glucose, lipid and glutamine processing.  Besides the mitogenic effects of FAK, evidence is accumulating supporting the assocn. between hyper-activated FAK and aberrant metab. in tumorigenesis.  FAK can promote glucose consumption, lipogenesis, and glutamine dependency to promote cancer cell proliferation, motility, and survival.  Clin. studies demonstrate that FAK-related alterations of tumor metab. are assocd. with increased risk of developing solid tumors.  Since FAK contributes to the malignant phenotype, small mol. inhibition of FAK-stimulated bioenergetic and biosynthetic processes can provide a novel approach for therapeutic intervention in tumor growth and invasion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopcqgT2ywkqbVg90H21EOLACvtfcHk0lhKniq68whLFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktFyiuw%253D%253D&md5=9cb0cd034003cf29b4141e9572e02f6d</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2013.12.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2013.12.003%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DHochwald%26aufirst%3DS.%2BN.%26atitle%3DThe%2520role%2520of%2520FAK%2520in%2520tumor%2520metabolism%2520and%2520therapy%26jtitle%3DPharmacol.%2520Ther.%26date%3D2014%26volume%3D142%26spage%3D154%26epage%3D163%26doi%3D10.1016%2Fj.pharmthera.2013.12.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cance, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurenova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marlowe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golubovskaya, V.</span></span> <span> </span><span class="NLM_article-title">Disrupting the scaffold to improve focal adhesion kinase-targeted cancer therapeutics</span>. <i>Sci. Signaling</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">pe10</span> <span class="refDoi"> DOI: 10.1126/scisignal.2004021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1126%2Fscisignal.2004021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=23532331" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&author=W.+G.+Canceauthor=E.+Kurenovaauthor=T.+Marloweauthor=V.+Golubovskaya&title=Disrupting+the+scaffold+to+improve+focal+adhesion+kinase-targeted+cancer+therapeutics&doi=10.1126%2Fscisignal.2004021"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1126%2Fscisignal.2004021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscisignal.2004021%26sid%3Dliteratum%253Aachs%26aulast%3DCance%26aufirst%3DW.%2BG.%26aulast%3DKurenova%26aufirst%3DE.%26aulast%3DMarlowe%26aufirst%3DT.%26aulast%3DGolubovskaya%26aufirst%3DV.%26atitle%3DDisrupting%2520the%2520scaffold%2520to%2520improve%2520focal%2520adhesion%2520kinase-targeted%2520cancer%2520therapeutics%26jtitle%3DSci.%2520Signaling%26date%3D2013%26volume%3D6%26doi%3D10.1126%2Fscisignal.2004021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lechertier, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodivala-Dilke, K.</span></span> <span> </span><span class="NLM_article-title">Focal adhesion kinase and tumour angiogenesis</span>. <i>J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>226</i></span>,  <span class="NLM_fpage">404</span>– <span class="NLM_lpage">412</span>, <span class="refDoi"> DOI: 10.1002/path.3018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1002%2Fpath.3018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=21984450" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFCqsb3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=226&publication_year=2012&pages=404-412&author=T.+Lechertierauthor=K.+Hodivala-Dilke&title=Focal+adhesion+kinase+and+tumour+angiogenesis&doi=10.1002%2Fpath.3018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Focal adhesion kinase and tumor angiogenesis</span></div><div class="casAuthors">Lechertier, Tanguy; Hodivala-Dilke, Kairbaan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pathology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">226</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">404-412</span>CODEN:
                <span class="NLM_cas:coden">JPTLAS</span>;
        ISSN:<span class="NLM_cas:issn">0022-3417</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A review.  Angiogenesis, the formation of new blood vessels from pre-existing ones, is essential for tumor development.  It is initiated and regulated by growth factors via their surface receptors, which activate several intracellular signalling pathways in endothelial cells.  Cell adhesion mols., such as integrins, also regulate angiogenesis.  Despite these facts, inhibitors of endothelial cell growth factor receptors or integrins have not been as effective as initially hoped in the long-term inhibition of angiogenesis in cancer patients.  Signalling downstream of growth factor receptors and integrins converge on the ubiquitously expressed non-receptor tyrosine kinase focal adhesion kinase (FAK).  FAK is involved in endothelial cell proliferation, migration and survival, is up-regulated in many cancers and has recently been shown to control tumor angiogenesis.  Indeed, FAK inhibitors are presently being developed for the treatment of cancer.  However, recent studies have indicated the complexities of understanding the precise role for FAK in angiogenesis.  Here we have summarized some of the key features of FAK, addressed some of the apparently contradictory roles of this mol. in angiogenesis and provided some perspectives for future studies.  Copyright © 2011 Pathol. Society of Great Britain and Ireland.  Published by John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSgXcP02UjgLVg90H21EOLACvtfcHk0lhKniq68whLFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFCqsb3J&md5=605e7ae8bd660cfc04792e904729addf</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1002%2Fpath.3018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.3018%26sid%3Dliteratum%253Aachs%26aulast%3DLechertier%26aufirst%3DT.%26aulast%3DHodivala-Dilke%26aufirst%3DK.%26atitle%3DFocal%2520adhesion%2520kinase%2520and%2520tumour%2520angiogenesis%26jtitle%3DJ.%2520Pathol.%26date%3D2012%26volume%3D226%26spage%3D404%26epage%3D412%26doi%3D10.1002%2Fpath.3018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gutenberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruck, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchfelder, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, H. C.</span></span> <span> </span><span class="NLM_article-title">Expression of tyrosine kinases FAK and Pyk2 in 331 human astrocytomas</span>. <i>Acta Neuropathol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">224</span>– <span class="NLM_lpage">230</span>, <span class="refDoi"> DOI: 10.1007/s00401-004-0886-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1007%2Fs00401-004-0886-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=15221336" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmt1Krur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2004&pages=224-230&author=A.+Gutenbergauthor=W.+Bruckauthor=M.+Buchfelderauthor=H.+C.+Ludwig&title=Expression+of+tyrosine+kinases+FAK+and+Pyk2+in+331+human+astrocytomas&doi=10.1007%2Fs00401-004-0886-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of tyrosine kinases FAK and Pyk2 in 331 human astrocytomas</span></div><div class="casAuthors">Gutenberg, A.; Brueck, W.; Buchfelder, M.; Ludwig, H. C.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Neuropathologica</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">224-230</span>CODEN:
                <span class="NLM_cas:coden">ANPTAL</span>;
        ISSN:<span class="NLM_cas:issn">0001-6322</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">The progression of malignancy from astrocytomas to glioblastomas remains clin. as well as histopathol. unpredictable.  The focal adhesion kinase (FAK) and the proline-rich Tyr kinase (Pyk2) show a high expression in glioma cell lines and have an influence on increased cell proliferation and migration of glioma cells in vitro and in vivo.  The aim of this study was to correlate the coexpression of FAK and Pyk2 to the WHO grade of malignancy in human astrocytomas.  Immunohistochem. staining scores of FAK and Pyk2 were analyzed in 331 astrocytomas and correlated to each other and to the WHO grade.  Significant coexpression of FAK and Pyk2 in astrocytomas was demonstrated.  Pyk2 expression occurred much more frequently and with higher expression scores within the different WHO grades.  Beyond this, a significant correlation between the WHO grade of malignancy of astrocytomas and the expression of FAK, as well as of Pyk2, was detected.  This connection and the roles of these 2 Tyr kinases in the progression of tumors should be confirmed by further studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUvlZv4lGN_rVg90H21EOLACvtfcHk0lhKniq68whLFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmt1Krur8%253D&md5=05f4ecbba6b2aabbef6fd97445398d27</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1007%2Fs00401-004-0886-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00401-004-0886-3%26sid%3Dliteratum%253Aachs%26aulast%3DGutenberg%26aufirst%3DA.%26aulast%3DBruck%26aufirst%3DW.%26aulast%3DBuchfelder%26aufirst%3DM.%26aulast%3DLudwig%26aufirst%3DH.%2BC.%26atitle%3DExpression%2520of%2520tyrosine%2520kinases%2520FAK%2520and%2520Pyk2%2520in%2520331%2520human%2520astrocytomas%26jtitle%3DActa%2520Neuropathol.%26date%3D2004%26volume%3D108%26spage%3D224%26epage%3D230%26doi%3D10.1007%2Fs00401-004-0886-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haskell, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natarajan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hecker, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, J.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grammer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gladson, C. L.</span></span> <span> </span><span class="NLM_article-title">Focal adhesion kinase is expressed in the angiogenic blood vessels of malignant astrocytic tumors in vivo and promotes capillary tube formation of brain microvascular endothelial cells</span>. <i>Clin Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">2157</span>– <span class="NLM_lpage">2165</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=12796381" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BD3sXksVWqu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=2157-2165&author=H.+Haskellauthor=M.+Natarajanauthor=T.+P.+Heckerauthor=Q.+Dingauthor=J.+Stewartauthor=R.+Grammerauthor=C.+L.+Gladson&title=Focal+adhesion+kinase+is+expressed+in+the+angiogenic+blood+vessels+of+malignant+astrocytic+tumors+in+vivo+and+promotes+capillary+tube+formation+of+brain+microvascular+endothelial+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Focal Adhesion Kinase Is Expressed in the Angiogenic Blood Vessels of Malignant Astrocytic Tumors in Vivo and Promotes Capillary Tube Formation of Brain Microvascular Endothelial Cells</span></div><div class="casAuthors">Haskell, Henry; Natarajan, Meera; Hecker, Timothy P.; Ding, Qiang; Stewart, Jerry, Jr.; Grammer, J. Robert; Gladson, Candece L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2157-2165</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Focal adhesion kinase (FAK) is a cytoplasmic tyrosine kinase that has been shown to promote proliferation, migration, and invasion of several cell types in vitro, and we have shown recently that FAK promotes proliferation of malignant astrocytoma cells in vivo.  To det. the role of FAK in angiogenesis in malignant astrocytic tumors, we investigated the expression and function of FAK in brain endothelial cells.  We characterized the expression of FAK and activated FAK in endothelial cells by immunohistochem.  We also detd. the function of FAK in brain microvascular endothelial cells by transfecting these cells with a dominant interfering form of FAK [FAK-related nonkinase (FRNK)] or a mutant FRNK (Leu-1034 to Ser) and assessed the effect on capillary tube formation and cell migration.  We found that FAK was expressed in the endothelial cells of grade III (4 of 9 samples) and IV (9 of 10 samples) astrocytoma biopsies but not in the endothelial cells of normal brain (0 of 9 samples) and not in grade I (0 of 5 samples) or II (0 of 4 samples) astrocytoma biopsies.  Furthermore, we found that both FAK and activated FAK were expressed in the endothelial cells in malignant astrocytoma tumors propagated intracerebrally in the severe combined immunodeficient mouse brain.  As expected, immunofluorescence anal. showed FRNK protein to localize to focal adhesions, whereas mutant FRNK protein did not.  FRNK-transfected endothelial cells showed a 55% redn. in branched tube formation and a 40% redn. in tube length when propagated in three-dimensional collagen gels, compared with cells transfected with the mutant FRNK construct.  Furthermore, FRNK-transfected cells showed a 35-50% redn. in haptotactic migration toward fibronectin and collagen, compared with mutant FRNK-transfected cells.  These data suggest that FAK promotes angiogenesis and that this occurs, at least in part, through the promotion of endothelial cell migration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCALutUF0sALVg90H21EOLACvtfcHk0liSPKsd7XLvTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXksVWqu78%253D&md5=cfd3ae0ef42e78179653df5a7f8df30e</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHaskell%26aufirst%3DH.%26aulast%3DNatarajan%26aufirst%3DM.%26aulast%3DHecker%26aufirst%3DT.%2BP.%26aulast%3DDing%26aufirst%3DQ.%26aulast%3DStewart%26aufirst%3DJ.%26aulast%3DGrammer%26aufirst%3DR.%26aulast%3DGladson%26aufirst%3DC.%2BL.%26atitle%3DFocal%2520adhesion%2520kinase%2520is%2520expressed%2520in%2520the%2520angiogenic%2520blood%2520vessels%2520of%2520malignant%2520astrocytic%2520tumors%2520in%2520vivo%2520and%2520promotes%2520capillary%2520tube%2520formation%2520of%2520brain%2520microvascular%2520endothelial%2520cells%26jtitle%3DClin%2520Cancer%2520Res.%26date%3D2003%26volume%3D9%26spage%3D2157%26epage%3D2165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Natarajan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hecker, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gladson, C. L.</span></span> <span> </span><span class="NLM_article-title">FAK signaling in anaplastic astrocytoma and glioblastoma tumors</span>. <i>Cancer J.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">126</span>– <span class="NLM_lpage">133</span>, <span class="refDoi"> DOI: 10.1097/00130404-200303000-00008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1097%2F00130404-200303000-00008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=12784878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlsVelsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=126-133&author=M.+Natarajanauthor=T.+P.+Heckerauthor=C.+L.+Gladson&title=FAK+signaling+in+anaplastic+astrocytoma+and+glioblastoma+tumors&doi=10.1097%2F00130404-200303000-00008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">FAK signaling in anaplastic astrocytoma and glioblastoma tumors</span></div><div class="casAuthors">Natarajan, Meera; Hecker, Timothy P.; Gladson, Candece L.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Journal (Sudbury, MA, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">126-133</span>CODEN:
                <span class="NLM_cas:coden">CAJOCB</span>;
        ISSN:<span class="NLM_cas:issn">1528-9117</span>.
    
            (<span class="NLM_cas:orgname">Jones and Bartlett Publishers</span>)
        </div><div class="casAbstract">A review.  Focal adhesion kinase (FAK) is a non-receptor cytoplasmic-tyrosine kinase that is activated by several different cell surface receptors shown to be upregulated on glioblastoma cells (integrins αvβ3 andαvβ35, and the epidermal growth factor receptor).  Activated FAK can signal through several different signaling pathways, which are reviewed here.  Published data are summarized that have demonstrated (1) elevated FAK expression in anaplastic astrocytoma and glioblastoma tumor biopsy samples, (2) a role for FAK in the promotion of glioblastoma cell proliferation, survival and migration in vitro, and (3) a role for FAK in the promotion of glioblastoma cell proliferation in vivo in an animal model.  The available data suggests that increased levels of FAK protein and activity may contribute to an increased ERK activity and cell proliferation in vivo in these tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqe19jb8wC2y7Vg90H21EOLACvtfcHk0liSPKsd7XLvTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlsVelsbk%253D&md5=905e6199904ef233df4d689126743cad</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1097%2F00130404-200303000-00008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00130404-200303000-00008%26sid%3Dliteratum%253Aachs%26aulast%3DNatarajan%26aufirst%3DM.%26aulast%3DHecker%26aufirst%3DT.%2BP.%26aulast%3DGladson%26aufirst%3DC.%2BL.%26atitle%3DFAK%2520signaling%2520in%2520anaplastic%2520astrocytoma%2520and%2520glioblastoma%2520tumors%26jtitle%3DCancer%2520J.%26date%3D2003%26volume%3D9%26spage%3D126%26epage%3D133%26doi%3D10.1097%2F00130404-200303000-00008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dehart, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S. T.</span></span> <span> </span><span class="NLM_article-title">Understanding the roles of FAK in cancer: inhibitors, genetic models, and new insights</span>. <i>J. Histochem. Cytochem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">114</span>– <span class="NLM_lpage">128</span>, <span class="refDoi"> DOI: 10.1369/0022155414561498</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1369%2F0022155414561498" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=25380750" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BC2MXislWrtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2015&pages=114-128&author=H.+Yoonauthor=J.+P.+Dehartauthor=J.+M.+Murphyauthor=S.+T.+Lim&title=Understanding+the+roles+of+FAK+in+cancer%3A+inhibitors%2C+genetic+models%2C+and+new+insights&doi=10.1369%2F0022155414561498"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding the roles of FAK in cancer: inhibitors, genetic models, and new insights</span></div><div class="casAuthors">Yoon, Hyunho; Dehart, Joshua P.; Murphy, James M.; Lim, Ssang-Taek Steve</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Histochemistry and Cytochemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">114-128/1-114-128/15, 15 pp.</span>CODEN:
                <span class="NLM_cas:coden">JHCYAS</span>;
        ISSN:<span class="NLM_cas:issn">0022-1554</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A review.  Focal adhesion kinase (FAK) is a protein tyrosine kinase that regulates cellular adhesion, motility, proliferation and survival in various types of cells.  Interestingly, FAK is activated and/or overexpressed in advanced cancers, and promotes cancer progression and metastasis.  For this reason, FAK became a potential therapeutic target in cancer, and small mol. FAK inhibitors have been developed and are being tested in clin. phase trials.  These inhibitors have demonstrated to be effective by inducing tumor cell apoptosis in addn. to reducing metastasis and angiogenesis.  Furthermore, several genetic FAK mouse models have made advancements in understanding the specific role of FAK both in tumors and in the tumor environment.  In this review, we discuss FAK inhibitors as well as genetic mouse models to provide mechanistic insights into FAK signaling and its potential in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro8FZcK4GQb7Vg90H21EOLACvtfcHk0lhIM-4zPL9eYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXislWrtb8%253D&md5=64ffaaef86e9fc737ba3bd825a64dd02</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1369%2F0022155414561498&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1369%252F0022155414561498%26sid%3Dliteratum%253Aachs%26aulast%3DYoon%26aufirst%3DH.%26aulast%3DDehart%26aufirst%3DJ.%2BP.%26aulast%3DMurphy%26aufirst%3DJ.%2BM.%26aulast%3DLim%26aufirst%3DS.%2BT.%26atitle%3DUnderstanding%2520the%2520roles%2520of%2520FAK%2520in%2520cancer%253A%2520inhibitors%252C%2520genetic%2520models%252C%2520and%2520new%2520insights%26jtitle%3DJ.%2520Histochem.%2520Cytochem.%26date%3D2015%26volume%3D63%26spage%3D114%26epage%3D128%26doi%3D10.1369%2F0022155414561498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span> <span> </span><span class="NLM_article-title">Antisense oligonucleotides targeting the focal adhesion kinase inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human glioma cells</span>. <i>J Neurooncol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">117</span>– <span class="NLM_lpage">123</span>, <span class="refDoi"> DOI: 10.1007/s11060-005-9025-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1007%2Fs11060-005-9025-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=16314954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A280%3ADC%252BD28vhs1Kmtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2006&pages=117-123&author=Z.+M.+Wuauthor=X.+H.+Yanauthor=P.+C.+Jiangauthor=Z.+Q.+Liauthor=T.+Wu&title=Antisense+oligonucleotides+targeting+the+focal+adhesion+kinase+inhibit+proliferation%2C+induce+apoptosis%2C+and+cooperate+with+cytotoxic+drugs+in+human+glioma+cells&doi=10.1007%2Fs11060-005-9025-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Antisense oligonucleodes targeting the focal adhesion kinase inhibit proliferation, induce apoptosis and cooperate with cytotoxic drugs in human glioma cells</span></div><div class="casAuthors">Wu Zhi-Min; Yuan Xian-Hou; Jiang Pu-Cha; Li Zhi-Qiang; Wu Tao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neuro-oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">117-23</span>
        ISSN:<span class="NLM_cas:issn">0167-594X</span>.
    </div><div class="casAbstract">To examine the role of focal adhesion kinase in human glioma cells, we studied its effects on proliferation and apoptosis using FAK antisense oligonucleotide.  U251 MG cells were transfected with ODNs, sense FAK, mismatch FAK and antisense-FAK, respectively.  Expression of FAK proteins were detected by Western blots and Immnofluoressence.  Cell apoptosis and mitochondrial membrane potential were analyzed by flow cytometry.  Caspase-3 activity was measured by spectrofluorometer.  MTT assay was used to examine changes in cell proliferation.  The protein expression of FAK in U251 MG cells decreased in antisense-FAK ODNs group significantly.  Caspase-3 activity increased in cells treated with antisense-FAK and down-regulated when treated with caspase-3 inhibitor.  The level of cell apoptosis and loss of mitochondrial membrane potential in antisense-FAK group was higher than in the mismatch sense group.  Cells proliferation was inhibited by antisense-FAK, and the effects were clearly additive when antisense oligonuceotides were added to cells treated with the anticancer agents.  The results suggest that antisense-FAK ODNs inhibit U251 MG cells proliferation and induce their apoptosis.  It is possible that FAK via mitochondrial and caspase-3 inhibits U251 MG cells apoptosis.  And antisense oligonucleotide treatment enhances U251 MG cells sensitivity to chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTQ32jP6yVt9LjnyZkbE8yXfW6udTcc2eb1NaqRVSX9Wbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28vhs1Kmtg%253D%253D&md5=0a8960708498dd21515d853be6128877</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1007%2Fs11060-005-9025-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11060-005-9025-9%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DZ.%2BM.%26aulast%3DYan%26aufirst%3DX.%2BH.%26aulast%3DJiang%26aufirst%3DP.%2BC.%26aulast%3DLi%26aufirst%3DZ.%2BQ.%26aulast%3DWu%26aufirst%3DT.%26atitle%3DAntisense%2520oligonucleotides%2520targeting%2520the%2520focal%2520adhesion%2520kinase%2520inhibit%2520proliferation%252C%2520induce%2520apoptosis%252C%2520and%2520cooperate%2520with%2520cytotoxic%2520drugs%2520in%2520human%2520glioma%2520cells%26jtitle%3DJ%2520Neurooncol.%26date%3D2006%26volume%3D77%26spage%3D117%26epage%3D123%26doi%3D10.1007%2Fs11060-005-9025-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lv, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, A. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H. L.</span></span> <span> </span><span class="NLM_article-title">FAK inhibitors in cancer, a patent review</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">139</span>– <span class="NLM_lpage">145</span>, <span class="refDoi"> DOI: 10.1080/13543776.2018.1414183</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1080%2F13543776.2018.1414183" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=29210300" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFOhtLnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=139-145&author=P.+C.+Lvauthor=A.+Q.+Jiangauthor=W.+M.+Zhangauthor=H.+L.+Zhu&title=FAK+inhibitors+in+cancer%2C+a+patent+review&doi=10.1080%2F13543776.2018.1414183"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">FAK inhibitors in Cancer, a patent review</span></div><div class="casAuthors">Lv, Peng-Cheng; Jiang, Ai-Qin; Zhang, Wei-Ming; Zhu, Hai-Liang</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">139-145</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that localizes at sites of cell adhesion to the extracellular matrix (ECM) and mediates signalling events downstream of integrin engagement of the ECM.  FAK is known to regulate cell survival, proliferation and migration.: FAK expression has also been shown to be up-regulated in many cancer types.  Previous study also indicates that FAK-mediated signaling and functions are intrinsically involved in the progression of tumor aggressiveness, suggesting that FAK is a promising target for anticancer therapies.  Small mol. FAK inhibitors have been developed and are being tested in clin. phase trials.: These inhibitors have demonstrated to be effective by inducing tumor cell apoptosis in addn. to reducing metastasis and angiogenesis.  In this review, we give updates on the design, synthesis and structure-activity relationship anal. of small mol. FAK inhibitors discovered from 2015 until now.  We also review the FAK inhibitors that are in clin. development and highlight the future prospects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCbfOByjX7iLVg90H21EOLACvtfcHk0ljL-UAiAF9HSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFOhtLnP&md5=2c199ec3a1247c3f2680d478b5f69c5b</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1080%2F13543776.2018.1414183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2018.1414183%26sid%3Dliteratum%253Aachs%26aulast%3DLv%26aufirst%3DP.%2BC.%26aulast%3DJiang%26aufirst%3DA.%2BQ.%26aulast%3DZhang%26aufirst%3DW.%2BM.%26aulast%3DZhu%26aufirst%3DH.%2BL.%26atitle%3DFAK%2520inhibitors%2520in%2520cancer%252C%2520a%2520patent%2520review%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2018%26volume%3D28%26spage%3D139%26epage%3D145%26doi%3D10.1080%2F13543776.2018.1414183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shanthi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishna, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arunesh, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkateswara, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sooriya, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viswanadhan, V. N.</span></span> <span> </span><span class="NLM_article-title">Focal adhesion kinase inhibitors in the treatment of metastatic cancer: a patent review</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1077</span>– <span class="NLM_lpage">1100</span>, <span class="refDoi"> DOI: 10.1517/13543776.2014.948845</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1517%2F13543776.2014.948845" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=25113248" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFGhtr7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=1077-1100&author=E.+Shanthiauthor=M.+H.+Krishnaauthor=G.+M.+Aruneshauthor=R.+K.+Venkateswaraauthor=K.+J.+Sooriyaauthor=V.+N.+Viswanadhan&title=Focal+adhesion+kinase+inhibitors+in+the+treatment+of+metastatic+cancer%3A+a+patent+review&doi=10.1517%2F13543776.2014.948845"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Focal adhesion kinase inhibitors in the treatment of metastatic cancer: a patent review</span></div><div class="casAuthors">Shanthi, Ekambaram; Krishna, Mudeenahally H.; Arunesh, Gubbi M.; Venkateswara Reddy, K.; Sooriya Kumar, Jegatheesan; Viswanadhan, Vellarkad N.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1077-1100</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Focal adhesion kinase (FAK) plays a prominent role in integrin signaling.  FAK activation increases phosphorylation of Tyr397 and other sites of the protein.  FAK-dependent activation of signaling pathways implicated in controlling essential cellular functions including growth, proliferation, survival and migration.  FERM (F for the 4.1 protein, ezrin, radixin and moesin) domain-enhanced p53 degrdn. plays a crit. role in proliferation and survival.  FAK, overexpressed in metastatic tumors, has emerged as an important therapeutic target for the development of selective inhibitors.  FAK inhibitors achieved tumor growth inhibition and induced apoptosis.  Strategies targeting FAK inhibition using novel compds. have created an exciting opportunity for anticancer therapy.  Areas covered: This review summarizes the current research with available data from early phase clin. trials and discusses the available small-mol. inhibitors of FAK from patents.  The importance of inhibiting FAK activity in cancer patients is discussed.  Expert opinion: Emerging data from clin. trials with orally available small-mol. inhibitors of FAK are promising.  Although this approach is appropriate as a targeted therapeutic approach against several metastatic cancer types, several compds. in research are yet to prove their preclin. efficacy.  This report lays special emphasis on the available patent data of FAK inhibitors for such targeted mol. therapies.  This review summarizes current knowledge about FAK inhibition in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopctvNfCHOWrVg90H21EOLACvtfcHk0ljL-UAiAF9HSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFGhtr7M&md5=b096e5c5be880bd4ef328b3b92c9ff42</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1517%2F13543776.2014.948845&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2014.948845%26sid%3Dliteratum%253Aachs%26aulast%3DShanthi%26aufirst%3DE.%26aulast%3DKrishna%26aufirst%3DM.%2BH.%26aulast%3DArunesh%26aufirst%3DG.%2BM.%26aulast%3DVenkateswara%26aufirst%3DR.%2BK.%26aulast%3DSooriya%26aufirst%3DK.%2BJ.%26aulast%3DViswanadhan%26aufirst%3DV.%2BN.%26atitle%3DFocal%2520adhesion%2520kinase%2520inhibitors%2520in%2520the%2520treatment%2520of%2520metastatic%2520cancer%253A%2520a%2520patent%2520review%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2014%26volume%3D24%26spage%3D1077%26epage%3D1100%26doi%3D10.1517%2F13543776.2014.948845" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hjelmeland, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keir, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wickman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohmori, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigner, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rich, J. N.</span></span> <span> </span><span class="NLM_article-title">A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth</span>. <i>Mol. Carcinog.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">488</span>– <span class="NLM_lpage">496</span>, <span class="refDoi"> DOI: 10.1002/mc.20297</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1002%2Fmc.20297" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=17219439" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BD2sXms1Olsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2007&pages=488-496&author=Q.+Shiauthor=A.+B.+Hjelmelandauthor=S.+T.+Keirauthor=L.+Songauthor=S.+Wickmanauthor=D.+Jacksonauthor=O.+Ohmoriauthor=D.+D.+Bignerauthor=H.+S.+Friedmanauthor=J.+N.+Rich&title=A+novel+low-molecular+weight+inhibitor+of+focal+adhesion+kinase%2C+TAE226%2C+inhibits+glioma+growth&doi=10.1002%2Fmc.20297"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth</span></div><div class="casAuthors">Shi, Qing; Hjelmeland, Anita B.; Keir, Stephen T.; Song, Linhua; Wickman, Sarah; Jackson, Dowdy; Ohmori, Osamu; Bigner, Darell D.; Friedman, Henry S.; Rich, Jeremy N.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Carcinogenesis</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">488-496</span>CODEN:
                <span class="NLM_cas:coden">MOCAE8</span>;
        ISSN:<span class="NLM_cas:issn">0899-1987</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Glioblastomas are highly lethal cancers that resist current therapies.  Novel therapies under development target mol. mechanisms that promote glioblastoma growth.  In glioblastoma patient specimens, the non-receptor tyrosine kinase focal adhesion kinase (FAK) is overexpressed.  Upon growth factor receptor stimulation or integrin engagement, FAK is activated by phosphorylation on crit. tyrosine residues.  Activated FAK initiates a signal transduction cascade which promotes glioma growth and invasion by increasing cellular adhesion, migration, invasion, and proliferation.  We find that human glioma cell lines express different levels of total FAK protein and activating phosphorylation of tyrosine residues Tyr397, Tyr861, and Tyr925.  As all glioma cell lines examd. expressed phosphorylated FAK, we examd. the efficacy of a novel low-mol. wt. inhibitor of FAK, TAE226, against human glioma cell lines.  TAE226 inhibited the phosphorylation of FAK as well as the downstream effectors AKT, extracellular signal-related kinase, and S6 ribosomal protein in multiple glioma cell lines.  TAE226 induced a concn.-dependent decrease in cellular proliferation with an assocd. G2 cell cycle arrest in every cell line and an increase in apoptosis in a cell-line-specific manner.  TAE226 also decreased glioma cell adhesion, migration, and invasion through an artificial extracellular matrix.  Together, these data demonstrate the potential benefit of TAE226 for glioma therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXL0wEDuHo9bVg90H21EOLACvtfcHk0ljL-UAiAF9HSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXms1Olsrg%253D&md5=83711a44fe2472eae4baf568ee4332a4</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1002%2Fmc.20297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmc.20297%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DHjelmeland%26aufirst%3DA.%2BB.%26aulast%3DKeir%26aufirst%3DS.%2BT.%26aulast%3DSong%26aufirst%3DL.%26aulast%3DWickman%26aufirst%3DS.%26aulast%3DJackson%26aufirst%3DD.%26aulast%3DOhmori%26aufirst%3DO.%26aulast%3DBigner%26aufirst%3DD.%2BD.%26aulast%3DFriedman%26aufirst%3DH.%2BS.%26aulast%3DRich%26aufirst%3DJ.%2BN.%26atitle%3DA%2520novel%2520low-molecular%2520weight%2520inhibitor%2520of%2520focal%2520adhesion%2520kinase%252C%2520TAE226%252C%2520inhibits%2520glioma%2520growth%26jtitle%3DMol.%2520Carcinog.%26date%3D2007%26volume%3D46%26spage%3D488%26epage%3D496%26doi%3D10.1002%2Fmc.20297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaFortune, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohmori, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatakeyama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Groot, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yung, W. K.</span></span> <span> </span><span class="NLM_article-title">Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1357</span>– <span class="NLM_lpage">1367</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-06-0476</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1158%2F1535-7163.MCT-06-0476" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=17431114" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BD2sXktFams7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=1357-1367&author=T.+J.+Liuauthor=T.+LaFortuneauthor=T.+Hondaauthor=O.+Ohmoriauthor=S.+Hatakeyamaauthor=T.+Meyerauthor=D.+Jacksonauthor=J.+de+Grootauthor=W.+K.+Yung&title=Inhibition+of+both+focal+adhesion+kinase+and+insulin-like+growth+factor-I+receptor+kinase+suppresses+glioma+proliferation+in+vitro+and+in+vivo&doi=10.1158%2F1535-7163.MCT-06-0476"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo</span></div><div class="casAuthors">Liu, Ta-Jen; LaFortune, Tiffany; Honda, Toshiyuki; Ohmori, Osamu; Hatakeyama, Shinji; Meyer, Thomas; Jackson, Dowdy; de Groot, John; Yung, W. K. Alfred</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1357-1367</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Multiple genetic aberrations in human gliomas contribute to their highly infiltrative and rapid growth characteristics.  Focal adhesion kinase (FAK) regulates tumor migration and invasion.  Insulin-like growth factor-I receptor (IGF-IR), whose expression correlates with tumor grade, is involved in proliferation and survival.  We hypothesized that inhibiting the phosphorylation of FAK and IGF-IR by NVP-TAE226 (hereafter called TAE226), a novel dual tyrosine kinase inhibitor of FAK and IGF-IR, would suppress the growth and invasion of glioma cells.  In culture, TAE226 inhibited extracellular matrix-induced autophosphorylation of FAK (Tyr397).  TAE226 also inhibited IGF-I-induced phosphorylation of IGF-IR and activity of its downstream target genes such as MAPK and Akt.  TAE226 retarded tumor cell growth as assessed by a cell viability assay and attenuated G2-M cell cycle progression assocd. with a decrease in cyclin B1 and phosphorylated cdc2 (Tyr15) protein expression.  TAE226 treatment inhibited tumor cell invasion by at least 50% compared with the control in an in vitro Matrigel invasion assay.  Interestingly, TAE226 treatment of tumor cells contg. wild-type p53 mainly exhibited G2-M arrest, whereas tumor cells bearing mutant p53 underwent apoptosis.  Induction of apoptosis by TAE226 was substantiated by detection of caspase-3/7 activation and poly(ADP-ribose) polymerase cleavage and by an Annexin V apoptosis assay.  More importantly, TAE226 treatment significantly increased the survival rate of animals in an intracranial glioma xenograft model.  Collectively, these data show that blocking the signaling pathways of FAK and IGF-IR with TAE226 has the potential to be an efficacious treatment for human gliomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQMIquqcQABrVg90H21EOLACvtfcHk0lhXusWwDrEraQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXktFams7o%253D&md5=1659c50e987e8bbb24c998e0aae14861</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-06-0476&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-06-0476%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DT.%2BJ.%26aulast%3DLaFortune%26aufirst%3DT.%26aulast%3DHonda%26aufirst%3DT.%26aulast%3DOhmori%26aufirst%3DO.%26aulast%3DHatakeyama%26aufirst%3DS.%26aulast%3DMeyer%26aufirst%3DT.%26aulast%3DJackson%26aufirst%3DD.%26aulast%3Dde%2BGroot%26aufirst%3DJ.%26aulast%3DYung%26aufirst%3DW.%2BK.%26atitle%3DInhibition%2520of%2520both%2520focal%2520adhesion%2520kinase%2520and%2520insulin-like%2520growth%2520factor-I%2520receptor%2520kinase%2520suppresses%2520glioma%2520proliferation%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D1357%26epage%3D1367%26doi%3D10.1158%2F1535-7163.MCT-06-0476" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lonsdale, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, R. A.</span></span> <span> </span><span class="NLM_article-title">Structure-based design of targeted covalent inhibitors</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">3816</span>– <span class="NLM_lpage">3830</span>, <span class="refDoi"> DOI: 10.1039/C7CS00220C</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1039%2FC7CS00220C" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=29620097" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntVGiurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2018&pages=3816-3830&author=R.+Lonsdaleauthor=R.+A.+Ward&title=Structure-based+design+of+targeted+covalent+inhibitors&doi=10.1039%2FC7CS00220C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based design of targeted covalent inhibitors</span></div><div class="casAuthors">Lonsdale, Richard; Ward, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3816-3830</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Covalent inhibition is a rapidly growing discipline within drug discovery.  Many historical covalent inhibitors were discovered by serendipity, with such a mechanism of action often regarded as undesirable due to potential toxicity issues.  Recent progress has seen a major shift in this outlook, as covalent inhibition shows promise for targets where previous efforts to identify non-covalent small mol. inhibitors have failed.  Targeted covalent inhibitors (TCIs) can offer drug discovery scientists the ability to increase the potency and/or selectivity of small mol. inhibitors, by attachment of reactive functional groups designed to covalently bind to specific sites in a target.  In this tutorial review we introduce the broader concept of covalent inhibition, discuss the potential benefits and challenges of such an approach, and provide an overview of the current status of the field.  We also describe some strategies and computational tools to enable successful covalent drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnSIGMuS3vm7Vg90H21EOLACvtfcHk0lhXusWwDrEraQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntVGiurs%253D&md5=a7e31b23cf8ecfcad1397ad10ea10b7b</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1039%2FC7CS00220C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7CS00220C%26sid%3Dliteratum%253Aachs%26aulast%3DLonsdale%26aufirst%3DR.%26aulast%3DWard%26aufirst%3DR.%2BA.%26atitle%3DStructure-based%2520design%2520of%2520targeted%2520covalent%2520inhibitors%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2018%26volume%3D47%26spage%3D3816%26epage%3D3830%26doi%3D10.1039%2FC7CS00220C" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barf, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaptein, A.</span></span> <span> </span><span class="NLM_article-title">Irreversible protein kinase inhibitors: balancing the benefits and risks</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">6243</span>– <span class="NLM_lpage">6262</span>, <span class="refDoi"> DOI: 10.1021/jm3003203</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3003203" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BC38XnsVerur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6243-6262&author=T.+Barfauthor=A.+Kaptein&title=Irreversible+protein+kinase+inhibitors%3A+balancing+the+benefits+and+risks&doi=10.1021%2Fjm3003203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks</span></div><div class="casAuthors">Barf, Tjeerd; Kaptein, Allard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6243-6262</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Not applicable for a Perspective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4PLlisO0OVbVg90H21EOLACvtfcHk0lgRsMnOs_sNzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnsVerur8%253D&md5=5d87850857d37faab02e6037ef8140a4</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm3003203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3003203%26sid%3Dliteratum%253Aachs%26aulast%3DBarf%26aufirst%3DT.%26aulast%3DKaptein%26aufirst%3DA.%26atitle%3DIrreversible%2520protein%2520kinase%2520inhibitors%253A%2520balancing%2520the%2520benefits%2520and%2520risks%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6243%26epage%3D6262%26doi%3D10.1021%2Fjm3003203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanizaki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aref, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capelletti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hur, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaudet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbie, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, J. R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammerman, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">E4869</span>– <span class="NLM_lpage">E4877</span>, <span class="refDoi"> DOI: 10.1073/pnas.1403438111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1073%2Fpnas.1403438111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=25349422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVWmsL%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=E4869-E4877&author=L.+Tanauthor=J.+Wangauthor=J.+Tanizakiauthor=Z.+Huangauthor=A.+R.+Arefauthor=M.+Rusanauthor=S.+J.+Zhuauthor=Y.+Zhangauthor=D.+Ercanauthor=R.+G.+Liaoauthor=M.+Capellettiauthor=W.+Zhouauthor=W.+Hurauthor=N.+Kimauthor=T.+Simauthor=S.+Gaudetauthor=D.+A.+Barbieauthor=J.+R.+J.+Yehauthor=C.+H.+Yunauthor=P.+S.+Hammermanauthor=M.+Mohammadiauthor=P.+A.+J%C3%A4nneauthor=N.+S.+Gray&title=Development+of+covalent+inhibitors+that+can+overcome+resistance+to+first-generation+FGFR+kinase+inhibitors&doi=10.1073%2Fpnas.1403438111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors</span></div><div class="casAuthors">Tan, Li; Wang, Jun; Tanizaki, Junko; Huang, Zhifeng; Aref, Amir R.; Rusan, Maria; Zhu, Su-Jie; Zhang, Yiyun; Ercan, Dalia; Liao, Rachel G.; Capelletti, Marzia; Zhou, Wenjun; Hur, Wooyoung; Kim, NamDoo; Sim, Taebo; Gaudet, Suzanne; Barbie, David A.; Yeh, Jing-Ruey Joanna; Yun, Cai-Hong; Hammerman, Peter S.; Mohammadi, Moosa; Janne, Pasi A.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">E4869-E4877</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The human FGF receptors (FGFRs) play crit. roles in various human cancers, and several FGFR inhibitors are currently under clin. investigation.  Resistance usually results from selection for mutant kinases that are impervious to the action of the drug or from up-regulation of compensatory signaling pathways.  Preclin. studies have demonstrated that resistance to FGFR inhibitors can be acquired through mutations in the FGFR gatekeeper residue, as clin. obsd. for FGFR4 in embryonal rhabdomyosarcoma and neuroendocrine breast carcinomas.  Here the authors report on the use of a structure-based drug design to develop two selective, next-generation covalent FGFR inhibitors, the FGFR irreversible inhibitors I and II.  To our knowledge, I and II are the first inhibitors that can potently inhibit the proliferation of cells dependent upon the gatekeeper mutants of FGFR1 or FGFR2, which confer resistance to first-generation clin. FGFR inhibitors such as NVP-BGJ398 and AZD4547.  Because of the conformational flexibility of the reactive acrylamide substituent, II has the unprecedented ability to inhibit both the EGF receptor (EGFR) and FGFR covalently by targeting two distinct cysteine residues.  The authors report the cocrystal structure of FGFR4 with I, which unexpectedly exhibits a "DFG-out" covalent binding mode.  The structural basis for dual FGFR and EGFR targeting by FIIN3 also is illustrated by crystal structures of II bound with FGFR4 V550L and EGFR L858R.  These results have important implications for the design of covalent FGFR inhibitors that can overcome clin. resistance and provide the first example, to the knowledge, of a kinase inhibitor that covalently targets cysteines located in different positions within the ATP-binding pocket.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmCbTDKPA32LVg90H21EOLACvtfcHk0lgRsMnOs_sNzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVWmsL%252FP&md5=fd4a7eac1e0c17e7c9f2651dd2d76ac7</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1403438111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1403438111%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DTanizaki%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DAref%26aufirst%3DA.%2BR.%26aulast%3DRusan%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DS.%2BJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DLiao%26aufirst%3DR.%2BG.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DHur%26aufirst%3DW.%26aulast%3DKim%26aufirst%3DN.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DGaudet%26aufirst%3DS.%26aulast%3DBarbie%26aufirst%3DD.%2BA.%26aulast%3DYeh%26aufirst%3DJ.%2BR.%2BJ.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DHammerman%26aufirst%3DP.%2BS.%26aulast%3DMohammadi%26aufirst%3DM.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDevelopment%2520of%2520covalent%2520inhibitors%2520that%2520can%2520overcome%2520resistance%2520to%2520first-generation%2520FGFR%2520kinase%2520inhibitors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2014%26volume%3D111%26spage%3DE4869%26epage%3DE4877%26doi%3D10.1073%2Fpnas.1403438111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yen-Pon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acebrón-Garcia-de-Eulate, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomkiewicz-Raulet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lietha, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frame, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coumoul, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbay, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Etheve-Quelquejeu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span> <span> </span><span class="NLM_article-title">Structure-based design, synthesis, and characterization of the first irreversible inhibitor of focal adhesion kinase</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">2067</span>– <span class="NLM_lpage">2073</span>, <span class="refDoi"> DOI: 10.1021/acschembio.8b00250</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.8b00250" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFWrtb%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=2067-2073&author=E.+Yen-Ponauthor=B.+Liauthor=M.+Acebr%C3%B3n-Garcia-de-Eulateauthor=C.+Tomkiewicz-Rauletauthor=J.+Dawsonauthor=D.+Liethaauthor=M.+C.+Frameauthor=X.+Coumoulauthor=C.+Garbayauthor=M.+Etheve-Quelquejeuauthor=H.+Chen&title=Structure-based+design%2C+synthesis%2C+and+characterization+of+the+first+irreversible+inhibitor+of+focal+adhesion+kinase&doi=10.1021%2Facschembio.8b00250"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design, Synthesis, and Characterization of the First Irreversible Inhibitor of Focal Adhesion Kinase</span></div><div class="casAuthors">Yen-Pon, Expedite; Li, Bo; Acebron-Garcia-de-Eulate, Marta; Tomkiewicz-Raulet, Celine; Dawson, John; Lietha, Daniel; Frame, Margaret C.; Coumoul, Xavier; Garbay, Christiane; Etheve-Quelquejeu, Melanie; Chen, Huixiong</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2067-2073</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Focal Adhesion Kinase signaling pathway and its functions have been involved in the development and aggressiveness of tumor malignancy, it then presents a promising cancer therapeutic target.  Several reversible FAK inhibitors have been developed and are being conducted in clin. trials.  Irreversible covalent inhibitors would bring many desirable pharmacol. features including high potency and increased duration of action.  Herein the authors report the structure-guided development of the first highly potent and irreversible inhibitor of the FAK kinase.  This inhibitor showed a very potent decrease of autophosphorylation of FAK in squamous cell carcinoma.  A co-crystal structure of the FAK kinase domain in complex with this compd. revealed the inhibitor binding mode within the ATP binding site and confirmed the covalent linkage between the targeted Cys 427 of the protein and the inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGry3Z3EZu1PlbVg90H21EOLACvtfcHk0ljFAZBqpT5pdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFWrtb%252FJ&md5=12f0e96763bba7196ff6eaf947cc9887</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facschembio.8b00250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.8b00250%26sid%3Dliteratum%253Aachs%26aulast%3DYen-Pon%26aufirst%3DE.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DAcebr%25C3%25B3n-Garcia-de-Eulate%26aufirst%3DM.%26aulast%3DTomkiewicz-Raulet%26aufirst%3DC.%26aulast%3DDawson%26aufirst%3DJ.%26aulast%3DLietha%26aufirst%3DD.%26aulast%3DFrame%26aufirst%3DM.%2BC.%26aulast%3DCoumoul%26aufirst%3DX.%26aulast%3DGarbay%26aufirst%3DC.%26aulast%3DEtheve-Quelquejeu%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DH.%26atitle%3DStructure-based%2520design%252C%2520synthesis%252C%2520and%2520characterization%2520of%2520the%2520first%2520irreversible%2520inhibitor%2520of%2520focal%2520adhesion%2520kinase%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2018%26volume%3D13%26spage%3D2067%26epage%3D2073%26doi%3D10.1021%2Facschembio.8b00250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ung, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whalen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hulford, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Autry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emerson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Alsina, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenzen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berliner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luzzio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaGreca, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jani, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wessel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marr, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vajdos, F.</span></span> <span> </span><span class="NLM_article-title">Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF 562,271</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">1935</span>– <span class="NLM_lpage">1944</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-5155</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1158%2F0008-5472.CAN-07-5155" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=18339875" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjtFOhtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=1935-1944&author=W.+G.+Robertsauthor=E.+Ungauthor=P.+Whalenauthor=B.+Cooperauthor=C.+Hulfordauthor=C.+Autryauthor=D.+Richterauthor=E.+Emersonauthor=J.+Linauthor=J.+Kathauthor=K.+Colemanauthor=L.+Yaoauthor=L.+Martinez-Alsinaauthor=M.+Lorenzenauthor=M.+Berlinerauthor=M.+Luzzioauthor=N.+Patelauthor=E.+Schmittauthor=S.+LaGrecaauthor=J.+Janiauthor=M.+Wesselauthor=E.+Marrauthor=M.+Grifforauthor=F.+Vajdos&title=Antitumor+activity+and+pharmacology+of+a+selective+focal+adhesion+kinase+inhibitor%2C+PF+562%2C271&doi=10.1158%2F0008-5472.CAN-07-5155"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor Activity and Pharmacology of a Selective Focal Adhesion Kinase Inhibitor, PF-562,271</span></div><div class="casAuthors">Roberts, Walter Gregory; Ung, Ethan; Whalen, Pamela; Cooper, Beth; Hulford, Catherine; Autry, Christofer; Richter, Daniel; Emerson, Earling; Lin, Jing; Kath, John; Coleman, Kevin; Yao, Lili; Martinez-Alsina, Luis; Lorenzen, Marianne; Berliner, Martin; Luzzio, Michael; Patel, Nandini; Schmitt, Erika; LaGreca, Susan; Jani, Jitesh; Wessel, Matt; Marr, Eric; Griffor, Matt; Vajdos, Felix</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1935-1944</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Cancer cells are characterized by the ability to grow in an anchorage-independent manner.  The activity of the nonreceptor tyrosine kinase, focal adhesion kinase (FAK), is thought to contribute to this phenotype.  FAK localizes in focal adhesion plaques and has a role as a scaffolding and signaling protein for other adhesion mols.  Recent studies show a strong correlation between increased FAK expression and phosphorylation status and the invasive phenotype of aggressive human tumors.  PF-562,271 is a potent, ATP-competitive, reversible inhibitor of FAK and Pyk2 catalytic activity with a IC50 of 1.5 and 14 nmol/L, resp.  Addnl., PF-562,271 displayed robust inhibition in an inducible cell-based assay measuring phospho-FAK with an IC50 of 5 nmol/L.  PF-562,271 was evaluated against multiple kinases and displays >100x selectivity against a long list of nontarget kinases.  PF-562,271 inhibits FAK phosphorylation in vivo in a dose-dependent fashion (calcd. EC50 of 93 ng/mL, total) after p.o. administration to tumor-bearing mice.  In vivo inhibition of FAK phosphorylation (>50%) was sustained for >4 h with a single p.o. dose of 33 mg/kg.  Antitumor efficacy and regressions were obsd. in multiple human s.c. xenograft models.  No wt. loss, morbidity, or mortality were obsd. in any in vivo expt.  Tumor growth inhibition was dose and drug exposure dependent.  Taken together, these data show that kinase inhibition with an ATP-competitive small mol. inhibitor of FAK decreases the phospho-status in vivo, resulting in robust antitumor activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofV3TtMU2E07Vg90H21EOLACvtfcHk0ljFAZBqpT5pdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjtFOhtrw%253D&md5=a5dad7cd49e32a9904de14fb34939be5</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-5155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-5155%26sid%3Dliteratum%253Aachs%26aulast%3DRoberts%26aufirst%3DW.%2BG.%26aulast%3DUng%26aufirst%3DE.%26aulast%3DWhalen%26aufirst%3DP.%26aulast%3DCooper%26aufirst%3DB.%26aulast%3DHulford%26aufirst%3DC.%26aulast%3DAutry%26aufirst%3DC.%26aulast%3DRichter%26aufirst%3DD.%26aulast%3DEmerson%26aufirst%3DE.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DKath%26aufirst%3DJ.%26aulast%3DColeman%26aufirst%3DK.%26aulast%3DYao%26aufirst%3DL.%26aulast%3DMartinez-Alsina%26aufirst%3DL.%26aulast%3DLorenzen%26aufirst%3DM.%26aulast%3DBerliner%26aufirst%3DM.%26aulast%3DLuzzio%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DN.%26aulast%3DSchmitt%26aufirst%3DE.%26aulast%3DLaGreca%26aufirst%3DS.%26aulast%3DJani%26aufirst%3DJ.%26aulast%3DWessel%26aufirst%3DM.%26aulast%3DMarr%26aufirst%3DE.%26aulast%3DGriffor%26aufirst%3DM.%26aulast%3DVajdos%26aufirst%3DF.%26atitle%3DAntitumor%2520activity%2520and%2520pharmacology%2520of%2520a%2520selective%2520focal%2520adhesion%2520kinase%2520inhibitor%252C%2520PF%2520562%252C271%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D1935%26epage%3D1944%26doi%3D10.1158%2F0008-5472.CAN-07-5155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Serafimova, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pufall, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maglathlin, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McFarland, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frödin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taunton, J.</span></span> <span> </span><span class="NLM_article-title">Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">471</span>– <span class="NLM_lpage">476</span>, <span class="refDoi"> DOI: 10.1038/nchembio.925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1038%2Fnchembio.925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=22466421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvVKitrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=471-476&author=I.+M.+Serafimovaauthor=M.+A.+Pufallauthor=S.+Krishnanauthor=K.+Dudaauthor=M.+S.+Cohenauthor=R.+L.+Maglathlinauthor=J.+M.+McFarlandauthor=R.+M.+Millerauthor=M.+Fr%C3%B6dinauthor=J.+Taunton&title=Reversible+targeting+of+noncatalytic+cysteines+with+chemically+tuned+electrophiles&doi=10.1038%2Fnchembio.925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles</span></div><div class="casAuthors">Serafimova, Iana M.; Pufall, Miles A.; Krishnan, Shyam; Duda, Katarzyna; Cohen, Michael S.; Maglathlin, Rebecca L.; McFarland, Jesse M.; Miller, Rand M.; Froedin, Morten; Taunton, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">471-476</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Targeting noncatalytic cysteine residues with irreversible acrylamide-based inhibitors is a powerful approach for enhancing pharmacol. potency and selectivity.  Nevertheless, concerns about off-target modification motivate the development of reversible cysteine-targeting strategies.  Here we show that electron-deficient olefins, including acrylamides, can be tuned to react with cysteine thiols in a rapidly reversible manner.  Installation of a nitrile group increased the olefins' intrinsic reactivity, but, paradoxically, eliminated the formation of irreversible adducts.  Incorporation of these electrophiles into a noncovalent kinase-recognition scaffold produced slowly dissocg., covalent inhibitors of the p90 ribosomal protein S6 kinase RSK2.  A cocrystal structure revealed specific noncovalent interactions that stabilize the complex by positioning the electrophilic carbon near the targeted cysteine.  Disruption of these interactions by protein unfolding or proteolysis promoted instantaneous cleavage of the covalent bond.  Our results establish a chem.-based framework for engineering sustained covalent inhibition without accumulating permanently modified proteins and peptides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlcv3GjPOB6rVg90H21EOLACvtfcHk0li4heduyn323g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvVKitrw%253D&md5=6455a9a029714beb317286f71ac1326b</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.925%26sid%3Dliteratum%253Aachs%26aulast%3DSerafimova%26aufirst%3DI.%2BM.%26aulast%3DPufall%26aufirst%3DM.%2BA.%26aulast%3DKrishnan%26aufirst%3DS.%26aulast%3DDuda%26aufirst%3DK.%26aulast%3DCohen%26aufirst%3DM.%2BS.%26aulast%3DMaglathlin%26aufirst%3DR.%2BL.%26aulast%3DMcFarland%26aufirst%3DJ.%2BM.%26aulast%3DMiller%26aufirst%3DR.%2BM.%26aulast%3DFr%25C3%25B6din%26aufirst%3DM.%26aulast%3DTaunton%26aufirst%3DJ.%26atitle%3DReversible%2520targeting%2520of%2520noncatalytic%2520cysteines%2520with%2520chemically%2520tuned%2520electrophiles%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2012%26volume%3D8%26spage%3D471%26epage%3D476%26doi%3D10.1038%2Fnchembio.925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schüttelkopf, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Aalten, D. M. F.</span></span> <span> </span><span class="NLM_article-title">PRODRG: a tool for high-throughput crystallography of protein-ligand complexes</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1355</span>– <span class="NLM_lpage">1363</span>, <span class="refDoi"> DOI: 10.1107/S0907444904011679</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1107%2FS0907444904011679" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=15272157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlvVegtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=1355-1363&author=A.+W.+Sch%C3%BCttelkopfauthor=D.+M.+F.+van+Aalten&title=PRODRG%3A+a+tool+for+high-throughput+crystallography+of+protein-ligand+complexes&doi=10.1107%2FS0907444904011679"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">PRODRG: a tool for high-throughput crystallography of protein-ligand complexes</span></div><div class="casAuthors">Schuettelkopf, Alexander W.; van Aalten, Daan M. F.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">D60</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1355-1363</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">The small-mol. topol. generator PRODRG is described, which takes input from existing coordinates or various two-dimensional formats and automatically generates coordinates and mol. topologies suitable for x-ray refinement of protein-ligand complexes.  Test results are described for automatic generation of topologies followed by energy minimization for a subset of compds. from the Cambridge Structural Database, which shows that, within the limits of the empirical GROMOS87 force field used, structures with good geometries are generated.  X-ray refinement in X-PLOR/CNS, REFMAC and SHELX using PRODRG-generated topologies produces results comparable to refinement with topologies from the std. libraries.  However, tests with distorted starting coordinates show that PRODRG topologies perform better, both in terms of ligand geometry and of crystallog. R factors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbflrch0bs97Vg90H21EOLACvtfcHk0li4heduyn323g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlvVegtbY%253D&md5=f9bfdb14be7b04ea5c0db67feb39f72a</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1107%2FS0907444904011679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444904011679%26sid%3Dliteratum%253Aachs%26aulast%3DSch%25C3%25BCttelkopf%26aufirst%3DA.%2BW.%26aulast%3Dvan%2BAalten%26aufirst%3DD.%2BM.%2BF.%26atitle%3DPRODRG%253A%2520a%2520tool%2520for%2520high-throughput%2520crystallography%2520of%2520protein-ligand%2520complexes%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2004%26volume%3D60%26spage%3D1355%26epage%3D1363%26doi%3D10.1107%2FS0907444904011679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lebedev, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isupov, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moroz, O. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vagin, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murshudov, G. N.</span></span> <span> </span><span class="NLM_article-title">JLigand: a graphical tool for the CCP4 template-restraint library</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">431</span>– <span class="NLM_lpage">440</span>, <span class="refDoi"> DOI: 10.1107/S090744491200251X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1107%2FS090744491200251X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=22505263" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BC38Xlt1Gnsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2012&pages=431-440&author=A.+A.+Lebedevauthor=P.+Youngauthor=M.+N.+Isupovauthor=O.+V.+Morozauthor=A.+A.+Vaginauthor=G.+N.+Murshudov&title=JLigand%3A+a+graphical+tool+for+the+CCP4+template-restraint+library&doi=10.1107%2FS090744491200251X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">JLigand: a graphical tool for the CCP4 template-restraint library</span></div><div class="casAuthors">Lebedev, Andrey A.; Young, Paul; Isupov, Michail N.; Moroz, Olga V.; Vagin, Alexey A.; Murshudov, Garib N.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">431-440</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Biol. macromols. are polymers and therefore the restraints for macromol. refinement can be subdivided into two sets: restraints that are applied to atoms that all belong to the same monomer and restraints that are assocd. with the covalent bonds between monomers.  The CCP4 template-restraint library contains three types of data entries defining template restraints: descriptions of monomers and their modifications, both used for intramonomer restraints, and descriptions of links for intermonomer restraints.  The library provides generic descriptions of modifications and links for protein, DNA and RNA chains, and for some post-translational modifications including glycosylation.  Structure-specific template restraints can be defined in a user's addnl. restraint library.  Here, JLigand, a new CCP4 graphical interface to LibCheck and REFMAC that has been developed to manage the user's library and generate new monomer entries is described, as well as new entries for links and assocd. modifications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_PAJI464bdLVg90H21EOLACvtfcHk0li4heduyn323g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xlt1Gnsr4%253D&md5=333c42dac336b0598540500f06350d3a</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1107%2FS090744491200251X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS090744491200251X%26sid%3Dliteratum%253Aachs%26aulast%3DLebedev%26aufirst%3DA.%2BA.%26aulast%3DYoung%26aufirst%3DP.%26aulast%3DIsupov%26aufirst%3DM.%2BN.%26aulast%3DMoroz%26aufirst%3DO.%2BV.%26aulast%3DVagin%26aufirst%3DA.%2BA.%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26atitle%3DJLigand%253A%2520a%2520graphical%2520tool%2520for%2520the%2520CCP4%2520template-restraint%2520library%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2012%26volume%3D68%26spage%3D431%26epage%3D440%26doi%3D10.1107%2FS090744491200251X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Richter, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kath, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luzzio, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keene, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berliner, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wessel, M. D.</span></span> <span> </span><span class="NLM_article-title">Selective addition of amines to 5-trifluoromethyl-2,4-dichloropyrimidine induced by Lewis acids</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">4610</span>– <span class="NLM_lpage">4612</span>, <span class="refDoi"> DOI: 10.1016/j.tetlet.2013.06.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1016%2Fj.tetlet.2013.06.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtV2ksrfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2013&pages=4610-4612&author=D.+T.+Richterauthor=J.+C.+Kathauthor=M.+J.+Luzzioauthor=N.+Keeneauthor=M.+A.+Berlinerauthor=M.+D.+Wessel&title=Selective+addition+of+amines+to+5-trifluoromethyl-2%2C4-dichloropyrimidine+induced+by+Lewis+acids&doi=10.1016%2Fj.tetlet.2013.06.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Selective addition of amines to 5-trifluoromethyl-2,4-dichloropyrimidine induced by Lewis acids</span></div><div class="casAuthors">Richter, Daniel T.; Kath, John C.; Luzzio, Michael J.; Keene, Nandell; Berliner, Martin A.; Wessel, Matthew D.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">4610-4612</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A variety of 2,4-diamino-pyrimidine systems can be prepd. from the corresponding 2,4-dichloro-pyrimidine by sequential addn. of two amines, the first adding selectively to the 4-position.  In contrast it was found that 2,4-dichloro-5-trifluoromethyl-pyrimidine yields a 1:1 mixt. of the two possible isomers.  Lewis acids were employed to increase the ratio of isomers to >10:1 in favor of the 2-addn. product, e. g., I.  Optimization of the effect of Lewis acid additives on this and other dichloropyrimidine systems will be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB8bhzGoYIgrVg90H21EOLACvtfcHk0li95DNtOpx-uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtV2ksrfK&md5=f67ba400cbbb568fe2afdfe5424019c0</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2013.06.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2013.06.025%26sid%3Dliteratum%253Aachs%26aulast%3DRichter%26aufirst%3DD.%2BT.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DLuzzio%26aufirst%3DM.%2BJ.%26aulast%3DKeene%26aufirst%3DN.%26aulast%3DBerliner%26aufirst%3DM.%2BA.%26aulast%3DWessel%26aufirst%3DM.%2BD.%26atitle%3DSelective%2520addition%2520of%2520amines%2520to%25205-trifluoromethyl-2%252C4-dichloropyrimidine%2520induced%2520by%2520Lewis%2520acids%26jtitle%3DTetrahedron%2520Lett.%26date%3D2013%26volume%3D54%26spage%3D4610%26epage%3D4612%26doi%3D10.1016%2Fj.tetlet.2013.06.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lough, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, H. L.</span></span> <span> </span><span class="NLM_article-title">Equilibrium reactions of N-butanethiol with some conjugated heteroenoid compounds</span>. <i>Can. J. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1968</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">775</span>– <span class="NLM_lpage">781</span>, <span class="refDoi"> DOI: 10.1139/v68-128</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1139%2Fv68-128" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADyaF1cXpsFSluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=1968&pages=775-781&author=R.+B.+Pritchardauthor=C.+E.+Loughauthor=D.+J.+Currieauthor=H.+L.+Holmes&title=Equilibrium+reactions+of+N-butanethiol+with+some+conjugated+heteroenoid+compounds&doi=10.1139%2Fv68-128"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Equilibrium reactions of butanethiol with some conjugated heteroenoid compounds</span></div><div class="casAuthors">Pritchard, R. B.; Lough, C. E.; Currie, D. J.; Holmes, Henry L.</div><div class="citationInfo"><span class="NLM_cas:title">Canadian Journal of Chemistry</span>
        (<span class="NLM_cas:date">1968</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">775-81</span>CODEN:
                <span class="NLM_cas:coden">CJCHAG</span>;
        ISSN:<span class="NLM_cas:issn">0008-4042</span>.
    </div><div class="casAbstract">The reactions of 2-benzal-1,3-indandiones and the cyano-contg. benzalmalononitriles, ethyl benzalcyanoacetates, benzalcyanoacetamides, and benzalcycanoacetanilides with butanethiol at 25° in 20% ethanol-80% pH 7 buffer attain equil. at a rate too fast to measure by standard methods.  The equil. consts. were calcd. and these in turn related to Hammett σ and Taft σ* consts.  The differences in the reactions of these and other gem difunctional systems which react virtually completely with butanethiol under the same exptl. conditions and at a measurable rate, are attributed to participation of the functional group cis to the Ph group in the reverse reaction.  It is shown that butanethiol adds to cinnamalacetophenone by a 1,4-mechanism and the reactions of this nucleophile with similar compds. having extended conjugated systems are discussed.  22 references.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKmmPRTCc-9rVg90H21EOLACvtfcHk0li95DNtOpx-uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF1cXpsFSluw%253D%253D&md5=4d45492d65fe1f3ad785210a7c5e4be2</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1139%2Fv68-128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1139%252Fv68-128%26sid%3Dliteratum%253Aachs%26aulast%3DPritchard%26aufirst%3DR.%2BB.%26aulast%3DLough%26aufirst%3DC.%2BE.%26aulast%3DCurrie%26aufirst%3DD.%2BJ.%26aulast%3DHolmes%26aufirst%3DH.%2BL.%26atitle%3DEquilibrium%2520reactions%2520of%2520N-butanethiol%2520with%2520some%2520conjugated%2520heteroenoid%2520compounds%26jtitle%3DCan.%2520J.%2520Chem.%26date%3D1968%26volume%3D46%26spage%3D775%26epage%3D781%26doi%3D10.1139%2Fv68-128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flippot, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magné, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vignot, S.</span></span> <span> </span><span class="NLM_article-title">FGF/FGFR Signalling: implication in oncogenesis and perspectives</span>. <i>Bull. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">516</span>– <span class="NLM_lpage">526</span>, <span class="refDoi"> DOI: 10.1016/j.bulcan.2015.04.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1016%2Fj.bulcan.2015.04.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=25986739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A280%3ADC%252BC2MfltVOlsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2015&pages=516-526&author=R.+Flippotauthor=M.+Koneauthor=N.+Magn%C3%A9author=S.+Vignot&title=FGF%2FFGFR+Signalling%3A+implication+in+oncogenesis+and+perspectives&doi=10.1016%2Fj.bulcan.2015.04.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">FGF/FGFR signalling: Implication in oncogenesis and perspectives</span></div><div class="casAuthors">Flippot Ronan; Kone Moumini; Magne Nicolas; Vignot Stephane</div><div class="citationInfo"><span class="NLM_cas:title">Bulletin du cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">516-26</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Deregulation of FGF (fibroblast growth factor)/FGFR (fibroblast growth factor receptor) signalling leads to the promotion of several oncogenic mechanisms: proliferation, epithelial-mesenchymal transition, cytoskeleton modifications, migration and angiogenesis.  Deregulation of this pathway is reported in various cancers at early stages, and can therefore be responsible for the emergence of the hallmarks of cancer.  It is necessary to precise downstream pathways of FGFR signalling to understand its oncogenic potential.  We will then describe its implications in different cancer types.  Oncogenic mechanisms will be studied through the example of melanoma, in which deregulation of FGF/FGFR pathway is considered as a driver event and occurs in nearly 90% of cases.  The FGF/FGFR signalling pathway is a putative therapeutic target.  Numerous agents are in active development, operating through a selective or multi-targeted approach.  Recent studies have shown rather disappointing results in non-selected patients, but promising results in patients with FGF/FGFR pathway alterations.  A careful screening of patients is the key to a valuable evaluation of these new targeted molecular therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR6HPunjVlFNq-9TkgmBqTqfW6udTcc2eYDzkZ0zUnoGbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MfltVOlsA%253D%253D&md5=b20bba3e85fa6601d18921e6bc344b08</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.bulcan.2015.04.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bulcan.2015.04.010%26sid%3Dliteratum%253Aachs%26aulast%3DFlippot%26aufirst%3DR.%26aulast%3DKone%26aufirst%3DM.%26aulast%3DMagn%25C3%25A9%26aufirst%3DN.%26aulast%3DVignot%26aufirst%3DS.%26atitle%3DFGF%252FFGFR%2520Signalling%253A%2520implication%2520in%2520oncogenesis%2520and%2520perspectives%26jtitle%3DBull.%2520Cancer%26date%3D2015%26volume%3D102%26spage%3D516%26epage%3D526%26doi%3D10.1016%2Fj.bulcan.2015.04.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chagoya, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwatra, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanni, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nullmeyergh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilmore, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spasojevic, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corcoran, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballman, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramakrishna, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markert, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesser, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwatra, M. M.</span></span> <span> </span><span class="NLM_article-title">Efficacy of osimertinib against EGFRvIII+ glioblastoma</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2074</span>– <span class="NLM_lpage">2082</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.27599</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.18632%2Foncotarget.27599" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=32547705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A280%3ADC%252BB38ngvVahsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=2074-2082&author=G.+Chagoyaauthor=S.+G.+Kwatraauthor=C.+W.+Nanniauthor=C.+M.+Robertsauthor=S.+M.+Phillipsauthor=S.+Nullmeyerghauthor=S.+P.+Gilmoreauthor=I.+Spasojevicauthor=D.+L.+Corcoranauthor=C.+C.+Youngauthor=K.+V.+Ballmanauthor=R.+Ramakrishnaauthor=D.+A.+Crossauthor=J.+M.+Markertauthor=M.+Limauthor=M.+R.+Gilbertauthor=G.+J.+Lesserauthor=M.+M.+Kwatra&title=Efficacy+of+osimertinib+against+EGFRvIII%2B+glioblastoma&doi=10.18632%2Foncotarget.27599"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of osimertinib against EGFRvIII+ glioblastoma</span></div><div class="casAuthors">Chagoya Gustavo; Markert James M; Kwatra Shawn G; Kwatra Shawn G; Nanni Cory W; Roberts Callie M; Gilmore Samuel P; Young Christopher C; Kwatra Madan M; Phillips Samantha M; Nullmeyergh Sarah; Kwatra Madan M; Spasojevic Ivan; Kwatra Madan M; Corcoran David L; Ballman Karla V; Ramakrishna Rohan; Cross Darren A; Lim Michael; Gilbert Mark R; Lesser Glenn J</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2074-2082</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Epidermal Growth Factor Receptor variant III (EGFRvIII) is an active mutant form of EGFR that drives tumor growth in a subset of glioblastoma (GBM).  It occurs in over 20% of GBMs, making it a promising receptor for small molecule targeted therapy.  We hypothesize that poor penetration of the blood-brain barrier by previously tested EGFR-tyrosine kinase inhibitors (EGFR-TKIs) such as afateninb, erlotinib, gefitinib, and lapatinib played a role in their limited efficacy.  The present study examined the effects of osimertinib (previously known as AZD9291) on EGFRvIII+ GBM models, both in vitro and in vivo.  Therefore, a panel of six GBM stem cells (GSCs) expressing EGFRvIII+ was evaluated.  The EGFRvIII+ GSC differed in the expression of EGFRvIII and other key genes.  The GSC line D317, which expresses high levels of EGFRvIII and has robust tyrosine kinase activity, was selected for assessing osimertinib's efficacy.  Herein, we report that osimertinib inhibits the constitutive activity of EGFRvIII tyrosine kinase with high potency (<100 nM) while also inhibiting its downstream signaling.  Further, osimertinib inhibited D317's growth in vitro and in both heterotopic and orthotopic xenograft models.  Additional preclinical studies are warranted to identify EGFRvIII+ GBM's molecular signature most responsive to osimertinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRPDwmlqQBUT8ve_zCu79I8fW6udTcc2eZhaxiJ_r7v77ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38ngvVahsQ%253D%253D&md5=c9e989f0f9f2a3514b123017a3220ba5</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.27599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.27599%26sid%3Dliteratum%253Aachs%26aulast%3DChagoya%26aufirst%3DG.%26aulast%3DKwatra%26aufirst%3DS.%2BG.%26aulast%3DNanni%26aufirst%3DC.%2BW.%26aulast%3DRoberts%26aufirst%3DC.%2BM.%26aulast%3DPhillips%26aufirst%3DS.%2BM.%26aulast%3DNullmeyergh%26aufirst%3DS.%26aulast%3DGilmore%26aufirst%3DS.%2BP.%26aulast%3DSpasojevic%26aufirst%3DI.%26aulast%3DCorcoran%26aufirst%3DD.%2BL.%26aulast%3DYoung%26aufirst%3DC.%2BC.%26aulast%3DBallman%26aufirst%3DK.%2BV.%26aulast%3DRamakrishna%26aufirst%3DR.%26aulast%3DCross%26aufirst%3DD.%2BA.%26aulast%3DMarkert%26aufirst%3DJ.%2BM.%26aulast%3DLim%26aufirst%3DM.%26aulast%3DGilbert%26aufirst%3DM.%2BR.%26aulast%3DLesser%26aufirst%3DG.%2BJ.%26aulast%3DKwatra%26aufirst%3DM.%2BM.%26atitle%3DEfficacy%2520of%2520osimertinib%2520against%2520EGFRvIII%252B%2520glioblastoma%26jtitle%3DOncotarget%26date%3D2020%26volume%3D11%26spage%3D2074%26epage%3D2082%26doi%3D10.18632%2Foncotarget.27599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mobley, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkaria, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span> <span> </span><span class="NLM_article-title">InsR/IGF1R pathway mediates resistance to EGFR inhibitors in glioblastoma</span>. <i>Clin Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1767</span>– <span class="NLM_lpage">1776</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-15-1677</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1158%2F1078-0432.CCR-15-1677" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=26561558" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BC28Xls1Kjtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=1767-1776&author=Y.+Maauthor=N.+Tangauthor=R.+C.+Thompsonauthor=B.+C.+Mobleyauthor=S.+W.+Clarkauthor=J.+N.+Sarkariaauthor=J.+Wang&title=InsR%2FIGF1R+pathway+mediates+resistance+to+EGFR+inhibitors+in+glioblastoma&doi=10.1158%2F1078-0432.CCR-15-1677"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma</span></div><div class="casAuthors">Ma, Yufang; Tang, Nan; Thompson, Reid C.; Mobley, Bret C.; Clark, Steven W.; Sarkaria, Jann N.; Wang, Jialiang</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1767-1776</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Aberrant activation of EGFR is a hallmark of glioblastoma.  However, EGFR inhibitors exhibit at best modest efficacy in glioblastoma.  This is in sharp contrast with the observations in EGFR-mutant lung cancer.  We examd. whether activation of functionally redundant receptor tyrosine kinases (RTKs) conferred resistance to EGFR inhibitors in glioblastoma.  Exptl. Design: We collected a panel of patient-derived glioblastoma xenograft (PDX) lines that maintained expression of wild-type or mutant EGFR in serial xenotransplantation and tissue cultures.  Using this physiol. relevant platform, we tested the abilities of several RTK ligands to protect glioblastoma cells against an EGFR inhibitor, gefitinib.  Based on the screening results, we further developed a combination therapy cotargeting EGFR and insulin receptor (InsR)/insulin-like growth factor 1 receptor (IGF1R).  Results: Insulin and IGF1 induced significant protection against gefitinib in the majority of EGFR-dependent PDX lines with one exception that did not express InsR or IGF1R.  Blockade of the InsR/IGF1R pathway synergistically improved sensitivity to gefitinib or dacomitinib.  Gefitinib alone effectively attenuated EGFR activities and the downstream MEK/ERK pathway.  However, repression of AKT and induction of apoptosis required concurrent inhibition of both EGFR and InsR/IGF1R.  A combination of gefitinib and OSI-906, a dual InsR/IGF1R inhibitor, was more effective than either agent alone to treat s.c. glioblastoma xenograft tumors.  Conclusions: Our results suggest that activation of the InsR/IGF1R pathway confers resistance to EGFR inhibitors in EGFR-dependent glioblastoma through AKT regulation.  Concurrent blockade of these two pathways holds promise to treat EGFR-dependent glioblastoma.  Clin Cancer Res; 22(7); 1767-76. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfsp3VSZQ4n7Vg90H21EOLACvtfcHk0lj-fIApzs7qvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xls1Kjtbw%253D&md5=cc93f6a60329e0ad6a13dc711c5525ef</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-1677&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-1677%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DY.%26aulast%3DTang%26aufirst%3DN.%26aulast%3DThompson%26aufirst%3DR.%2BC.%26aulast%3DMobley%26aufirst%3DB.%2BC.%26aulast%3DClark%26aufirst%3DS.%2BW.%26aulast%3DSarkaria%26aufirst%3DJ.%2BN.%26aulast%3DWang%26aufirst%3DJ.%26atitle%3DInsR%252FIGF1R%2520pathway%2520mediates%2520resistance%2520to%2520EGFR%2520inhibitors%2520in%2520glioblastoma%26jtitle%3DClin%2520Cancer%2520Res.%26date%3D2016%26volume%3D22%26spage%3D1767%26epage%3D1776%26doi%3D10.1158%2F1078-0432.CCR-15-1677" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kurio, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukazawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takaoka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okui, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassan, N. M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honami, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatakeyama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naomoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, A.</span></span> <span> </span><span class="NLM_article-title">Anti-tumor effect in human breast cancer by TAE226, a dual inhibitor for FAK and IGF-IR in vitro and in vivo</span>. <i>Exp Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>317</i></span>,  <span class="NLM_fpage">1134</span>– <span class="NLM_lpage">1146</span>, <span class="refDoi"> DOI: 10.1016/j.yexcr.2011.02.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1016%2Fj.yexcr.2011.02.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=21338601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkt12ntr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=317&publication_year=2011&pages=1134-1146&author=N.+Kurioauthor=T.+Shimoauthor=T.+Fukazawaauthor=M.+Takaokaauthor=T.+Okuiauthor=N.+M.+M.+Hassanauthor=T.+Honamiauthor=S.+Hatakeyamaauthor=M.+Ikedaauthor=Y.+Naomotoauthor=A.+Sasaki&title=Anti-tumor+effect+in+human+breast+cancer+by+TAE226%2C+a+dual+inhibitor+for+FAK+and+IGF-IR+in+vitro+and+in+vivo&doi=10.1016%2Fj.yexcr.2011.02.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-tumor effect in human breast cancer by TAE226, a dual inhibitor for FAK and IGF-IR in vitro and in vivo</span></div><div class="casAuthors">Kurio, Naito; Shimo, Tsuyoshi; Fukazawa, Takuya; Takaoka, Munenori; Okui, Tatsuo; Hassan, Nur Mohammad Monsur; Honami, Tatsuki; Hatakeyama, Shinji; Ikeda, Masahiko; Naomoto, Yoshio; Sasaki, Akira</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Cell Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">317</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1134-1146</span>CODEN:
                <span class="NLM_cas:coden">ECREAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-4827</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Focal adhesion kinase (FAK) is a 125-kDa non-receptor type tyrosine kinase that localizes to focal adhesions.  FAK overexpression is frequently found in invasive and metastatic cancers of the breast, colon, thyroid, and prostate, but its role in osteolytic metastasis is not well understood.  In this study, we have analyzed antitumor effects of the novel FAK Tyr397 inhibitor TAE226 against bone metastasis in breast cancer by using TAE226.  Oral administration of TAE226 in mice significantly decreased bone metastasis and osteoclasts involved which were induced by MDA-MB-231 breast cancer cells and increased the survival rate of the mouse models of bone metastasis.  TAE226 also suppressed the growth of s.c. tumors in vivo and the proliferation and migration of MDA-MB-231 cells in vitro.  Significantly, TAE226 inhibited the osteoclast formation in murine pre-osteoclastic RAW264.7 cells, and actin ring and pit formation in mature osteoclasts.  Moreover, TAE226 inhibited the receptor activator for nuclear factor κ B Ligand (RANKL) gene expression induced by parathyroid hormone-related protein (PTHrP) in bone stromal ST2 cells and blood free calcium concn. induced by PTHrP administration in vivo.  These findings suggest that FAK was critically involved in osteolytic metastasis and activated in tumors, pre-osteoclasts, mature osteoclasts, and bone stromal cells and TAE226 can be effectively used for the treatment of cancer induced bone metastasis and other bone diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr55W5F5GlRfbVg90H21EOLACvtfcHk0lj_H6hp6wPxTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkt12ntr0%253D&md5=1083838b4f36a4eaf62504d577b59ae5</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.yexcr.2011.02.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yexcr.2011.02.008%26sid%3Dliteratum%253Aachs%26aulast%3DKurio%26aufirst%3DN.%26aulast%3DShimo%26aufirst%3DT.%26aulast%3DFukazawa%26aufirst%3DT.%26aulast%3DTakaoka%26aufirst%3DM.%26aulast%3DOkui%26aufirst%3DT.%26aulast%3DHassan%26aufirst%3DN.%2BM.%2BM.%26aulast%3DHonami%26aufirst%3DT.%26aulast%3DHatakeyama%26aufirst%3DS.%26aulast%3DIkeda%26aufirst%3DM.%26aulast%3DNaomoto%26aufirst%3DY.%26aulast%3DSasaki%26aufirst%3DA.%26atitle%3DAnti-tumor%2520effect%2520in%2520human%2520breast%2520cancer%2520by%2520TAE226%252C%2520a%2520dual%2520inhibitor%2520for%2520FAK%2520and%2520IGF-IR%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DExp%2520Cell%2520Res.%26date%3D2011%26volume%3D317%26spage%3D1134%26epage%3D1146%26doi%3D10.1016%2Fj.yexcr.2011.02.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomkiewicz-Raule, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen-Pon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camacho-Artacho, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lietha, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbeuval, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coumoul, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbay, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and evaluation of novel imidazo[1,2-a][1,3,5]triazines and their derivatives as focal adhesion kinase inhibitors with antitumor activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">237</span>– <span class="NLM_lpage">251</span>, <span class="refDoi"> DOI: 10.1021/jm500784e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500784e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGhtLzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=237-251&author=P.+Daoauthor=N.+Smithauthor=C.+Tomkiewicz-Rauleauthor=E.+Yen-Ponauthor=M.+Camacho-Artachoauthor=D.+Liethaauthor=J.+P.+Herbeuvalauthor=X.+Coumoulauthor=C.+Garbayauthor=H.+Chen&title=Design%2C+Synthesis%2C+and+evaluation+of+novel+imidazo%5B1%2C2-a%5D%5B1%2C3%2C5%5Dtriazines+and+their+derivatives+as+focal+adhesion+kinase+inhibitors+with+antitumor+activity&doi=10.1021%2Fjm500784e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Evaluation of Novel Imidazo[1,2-a][1,3,5]triazines and Their Derivatives as Focal Adhesion Kinase Inhibitors with Antitumor Activity</span></div><div class="casAuthors">Dao, Pascal; Smith, Nikaia; Tomkiewicz-Raulet, Celine; Yen-Pon, Expedite; Camacho-Artacho, Marta; Lietha, Daniel; Herbeuval, Jean-Phillipe; Coumoul, Xavier; Garbay, Christiane; Chen, Huixiong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">237-251</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of triazinic inhibitors of focal adhesion kinase (FAK) have been recently shown to exert antiangiogenic activity against HUVEC cells and anticancer efficacy against several cancer cell lines.  We report herein that we further explored the heterocyclic core of these inhibitors by a fused imidazole ring with the triazine to provide imidazo[1,2-a][1,3,5]triazines, e.g., I.  Importantly, these new compds. displayed 10-7-10-8 M IC50 values, and the best inhibitor showed IC50 value of 50 nM against FAK enzymic activity.  Several inhibitors potently inhibited the proliferation of a panel of cancer cell lines expressing high levels of FAK.  Apoptosis anal. in U87-MG and HCT-116 cell lines suggested that these compds. delayed cell cycle progression by arresting cells in the G2/M phase of the cell cycle, retarding cell growth.  Further investigation demonstrated that these compds. strongly inhibited cell-matrix adhesion, migration, and invasion of U87-MG cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3lpXckaeVGrVg90H21EOLACvtfcHk0lj_H6hp6wPxTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGhtLzE&md5=0d2c7ef1b00e45bd462ea913b1bdc128</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm500784e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500784e%26sid%3Dliteratum%253Aachs%26aulast%3DDao%26aufirst%3DP.%26aulast%3DSmith%26aufirst%3DN.%26aulast%3DTomkiewicz-Raule%26aufirst%3DC.%26aulast%3DYen-Pon%26aufirst%3DE.%26aulast%3DCamacho-Artacho%26aufirst%3DM.%26aulast%3DLietha%26aufirst%3DD.%26aulast%3DHerbeuval%26aufirst%3DJ.%2BP.%26aulast%3DCoumoul%26aufirst%3DX.%26aulast%3DGarbay%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DH.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520evaluation%2520of%2520novel%2520imidazo%255B1%252C2-a%255D%255B1%252C3%252C5%255Dtriazines%2520and%2520their%2520derivatives%2520as%2520focal%2520adhesion%2520kinase%2520inhibitors%2520with%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D237%26epage%3D251%26doi%3D10.1021%2Fjm500784e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span> <span> </span><span class="NLM_article-title">FAK inhibitors induce cell multinucleation and dramatically increase pro-tumoral cytokine expression in RAW 264.7 macrophages</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>591</i></span>,  <span class="NLM_fpage">3861</span>– <span class="NLM_lpage">3871</span>, <span class="refDoi"> DOI: 10.1002/1873-3468.12895</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1002%2F1873-3468.12895" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=29090460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVKht7zJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=591&publication_year=2017&pages=3861-3871&author=X.+Heauthor=X.+Chenauthor=B.+Liauthor=J.+Jiauthor=S.+Chen&title=FAK+inhibitors+induce+cell+multinucleation+and+dramatically+increase+pro-tumoral+cytokine+expression+in+RAW+264.7+macrophages&doi=10.1002%2F1873-3468.12895"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">FAK inhibitors induce cell multinucleation and dramatically increase pro-tumoral cytokine expression in RAW 264.7 macrophages</span></div><div class="casAuthors">He, Xia; Chen, Xin; Li, Bogang; Ji, Jianxin; Chen, Shuang</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">591</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3861-3871</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Macrophages are abundant in the tumor microenvironment.  They are highly plastic and able to acquire pro-tumoral phenotypes in response to microenvironmental stimuli.  When we treated RAW 264.7 macrophages with inhibitors of various oncogenic pathways, we found that the focal adhesion kinase (FAK) inhibitors PF573228 and TAE226 could induce cell multi-nucleation by suppressing furrowing and cytokinesis.  This failure in cytokinesis involves Rac1, whose activity is elevated by FAK inhibitors, and the p21-activated kinases, comprising the downstream effectors of Rac.  We also investigated the influence of cell multi-nucleation on macrophage physiol. in RAW 264.7 cells.  This is the first study to report that FAK inhibitors suppress furrow ingression and early cytokinesis.  Of note, we found that FAK inhibitors caused a dramatic increase in pro-tumoral cytokines in multi-nuclear cells, suggesting the potential to convert macrophages into pro-tumoral phenotypes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrxjlS1jLRybVg90H21EOLACvtfcHk0lj_H6hp6wPxTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVKht7zJ&md5=c47e893ccd63810c06fd4cf2d399d09d</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1002%2F1873-3468.12895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1873-3468.12895%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DJi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DS.%26atitle%3DFAK%2520inhibitors%2520induce%2520cell%2520multinucleation%2520and%2520dramatically%2520increase%2520pro-tumoral%2520cytokine%2520expression%2520in%2520RAW%2520264.7%2520macrophages%26jtitle%3DFEBS%2520Lett.%26date%3D2017%26volume%3D591%26spage%3D3861%26epage%3D3871%26doi%3D10.1002%2F1873-3468.12895" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, J. A.</span></span> <span> </span><span class="NLM_article-title">Actin, a central player in cell shape and movement</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>326</i></span>,  <span class="NLM_fpage">1208</span>– <span class="NLM_lpage">1212</span>, <span class="refDoi"> DOI: 10.1126/science.1175862</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1126%2Fscience.1175862" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=19965462" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVKhur7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=326&publication_year=2009&pages=1208-1212&author=T.+D.+Pollardauthor=J.+A.+Cooper&title=Actin%2C+a+central+player+in+cell+shape+and+movement&doi=10.1126%2Fscience.1175862"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Actin, a central player in cell shape and movement</span></div><div class="casAuthors">Pollard, Thomas D.; Cooper, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">326</span>
        (<span class="NLM_cas:issue">5957</span>),
    <span class="NLM_cas:pages">1208-1212</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review.  Actin forms filaments that provide cells with mech. support and driving forces for movement.  Actin contributes to biol. processes such as sensing environmental forces, internalizing membrane vesicles, moving over surfaces, and dividing the cell in two.  These cellular activities are complex; they depend on interactions of actin monomers and filaments with numerous other proteins.  Here, the authors present a summary of the key questions in the field and suggest how those questions might be answered.  Understanding actin-based biol. phenomena will depend on identifying the participating mols. and defining their mol. mechanisms.  Comparisons of quant. measurements of reactions in live cells with computer simulations of math. models will also help generate meaningful insights.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvOwpGQVc49rVg90H21EOLACvtfcHk0lh_TAJL9OdH5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVKhur7L&md5=24c5374707cad687458434e5ee440f33</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1126%2Fscience.1175862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1175862%26sid%3Dliteratum%253Aachs%26aulast%3DPollard%26aufirst%3DT.%2BD.%26aulast%3DCooper%26aufirst%3DJ.%2BA.%26atitle%3DActin%252C%2520a%2520central%2520player%2520in%2520cell%2520shape%2520and%2520movement%26jtitle%3DScience%26date%3D2009%26volume%3D326%26spage%3D1208%26epage%3D1212%26doi%3D10.1126%2Fscience.1175862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tojkander, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gateva, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lappalainen, P.</span></span> <span> </span><span class="NLM_article-title">Actin stress fibers-assembly, dynamics and biological roles</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">1855</span>– <span class="NLM_lpage">1864</span>, <span class="refDoi"> DOI: 10.1242/jcs.098087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1242%2Fjcs.098087" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=22544950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVGltrzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2012&pages=1855-1864&author=S.+Tojkanderauthor=G.+Gatevaauthor=P.+Lappalainen&title=Actin+stress+fibers-assembly%2C+dynamics+and+biological+roles&doi=10.1242%2Fjcs.098087"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Actin stress fibers - assembly, dynamics and biological roles</span></div><div class="casAuthors">Tojkander, Sari; Gateva, Gergana; Lappalainen, Pekka</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1855-1864</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">A review.  Actin filaments assemble into diverse protrusive and contractile structures to provide force for a no. of vital cellular processes.  Stress fibers are contractile actomyosin bundles found in many cultured non-muscle cells, where they have a central role in cell adhesion and morphogenesis.  Focal-adhesion-anchored stress fibers also have an important role in mechanotransduction.  In animal tissues, stress fibers are esp. abundant in endothelial cells, myofibroblasts and epithelial cells.  Importantly, recent live-cell imaging studies have provided new information regarding the mechanisms of stress fiber assembly and how their contractility is regulated in cells.  In addn., these studies might elucidate the general mechanisms by which contractile actomyosin arrays, including muscle cell myofibrils and cytokinetic contractile ring, can be generated in cells.  In this Commentary, we discuss recent findings concerning the physiol. roles of stress fibers and the mechanism by which these structures are generated in cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4NnkBM0jRo7Vg90H21EOLACvtfcHk0lh_TAJL9OdH5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVGltrzF&md5=831f7cecfedc5bd7cd3bb3008c139607</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1242%2Fjcs.098087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.098087%26sid%3Dliteratum%253Aachs%26aulast%3DTojkander%26aufirst%3DS.%26aulast%3DGateva%26aufirst%3DG.%26aulast%3DLappalainen%26aufirst%3DP.%26atitle%3DActin%2520stress%2520fibers-assembly%252C%2520dynamics%2520and%2520biological%2520roles%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2012%26volume%3D125%26spage%3D1855%26epage%3D1864%26doi%3D10.1242%2Fjcs.098087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shannon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Entersz, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beelen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carcione, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carcione, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahtabfar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaca, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shreiber, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahn, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foty, R. A.</span></span> <span> </span><span class="NLM_article-title">Inhibition of glioblastoma dispersal by the MEK inhibitor PD0325901</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>, <span class="NLM_elocation-id">121</span> <span class="refDoi"> DOI: 10.1186/s12885-017-3107-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1186%2Fs12885-017-3107-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=28187762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjvVWhsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&author=S.+Shannonauthor=D.+Jiaauthor=I.+Enterszauthor=P.+Beelenauthor=M.+Yuauthor=C.+Carcioneauthor=J.+Carcioneauthor=A.+Mahtabfarauthor=C.+Vacaauthor=M.+Weaverauthor=D.+Shreiberauthor=J.+D.+Zahnauthor=L.+Liuauthor=H.+Linauthor=R.+A.+Foty&title=Inhibition+of+glioblastoma+dispersal+by+the+MEK+inhibitor+PD0325901&doi=10.1186%2Fs12885-017-3107-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of glioblastoma dispersal by the MEK inhibitor PD0325901</span></div><div class="casAuthors">Shannon, Stephen; Jia, Dongxuan; Entersz, Ildiko; Beelen, Paul; Yu, Miao; Carcione, Christian; Carcione, Jonathan; Mahtabfar, Aria; Vaca, Connan; Weaver, Michael; Shreiber, David; Zahn, Jeffrey D.; Liu, Liping; Lin, Hao; Foty, Ramsey A.</div><div class="citationInfo"><span class="NLM_cas:title">BMC Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">121/1-121/11</span>CODEN:
                <span class="NLM_cas:coden">BCMACL</span>;
        ISSN:<span class="NLM_cas:issn">1471-2407</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Dispersal of glioblastoma (GBM) cells leads to recurrence and poor prognosis.  Accordingly, mol. pathways involved in dispersal are potential therapeutic targets.  The mitogen activated protein kinase/extracellular signal regulated kinase (MAPK/ERK) pathway is commonly dysregulated in GBM, and targeting this pathway with MEK inhibitors has proven effective in controlling tumor growth.  Since this pathway also regulates ECM remodeling and actin organization - processes crucial to cell adhesion, substrate attachment, and cell motility - the aim of this study was to det. whether inhibiting this pathway could also impede dispersal.  Methods: A variety of methods were used to quantify the effects of the MEK inhibitor, PD0325901, on potential regulators of dispersal.  Cohesion, stiffness and viscosity were quantified using a method based on ellipsoid relaxation after removal of a deforming external force.  Attachment strength, cell motility, spheroid dispersal velocity, and 3D growth rate were quantified using previously described methods.  Results: We show that PD0325901 significantly increases aggregate cohesion, stiffness, and viscosity but only when tumor cells have access to high concns. of fibronectin.  Treatment also results in reorganization of actin from cortical into stress fibers, in both 2D and 3D culture.  Moreover, drug treatment localized pFAK at sites of cell-substratum adhesion.  Collectively, these changes resulted in increased strength of substrate attachment and decreased motility, a decrease in aggregate dispersal velocity, and in a marked decrease in growth rate of both 2D and 3D cultures.  Conclusions: Inhibition of the MAPK/ERK pathway by PD0325901 may be an effective therapy for reducing dispersal and growth of GBM cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdyWA292c227Vg90H21EOLACvtfcHk0lh_TAJL9OdH5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjvVWhsrs%253D&md5=ebc4d54360e6441d85e2bc6195a067b4</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1186%2Fs12885-017-3107-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12885-017-3107-x%26sid%3Dliteratum%253Aachs%26aulast%3DShannon%26aufirst%3DS.%26aulast%3DJia%26aufirst%3DD.%26aulast%3DEntersz%26aufirst%3DI.%26aulast%3DBeelen%26aufirst%3DP.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DCarcione%26aufirst%3DC.%26aulast%3DCarcione%26aufirst%3DJ.%26aulast%3DMahtabfar%26aufirst%3DA.%26aulast%3DVaca%26aufirst%3DC.%26aulast%3DWeaver%26aufirst%3DM.%26aulast%3DShreiber%26aufirst%3DD.%26aulast%3DZahn%26aufirst%3DJ.%2BD.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DFoty%26aufirst%3DR.%2BA.%26atitle%3DInhibition%2520of%2520glioblastoma%2520dispersal%2520by%2520the%2520MEK%2520inhibitor%2520PD0325901%26jtitle%3DBMC%2520Cancer%26date%3D2017%26volume%3D17%26doi%3D10.1186%2Fs12885-017-3107-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuller, G. N.</span></span> <span> </span><span class="NLM_article-title">Analysis of the activation status of Akt, NFkappaB, and Stat3 in human diffuse gliomas</span>. <i>Lab Invest.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">941</span>– <span class="NLM_lpage">951</span>, <span class="refDoi"> DOI: 10.1038/labinvest.3700123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1038%2Flabinvest.3700123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=15184909" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmvF2ksL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2004&pages=941-951&author=H.+Wangauthor=H.+Wangauthor=W.+Zhangauthor=H.+J.+Huangauthor=W.+S.+Liaoauthor=G.+N.+Fuller&title=Analysis+of+the+activation+status+of+Akt%2C+NFkappaB%2C+and+Stat3+in+human+diffuse+gliomas&doi=10.1038%2Flabinvest.3700123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of the activation status of Akt, NF.vkappa.B, and Stat3 in human diffuse gliomas</span></div><div class="casAuthors">Wang, Huamin; Wang, Hua; Zhang, Wei; Huang, Helen J.; Liao, Warren S. L.; Fuller, Gregory N.</div><div class="citationInfo"><span class="NLM_cas:title">Laboratory Investigation</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">941-951</span>CODEN:
                <span class="NLM_cas:coden">LAINAW</span>;
        ISSN:<span class="NLM_cas:issn">0023-6837</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Loss of phosphatase and tensin homolog (PTEN) and amplification of the epidermal growth factor receptor (EGFR) gene contribute to the progression of gliomas.  As downstream targets of the PTEN and EGFR signaling pathways, Akt, NF.vkappa.B, and signal transducer and activator of transcription-3 (Stat3) have been shown to play important roles in the control of cell proliferation, apoptosis, and oncogenesis.  The authors examd. the activation status of Akt, NF.vkappa.B, and Stat3 in 259 diffuse gliomas using tissue microarrays and immunohistochem., and evaluated their assocn. with glioma grade.  They obsd. significant pos. correlations between the activation status of Akt and NF.vkappa.B and glioma grade.  In contrast, only focal immunoreactivity for phospho-Stat3 was obsd. in <9% of high-grade gliomas.  In addn., they obsd. a significant correlation between the activation of Akt and NF.vkappa.B.  Functional correlation between Akt activation and the activation of NF.vkappa.B was confirmed in U251 MG GBM cells in which inhibition of Akt activation either by stable expression of PTEN or by the PI3-kinase inhibitors, wortmannin and LY294002, led to a concomitant decrease in NF.vkappa.B-binding activity.  Thus, the authors' results demonstrate that constitutive activation of Akt and NF.vkappa.B, but not Stat3, contributes significantly to the progression of diffuse gliomas, and activation of Akt may lead to NF.vkappa.B activation in high-grade gliomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCYk8nPy5DIrVg90H21EOLACvtfcHk0lgp7RoZD2SWwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmvF2ksL0%253D&md5=a7ac839b176336b8df970226fbe92e10</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Flabinvest.3700123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Flabinvest.3700123%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DH.%2BJ.%26aulast%3DLiao%26aufirst%3DW.%2BS.%26aulast%3DFuller%26aufirst%3DG.%2BN.%26atitle%3DAnalysis%2520of%2520the%2520activation%2520status%2520of%2520Akt%252C%2520NFkappaB%252C%2520and%2520Stat3%2520in%2520human%2520diffuse%2520gliomas%26jtitle%3DLab%2520Invest.%26date%3D2004%26volume%3D84%26spage%3D941%26epage%3D951%26doi%3D10.1038%2Flabinvest.3700123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sudheerkumar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiras, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jagtap, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shastry, P.</span></span> <span> </span><span class="NLM_article-title">Independent activation of Akt and NF-kappaB pathways and their role in resistance to TNF-alpha mediated cytotoxicity in gliomas</span>. <i>Mol. Carcinog.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">126</span>– <span class="NLM_lpage">136</span>, <span class="refDoi"> DOI: 10.1002/mc.20372</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1002%2Fmc.20372" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=17849421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A280%3ADC%252BD1c%252FlsFCqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2008&pages=126-136&author=P.+Sudheerkumarauthor=A.+Shirasauthor=G.+Dasauthor=J.+C.+Jagtapauthor=V.+Prasadauthor=P.+Shastry&title=Independent+activation+of+Akt+and+NF-kappaB+pathways+and+their+role+in+resistance+to+TNF-alpha+mediated+cytotoxicity+in+gliomas&doi=10.1002%2Fmc.20372"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Independent activation of Akt and NF-kappaB pathways and their role in resistance to TNF-alpha mediated cytotoxicity in gliomas</span></div><div class="casAuthors">Sudheerkumar P; Shiras Anjali; Das Gowry; Jagtap Jayashree C; Prasad Vandna; Shastry Padma</div><div class="citationInfo"><span class="NLM_cas:title">Molecular carcinogenesis</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">126-36</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Tumor associated macrophages (TAMs) constitute a substantial mass in gliomas.  The activated macrophages secrete various cytokines that affect diverse functions of tumors.  The aim of this study was to elucidate the role of Akt and NF-kappaB pathways in resistance to TNF-alpha mediated cell death in human gliomas using monolayers and multicellular spheroids (MCS) as in vitro models.  Akt and NF-kappaB are constitutively expressed and intimately involved in progression of gliomas.  The activation of these pathways also renders the tumors resistant to conventional treatments including chemotherapy.  While PI3K/Akt is shown to regulate the NF-kappaB activation in diverse systems, other studies place NF-kappaB upstream of Akt activation.  Using a stable IkappaBalpha mutant LN-18 cell line and pharmacological inhibitors to PI3K/Akt (LY294002) and Akt (Akt2), we provide evidence that Akt and NF-kappaB are activated independently on stimulation with TNF-alpha and both the pathways contribute towards resistance to TNF-alpha mediated cell death.  TNF-alpha-induced NF-kappaB activation independent of PI3K/Akt pathway was also confirmed in human glioma cell lines-LN-229 and U373MG.  We also show that NF-kappaB and Akt are activated during spheroidogenesis and their expression is further enhanced on stimulation with TNF-alpha implicating their involvement in resistance to cell death.  The findings thus underscore the relevance of spheroids as appropriate in vitro models for studying the signaling pathways in drug induced resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTAmbGdw5-hXax48Rj5GnGofW6udTcc2ebbdOLCF7bUF7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c%252FlsFCqtw%253D%253D&md5=534540554597cd9be5a7bea5d680fa25</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1002%2Fmc.20372&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmc.20372%26sid%3Dliteratum%253Aachs%26aulast%3DSudheerkumar%26aufirst%3DP.%26aulast%3DShiras%26aufirst%3DA.%26aulast%3DDas%26aufirst%3DG.%26aulast%3DJagtap%26aufirst%3DJ.%2BC.%26aulast%3DPrasad%26aufirst%3DV.%26aulast%3DShastry%26aufirst%3DP.%26atitle%3DIndependent%2520activation%2520of%2520Akt%2520and%2520NF-kappaB%2520pathways%2520and%2520their%2520role%2520in%2520resistance%2520to%2520TNF-alpha%2520mediated%2520cytotoxicity%2520in%2520gliomas%26jtitle%3DMol.%2520Carcinog.%26date%3D2008%26volume%3D47%26spage%3D126%26epage%3D136%26doi%3D10.1002%2Fmc.20372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krippendorff, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuhaus, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lienau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huisinga, W. J.</span></span> <span> </span><span class="NLM_article-title">Mechanism-based inhibition: deriving KI and kinact directly from time-dependent IC50 values</span>. <i>J. Biomol. Screening</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">913</span>– <span class="NLM_lpage">919</span>, <span class="refDoi"> DOI: 10.1177/1087057109336751</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1177%2F1087057109336751" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=19675314" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlSjtLjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=913-919&author=B.+F.+Krippendorffauthor=R.+Neuhausauthor=P.+Lienauauthor=A.+Reichelauthor=W.+J.+Huisinga&title=Mechanism-based+inhibition%3A+deriving+KI+and+kinact+directly+from+time-dependent+IC50+values&doi=10.1177%2F1087057109336751"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism-based inhibition: deriving KI and kinact directly from time-dependent IC50 values</span></div><div class="casAuthors">Krippendorff, Ben-Fillippo; Neuhaus, Roland; Lienau, Philip; Reichel, Andreas; Huisinga, Wilhelm</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">913-923</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">The potential of enzyme inhibition of a drug is frequently quantified in terms of IC50 values.  Although this is a suitable quantity for reversible inhibitors, concerns arise when dealing with irreversible or mechanism-based inhibitors (MBIs).  IC50 values of MBIs are time dependent, causing serious problems when aiming at ranking different compds. with respect to their inhibitory potential.  As a consequence, most studies and ranking schemes related to MBIs rely on the inhibition const. (KI) and the rate of enzyme inactivation (kinact) rather than on IC50 values.  In this article, the authors derive a novel relation between potentially time-dependent IC50 values and KI, kinact parameters for different types of inhibition.  This allows for direct estn. of KI and kinact values from time-dependent IC50 values, even without the need of addnl. preincubation expts.  The application of this approach is illustrated using a fluorimetric assay to access the drug-drug interaction potential assocd. with new chem. entities.  The approach can easily be implemented using std. software tools (e.g., XLfit) and may also be suitable for applications where mechanism-based inhibition is a desired mode of action (e.g., at particular pharmacol. drug targets).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSOIpe0vN8JLVg90H21EOLACvtfcHk0lgp7RoZD2SWwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlSjtLjF&md5=93cb5f8644c7e1bdf872cf46756039cf</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1177%2F1087057109336751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057109336751%26sid%3Dliteratum%253Aachs%26aulast%3DKrippendorff%26aufirst%3DB.%2BF.%26aulast%3DNeuhaus%26aufirst%3DR.%26aulast%3DLienau%26aufirst%3DP.%26aulast%3DReichel%26aufirst%3DA.%26aulast%3DHuisinga%26aufirst%3DW.%2BJ.%26atitle%3DMechanism-based%2520inhibition%253A%2520deriving%2520KI%2520and%2520kinact%2520directly%2520from%2520time-dependent%2520IC50%2520values%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2009%26volume%3D14%26spage%3D913%26epage%3D919%26doi%3D10.1177%2F1087057109336751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 3 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chao-Jie  Wang</span>, <span class="hlFld-ContribAuthor ">Xinxin  Guo</span>, <span class="hlFld-ContribAuthor ">Rui-Qin  Zhai</span>, <span class="hlFld-ContribAuthor ">Changning  Sun</span>, <span class="hlFld-ContribAuthor ">Guokai  Xiao</span>, <span class="hlFld-ContribAuthor ">Jin  Chen</span>, <span class="hlFld-ContribAuthor ">Mei-Yan  Wei</span>, <span class="hlFld-ContribAuthor ">Chang-Lun  Shao</span>, <span class="hlFld-ContribAuthor ">Yuchao  Gu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of penipanoid C-inspired 2-(3,4,5-trimethoxybenzoyl)quinazolin-4(3H)-one derivatives as potential anticancer agents by inhibiting cell proliferation and inducing apoptosis in hepatocellular carcinoma cells. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>224 </em>, 113671. <a href="https://doi.org/10.1016/j.ejmech.2021.113671" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113671</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113671&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113671%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bpenipanoid%252BC-inspired%252B2-%2525283%25252C4%25252C5-trimethoxybenzoyl%252529quinazolin-4%2525283H%252529-one%252Bderivatives%252Bas%252Bpotential%252Banticancer%252Bagents%252Bby%252Binhibiting%252Bcell%252Bproliferation%252Band%252Binducing%252Bapoptosis%252Bin%252Bhepatocellular%252Bcarcinoma%252Bcells%26aulast%3DWang%26aufirst%3DChao-Jie%26date%3D2021%26volume%3D224%26spage%3D113671" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiao-Jing  Pang</span>, <span class="hlFld-ContribAuthor ">Xiu-Juan  Liu</span>, <span class="hlFld-ContribAuthor ">Yuan  Liu</span>, <span class="hlFld-ContribAuthor ">Wen-Bo  Liu</span>, <span class="hlFld-ContribAuthor ">Yin-Ru  Li</span>, <span class="hlFld-ContribAuthor ">Guang-Xi  Yu</span>, <span class="hlFld-ContribAuthor ">Xin-Yi  Tian</span>, <span class="hlFld-ContribAuthor ">Yan-Bing  Zhang</span>, <span class="hlFld-ContribAuthor ">Jian  Song</span>, <span class="hlFld-ContribAuthor ">Cheng-Yun  Jin</span>, <span class="hlFld-ContribAuthor ">Sai-Yang  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Drug Discovery Targeting Focal Adhesion Kinase (FAK) as a Promising Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (14)
                                     , 4250. <a href="https://doi.org/10.3390/molecules26144250" title="DOI URL">https://doi.org/10.3390/molecules26144250</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26144250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26144250%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DDrug%252BDiscovery%252BTargeting%252BFocal%252BAdhesion%252BKinase%252B%252528FAK%252529%252Bas%252Ba%252BPromising%252BCancer%252BTherapy%26aulast%3DPang%26aufirst%3DXiao-Jing%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D14%26spage%3D4250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kaibo  Guo</span>, <span class="hlFld-ContribAuthor ">Yuqian  Feng</span>, <span class="hlFld-ContribAuthor ">Xueer  Zheng</span>, <span class="hlFld-ContribAuthor ">Leitao  Sun</span>, <span class="hlFld-ContribAuthor ">Harpreet S.  Wasan</span>, <span class="hlFld-ContribAuthor ">Shanming  Ruan</span>, <span class="hlFld-ContribAuthor ">Minhe  Shen</span>. </span><span class="cited-content_cbyCitation_article-title">Resveratrol and Its Analogs: Potent Agents to Reverse Epithelial-to-Mesenchymal Transition in Tumors. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Oncology</span><span> <strong>2021,</strong> <em>11 </em><a href="https://doi.org/10.3389/fonc.2021.644134" title="DOI URL">https://doi.org/10.3389/fonc.2021.644134</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fonc.2021.644134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffonc.2021.644134%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Oncology%26atitle%3DResveratrol%252Band%252BIts%252BAnalogs%25253A%252BPotent%252BAgents%252Bto%252BReverse%252BEpithelial-to-Mesenchymal%252BTransition%252Bin%252BTumors%26aulast%3DGuo%26aufirst%3DKaibo%26date%3D2021%26date%3D2021%26volume%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/medium/jm0c01059_0014.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/large/jm0c01059_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01059&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/medium/jm0c01059_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/large/jm0c01059_0002.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of FAK inhibitors in preclinical and clinical trials.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/large/jm0c01059_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01059&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/medium/jm0c01059_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/large/jm0c01059_0003.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Design strategy of FAK covalent inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/large/jm0c01059_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01059&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/medium/jm0c01059_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/large/jm0c01059_0010.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Reagents and conditions<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/large/jm0c01059_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01059&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) Substituted aniline, NaHCO<sub>3</sub>, EtOH, reflux, overnight (for <b>1a–b</b>); (b) benzylamine derivatives (or pyridin-3-ylmethanamine derivative for <b>1f</b>), DIPEA, THF, rt, overnight (for <b>1c–f</b>); (c) allyl(4-aminobenzyl)carbamate, HCl in dioxane, <i>n</i>-BuOH, 100 °C, overnight (for <b>2a</b>, <b>2c</b>–<b>2f</b>); (d) <i>tert</i>-butyl(4-aminobenzyl)carbamate, Pd<sub>2</sub>(dba)<sub>3</sub>, XantPhos, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, reflux, 24 h (for <b>2b</b>); (e) allyl(4-aminobenzyl)carbamate, zinc chloride, Et<sub>3</sub>N, <i>t</i>-BuOH/dichloromethane (DCM) (1/1), 0 °C—rt, 6 h; (f) 2-amino-<i>N</i>-methylbenzamide, HCl in dioxane, DMF, 90 °C, 7 h.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/medium/jm0c01059_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/large/jm0c01059_0011.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Reagents and Conditions<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/large/jm0c01059_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01059&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) Morpholine, Pd(PPh<sub>3</sub>)<sub>4</sub>, THF or DMF, rt, 3 h (for <b>2a</b>, <b>2c–g</b>), or TFA/DCM (v/v = 1/1), rt, 30 min (for <b>2b</b>); (b) DIPEA, <i>tert</i>-butyl(2-((2-methoxyl-3,4-dioxacyclobut-1-en-1-yl)amino)ethyl)carbamate, DMF, 75 °C, overnight; (c) TFA/DCM (v/v = 1/1), rt, 30 min; (d) appropriate chloride (acryloyl chloride for <b>7a<sub>1</sub>–g</b>, 2-chloroacetyl chloride for <b>7a<sub>2</sub></b>), 0 °C—rt, 12 h.</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/medium/jm0c01059_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/large/jm0c01059_0012.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Reagents and Conditions<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/large/jm0c01059_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01059&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) Cyanoacetic acid, EDCI, HOBT, DIPEA, DMF, 0 °C—rt, overnight; (b) appropriate aldehyde, AcOH, piperidine, DMF, 100 °C, 2 h.</p></p></figure><figure data-id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/medium/jm0c01059_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/large/jm0c01059_0004.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. β-Mercaptoethanol addition to compounds <b>7a</b><sub><b>1</b></sub> and <b>9c</b> monitored by LC–MS/MS.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/large/jm0c01059_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01059&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/medium/jm0c01059_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/large/jm0c01059_0005.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Inhibition of FAK autophosphorylation in U-87 MG cells. (A) Cells were treated for 48 h with compounds <b>7a</b><sub><b>1</b></sub>, <b>9b</b>, <b>9c</b> or TAE-226 as control at 0.6 and 3 μM. (B) TAE-226 and compounds <b>7a</b><sub><b>1</b></sub>, <b>9b</b>, and <b>9c</b> inhibited FAK autophosphorylation in a dose-dependent manner. (C) Compounds <b>7a</b><sub><b>1</b></sub>, <b>9b</b>, and <b>9c</b> sustained inhibition of FAK autophosphorylation after washout experiments, which is not the case for TAE-226. Data obtained represent the mean of triplicate readings of three independent experiments. *<i>p</i> < 0.05 and **<i>p</i> < 0.01 compared with the control group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/large/jm0c01059_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01059&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/medium/jm0c01059_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/large/jm0c01059_0006.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) U-87 MG cells were plated at 10<sup>5</sup> cells/well in a six-well culture dish, incubated overnight, and then treated with <b>7a</b><sub><b>1</b></sub>, <b>7g</b>, <b>9b</b>, <b>9c</b>, or TAE-226 at 10 μM for 48 h. Cells were stained with annexin V-FITC and propidium iodide and analyzed by FACS Calibur. Cells were then classified as alive with no apoptosis (i.e., PE negative, annexin V negative), dead (i.e., PE positive), or apoptotic (i.e., annexin V positive). One representative experiment is shown. (B) Immunofluorescence staining of U-87 MG cells treated with <b>7a</b><sub><b>1</b></sub>, <b>7g</b>, <b>9b</b>, <b>9c</b>, or TAE-226 at 1 μM for 48 h. Nuclei were stained with TO-PRO-3. The organization of filamentous actin and paxillin was detected after staining with FITC-conjugated phalloidin and paxillin antibodies. Pictures were taken to depict actin in green and paxillin in red using a Zeiss microscope equipped with appropriate filters. Scale bar = 20 μm.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/large/jm0c01059_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01059&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/medium/jm0c01059_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/large/jm0c01059_0007.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Cell cycle distribution in each phase was studied by flow cytometry: (A) U-87 MG cells were plated at 10<sup>5</sup>/well in a six-well culture dish, incubated overnight, and then exposed to <b>7a</b><sub><b>1</b></sub>, <b>7g</b>, <b>9b</b>, <b>9c</b>, or TAE-226 along with DMSO control for 24 h. After incubation in 10% serum, cells were collected and stained with propidium iodide for cell cycle analysis. (B) Representative histograms of glioblastoma cells treated with 1 μM inhibitor show an increased G2 cell cycle fraction.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/large/jm0c01059_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01059&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/medium/jm0c01059_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/large/jm0c01059_0008.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Effects of compounds <b>7a</b><sub><b>1</b></sub>, <b>7g</b>, <b>9b</b>, and <b>9c</b> at 0.2 and 1 μM on U-87 MG cell migration in a scratch-wound assay. Top, images of control and treatments at 0.2 μM, with time 0 and 24 h scratch positions marked. Scale bar = 250 μm. Bottom, quantification of migration. Representative data from three independent experiments. *<i>p</i> <0.05 and **<i>p</i> <0.01 compared with the control group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/large/jm0c01059_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01059&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/medium/jm0c01059_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/large/jm0c01059_0009.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Effects of compounds <b>7a</b><sub><b>1</b></sub>, <b>9b</b>, and <b>9c</b> produced by the inhibition of FAK on FAK-mediated signal pathways compared with an ATP-competitive FAK inhibitor, TAE-226.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c01059/20201105/images/large/jm0c01059_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01059&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i84">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86821" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86821" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 45 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butowski, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, S.</span></span> <span> </span><span class="NLM_article-title">Recent advances in therapy for glioblastoma</span>. <i>Arch. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">279</span>– <span class="NLM_lpage">283</span>, <span class="refDoi"> DOI: 10.1001/archneurol.2010.5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1001%2Farchneurol.2010.5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=20212224" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A280%3ADC%252BC3c7ms1yhsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2010&pages=279-283&author=J.+Clarkeauthor=N.+Butowskiauthor=S.+Chang&title=Recent+advances+in+therapy+for+glioblastoma&doi=10.1001%2Farchneurol.2010.5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in therapy for glioblastoma</span></div><div class="casAuthors">Clarke Jennifer; Butowski Nicholas; Chang Susan</div><div class="citationInfo"><span class="NLM_cas:title">Archives of neurology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">279-83</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Glioblastoma is the most common primary malignant brain tumor in adults and is a challenging disease to treat.  The current standard of care includes maximal safe surgical resection, followed by a combination of radiation and chemotherapy with temozolomide.  Despite that, recurrence is quite common, and so we continue to search for more effective treatments both for initial therapy and at the time of recurrence.  This article will review recent advances in therapy for glioblastoma, including surgery, radiotherapy, cytotoxic chemotherapies, molecularly targeted agents, and immunotherapy; the role of antiangiogenic agents in the treatment of glioblastoma is discussed in a separate article in this issue of the Archives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSGJ5vxZEjTdkwlCcfExbvbfW6udTcc2ebdvjkQI2qbB7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c7ms1yhsA%253D%253D&md5=ac2c3e292cb0f821f4a843235426b4c9</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1001%2Farchneurol.2010.5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchneurol.2010.5%26sid%3Dliteratum%253Aachs%26aulast%3DClarke%26aufirst%3DJ.%26aulast%3DButowski%26aufirst%3DN.%26aulast%3DChang%26aufirst%3DS.%26atitle%3DRecent%2520advances%2520in%2520therapy%2520for%2520glioblastoma%26jtitle%3DArch.%2520Neurol.%26date%3D2010%26volume%3D67%26spage%3D279%26epage%3D283%26doi%3D10.1001%2Farchneurol.2010.5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grobben, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Deyn, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slegers, H.</span></span> <span> </span><span class="NLM_article-title">Rat C6 glioma as experimental model system for the study of glioblastoma growth and invasion</span>. <i>Cell Tissue Res.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>310</i></span>,  <span class="NLM_fpage">257</span>– <span class="NLM_lpage">270</span>, <span class="refDoi"> DOI: 10.1007/s00441-002-0651-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1007%2Fs00441-002-0651-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=12457224" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BD3sXos1Cruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=310&publication_year=2002&pages=257-270&author=B.+Grobbenauthor=P.+P.+De+Deynauthor=H.+Slegers&title=Rat+C6+glioma+as+experimental+model+system+for+the+study+of+glioblastoma+growth+and+invasion&doi=10.1007%2Fs00441-002-0651-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Rat C6 glioma as experimental model system for the study of glioblastoma growth and invasion</span></div><div class="casAuthors">Grobben, Bert; De Deyn, Peter Paul; Slegers, Herman</div><div class="citationInfo"><span class="NLM_cas:title">Cell & Tissue Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">310</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">257-270</span>CODEN:
                <span class="NLM_cas:coden">CTSRCS</span>;
        ISSN:<span class="NLM_cas:issn">0302-766X</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">A review.  Infiltration of the central nervous system by neoplastic cells in patients with glioblastoma multiforme (GBM) leads to neurol. dysfunction and eventually to death.  The elucidation of the mechanisms underlying the aggressive nature of GBM aims at improving radio-, chemo- and gene therapy.  This review is focused on the use of rat C6 glioma as an exptl. model system for GBM and provides an overview of the exptl. data published in the literature using this cell line in elucidating the mechanism of tumor growth, angiogenesis and invasion, and in the design and evaluation of anticancer therapies.  Understanding the stages of malignant brain tumor progression requires a series of exptl. approaches with a varying degree of complexity.  Implantation of malignant cells into animal brain tissue closely resembles in vivo tumor growth and has the advantage over simplified models that inflammatory and vascular mechanisms are activated.  However, the complexity of these models makes it difficult to identify the individual processes involved in sustained tumor growth, angiogenesis and invasion.  In cell culture models, the effect of growth factors, extracellular matrix components, proteases and adhesion mols. can be investigated.  The secretion of tumor-derived factors into the medium can also be analyzed when simplified models are used.  This review is a compilation of exptl. data focused on the characterization of tumor-related processes and on the evaluation of new therapies for the treatment of malignant glial neoplasms using rat C6 glioma as a model system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVhBTbKj6JnbVg90H21EOLACvtfcHk0lgUkF_K6s_WcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXos1Cruw%253D%253D&md5=e3745b59b0a152ded9784a09647d47cb</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1007%2Fs00441-002-0651-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00441-002-0651-7%26sid%3Dliteratum%253Aachs%26aulast%3DGrobben%26aufirst%3DB.%26aulast%3DDe%2BDeyn%26aufirst%3DP.%2BP.%26aulast%3DSlegers%26aufirst%3DH.%26atitle%3DRat%2520C6%2520glioma%2520as%2520experimental%2520model%2520system%2520for%2520the%2520study%2520of%2520glioblastoma%2520growth%2520and%2520invasion%26jtitle%3DCell%2520Tissue%2520Res.%26date%3D2002%26volume%3D310%26spage%3D257%26epage%3D270%26doi%3D10.1007%2Fs00441-002-0651-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Furnari, F. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenton, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachoo, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukasa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stommel, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stegh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligon, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louis, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DePinho, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavenee, W. K.</span></span> <span> </span><span class="NLM_article-title">Malignant astrocytic glioma: genetics, biology, and paths to treatment</span>. <i>Genes Dev.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2683</span>– <span class="NLM_lpage">2710</span>, <span class="refDoi"> DOI: 10.1101/gad.1596707</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1101%2Fgad.1596707" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=17974913" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlSitLrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=2683-2710&author=F.+B.+Furnariauthor=T.+Fentonauthor=R.+M.+Bachooauthor=A.+Mukasaauthor=J.+M.+Stommelauthor=A.+Steghauthor=W.+C.+Hahnauthor=K.+L.+Ligonauthor=D.+N.+Louisauthor=C.+Brennanauthor=L.+Chinauthor=R.+A.+DePinhoauthor=W.+K.+Cavenee&title=Malignant+astrocytic+glioma%3A+genetics%2C+biology%2C+and+paths+to+treatment&doi=10.1101%2Fgad.1596707"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Malignant astrocytic glioma: genetics, biology, and paths to treatment</span></div><div class="casAuthors">Furnari, Frank B.; Fenton, Tim; Bachoo, Robert M.; Mukasa, Akitake; Stommel, Jayne M.; Stegh, Alexander; Hahn, William C.; Ligon, Keith L.; Louis, David N.; Brennan, Cameron; Chin, Lynda; DePinho, Ronald A.; Cavenee, Webster K.</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Development</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2683-2710</span>CODEN:
                <span class="NLM_cas:coden">GEDEEP</span>;
        ISSN:<span class="NLM_cas:issn">0890-9369</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">A review.  Malignant astrocytic gliomas such as glioblastoma are the most common and lethal intracranial tumors.  These cancers exhibit a relentless malignant progression characterized by widespread invasion throughout the brain, resistance to traditional and newer targeted therapeutic approaches, destruction of normal brain tissue, and certain death.  The recent confluence of advances in stem cell biol., cell signaling, genome and computational science and genetic model systems have revolutionized our understanding of the mechanisms underlying the genetics, biol. and clin. behavior of glioblastoma.  This progress is fueling new opportunities for understanding the fundamental basis for development of this devastating disease and also novel therapies that, for the first time, portend meaningful clin. responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDlfTN9OqeLLVg90H21EOLACvtfcHk0lgUkF_K6s_WcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlSitLrO&md5=5b89b311117f70e3708194afa9165414</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1101%2Fgad.1596707&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.1596707%26sid%3Dliteratum%253Aachs%26aulast%3DFurnari%26aufirst%3DF.%2BB.%26aulast%3DFenton%26aufirst%3DT.%26aulast%3DBachoo%26aufirst%3DR.%2BM.%26aulast%3DMukasa%26aufirst%3DA.%26aulast%3DStommel%26aufirst%3DJ.%2BM.%26aulast%3DStegh%26aufirst%3DA.%26aulast%3DHahn%26aufirst%3DW.%2BC.%26aulast%3DLigon%26aufirst%3DK.%2BL.%26aulast%3DLouis%26aufirst%3DD.%2BN.%26aulast%3DBrennan%26aufirst%3DC.%26aulast%3DChin%26aufirst%3DL.%26aulast%3DDePinho%26aufirst%3DR.%2BA.%26aulast%3DCavenee%26aufirst%3DW.%2BK.%26atitle%3DMalignant%2520astrocytic%2520glioma%253A%2520genetics%252C%2520biology%252C%2520and%2520paths%2520to%2520treatment%26jtitle%3DGenes%2520Dev.%26date%3D2007%26volume%3D21%26spage%3D2683%26epage%3D2710%26doi%3D10.1101%2Fgad.1596707" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ziegler, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kieran, M. W.</span></span> <span> </span><span class="NLM_article-title">Anti-apoptosis mechanisms inmalignant gliomas</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">493</span>– <span class="NLM_lpage">500</span>, <span class="refDoi"> DOI: 10.1200/JCO.2007.13.9717</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1200%2FJCO.2007.13.9717" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=18202424" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitVGnu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=493-500&author=D.+S.+Zieglerauthor=A.+L.+Kungauthor=M.+W.+Kieran&title=Anti-apoptosis+mechanisms+inmalignant+gliomas&doi=10.1200%2FJCO.2007.13.9717"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-apoptosis mechanisms in malignant gliomas</span></div><div class="casAuthors">Ziegler, David S.; Kung, Andrew L.; Kieran, Mark W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">493-500</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  Malignant gliomas are characterized by an intrinsic resistance to apoptosis.  Increasing evidence suggests that this is a fundamental mechanism by which gliomas evade elimination when treated with both conventional and targeted therapies.  In this review, we describe the multiple anti-apoptotic signals that have been demonstrated to be active in malignant gliomas.  We describe the preclin. evidence that suggests that targeting those signaling anomalies can increase tumor responsiveness and enhance the elimination of gliomas in preclin. models.  We discuss recent advances in translating pro-apoptotic compds. to clin. trial, and the potential for implementing agents that target the apoptotic pathway as a strategy for improving the outcomes for patients with high-grade gliomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqbiNBLFKEN7Vg90H21EOLACvtfcHk0lgUkF_K6s_WcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitVGnu7w%253D&md5=5019f2250e3b46e1e969573d2dc34985</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1200%2FJCO.2007.13.9717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2007.13.9717%26sid%3Dliteratum%253Aachs%26aulast%3DZiegler%26aufirst%3DD.%2BS.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DKieran%26aufirst%3DM.%2BW.%26atitle%3DAnti-apoptosis%2520mechanisms%2520inmalignant%2520gliomas%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26spage%3D493%26epage%3D500%26doi%3D10.1200%2FJCO.2007.13.9717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garnier, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renoult, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alves-Guerra, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paris, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pecqueur, C.</span></span> <span> </span><span class="NLM_article-title">Glioblastoma stem-like cells, metabolic strategy to kill a challenging target</span>. <i>Front Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">118</span> <span class="refDoi"> DOI: 10.3389/fonc.2019.00118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.3389%2Ffonc.2019.00118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=30895167" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A280%3ADC%252BB3cbmsFSjuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&author=D.+Garnierauthor=O.+Renoultauthor=M.+C.+Alves-Guerraauthor=F.+Parisauthor=C.+Pecqueur&title=Glioblastoma+stem-like+cells%2C+metabolic+strategy+to+kill+a+challenging+target&doi=10.3389%2Ffonc.2019.00118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Glioblastoma Stem-Like Cells, Metabolic Strategy to Kill a Challenging Target</span></div><div class="casAuthors">Garnier Delphine; Renoult Ophelie; Paris Francois; Pecqueur Claire; Alves-Guerra Marie-Clotilde; Alves-Guerra Marie-Clotilde; Paris Francois; Pecqueur Claire</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">118</span>
        ISSN:<span class="NLM_cas:issn">2234-943X</span>.
    </div><div class="casAbstract">Over the years, substantial evidence has definitively confirmed the existence of cancer stem-like cells within tumors such as Glioblastoma (GBM).  The importance of Glioblastoma stem-like cells (GSCs) in tumor progression and relapse clearly highlights that cancer eradication requires killing of GSCs that are intrinsically resistant to conventional therapies as well as eradication of the non-GSCs cells since GSCs emergence relies on a dynamic process.  The past decade of research highlights that metabolism is a significant player in tumor progression and actually might orchestrate it.  The growing interest in cancer metabolism reprogrammation can lead to innovative approaches exploiting metabolic vulnerabilities of cancer cells.  These approaches are challenging since they require overcoming the compensatory and adaptive responses of GSCs.  In this review, we will summarize the current knowledge on GSCs with a particular focus on their metabolic complexity.  We will also discuss potential approaches targeting GSCs metabolism to potentially improve clinical care.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSAjc-w0X6rAQMthz5_Rx5rfW6udTcc2eaXlW50vrKI4rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbmsFSjuw%253D%253D&md5=59b1174ee9c9111d87016d158f1ff0c1</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2019.00118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2019.00118%26sid%3Dliteratum%253Aachs%26aulast%3DGarnier%26aufirst%3DD.%26aulast%3DRenoult%26aufirst%3DO.%26aulast%3DAlves-Guerra%26aufirst%3DM.%2BC.%26aulast%3DParis%26aufirst%3DF.%26aulast%3DPecqueur%26aufirst%3DC.%26atitle%3DGlioblastoma%2520stem-like%2520cells%252C%2520metabolic%2520strategy%2520to%2520kill%2520a%2520challenging%2520target%26jtitle%3DFront%2520Oncol.%26date%3D2019%26volume%3D9%26doi%3D10.3389%2Ffonc.2019.00118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Djedid, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiss, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefranc, F.</span></span> <span> </span><span class="NLM_article-title">Targeted therapy of glioblastomas: a 5 year view</span>. <i>Therapy</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">351</span>– <span class="NLM_lpage">370</span>, <span class="refDoi"> DOI: 10.2217/thy.09.12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.2217%2Fthy.09.12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlvF2lsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2009&pages=351-370&author=R.+Djedidauthor=R.+Kissauthor=F.+Lefranc&title=Targeted+therapy+of+glioblastomas%3A+a+5+year+view&doi=10.2217%2Fthy.09.12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted therapy of glioblastomas: a 5-year view</span></div><div class="casAuthors">Djedid, Ryad; Kiss, Robert; Lefranc, Florence</div><div class="citationInfo"><span class="NLM_cas:title">Therapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">351-370</span>CODEN:
                <span class="NLM_cas:coden">THERCR</span>;
        ISSN:<span class="NLM_cas:issn">1475-0708</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  The treatment of glioblastomas requires a multidisciplinary approach that takes the presently incurable nature of the disease into consideration.  Treatments are multimodal and include surgery, radiotherapy and chemotherapy.  Current recommendations are that patients with glioblastoma should undergo max. surgical resection followed by concurrent radiation and chemotherapy with the novel alkylating drug temozolomide, followed subsequently by addnl. adjuvant temozolomide for a period of up to 6 mo.  We describe here the major signaling pathways that can be constitutively activated in migrating glioma cells, and which render these cells resistant to pro-apoptotic insults such as conventional chemotherapies.  In light of this resistance, we therefore describe the mol. therapies and local drug delivery systems that could be used to complement conventional treatments.  We have reviewed more than 400 ongoing clin. trials with respect to these new targeted therapy approaches alone or in combination for glioblastoma therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC0RlzsP6hxLVg90H21EOLACvtfcHk0ljUUNSeN1WbJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlvF2lsL4%253D&md5=3f13563fc0e2d1bf80fdfc7b012b8039</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.2217%2Fthy.09.12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Fthy.09.12%26sid%3Dliteratum%253Aachs%26aulast%3DDjedid%26aufirst%3DR.%26aulast%3DKiss%26aufirst%3DR.%26aulast%3DLefranc%26aufirst%3DF.%26atitle%3DTargeted%2520therapy%2520of%2520glioblastomas%253A%2520a%25205%2520year%2520view%26jtitle%3DTherapy%26date%3D2009%26volume%3D6%26spage%3D351%26epage%3D370%26doi%3D10.2217%2Fthy.09.12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stupp, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Den Bent, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taphoorn, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belanger, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandes, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marosi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogdahn, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curschmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janzer, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwin, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorlia, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allgeier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacombe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cairncross, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenhauer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirimanoff, R. O.</span></span> <span> </span><span class="NLM_article-title">Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>352</i></span>,  <span class="NLM_fpage">987</span>– <span class="NLM_lpage">996</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa043330</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1056%2FNEJMoa043330" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=15758009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BD2MXit1Wksbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=987-996&author=R.+Stuppauthor=W.+P.+Masonauthor=M.+J.+Van+Den+Bentauthor=M.+Wellerauthor=B.+Fisherauthor=M.+J.+Taphoornauthor=K.+Belangerauthor=A.+A.+Brandesauthor=C.+Marosiauthor=U.+Bogdahnauthor=J.+Curschmannauthor=R.+C.+Janzerauthor=S.+K.+Ludwinauthor=T.+Gorliaauthor=A.+Allgeierauthor=D.+Lacombeauthor=J.+G.+Cairncrossauthor=E.+Eisenhauerauthor=R.+O.+Mirimanoff&title=Radiotherapy+plus+concomitant+and+adjuvant+temozolomide+for+glioblastoma&doi=10.1056%2FNEJMoa043330"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma</span></div><div class="casAuthors">Stupp, Roger; Mason, Warren P.; van den Bent, Martin J.; Weller, Michael; Fisher, Barbara; Taphoorn, Martin J. B.; Belanger, Karl; Brandes, Alba A.; Marosi, Christine; Bogdahn, Ulrich; Curschmann, Jurgen; Janzer, Robert C.; Ludwin, Samuel K.; Gorlia, Thierry; Allgeier, Anouk; Lacombe, Denis; Cairncross, J. Gregory; Eisenhauer, Elizabeth; Mirimanoff, Rene O.; Forsyth, P.; Fulton, D.; Kirby, S.; Wong, R.; Fenton, D.; Fisher, B.; Cairncross, G.; Whitlock, P.; Belanger, K.; Burdette-Radoux, S.; Gertler, S.; Saunders, S.; Laing, K.; Siddiqui, J.; Martin, L. A.; Gulavita, S.; Perry, J.; Mason, W.; Thiessen, B.; Pai, H.; Alam, Z. Y.; Eisenstat, D.; Mingrone, W.; Hofer, S.; Pesce, G.; Curschmann, J.; Dietrich, P. Y.; Stupp, R.; Mirimanoff, R. O.; Thum, P.; Baumert, B.; Ryan, G.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">987-996</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Glioblastoma, the most common primary brain tumor in adults, is usually rapidly fatal.  The current std. of care for newly diagnosed glioblastoma is surgical resection to the extent feasible, followed by adjuvant radiotherapy.  In this trial we compared radiotherapy alone with radiotherapy plus temozolomide, given concomitantly with and after radiotherapy, in terms of efficacy and safety.  METHODS Patients with newly diagnosed, histol. confirmed glioblastoma were randomly assigned to receive radiotherapy alone (fractionated focal irradn. in daily fractions of 2 Gy given 5 days per wk for 6 wk, for a total of 60 Gy) or radiotherapy plus continuous daily temozolomide (75 mg per square meter of body-surface area per day, 7 days per wk from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28-day cycle).  The primary end point was overall survival.  RESULTS A total of 573 patients from 85 centers underwent randomization.  The median age was 56 years, and 84 % of patients had undergone debulking surgery.  At a median follow-up of 28 mo, the median survival was 14.6 mo with radiotherapy plus temozolomide and 12.1 mo with radiotherapy alone.  The unadjusted hazard ratio for death in the radiotherapy-plus-temozolomide group was 0.63 (95 % confidence interval, 0.52 to 0.75; P<0.001 by the log-rank test).  The two-year survival rate was 26.5 % with radiotherapy plus temozolomide and 10.4 % with radiotherapy alone.  Concomitant treatment with radiotherapy plus temozolomide resulted in grade 3 or 4 hematol. toxic effects in 7 % of patients.  Conclusions The addn. of temozolomide to radiotherapy for newly diagnosed glioblastoma resulted in a clin. meaningful and statistically significant survival benefit with minimal addnl. toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdNLD2mISWE7Vg90H21EOLACvtfcHk0ljUUNSeN1WbJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXit1Wksbk%253D&md5=28546eb2e78f7346974d7d029c9fa916</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa043330&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa043330%26sid%3Dliteratum%253Aachs%26aulast%3DStupp%26aufirst%3DR.%26aulast%3DMason%26aufirst%3DW.%2BP.%26aulast%3DVan%2BDen%2BBent%26aufirst%3DM.%2BJ.%26aulast%3DWeller%26aufirst%3DM.%26aulast%3DFisher%26aufirst%3DB.%26aulast%3DTaphoorn%26aufirst%3DM.%2BJ.%26aulast%3DBelanger%26aufirst%3DK.%26aulast%3DBrandes%26aufirst%3DA.%2BA.%26aulast%3DMarosi%26aufirst%3DC.%26aulast%3DBogdahn%26aufirst%3DU.%26aulast%3DCurschmann%26aufirst%3DJ.%26aulast%3DJanzer%26aufirst%3DR.%2BC.%26aulast%3DLudwin%26aufirst%3DS.%2BK.%26aulast%3DGorlia%26aufirst%3DT.%26aulast%3DAllgeier%26aufirst%3DA.%26aulast%3DLacombe%26aufirst%3DD.%26aulast%3DCairncross%26aufirst%3DJ.%2BG.%26aulast%3DEisenhauer%26aufirst%3DE.%26aulast%3DMirimanoff%26aufirst%3DR.%2BO.%26atitle%3DRadiotherapy%2520plus%2520concomitant%2520and%2520adjuvant%2520temozolomide%2520for%2520glioblastoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26spage%3D987%26epage%3D996%26doi%3D10.1056%2FNEJMoa043330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaFortune, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohmori, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatakeyama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Groot, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yung, W. K.</span></span> <span> </span><span class="NLM_article-title">Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1357</span>– <span class="NLM_lpage">1367</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-06-0476</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1158%2F1535-7163.MCT-06-0476" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=17431114" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BD2sXktFams7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=1357-1367&author=T.+J.+Liuauthor=T.+LaFortuneauthor=T.+Hondaauthor=O.+Ohmoriauthor=S.+Hatakeyamaauthor=T.+Meyerauthor=D.+Jacksonauthor=J.+de+Grootauthor=W.+K.+Yung&title=Inhibition+of+both+focal+adhesion+kinase+and+insulin-like+growth+factor-I+receptor+kinase+suppresses+glioma+proliferation+in+vitro+and+in+vivo&doi=10.1158%2F1535-7163.MCT-06-0476"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo</span></div><div class="casAuthors">Liu, Ta-Jen; LaFortune, Tiffany; Honda, Toshiyuki; Ohmori, Osamu; Hatakeyama, Shinji; Meyer, Thomas; Jackson, Dowdy; de Groot, John; Yung, W. K. Alfred</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1357-1367</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Multiple genetic aberrations in human gliomas contribute to their highly infiltrative and rapid growth characteristics.  Focal adhesion kinase (FAK) regulates tumor migration and invasion.  Insulin-like growth factor-I receptor (IGF-IR), whose expression correlates with tumor grade, is involved in proliferation and survival.  We hypothesized that inhibiting the phosphorylation of FAK and IGF-IR by NVP-TAE226 (hereafter called TAE226), a novel dual tyrosine kinase inhibitor of FAK and IGF-IR, would suppress the growth and invasion of glioma cells.  In culture, TAE226 inhibited extracellular matrix-induced autophosphorylation of FAK (Tyr397).  TAE226 also inhibited IGF-I-induced phosphorylation of IGF-IR and activity of its downstream target genes such as MAPK and Akt.  TAE226 retarded tumor cell growth as assessed by a cell viability assay and attenuated G2-M cell cycle progression assocd. with a decrease in cyclin B1 and phosphorylated cdc2 (Tyr15) protein expression.  TAE226 treatment inhibited tumor cell invasion by at least 50% compared with the control in an in vitro Matrigel invasion assay.  Interestingly, TAE226 treatment of tumor cells contg. wild-type p53 mainly exhibited G2-M arrest, whereas tumor cells bearing mutant p53 underwent apoptosis.  Induction of apoptosis by TAE226 was substantiated by detection of caspase-3/7 activation and poly(ADP-ribose) polymerase cleavage and by an Annexin V apoptosis assay.  More importantly, TAE226 treatment significantly increased the survival rate of animals in an intracranial glioma xenograft model.  Collectively, these data show that blocking the signaling pathways of FAK and IGF-IR with TAE226 has the potential to be an efficacious treatment for human gliomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQMIquqcQABrVg90H21EOLACvtfcHk0liizFQdybxGLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXktFams7o%253D&md5=1659c50e987e8bbb24c998e0aae14861</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-06-0476&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-06-0476%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DT.%2BJ.%26aulast%3DLaFortune%26aufirst%3DT.%26aulast%3DHonda%26aufirst%3DT.%26aulast%3DOhmori%26aufirst%3DO.%26aulast%3DHatakeyama%26aufirst%3DS.%26aulast%3DMeyer%26aufirst%3DT.%26aulast%3DJackson%26aufirst%3DD.%26aulast%3Dde%2BGroot%26aufirst%3DJ.%26aulast%3DYung%26aufirst%3DW.%2BK.%26atitle%3DInhibition%2520of%2520both%2520focal%2520adhesion%2520kinase%2520and%2520insulin-like%2520growth%2520factor-I%2520receptor%2520kinase%2520suppresses%2520glioma%2520proliferation%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D1357%26epage%3D1367%26doi%3D10.1158%2F1535-7163.MCT-06-0476" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hjelmeland, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keir, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wickman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohmori, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigner, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rich, J. N.</span></span> <span> </span><span class="NLM_article-title">A novel low molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth</span>. <i>Mol. Carcinog.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">488</span>– <span class="NLM_lpage">496</span>, <span class="refDoi"> DOI: 10.1002/mc.20297</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1002%2Fmc.20297" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=17219439" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BD2sXms1Olsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2007&pages=488-496&author=Q.+Shiauthor=A.+B.+Hjelmelandauthor=S.+T.+Keirauthor=L.+Songauthor=S.+Wickmanauthor=D.+Jacksonauthor=O.+Ohmoriauthor=D.+D.+Bignerauthor=H.+S.+Friedmanauthor=J.+N.+Rich&title=A+novel+low+molecular+weight+inhibitor+of+focal+adhesion+kinase%2C+TAE226%2C+inhibits+glioma+growth&doi=10.1002%2Fmc.20297"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth</span></div><div class="casAuthors">Shi, Qing; Hjelmeland, Anita B.; Keir, Stephen T.; Song, Linhua; Wickman, Sarah; Jackson, Dowdy; Ohmori, Osamu; Bigner, Darell D.; Friedman, Henry S.; Rich, Jeremy N.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Carcinogenesis</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">488-496</span>CODEN:
                <span class="NLM_cas:coden">MOCAE8</span>;
        ISSN:<span class="NLM_cas:issn">0899-1987</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Glioblastomas are highly lethal cancers that resist current therapies.  Novel therapies under development target mol. mechanisms that promote glioblastoma growth.  In glioblastoma patient specimens, the non-receptor tyrosine kinase focal adhesion kinase (FAK) is overexpressed.  Upon growth factor receptor stimulation or integrin engagement, FAK is activated by phosphorylation on crit. tyrosine residues.  Activated FAK initiates a signal transduction cascade which promotes glioma growth and invasion by increasing cellular adhesion, migration, invasion, and proliferation.  We find that human glioma cell lines express different levels of total FAK protein and activating phosphorylation of tyrosine residues Tyr397, Tyr861, and Tyr925.  As all glioma cell lines examd. expressed phosphorylated FAK, we examd. the efficacy of a novel low-mol. wt. inhibitor of FAK, TAE226, against human glioma cell lines.  TAE226 inhibited the phosphorylation of FAK as well as the downstream effectors AKT, extracellular signal-related kinase, and S6 ribosomal protein in multiple glioma cell lines.  TAE226 induced a concn.-dependent decrease in cellular proliferation with an assocd. G2 cell cycle arrest in every cell line and an increase in apoptosis in a cell-line-specific manner.  TAE226 also decreased glioma cell adhesion, migration, and invasion through an artificial extracellular matrix.  Together, these data demonstrate the potential benefit of TAE226 for glioma therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXL0wEDuHo9bVg90H21EOLACvtfcHk0liizFQdybxGLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXms1Olsrg%253D&md5=83711a44fe2472eae4baf568ee4332a4</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1002%2Fmc.20297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmc.20297%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DHjelmeland%26aufirst%3DA.%2BB.%26aulast%3DKeir%26aufirst%3DS.%2BT.%26aulast%3DSong%26aufirst%3DL.%26aulast%3DWickman%26aufirst%3DS.%26aulast%3DJackson%26aufirst%3DD.%26aulast%3DOhmori%26aufirst%3DO.%26aulast%3DBigner%26aufirst%3DD.%2BD.%26aulast%3DFriedman%26aufirst%3DH.%2BS.%26aulast%3DRich%26aufirst%3DJ.%2BN.%26atitle%3DA%2520novel%2520low%2520molecular%2520weight%2520inhibitor%2520of%2520focal%2520adhesion%2520kinase%252C%2520TAE226%252C%2520inhibits%2520glioma%2520growth%26jtitle%3DMol.%2520Carcinog.%26date%3D2007%26volume%3D46%26spage%3D488%26epage%3D496%26doi%3D10.1002%2Fmc.20297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chilukuri, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brady, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulos, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kappes, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galileo, D. S.</span></span> <span> </span><span class="NLM_article-title">L1 stimulation of human glioma cell motility correlates with FAK activation</span>. <i>J Neurooncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">44</span>, <span class="refDoi"> DOI: 10.1007/s11060-011-0557-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1007%2Fs11060-011-0557-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=21373966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A280%3ADC%252BC3MfjsFensw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2011&pages=27-44&author=M.+Yangauthor=Y.+Liauthor=K.+Chilukuriauthor=O.+A.+Bradyauthor=M.+I.+Boulosauthor=J.+C.+Kappesauthor=D.+S.+Galileo&title=L1+stimulation+of+human+glioma+cell+motility+correlates+with+FAK+activation&doi=10.1007%2Fs11060-011-0557-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">L1 stimulation of human glioma cell motility correlates with FAK activation</span></div><div class="casAuthors">Yang Muhua; Li Yupei; Chilukuri Kalyani; Brady Owen A; Boulos Magdy I; Kappes John C; Galileo Deni S</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neuro-oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-44</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The neural adhesion/recognition protein L1 (L1CAM; CD171) has been shown or implicated to function in stimulation of cell motility in several cancer types, including high-grade gliomas.  Our previous work demonstrated the expression and function of L1 protein in stimulation of cell motility in rat glioma cells.  However, the mechanism of this stimulation is still unclear.  This study further investigated the function of L1 and L1 proteolysis in human glioblastoma multiforme (GBM) cell migration and invasion, as well as the mechanism of this stimulation.  L1 mRNA was found to be present in human T98G GBM cell line but not in U-118 MG grade III human glioma cell line.  L1 protein expression, proteolysis, and release were found in T98G cells and human surgical GBM cells by Western blotting.  Exosome-like vesicles released by T98G cells were purified and contained full-length L1.  In a scratch assay, T98G cells that migrated into the denuded scratch area exhibited upregulation of ADAM10 protease expression coincident with loss of surface L1.  GBM surgical specimen cells exhibited a similar loss of cell surface L1 when xenografted into the chick embryo brain.  When lentivirally introduced shRNA was used to attenuate L1 expression, such T98G/shL1 cells exhibited significantly decreased cell motility by time lapse microscopy in our quantitative Super Scratch assay.  These cells also showed a decrease in FAK activity and exhibited increased focal complexes.  L1 binding integrins which activate FAK were found in T98G and U-118 MG cells.  Addition of L1 ectodomain-containing media (1) rescued the decreased cell motility of T98G/shL1 cells and (2) increased cell motility of U-118 MG cells but (3) did not further increase T98G cell motility.  Injection of L1-attenuated T98G/shL1 cells into embryonic chick brains resulted in the absence of detectable invasion compared to control cells which invaded brain tissue.  These studies support a mechanism where glioma cells at the edge of a cell mass upregulate ADAM10 to proteolyze surface L1 and the resultant ectodomain increases human glioma cell migration and invasion by binding to integrin receptors, activating FAK, and increasing turnover of focal complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRUFN-7xleI5xJ5E29YNGvQfW6udTcc2eZ5uyW-HfazRbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MfjsFensw%253D%253D&md5=d8e05ff5761c0576f0c48e9c5ea26657</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1007%2Fs11060-011-0557-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11060-011-0557-x%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DChilukuri%26aufirst%3DK.%26aulast%3DBrady%26aufirst%3DO.%2BA.%26aulast%3DBoulos%26aufirst%3DM.%2BI.%26aulast%3DKappes%26aufirst%3DJ.%2BC.%26aulast%3DGalileo%26aufirst%3DD.%2BS.%26atitle%3DL1%2520stimulation%2520of%2520human%2520glioma%2520cell%2520motility%2520correlates%2520with%2520FAK%2520activation%26jtitle%3DJ%2520Neurooncol.%26date%3D2011%26volume%3D105%26spage%3D27%26epage%3D44%26doi%3D10.1007%2Fs11060-011-0557-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cornillon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campos, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guyotat, D.</span></span> <span> </span><span class="NLM_article-title">Focal adhesion kinase (FAK), une protéine aux fonctions multiples</span>. <i>Med. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">743</span>– <span class="NLM_lpage">752</span>, <span class="refDoi"> DOI: 10.1051/medsci/20031967743</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1051%2Fmedsci%2F20031967743" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A280%3ADC%252BD3svgtlKisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2003&pages=743-752&author=J.+Cornillonauthor=L.+Camposauthor=D.+Guyotat&title=Focal+adhesion+kinase+%28FAK%29%2C+une+prot%C3%A9ine+aux+fonctions+multiples&doi=10.1051%2Fmedsci%2F20031967743"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Focal adhesion kinase (FAK), a multifunctional protein</span></div><div class="casAuthors">Cornillon Jerome; Campos Lydia; Guyotat Denis</div><div class="citationInfo"><span class="NLM_cas:title">Medecine sciences : M/S</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6-7</span>),
    <span class="NLM_cas:pages">743-52</span>
        ISSN:<span class="NLM_cas:issn">0767-0974</span>.
    </div><div class="casAbstract">Focal adhesion kinase (FAK) is a cytoplasmic protein tyrosine kinase localized to regions called focal adhesions.  Many stimuli can induce tyrosine phosphorylation and activation of FAK, including integrins and growth factors.  The major site of autophosphorylation, tyrosine 397, is a docking site for the SH2 domains of Src family proteins.  The other sites of phosphorylation are phosphorylated by Src kinases.  Phosphorylated FAK binds proteins of focal adhesion and can activate them directly or indirectly by phosphorylation.  These activated proteins forming the FAK complex facilitate the generation of downstream signals necessary to regulate cell functions, like motility, survival and proliferation.  Dysregulation of FAK could participate in the development of cancer.  This review will focus upon the mechanisms by which FAK transmits biochemical signals and elicits biological effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ649HwIg5BIf69nzq6467DfW6udTcc2eYOQWabawQN5bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3svgtlKisg%253D%253D&md5=d0da696545b44f37f28ec55e93f4b643</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1051%2Fmedsci%2F20031967743&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1051%252Fmedsci%252F20031967743%26sid%3Dliteratum%253Aachs%26aulast%3DCornillon%26aufirst%3DJ.%26aulast%3DCampos%26aufirst%3DL.%26aulast%3DGuyotat%26aufirst%3DD.%26atitle%3DFocal%2520adhesion%2520kinase%2520%2528FAK%2529%252C%2520une%2520prot%25C3%25A9ine%2520aux%2520fonctions%2520multiples%26jtitle%3DMed.%2520Sci.%26date%3D2003%26volume%3D19%26spage%3D743%26epage%3D752%26doi%3D10.1051%2Fmedsci%2F20031967743" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochwald, S. N.</span></span> <span> </span><span class="NLM_article-title">The role of FAK in tumor metabolism and therapy</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">154</span>– <span class="NLM_lpage">163</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2013.12.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1016%2Fj.pharmthera.2013.12.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=24333503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktFyiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2014&pages=154-163&author=J.+Zhangauthor=S.+N.+Hochwald&title=The+role+of+FAK+in+tumor+metabolism+and+therapy&doi=10.1016%2Fj.pharmthera.2013.12.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">The role of FAK in tumor metabolism and therapy</span></div><div class="casAuthors">Zhang, Jianliang; Hochwald, Steven N.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">154-163</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Focal adhesion kinase (FAK) plays a vital role in tumor cell proliferation, survival and migration.  Altered metabolic pathways fuel rapid tumor growth by accelerating glucose, lipid and glutamine processing.  Besides the mitogenic effects of FAK, evidence is accumulating supporting the assocn. between hyper-activated FAK and aberrant metab. in tumorigenesis.  FAK can promote glucose consumption, lipogenesis, and glutamine dependency to promote cancer cell proliferation, motility, and survival.  Clin. studies demonstrate that FAK-related alterations of tumor metab. are assocd. with increased risk of developing solid tumors.  Since FAK contributes to the malignant phenotype, small mol. inhibition of FAK-stimulated bioenergetic and biosynthetic processes can provide a novel approach for therapeutic intervention in tumor growth and invasion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopcqgT2ywkqbVg90H21EOLACvtfcHk0ljHkeh4BOtWAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktFyiuw%253D%253D&md5=9cb0cd034003cf29b4141e9572e02f6d</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2013.12.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2013.12.003%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DHochwald%26aufirst%3DS.%2BN.%26atitle%3DThe%2520role%2520of%2520FAK%2520in%2520tumor%2520metabolism%2520and%2520therapy%26jtitle%3DPharmacol.%2520Ther.%26date%3D2014%26volume%3D142%26spage%3D154%26epage%3D163%26doi%3D10.1016%2Fj.pharmthera.2013.12.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cance, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurenova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marlowe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golubovskaya, V.</span></span> <span> </span><span class="NLM_article-title">Disrupting the scaffold to improve focal adhesion kinase-targeted cancer therapeutics</span>. <i>Sci. Signaling</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">pe10</span> <span class="refDoi"> DOI: 10.1126/scisignal.2004021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1126%2Fscisignal.2004021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=23532331" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&author=W.+G.+Canceauthor=E.+Kurenovaauthor=T.+Marloweauthor=V.+Golubovskaya&title=Disrupting+the+scaffold+to+improve+focal+adhesion+kinase-targeted+cancer+therapeutics&doi=10.1126%2Fscisignal.2004021"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1126%2Fscisignal.2004021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscisignal.2004021%26sid%3Dliteratum%253Aachs%26aulast%3DCance%26aufirst%3DW.%2BG.%26aulast%3DKurenova%26aufirst%3DE.%26aulast%3DMarlowe%26aufirst%3DT.%26aulast%3DGolubovskaya%26aufirst%3DV.%26atitle%3DDisrupting%2520the%2520scaffold%2520to%2520improve%2520focal%2520adhesion%2520kinase-targeted%2520cancer%2520therapeutics%26jtitle%3DSci.%2520Signaling%26date%3D2013%26volume%3D6%26doi%3D10.1126%2Fscisignal.2004021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lechertier, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodivala-Dilke, K.</span></span> <span> </span><span class="NLM_article-title">Focal adhesion kinase and tumour angiogenesis</span>. <i>J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>226</i></span>,  <span class="NLM_fpage">404</span>– <span class="NLM_lpage">412</span>, <span class="refDoi"> DOI: 10.1002/path.3018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1002%2Fpath.3018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=21984450" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFCqsb3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=226&publication_year=2012&pages=404-412&author=T.+Lechertierauthor=K.+Hodivala-Dilke&title=Focal+adhesion+kinase+and+tumour+angiogenesis&doi=10.1002%2Fpath.3018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Focal adhesion kinase and tumor angiogenesis</span></div><div class="casAuthors">Lechertier, Tanguy; Hodivala-Dilke, Kairbaan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pathology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">226</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">404-412</span>CODEN:
                <span class="NLM_cas:coden">JPTLAS</span>;
        ISSN:<span class="NLM_cas:issn">0022-3417</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A review.  Angiogenesis, the formation of new blood vessels from pre-existing ones, is essential for tumor development.  It is initiated and regulated by growth factors via their surface receptors, which activate several intracellular signalling pathways in endothelial cells.  Cell adhesion mols., such as integrins, also regulate angiogenesis.  Despite these facts, inhibitors of endothelial cell growth factor receptors or integrins have not been as effective as initially hoped in the long-term inhibition of angiogenesis in cancer patients.  Signalling downstream of growth factor receptors and integrins converge on the ubiquitously expressed non-receptor tyrosine kinase focal adhesion kinase (FAK).  FAK is involved in endothelial cell proliferation, migration and survival, is up-regulated in many cancers and has recently been shown to control tumor angiogenesis.  Indeed, FAK inhibitors are presently being developed for the treatment of cancer.  However, recent studies have indicated the complexities of understanding the precise role for FAK in angiogenesis.  Here we have summarized some of the key features of FAK, addressed some of the apparently contradictory roles of this mol. in angiogenesis and provided some perspectives for future studies.  Copyright © 2011 Pathol. Society of Great Britain and Ireland.  Published by John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSgXcP02UjgLVg90H21EOLACvtfcHk0ljHkeh4BOtWAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFCqsb3J&md5=605e7ae8bd660cfc04792e904729addf</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1002%2Fpath.3018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.3018%26sid%3Dliteratum%253Aachs%26aulast%3DLechertier%26aufirst%3DT.%26aulast%3DHodivala-Dilke%26aufirst%3DK.%26atitle%3DFocal%2520adhesion%2520kinase%2520and%2520tumour%2520angiogenesis%26jtitle%3DJ.%2520Pathol.%26date%3D2012%26volume%3D226%26spage%3D404%26epage%3D412%26doi%3D10.1002%2Fpath.3018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gutenberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruck, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchfelder, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, H. C.</span></span> <span> </span><span class="NLM_article-title">Expression of tyrosine kinases FAK and Pyk2 in 331 human astrocytomas</span>. <i>Acta Neuropathol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">224</span>– <span class="NLM_lpage">230</span>, <span class="refDoi"> DOI: 10.1007/s00401-004-0886-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1007%2Fs00401-004-0886-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=15221336" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmt1Krur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2004&pages=224-230&author=A.+Gutenbergauthor=W.+Bruckauthor=M.+Buchfelderauthor=H.+C.+Ludwig&title=Expression+of+tyrosine+kinases+FAK+and+Pyk2+in+331+human+astrocytomas&doi=10.1007%2Fs00401-004-0886-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of tyrosine kinases FAK and Pyk2 in 331 human astrocytomas</span></div><div class="casAuthors">Gutenberg, A.; Brueck, W.; Buchfelder, M.; Ludwig, H. C.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Neuropathologica</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">224-230</span>CODEN:
                <span class="NLM_cas:coden">ANPTAL</span>;
        ISSN:<span class="NLM_cas:issn">0001-6322</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">The progression of malignancy from astrocytomas to glioblastomas remains clin. as well as histopathol. unpredictable.  The focal adhesion kinase (FAK) and the proline-rich Tyr kinase (Pyk2) show a high expression in glioma cell lines and have an influence on increased cell proliferation and migration of glioma cells in vitro and in vivo.  The aim of this study was to correlate the coexpression of FAK and Pyk2 to the WHO grade of malignancy in human astrocytomas.  Immunohistochem. staining scores of FAK and Pyk2 were analyzed in 331 astrocytomas and correlated to each other and to the WHO grade.  Significant coexpression of FAK and Pyk2 in astrocytomas was demonstrated.  Pyk2 expression occurred much more frequently and with higher expression scores within the different WHO grades.  Beyond this, a significant correlation between the WHO grade of malignancy of astrocytomas and the expression of FAK, as well as of Pyk2, was detected.  This connection and the roles of these 2 Tyr kinases in the progression of tumors should be confirmed by further studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUvlZv4lGN_rVg90H21EOLACvtfcHk0lhYFDE18XUqdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmt1Krur8%253D&md5=05f4ecbba6b2aabbef6fd97445398d27</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1007%2Fs00401-004-0886-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00401-004-0886-3%26sid%3Dliteratum%253Aachs%26aulast%3DGutenberg%26aufirst%3DA.%26aulast%3DBruck%26aufirst%3DW.%26aulast%3DBuchfelder%26aufirst%3DM.%26aulast%3DLudwig%26aufirst%3DH.%2BC.%26atitle%3DExpression%2520of%2520tyrosine%2520kinases%2520FAK%2520and%2520Pyk2%2520in%2520331%2520human%2520astrocytomas%26jtitle%3DActa%2520Neuropathol.%26date%3D2004%26volume%3D108%26spage%3D224%26epage%3D230%26doi%3D10.1007%2Fs00401-004-0886-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haskell, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natarajan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hecker, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, J.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grammer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gladson, C. L.</span></span> <span> </span><span class="NLM_article-title">Focal adhesion kinase is expressed in the angiogenic blood vessels of malignant astrocytic tumors in vivo and promotes capillary tube formation of brain microvascular endothelial cells</span>. <i>Clin Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">2157</span>– <span class="NLM_lpage">2165</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=12796381" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BD3sXksVWqu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=2157-2165&author=H.+Haskellauthor=M.+Natarajanauthor=T.+P.+Heckerauthor=Q.+Dingauthor=J.+Stewartauthor=R.+Grammerauthor=C.+L.+Gladson&title=Focal+adhesion+kinase+is+expressed+in+the+angiogenic+blood+vessels+of+malignant+astrocytic+tumors+in+vivo+and+promotes+capillary+tube+formation+of+brain+microvascular+endothelial+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Focal Adhesion Kinase Is Expressed in the Angiogenic Blood Vessels of Malignant Astrocytic Tumors in Vivo and Promotes Capillary Tube Formation of Brain Microvascular Endothelial Cells</span></div><div class="casAuthors">Haskell, Henry; Natarajan, Meera; Hecker, Timothy P.; Ding, Qiang; Stewart, Jerry, Jr.; Grammer, J. Robert; Gladson, Candece L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2157-2165</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Focal adhesion kinase (FAK) is a cytoplasmic tyrosine kinase that has been shown to promote proliferation, migration, and invasion of several cell types in vitro, and we have shown recently that FAK promotes proliferation of malignant astrocytoma cells in vivo.  To det. the role of FAK in angiogenesis in malignant astrocytic tumors, we investigated the expression and function of FAK in brain endothelial cells.  We characterized the expression of FAK and activated FAK in endothelial cells by immunohistochem.  We also detd. the function of FAK in brain microvascular endothelial cells by transfecting these cells with a dominant interfering form of FAK [FAK-related nonkinase (FRNK)] or a mutant FRNK (Leu-1034 to Ser) and assessed the effect on capillary tube formation and cell migration.  We found that FAK was expressed in the endothelial cells of grade III (4 of 9 samples) and IV (9 of 10 samples) astrocytoma biopsies but not in the endothelial cells of normal brain (0 of 9 samples) and not in grade I (0 of 5 samples) or II (0 of 4 samples) astrocytoma biopsies.  Furthermore, we found that both FAK and activated FAK were expressed in the endothelial cells in malignant astrocytoma tumors propagated intracerebrally in the severe combined immunodeficient mouse brain.  As expected, immunofluorescence anal. showed FRNK protein to localize to focal adhesions, whereas mutant FRNK protein did not.  FRNK-transfected endothelial cells showed a 55% redn. in branched tube formation and a 40% redn. in tube length when propagated in three-dimensional collagen gels, compared with cells transfected with the mutant FRNK construct.  Furthermore, FRNK-transfected cells showed a 35-50% redn. in haptotactic migration toward fibronectin and collagen, compared with mutant FRNK-transfected cells.  These data suggest that FAK promotes angiogenesis and that this occurs, at least in part, through the promotion of endothelial cell migration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCALutUF0sALVg90H21EOLACvtfcHk0lhYFDE18XUqdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXksVWqu78%253D&md5=cfd3ae0ef42e78179653df5a7f8df30e</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHaskell%26aufirst%3DH.%26aulast%3DNatarajan%26aufirst%3DM.%26aulast%3DHecker%26aufirst%3DT.%2BP.%26aulast%3DDing%26aufirst%3DQ.%26aulast%3DStewart%26aufirst%3DJ.%26aulast%3DGrammer%26aufirst%3DR.%26aulast%3DGladson%26aufirst%3DC.%2BL.%26atitle%3DFocal%2520adhesion%2520kinase%2520is%2520expressed%2520in%2520the%2520angiogenic%2520blood%2520vessels%2520of%2520malignant%2520astrocytic%2520tumors%2520in%2520vivo%2520and%2520promotes%2520capillary%2520tube%2520formation%2520of%2520brain%2520microvascular%2520endothelial%2520cells%26jtitle%3DClin%2520Cancer%2520Res.%26date%3D2003%26volume%3D9%26spage%3D2157%26epage%3D2165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Natarajan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hecker, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gladson, C. L.</span></span> <span> </span><span class="NLM_article-title">FAK signaling in anaplastic astrocytoma and glioblastoma tumors</span>. <i>Cancer J.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">126</span>– <span class="NLM_lpage">133</span>, <span class="refDoi"> DOI: 10.1097/00130404-200303000-00008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1097%2F00130404-200303000-00008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=12784878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlsVelsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=126-133&author=M.+Natarajanauthor=T.+P.+Heckerauthor=C.+L.+Gladson&title=FAK+signaling+in+anaplastic+astrocytoma+and+glioblastoma+tumors&doi=10.1097%2F00130404-200303000-00008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">FAK signaling in anaplastic astrocytoma and glioblastoma tumors</span></div><div class="casAuthors">Natarajan, Meera; Hecker, Timothy P.; Gladson, Candece L.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Journal (Sudbury, MA, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">126-133</span>CODEN:
                <span class="NLM_cas:coden">CAJOCB</span>;
        ISSN:<span class="NLM_cas:issn">1528-9117</span>.
    
            (<span class="NLM_cas:orgname">Jones and Bartlett Publishers</span>)
        </div><div class="casAbstract">A review.  Focal adhesion kinase (FAK) is a non-receptor cytoplasmic-tyrosine kinase that is activated by several different cell surface receptors shown to be upregulated on glioblastoma cells (integrins αvβ3 andαvβ35, and the epidermal growth factor receptor).  Activated FAK can signal through several different signaling pathways, which are reviewed here.  Published data are summarized that have demonstrated (1) elevated FAK expression in anaplastic astrocytoma and glioblastoma tumor biopsy samples, (2) a role for FAK in the promotion of glioblastoma cell proliferation, survival and migration in vitro, and (3) a role for FAK in the promotion of glioblastoma cell proliferation in vivo in an animal model.  The available data suggests that increased levels of FAK protein and activity may contribute to an increased ERK activity and cell proliferation in vivo in these tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqe19jb8wC2y7Vg90H21EOLACvtfcHk0lgWQFcX9_jQIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlsVelsbk%253D&md5=905e6199904ef233df4d689126743cad</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1097%2F00130404-200303000-00008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00130404-200303000-00008%26sid%3Dliteratum%253Aachs%26aulast%3DNatarajan%26aufirst%3DM.%26aulast%3DHecker%26aufirst%3DT.%2BP.%26aulast%3DGladson%26aufirst%3DC.%2BL.%26atitle%3DFAK%2520signaling%2520in%2520anaplastic%2520astrocytoma%2520and%2520glioblastoma%2520tumors%26jtitle%3DCancer%2520J.%26date%3D2003%26volume%3D9%26spage%3D126%26epage%3D133%26doi%3D10.1097%2F00130404-200303000-00008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dehart, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S. T.</span></span> <span> </span><span class="NLM_article-title">Understanding the roles of FAK in cancer: inhibitors, genetic models, and new insights</span>. <i>J. Histochem. Cytochem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">114</span>– <span class="NLM_lpage">128</span>, <span class="refDoi"> DOI: 10.1369/0022155414561498</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1369%2F0022155414561498" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=25380750" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BC2MXislWrtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2015&pages=114-128&author=H.+Yoonauthor=J.+P.+Dehartauthor=J.+M.+Murphyauthor=S.+T.+Lim&title=Understanding+the+roles+of+FAK+in+cancer%3A+inhibitors%2C+genetic+models%2C+and+new+insights&doi=10.1369%2F0022155414561498"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding the roles of FAK in cancer: inhibitors, genetic models, and new insights</span></div><div class="casAuthors">Yoon, Hyunho; Dehart, Joshua P.; Murphy, James M.; Lim, Ssang-Taek Steve</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Histochemistry and Cytochemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">114-128/1-114-128/15, 15 pp.</span>CODEN:
                <span class="NLM_cas:coden">JHCYAS</span>;
        ISSN:<span class="NLM_cas:issn">0022-1554</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A review.  Focal adhesion kinase (FAK) is a protein tyrosine kinase that regulates cellular adhesion, motility, proliferation and survival in various types of cells.  Interestingly, FAK is activated and/or overexpressed in advanced cancers, and promotes cancer progression and metastasis.  For this reason, FAK became a potential therapeutic target in cancer, and small mol. FAK inhibitors have been developed and are being tested in clin. phase trials.  These inhibitors have demonstrated to be effective by inducing tumor cell apoptosis in addn. to reducing metastasis and angiogenesis.  Furthermore, several genetic FAK mouse models have made advancements in understanding the specific role of FAK both in tumors and in the tumor environment.  In this review, we discuss FAK inhibitors as well as genetic mouse models to provide mechanistic insights into FAK signaling and its potential in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro8FZcK4GQb7Vg90H21EOLACvtfcHk0lgWQFcX9_jQIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXislWrtb8%253D&md5=64ffaaef86e9fc737ba3bd825a64dd02</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1369%2F0022155414561498&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1369%252F0022155414561498%26sid%3Dliteratum%253Aachs%26aulast%3DYoon%26aufirst%3DH.%26aulast%3DDehart%26aufirst%3DJ.%2BP.%26aulast%3DMurphy%26aufirst%3DJ.%2BM.%26aulast%3DLim%26aufirst%3DS.%2BT.%26atitle%3DUnderstanding%2520the%2520roles%2520of%2520FAK%2520in%2520cancer%253A%2520inhibitors%252C%2520genetic%2520models%252C%2520and%2520new%2520insights%26jtitle%3DJ.%2520Histochem.%2520Cytochem.%26date%3D2015%26volume%3D63%26spage%3D114%26epage%3D128%26doi%3D10.1369%2F0022155414561498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span> <span> </span><span class="NLM_article-title">Antisense oligonucleotides targeting the focal adhesion kinase inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human glioma cells</span>. <i>J Neurooncol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">117</span>– <span class="NLM_lpage">123</span>, <span class="refDoi"> DOI: 10.1007/s11060-005-9025-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1007%2Fs11060-005-9025-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=16314954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A280%3ADC%252BD28vhs1Kmtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2006&pages=117-123&author=Z.+M.+Wuauthor=X.+H.+Yanauthor=P.+C.+Jiangauthor=Z.+Q.+Liauthor=T.+Wu&title=Antisense+oligonucleotides+targeting+the+focal+adhesion+kinase+inhibit+proliferation%2C+induce+apoptosis%2C+and+cooperate+with+cytotoxic+drugs+in+human+glioma+cells&doi=10.1007%2Fs11060-005-9025-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Antisense oligonucleodes targeting the focal adhesion kinase inhibit proliferation, induce apoptosis and cooperate with cytotoxic drugs in human glioma cells</span></div><div class="casAuthors">Wu Zhi-Min; Yuan Xian-Hou; Jiang Pu-Cha; Li Zhi-Qiang; Wu Tao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neuro-oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">117-23</span>
        ISSN:<span class="NLM_cas:issn">0167-594X</span>.
    </div><div class="casAbstract">To examine the role of focal adhesion kinase in human glioma cells, we studied its effects on proliferation and apoptosis using FAK antisense oligonucleotide.  U251 MG cells were transfected with ODNs, sense FAK, mismatch FAK and antisense-FAK, respectively.  Expression of FAK proteins were detected by Western blots and Immnofluoressence.  Cell apoptosis and mitochondrial membrane potential were analyzed by flow cytometry.  Caspase-3 activity was measured by spectrofluorometer.  MTT assay was used to examine changes in cell proliferation.  The protein expression of FAK in U251 MG cells decreased in antisense-FAK ODNs group significantly.  Caspase-3 activity increased in cells treated with antisense-FAK and down-regulated when treated with caspase-3 inhibitor.  The level of cell apoptosis and loss of mitochondrial membrane potential in antisense-FAK group was higher than in the mismatch sense group.  Cells proliferation was inhibited by antisense-FAK, and the effects were clearly additive when antisense oligonuceotides were added to cells treated with the anticancer agents.  The results suggest that antisense-FAK ODNs inhibit U251 MG cells proliferation and induce their apoptosis.  It is possible that FAK via mitochondrial and caspase-3 inhibits U251 MG cells apoptosis.  And antisense oligonucleotide treatment enhances U251 MG cells sensitivity to chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTQ32jP6yVt9LjnyZkbE8yXfW6udTcc2ebq0-HJxxVhl7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28vhs1Kmtg%253D%253D&md5=0a8960708498dd21515d853be6128877</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1007%2Fs11060-005-9025-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11060-005-9025-9%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DZ.%2BM.%26aulast%3DYan%26aufirst%3DX.%2BH.%26aulast%3DJiang%26aufirst%3DP.%2BC.%26aulast%3DLi%26aufirst%3DZ.%2BQ.%26aulast%3DWu%26aufirst%3DT.%26atitle%3DAntisense%2520oligonucleotides%2520targeting%2520the%2520focal%2520adhesion%2520kinase%2520inhibit%2520proliferation%252C%2520induce%2520apoptosis%252C%2520and%2520cooperate%2520with%2520cytotoxic%2520drugs%2520in%2520human%2520glioma%2520cells%26jtitle%3DJ%2520Neurooncol.%26date%3D2006%26volume%3D77%26spage%3D117%26epage%3D123%26doi%3D10.1007%2Fs11060-005-9025-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lv, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, A. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H. L.</span></span> <span> </span><span class="NLM_article-title">FAK inhibitors in cancer, a patent review</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">139</span>– <span class="NLM_lpage">145</span>, <span class="refDoi"> DOI: 10.1080/13543776.2018.1414183</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1080%2F13543776.2018.1414183" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=29210300" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFOhtLnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=139-145&author=P.+C.+Lvauthor=A.+Q.+Jiangauthor=W.+M.+Zhangauthor=H.+L.+Zhu&title=FAK+inhibitors+in+cancer%2C+a+patent+review&doi=10.1080%2F13543776.2018.1414183"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">FAK inhibitors in Cancer, a patent review</span></div><div class="casAuthors">Lv, Peng-Cheng; Jiang, Ai-Qin; Zhang, Wei-Ming; Zhu, Hai-Liang</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">139-145</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that localizes at sites of cell adhesion to the extracellular matrix (ECM) and mediates signalling events downstream of integrin engagement of the ECM.  FAK is known to regulate cell survival, proliferation and migration.: FAK expression has also been shown to be up-regulated in many cancer types.  Previous study also indicates that FAK-mediated signaling and functions are intrinsically involved in the progression of tumor aggressiveness, suggesting that FAK is a promising target for anticancer therapies.  Small mol. FAK inhibitors have been developed and are being tested in clin. phase trials.: These inhibitors have demonstrated to be effective by inducing tumor cell apoptosis in addn. to reducing metastasis and angiogenesis.  In this review, we give updates on the design, synthesis and structure-activity relationship anal. of small mol. FAK inhibitors discovered from 2015 until now.  We also review the FAK inhibitors that are in clin. development and highlight the future prospects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCbfOByjX7iLVg90H21EOLACvtfcHk0lgNKGsAmQ3WdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFOhtLnP&md5=2c199ec3a1247c3f2680d478b5f69c5b</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1080%2F13543776.2018.1414183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2018.1414183%26sid%3Dliteratum%253Aachs%26aulast%3DLv%26aufirst%3DP.%2BC.%26aulast%3DJiang%26aufirst%3DA.%2BQ.%26aulast%3DZhang%26aufirst%3DW.%2BM.%26aulast%3DZhu%26aufirst%3DH.%2BL.%26atitle%3DFAK%2520inhibitors%2520in%2520cancer%252C%2520a%2520patent%2520review%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2018%26volume%3D28%26spage%3D139%26epage%3D145%26doi%3D10.1080%2F13543776.2018.1414183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shanthi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishna, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arunesh, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkateswara, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sooriya, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viswanadhan, V. N.</span></span> <span> </span><span class="NLM_article-title">Focal adhesion kinase inhibitors in the treatment of metastatic cancer: a patent review</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1077</span>– <span class="NLM_lpage">1100</span>, <span class="refDoi"> DOI: 10.1517/13543776.2014.948845</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1517%2F13543776.2014.948845" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=25113248" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFGhtr7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=1077-1100&author=E.+Shanthiauthor=M.+H.+Krishnaauthor=G.+M.+Aruneshauthor=R.+K.+Venkateswaraauthor=K.+J.+Sooriyaauthor=V.+N.+Viswanadhan&title=Focal+adhesion+kinase+inhibitors+in+the+treatment+of+metastatic+cancer%3A+a+patent+review&doi=10.1517%2F13543776.2014.948845"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Focal adhesion kinase inhibitors in the treatment of metastatic cancer: a patent review</span></div><div class="casAuthors">Shanthi, Ekambaram; Krishna, Mudeenahally H.; Arunesh, Gubbi M.; Venkateswara Reddy, K.; Sooriya Kumar, Jegatheesan; Viswanadhan, Vellarkad N.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1077-1100</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Focal adhesion kinase (FAK) plays a prominent role in integrin signaling.  FAK activation increases phosphorylation of Tyr397 and other sites of the protein.  FAK-dependent activation of signaling pathways implicated in controlling essential cellular functions including growth, proliferation, survival and migration.  FERM (F for the 4.1 protein, ezrin, radixin and moesin) domain-enhanced p53 degrdn. plays a crit. role in proliferation and survival.  FAK, overexpressed in metastatic tumors, has emerged as an important therapeutic target for the development of selective inhibitors.  FAK inhibitors achieved tumor growth inhibition and induced apoptosis.  Strategies targeting FAK inhibition using novel compds. have created an exciting opportunity for anticancer therapy.  Areas covered: This review summarizes the current research with available data from early phase clin. trials and discusses the available small-mol. inhibitors of FAK from patents.  The importance of inhibiting FAK activity in cancer patients is discussed.  Expert opinion: Emerging data from clin. trials with orally available small-mol. inhibitors of FAK are promising.  Although this approach is appropriate as a targeted therapeutic approach against several metastatic cancer types, several compds. in research are yet to prove their preclin. efficacy.  This report lays special emphasis on the available patent data of FAK inhibitors for such targeted mol. therapies.  This review summarizes current knowledge about FAK inhibition in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopctvNfCHOWrVg90H21EOLACvtfcHk0lgNKGsAmQ3WdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFGhtr7M&md5=b096e5c5be880bd4ef328b3b92c9ff42</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1517%2F13543776.2014.948845&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2014.948845%26sid%3Dliteratum%253Aachs%26aulast%3DShanthi%26aufirst%3DE.%26aulast%3DKrishna%26aufirst%3DM.%2BH.%26aulast%3DArunesh%26aufirst%3DG.%2BM.%26aulast%3DVenkateswara%26aufirst%3DR.%2BK.%26aulast%3DSooriya%26aufirst%3DK.%2BJ.%26aulast%3DViswanadhan%26aufirst%3DV.%2BN.%26atitle%3DFocal%2520adhesion%2520kinase%2520inhibitors%2520in%2520the%2520treatment%2520of%2520metastatic%2520cancer%253A%2520a%2520patent%2520review%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2014%26volume%3D24%26spage%3D1077%26epage%3D1100%26doi%3D10.1517%2F13543776.2014.948845" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hjelmeland, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keir, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wickman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohmori, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigner, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rich, J. N.</span></span> <span> </span><span class="NLM_article-title">A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth</span>. <i>Mol. Carcinog.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">488</span>– <span class="NLM_lpage">496</span>, <span class="refDoi"> DOI: 10.1002/mc.20297</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1002%2Fmc.20297" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=17219439" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BD2sXms1Olsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2007&pages=488-496&author=Q.+Shiauthor=A.+B.+Hjelmelandauthor=S.+T.+Keirauthor=L.+Songauthor=S.+Wickmanauthor=D.+Jacksonauthor=O.+Ohmoriauthor=D.+D.+Bignerauthor=H.+S.+Friedmanauthor=J.+N.+Rich&title=A+novel+low-molecular+weight+inhibitor+of+focal+adhesion+kinase%2C+TAE226%2C+inhibits+glioma+growth&doi=10.1002%2Fmc.20297"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth</span></div><div class="casAuthors">Shi, Qing; Hjelmeland, Anita B.; Keir, Stephen T.; Song, Linhua; Wickman, Sarah; Jackson, Dowdy; Ohmori, Osamu; Bigner, Darell D.; Friedman, Henry S.; Rich, Jeremy N.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Carcinogenesis</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">488-496</span>CODEN:
                <span class="NLM_cas:coden">MOCAE8</span>;
        ISSN:<span class="NLM_cas:issn">0899-1987</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Glioblastomas are highly lethal cancers that resist current therapies.  Novel therapies under development target mol. mechanisms that promote glioblastoma growth.  In glioblastoma patient specimens, the non-receptor tyrosine kinase focal adhesion kinase (FAK) is overexpressed.  Upon growth factor receptor stimulation or integrin engagement, FAK is activated by phosphorylation on crit. tyrosine residues.  Activated FAK initiates a signal transduction cascade which promotes glioma growth and invasion by increasing cellular adhesion, migration, invasion, and proliferation.  We find that human glioma cell lines express different levels of total FAK protein and activating phosphorylation of tyrosine residues Tyr397, Tyr861, and Tyr925.  As all glioma cell lines examd. expressed phosphorylated FAK, we examd. the efficacy of a novel low-mol. wt. inhibitor of FAK, TAE226, against human glioma cell lines.  TAE226 inhibited the phosphorylation of FAK as well as the downstream effectors AKT, extracellular signal-related kinase, and S6 ribosomal protein in multiple glioma cell lines.  TAE226 induced a concn.-dependent decrease in cellular proliferation with an assocd. G2 cell cycle arrest in every cell line and an increase in apoptosis in a cell-line-specific manner.  TAE226 also decreased glioma cell adhesion, migration, and invasion through an artificial extracellular matrix.  Together, these data demonstrate the potential benefit of TAE226 for glioma therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXL0wEDuHo9bVg90H21EOLACvtfcHk0lgNKGsAmQ3WdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXms1Olsrg%253D&md5=83711a44fe2472eae4baf568ee4332a4</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1002%2Fmc.20297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmc.20297%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DHjelmeland%26aufirst%3DA.%2BB.%26aulast%3DKeir%26aufirst%3DS.%2BT.%26aulast%3DSong%26aufirst%3DL.%26aulast%3DWickman%26aufirst%3DS.%26aulast%3DJackson%26aufirst%3DD.%26aulast%3DOhmori%26aufirst%3DO.%26aulast%3DBigner%26aufirst%3DD.%2BD.%26aulast%3DFriedman%26aufirst%3DH.%2BS.%26aulast%3DRich%26aufirst%3DJ.%2BN.%26atitle%3DA%2520novel%2520low-molecular%2520weight%2520inhibitor%2520of%2520focal%2520adhesion%2520kinase%252C%2520TAE226%252C%2520inhibits%2520glioma%2520growth%26jtitle%3DMol.%2520Carcinog.%26date%3D2007%26volume%3D46%26spage%3D488%26epage%3D496%26doi%3D10.1002%2Fmc.20297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaFortune, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohmori, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatakeyama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Groot, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yung, W. K.</span></span> <span> </span><span class="NLM_article-title">Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1357</span>– <span class="NLM_lpage">1367</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-06-0476</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1158%2F1535-7163.MCT-06-0476" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=17431114" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BD2sXktFams7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=1357-1367&author=T.+J.+Liuauthor=T.+LaFortuneauthor=T.+Hondaauthor=O.+Ohmoriauthor=S.+Hatakeyamaauthor=T.+Meyerauthor=D.+Jacksonauthor=J.+de+Grootauthor=W.+K.+Yung&title=Inhibition+of+both+focal+adhesion+kinase+and+insulin-like+growth+factor-I+receptor+kinase+suppresses+glioma+proliferation+in+vitro+and+in+vivo&doi=10.1158%2F1535-7163.MCT-06-0476"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo</span></div><div class="casAuthors">Liu, Ta-Jen; LaFortune, Tiffany; Honda, Toshiyuki; Ohmori, Osamu; Hatakeyama, Shinji; Meyer, Thomas; Jackson, Dowdy; de Groot, John; Yung, W. K. Alfred</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1357-1367</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Multiple genetic aberrations in human gliomas contribute to their highly infiltrative and rapid growth characteristics.  Focal adhesion kinase (FAK) regulates tumor migration and invasion.  Insulin-like growth factor-I receptor (IGF-IR), whose expression correlates with tumor grade, is involved in proliferation and survival.  We hypothesized that inhibiting the phosphorylation of FAK and IGF-IR by NVP-TAE226 (hereafter called TAE226), a novel dual tyrosine kinase inhibitor of FAK and IGF-IR, would suppress the growth and invasion of glioma cells.  In culture, TAE226 inhibited extracellular matrix-induced autophosphorylation of FAK (Tyr397).  TAE226 also inhibited IGF-I-induced phosphorylation of IGF-IR and activity of its downstream target genes such as MAPK and Akt.  TAE226 retarded tumor cell growth as assessed by a cell viability assay and attenuated G2-M cell cycle progression assocd. with a decrease in cyclin B1 and phosphorylated cdc2 (Tyr15) protein expression.  TAE226 treatment inhibited tumor cell invasion by at least 50% compared with the control in an in vitro Matrigel invasion assay.  Interestingly, TAE226 treatment of tumor cells contg. wild-type p53 mainly exhibited G2-M arrest, whereas tumor cells bearing mutant p53 underwent apoptosis.  Induction of apoptosis by TAE226 was substantiated by detection of caspase-3/7 activation and poly(ADP-ribose) polymerase cleavage and by an Annexin V apoptosis assay.  More importantly, TAE226 treatment significantly increased the survival rate of animals in an intracranial glioma xenograft model.  Collectively, these data show that blocking the signaling pathways of FAK and IGF-IR with TAE226 has the potential to be an efficacious treatment for human gliomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQMIquqcQABrVg90H21EOLACvtfcHk0ljolJuRXLtPOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXktFams7o%253D&md5=1659c50e987e8bbb24c998e0aae14861</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-06-0476&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-06-0476%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DT.%2BJ.%26aulast%3DLaFortune%26aufirst%3DT.%26aulast%3DHonda%26aufirst%3DT.%26aulast%3DOhmori%26aufirst%3DO.%26aulast%3DHatakeyama%26aufirst%3DS.%26aulast%3DMeyer%26aufirst%3DT.%26aulast%3DJackson%26aufirst%3DD.%26aulast%3Dde%2BGroot%26aufirst%3DJ.%26aulast%3DYung%26aufirst%3DW.%2BK.%26atitle%3DInhibition%2520of%2520both%2520focal%2520adhesion%2520kinase%2520and%2520insulin-like%2520growth%2520factor-I%2520receptor%2520kinase%2520suppresses%2520glioma%2520proliferation%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D1357%26epage%3D1367%26doi%3D10.1158%2F1535-7163.MCT-06-0476" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lonsdale, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, R. A.</span></span> <span> </span><span class="NLM_article-title">Structure-based design of targeted covalent inhibitors</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">3816</span>– <span class="NLM_lpage">3830</span>, <span class="refDoi"> DOI: 10.1039/C7CS00220C</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1039%2FC7CS00220C" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=29620097" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntVGiurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2018&pages=3816-3830&author=R.+Lonsdaleauthor=R.+A.+Ward&title=Structure-based+design+of+targeted+covalent+inhibitors&doi=10.1039%2FC7CS00220C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based design of targeted covalent inhibitors</span></div><div class="casAuthors">Lonsdale, Richard; Ward, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3816-3830</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Covalent inhibition is a rapidly growing discipline within drug discovery.  Many historical covalent inhibitors were discovered by serendipity, with such a mechanism of action often regarded as undesirable due to potential toxicity issues.  Recent progress has seen a major shift in this outlook, as covalent inhibition shows promise for targets where previous efforts to identify non-covalent small mol. inhibitors have failed.  Targeted covalent inhibitors (TCIs) can offer drug discovery scientists the ability to increase the potency and/or selectivity of small mol. inhibitors, by attachment of reactive functional groups designed to covalently bind to specific sites in a target.  In this tutorial review we introduce the broader concept of covalent inhibition, discuss the potential benefits and challenges of such an approach, and provide an overview of the current status of the field.  We also describe some strategies and computational tools to enable successful covalent drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnSIGMuS3vm7Vg90H21EOLACvtfcHk0ljolJuRXLtPOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntVGiurs%253D&md5=a7e31b23cf8ecfcad1397ad10ea10b7b</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1039%2FC7CS00220C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7CS00220C%26sid%3Dliteratum%253Aachs%26aulast%3DLonsdale%26aufirst%3DR.%26aulast%3DWard%26aufirst%3DR.%2BA.%26atitle%3DStructure-based%2520design%2520of%2520targeted%2520covalent%2520inhibitors%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2018%26volume%3D47%26spage%3D3816%26epage%3D3830%26doi%3D10.1039%2FC7CS00220C" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barf, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaptein, A.</span></span> <span> </span><span class="NLM_article-title">Irreversible protein kinase inhibitors: balancing the benefits and risks</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">6243</span>– <span class="NLM_lpage">6262</span>, <span class="refDoi"> DOI: 10.1021/jm3003203</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3003203" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BC38XnsVerur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6243-6262&author=T.+Barfauthor=A.+Kaptein&title=Irreversible+protein+kinase+inhibitors%3A+balancing+the+benefits+and+risks&doi=10.1021%2Fjm3003203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks</span></div><div class="casAuthors">Barf, Tjeerd; Kaptein, Allard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6243-6262</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Not applicable for a Perspective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4PLlisO0OVbVg90H21EOLACvtfcHk0lgmB2gqf3TqPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnsVerur8%253D&md5=5d87850857d37faab02e6037ef8140a4</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm3003203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3003203%26sid%3Dliteratum%253Aachs%26aulast%3DBarf%26aufirst%3DT.%26aulast%3DKaptein%26aufirst%3DA.%26atitle%3DIrreversible%2520protein%2520kinase%2520inhibitors%253A%2520balancing%2520the%2520benefits%2520and%2520risks%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6243%26epage%3D6262%26doi%3D10.1021%2Fjm3003203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanizaki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aref, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capelletti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hur, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaudet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbie, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, J. R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammerman, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">E4869</span>– <span class="NLM_lpage">E4877</span>, <span class="refDoi"> DOI: 10.1073/pnas.1403438111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1073%2Fpnas.1403438111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=25349422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVWmsL%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=E4869-E4877&author=L.+Tanauthor=J.+Wangauthor=J.+Tanizakiauthor=Z.+Huangauthor=A.+R.+Arefauthor=M.+Rusanauthor=S.+J.+Zhuauthor=Y.+Zhangauthor=D.+Ercanauthor=R.+G.+Liaoauthor=M.+Capellettiauthor=W.+Zhouauthor=W.+Hurauthor=N.+Kimauthor=T.+Simauthor=S.+Gaudetauthor=D.+A.+Barbieauthor=J.+R.+J.+Yehauthor=C.+H.+Yunauthor=P.+S.+Hammermanauthor=M.+Mohammadiauthor=P.+A.+J%C3%A4nneauthor=N.+S.+Gray&title=Development+of+covalent+inhibitors+that+can+overcome+resistance+to+first-generation+FGFR+kinase+inhibitors&doi=10.1073%2Fpnas.1403438111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors</span></div><div class="casAuthors">Tan, Li; Wang, Jun; Tanizaki, Junko; Huang, Zhifeng; Aref, Amir R.; Rusan, Maria; Zhu, Su-Jie; Zhang, Yiyun; Ercan, Dalia; Liao, Rachel G.; Capelletti, Marzia; Zhou, Wenjun; Hur, Wooyoung; Kim, NamDoo; Sim, Taebo; Gaudet, Suzanne; Barbie, David A.; Yeh, Jing-Ruey Joanna; Yun, Cai-Hong; Hammerman, Peter S.; Mohammadi, Moosa; Janne, Pasi A.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">E4869-E4877</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The human FGF receptors (FGFRs) play crit. roles in various human cancers, and several FGFR inhibitors are currently under clin. investigation.  Resistance usually results from selection for mutant kinases that are impervious to the action of the drug or from up-regulation of compensatory signaling pathways.  Preclin. studies have demonstrated that resistance to FGFR inhibitors can be acquired through mutations in the FGFR gatekeeper residue, as clin. obsd. for FGFR4 in embryonal rhabdomyosarcoma and neuroendocrine breast carcinomas.  Here the authors report on the use of a structure-based drug design to develop two selective, next-generation covalent FGFR inhibitors, the FGFR irreversible inhibitors I and II.  To our knowledge, I and II are the first inhibitors that can potently inhibit the proliferation of cells dependent upon the gatekeeper mutants of FGFR1 or FGFR2, which confer resistance to first-generation clin. FGFR inhibitors such as NVP-BGJ398 and AZD4547.  Because of the conformational flexibility of the reactive acrylamide substituent, II has the unprecedented ability to inhibit both the EGF receptor (EGFR) and FGFR covalently by targeting two distinct cysteine residues.  The authors report the cocrystal structure of FGFR4 with I, which unexpectedly exhibits a "DFG-out" covalent binding mode.  The structural basis for dual FGFR and EGFR targeting by FIIN3 also is illustrated by crystal structures of II bound with FGFR4 V550L and EGFR L858R.  These results have important implications for the design of covalent FGFR inhibitors that can overcome clin. resistance and provide the first example, to the knowledge, of a kinase inhibitor that covalently targets cysteines located in different positions within the ATP-binding pocket.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmCbTDKPA32LVg90H21EOLACvtfcHk0lgmB2gqf3TqPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVWmsL%252FP&md5=fd4a7eac1e0c17e7c9f2651dd2d76ac7</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1403438111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1403438111%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DTanizaki%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DAref%26aufirst%3DA.%2BR.%26aulast%3DRusan%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DS.%2BJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DLiao%26aufirst%3DR.%2BG.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DHur%26aufirst%3DW.%26aulast%3DKim%26aufirst%3DN.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DGaudet%26aufirst%3DS.%26aulast%3DBarbie%26aufirst%3DD.%2BA.%26aulast%3DYeh%26aufirst%3DJ.%2BR.%2BJ.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DHammerman%26aufirst%3DP.%2BS.%26aulast%3DMohammadi%26aufirst%3DM.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDevelopment%2520of%2520covalent%2520inhibitors%2520that%2520can%2520overcome%2520resistance%2520to%2520first-generation%2520FGFR%2520kinase%2520inhibitors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2014%26volume%3D111%26spage%3DE4869%26epage%3DE4877%26doi%3D10.1073%2Fpnas.1403438111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yen-Pon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acebrón-Garcia-de-Eulate, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomkiewicz-Raulet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lietha, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frame, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coumoul, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbay, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Etheve-Quelquejeu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span> <span> </span><span class="NLM_article-title">Structure-based design, synthesis, and characterization of the first irreversible inhibitor of focal adhesion kinase</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">2067</span>– <span class="NLM_lpage">2073</span>, <span class="refDoi"> DOI: 10.1021/acschembio.8b00250</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.8b00250" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFWrtb%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=2067-2073&author=E.+Yen-Ponauthor=B.+Liauthor=M.+Acebr%C3%B3n-Garcia-de-Eulateauthor=C.+Tomkiewicz-Rauletauthor=J.+Dawsonauthor=D.+Liethaauthor=M.+C.+Frameauthor=X.+Coumoulauthor=C.+Garbayauthor=M.+Etheve-Quelquejeuauthor=H.+Chen&title=Structure-based+design%2C+synthesis%2C+and+characterization+of+the+first+irreversible+inhibitor+of+focal+adhesion+kinase&doi=10.1021%2Facschembio.8b00250"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design, Synthesis, and Characterization of the First Irreversible Inhibitor of Focal Adhesion Kinase</span></div><div class="casAuthors">Yen-Pon, Expedite; Li, Bo; Acebron-Garcia-de-Eulate, Marta; Tomkiewicz-Raulet, Celine; Dawson, John; Lietha, Daniel; Frame, Margaret C.; Coumoul, Xavier; Garbay, Christiane; Etheve-Quelquejeu, Melanie; Chen, Huixiong</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2067-2073</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Focal Adhesion Kinase signaling pathway and its functions have been involved in the development and aggressiveness of tumor malignancy, it then presents a promising cancer therapeutic target.  Several reversible FAK inhibitors have been developed and are being conducted in clin. trials.  Irreversible covalent inhibitors would bring many desirable pharmacol. features including high potency and increased duration of action.  Herein the authors report the structure-guided development of the first highly potent and irreversible inhibitor of the FAK kinase.  This inhibitor showed a very potent decrease of autophosphorylation of FAK in squamous cell carcinoma.  A co-crystal structure of the FAK kinase domain in complex with this compd. revealed the inhibitor binding mode within the ATP binding site and confirmed the covalent linkage between the targeted Cys 427 of the protein and the inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGry3Z3EZu1PlbVg90H21EOLACvtfcHk0lgmB2gqf3TqPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFWrtb%252FJ&md5=12f0e96763bba7196ff6eaf947cc9887</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facschembio.8b00250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.8b00250%26sid%3Dliteratum%253Aachs%26aulast%3DYen-Pon%26aufirst%3DE.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DAcebr%25C3%25B3n-Garcia-de-Eulate%26aufirst%3DM.%26aulast%3DTomkiewicz-Raulet%26aufirst%3DC.%26aulast%3DDawson%26aufirst%3DJ.%26aulast%3DLietha%26aufirst%3DD.%26aulast%3DFrame%26aufirst%3DM.%2BC.%26aulast%3DCoumoul%26aufirst%3DX.%26aulast%3DGarbay%26aufirst%3DC.%26aulast%3DEtheve-Quelquejeu%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DH.%26atitle%3DStructure-based%2520design%252C%2520synthesis%252C%2520and%2520characterization%2520of%2520the%2520first%2520irreversible%2520inhibitor%2520of%2520focal%2520adhesion%2520kinase%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2018%26volume%3D13%26spage%3D2067%26epage%3D2073%26doi%3D10.1021%2Facschembio.8b00250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ung, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whalen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hulford, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Autry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emerson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Alsina, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenzen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berliner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luzzio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaGreca, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jani, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wessel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marr, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vajdos, F.</span></span> <span> </span><span class="NLM_article-title">Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF 562,271</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">1935</span>– <span class="NLM_lpage">1944</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-5155</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1158%2F0008-5472.CAN-07-5155" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=18339875" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjtFOhtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=1935-1944&author=W.+G.+Robertsauthor=E.+Ungauthor=P.+Whalenauthor=B.+Cooperauthor=C.+Hulfordauthor=C.+Autryauthor=D.+Richterauthor=E.+Emersonauthor=J.+Linauthor=J.+Kathauthor=K.+Colemanauthor=L.+Yaoauthor=L.+Martinez-Alsinaauthor=M.+Lorenzenauthor=M.+Berlinerauthor=M.+Luzzioauthor=N.+Patelauthor=E.+Schmittauthor=S.+LaGrecaauthor=J.+Janiauthor=M.+Wesselauthor=E.+Marrauthor=M.+Grifforauthor=F.+Vajdos&title=Antitumor+activity+and+pharmacology+of+a+selective+focal+adhesion+kinase+inhibitor%2C+PF+562%2C271&doi=10.1158%2F0008-5472.CAN-07-5155"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor Activity and Pharmacology of a Selective Focal Adhesion Kinase Inhibitor, PF-562,271</span></div><div class="casAuthors">Roberts, Walter Gregory; Ung, Ethan; Whalen, Pamela; Cooper, Beth; Hulford, Catherine; Autry, Christofer; Richter, Daniel; Emerson, Earling; Lin, Jing; Kath, John; Coleman, Kevin; Yao, Lili; Martinez-Alsina, Luis; Lorenzen, Marianne; Berliner, Martin; Luzzio, Michael; Patel, Nandini; Schmitt, Erika; LaGreca, Susan; Jani, Jitesh; Wessel, Matt; Marr, Eric; Griffor, Matt; Vajdos, Felix</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1935-1944</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Cancer cells are characterized by the ability to grow in an anchorage-independent manner.  The activity of the nonreceptor tyrosine kinase, focal adhesion kinase (FAK), is thought to contribute to this phenotype.  FAK localizes in focal adhesion plaques and has a role as a scaffolding and signaling protein for other adhesion mols.  Recent studies show a strong correlation between increased FAK expression and phosphorylation status and the invasive phenotype of aggressive human tumors.  PF-562,271 is a potent, ATP-competitive, reversible inhibitor of FAK and Pyk2 catalytic activity with a IC50 of 1.5 and 14 nmol/L, resp.  Addnl., PF-562,271 displayed robust inhibition in an inducible cell-based assay measuring phospho-FAK with an IC50 of 5 nmol/L.  PF-562,271 was evaluated against multiple kinases and displays >100x selectivity against a long list of nontarget kinases.  PF-562,271 inhibits FAK phosphorylation in vivo in a dose-dependent fashion (calcd. EC50 of 93 ng/mL, total) after p.o. administration to tumor-bearing mice.  In vivo inhibition of FAK phosphorylation (>50%) was sustained for >4 h with a single p.o. dose of 33 mg/kg.  Antitumor efficacy and regressions were obsd. in multiple human s.c. xenograft models.  No wt. loss, morbidity, or mortality were obsd. in any in vivo expt.  Tumor growth inhibition was dose and drug exposure dependent.  Taken together, these data show that kinase inhibition with an ATP-competitive small mol. inhibitor of FAK decreases the phospho-status in vivo, resulting in robust antitumor activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofV3TtMU2E07Vg90H21EOLACvtfcHk0lh3TtAbe19C2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjtFOhtrw%253D&md5=a5dad7cd49e32a9904de14fb34939be5</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-5155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-5155%26sid%3Dliteratum%253Aachs%26aulast%3DRoberts%26aufirst%3DW.%2BG.%26aulast%3DUng%26aufirst%3DE.%26aulast%3DWhalen%26aufirst%3DP.%26aulast%3DCooper%26aufirst%3DB.%26aulast%3DHulford%26aufirst%3DC.%26aulast%3DAutry%26aufirst%3DC.%26aulast%3DRichter%26aufirst%3DD.%26aulast%3DEmerson%26aufirst%3DE.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DKath%26aufirst%3DJ.%26aulast%3DColeman%26aufirst%3DK.%26aulast%3DYao%26aufirst%3DL.%26aulast%3DMartinez-Alsina%26aufirst%3DL.%26aulast%3DLorenzen%26aufirst%3DM.%26aulast%3DBerliner%26aufirst%3DM.%26aulast%3DLuzzio%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DN.%26aulast%3DSchmitt%26aufirst%3DE.%26aulast%3DLaGreca%26aufirst%3DS.%26aulast%3DJani%26aufirst%3DJ.%26aulast%3DWessel%26aufirst%3DM.%26aulast%3DMarr%26aufirst%3DE.%26aulast%3DGriffor%26aufirst%3DM.%26aulast%3DVajdos%26aufirst%3DF.%26atitle%3DAntitumor%2520activity%2520and%2520pharmacology%2520of%2520a%2520selective%2520focal%2520adhesion%2520kinase%2520inhibitor%252C%2520PF%2520562%252C271%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D1935%26epage%3D1944%26doi%3D10.1158%2F0008-5472.CAN-07-5155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Serafimova, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pufall, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maglathlin, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McFarland, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frödin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taunton, J.</span></span> <span> </span><span class="NLM_article-title">Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">471</span>– <span class="NLM_lpage">476</span>, <span class="refDoi"> DOI: 10.1038/nchembio.925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1038%2Fnchembio.925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=22466421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvVKitrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=471-476&author=I.+M.+Serafimovaauthor=M.+A.+Pufallauthor=S.+Krishnanauthor=K.+Dudaauthor=M.+S.+Cohenauthor=R.+L.+Maglathlinauthor=J.+M.+McFarlandauthor=R.+M.+Millerauthor=M.+Fr%C3%B6dinauthor=J.+Taunton&title=Reversible+targeting+of+noncatalytic+cysteines+with+chemically+tuned+electrophiles&doi=10.1038%2Fnchembio.925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles</span></div><div class="casAuthors">Serafimova, Iana M.; Pufall, Miles A.; Krishnan, Shyam; Duda, Katarzyna; Cohen, Michael S.; Maglathlin, Rebecca L.; McFarland, Jesse M.; Miller, Rand M.; Froedin, Morten; Taunton, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">471-476</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Targeting noncatalytic cysteine residues with irreversible acrylamide-based inhibitors is a powerful approach for enhancing pharmacol. potency and selectivity.  Nevertheless, concerns about off-target modification motivate the development of reversible cysteine-targeting strategies.  Here we show that electron-deficient olefins, including acrylamides, can be tuned to react with cysteine thiols in a rapidly reversible manner.  Installation of a nitrile group increased the olefins' intrinsic reactivity, but, paradoxically, eliminated the formation of irreversible adducts.  Incorporation of these electrophiles into a noncovalent kinase-recognition scaffold produced slowly dissocg., covalent inhibitors of the p90 ribosomal protein S6 kinase RSK2.  A cocrystal structure revealed specific noncovalent interactions that stabilize the complex by positioning the electrophilic carbon near the targeted cysteine.  Disruption of these interactions by protein unfolding or proteolysis promoted instantaneous cleavage of the covalent bond.  Our results establish a chem.-based framework for engineering sustained covalent inhibition without accumulating permanently modified proteins and peptides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlcv3GjPOB6rVg90H21EOLACvtfcHk0lh3TtAbe19C2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvVKitrw%253D&md5=6455a9a029714beb317286f71ac1326b</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.925%26sid%3Dliteratum%253Aachs%26aulast%3DSerafimova%26aufirst%3DI.%2BM.%26aulast%3DPufall%26aufirst%3DM.%2BA.%26aulast%3DKrishnan%26aufirst%3DS.%26aulast%3DDuda%26aufirst%3DK.%26aulast%3DCohen%26aufirst%3DM.%2BS.%26aulast%3DMaglathlin%26aufirst%3DR.%2BL.%26aulast%3DMcFarland%26aufirst%3DJ.%2BM.%26aulast%3DMiller%26aufirst%3DR.%2BM.%26aulast%3DFr%25C3%25B6din%26aufirst%3DM.%26aulast%3DTaunton%26aufirst%3DJ.%26atitle%3DReversible%2520targeting%2520of%2520noncatalytic%2520cysteines%2520with%2520chemically%2520tuned%2520electrophiles%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2012%26volume%3D8%26spage%3D471%26epage%3D476%26doi%3D10.1038%2Fnchembio.925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schüttelkopf, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Aalten, D. M. F.</span></span> <span> </span><span class="NLM_article-title">PRODRG: a tool for high-throughput crystallography of protein-ligand complexes</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1355</span>– <span class="NLM_lpage">1363</span>, <span class="refDoi"> DOI: 10.1107/S0907444904011679</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1107%2FS0907444904011679" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=15272157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlvVegtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=1355-1363&author=A.+W.+Sch%C3%BCttelkopfauthor=D.+M.+F.+van+Aalten&title=PRODRG%3A+a+tool+for+high-throughput+crystallography+of+protein-ligand+complexes&doi=10.1107%2FS0907444904011679"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">PRODRG: a tool for high-throughput crystallography of protein-ligand complexes</span></div><div class="casAuthors">Schuettelkopf, Alexander W.; van Aalten, Daan M. F.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">D60</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1355-1363</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">The small-mol. topol. generator PRODRG is described, which takes input from existing coordinates or various two-dimensional formats and automatically generates coordinates and mol. topologies suitable for x-ray refinement of protein-ligand complexes.  Test results are described for automatic generation of topologies followed by energy minimization for a subset of compds. from the Cambridge Structural Database, which shows that, within the limits of the empirical GROMOS87 force field used, structures with good geometries are generated.  X-ray refinement in X-PLOR/CNS, REFMAC and SHELX using PRODRG-generated topologies produces results comparable to refinement with topologies from the std. libraries.  However, tests with distorted starting coordinates show that PRODRG topologies perform better, both in terms of ligand geometry and of crystallog. R factors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbflrch0bs97Vg90H21EOLACvtfcHk0lipd25ByWFQAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlvVegtbY%253D&md5=f9bfdb14be7b04ea5c0db67feb39f72a</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1107%2FS0907444904011679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444904011679%26sid%3Dliteratum%253Aachs%26aulast%3DSch%25C3%25BCttelkopf%26aufirst%3DA.%2BW.%26aulast%3Dvan%2BAalten%26aufirst%3DD.%2BM.%2BF.%26atitle%3DPRODRG%253A%2520a%2520tool%2520for%2520high-throughput%2520crystallography%2520of%2520protein-ligand%2520complexes%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2004%26volume%3D60%26spage%3D1355%26epage%3D1363%26doi%3D10.1107%2FS0907444904011679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lebedev, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isupov, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moroz, O. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vagin, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murshudov, G. N.</span></span> <span> </span><span class="NLM_article-title">JLigand: a graphical tool for the CCP4 template-restraint library</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">431</span>– <span class="NLM_lpage">440</span>, <span class="refDoi"> DOI: 10.1107/S090744491200251X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1107%2FS090744491200251X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=22505263" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BC38Xlt1Gnsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2012&pages=431-440&author=A.+A.+Lebedevauthor=P.+Youngauthor=M.+N.+Isupovauthor=O.+V.+Morozauthor=A.+A.+Vaginauthor=G.+N.+Murshudov&title=JLigand%3A+a+graphical+tool+for+the+CCP4+template-restraint+library&doi=10.1107%2FS090744491200251X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">JLigand: a graphical tool for the CCP4 template-restraint library</span></div><div class="casAuthors">Lebedev, Andrey A.; Young, Paul; Isupov, Michail N.; Moroz, Olga V.; Vagin, Alexey A.; Murshudov, Garib N.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">431-440</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Biol. macromols. are polymers and therefore the restraints for macromol. refinement can be subdivided into two sets: restraints that are applied to atoms that all belong to the same monomer and restraints that are assocd. with the covalent bonds between monomers.  The CCP4 template-restraint library contains three types of data entries defining template restraints: descriptions of monomers and their modifications, both used for intramonomer restraints, and descriptions of links for intermonomer restraints.  The library provides generic descriptions of modifications and links for protein, DNA and RNA chains, and for some post-translational modifications including glycosylation.  Structure-specific template restraints can be defined in a user's addnl. restraint library.  Here, JLigand, a new CCP4 graphical interface to LibCheck and REFMAC that has been developed to manage the user's library and generate new monomer entries is described, as well as new entries for links and assocd. modifications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_PAJI464bdLVg90H21EOLACvtfcHk0lipd25ByWFQAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xlt1Gnsr4%253D&md5=333c42dac336b0598540500f06350d3a</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1107%2FS090744491200251X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS090744491200251X%26sid%3Dliteratum%253Aachs%26aulast%3DLebedev%26aufirst%3DA.%2BA.%26aulast%3DYoung%26aufirst%3DP.%26aulast%3DIsupov%26aufirst%3DM.%2BN.%26aulast%3DMoroz%26aufirst%3DO.%2BV.%26aulast%3DVagin%26aufirst%3DA.%2BA.%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26atitle%3DJLigand%253A%2520a%2520graphical%2520tool%2520for%2520the%2520CCP4%2520template-restraint%2520library%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2012%26volume%3D68%26spage%3D431%26epage%3D440%26doi%3D10.1107%2FS090744491200251X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Richter, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kath, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luzzio, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keene, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berliner, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wessel, M. D.</span></span> <span> </span><span class="NLM_article-title">Selective addition of amines to 5-trifluoromethyl-2,4-dichloropyrimidine induced by Lewis acids</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">4610</span>– <span class="NLM_lpage">4612</span>, <span class="refDoi"> DOI: 10.1016/j.tetlet.2013.06.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1016%2Fj.tetlet.2013.06.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtV2ksrfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2013&pages=4610-4612&author=D.+T.+Richterauthor=J.+C.+Kathauthor=M.+J.+Luzzioauthor=N.+Keeneauthor=M.+A.+Berlinerauthor=M.+D.+Wessel&title=Selective+addition+of+amines+to+5-trifluoromethyl-2%2C4-dichloropyrimidine+induced+by+Lewis+acids&doi=10.1016%2Fj.tetlet.2013.06.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Selective addition of amines to 5-trifluoromethyl-2,4-dichloropyrimidine induced by Lewis acids</span></div><div class="casAuthors">Richter, Daniel T.; Kath, John C.; Luzzio, Michael J.; Keene, Nandell; Berliner, Martin A.; Wessel, Matthew D.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">4610-4612</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A variety of 2,4-diamino-pyrimidine systems can be prepd. from the corresponding 2,4-dichloro-pyrimidine by sequential addn. of two amines, the first adding selectively to the 4-position.  In contrast it was found that 2,4-dichloro-5-trifluoromethyl-pyrimidine yields a 1:1 mixt. of the two possible isomers.  Lewis acids were employed to increase the ratio of isomers to >10:1 in favor of the 2-addn. product, e. g., I.  Optimization of the effect of Lewis acid additives on this and other dichloropyrimidine systems will be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB8bhzGoYIgrVg90H21EOLACvtfcHk0lipd25ByWFQAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtV2ksrfK&md5=f67ba400cbbb568fe2afdfe5424019c0</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2013.06.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2013.06.025%26sid%3Dliteratum%253Aachs%26aulast%3DRichter%26aufirst%3DD.%2BT.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DLuzzio%26aufirst%3DM.%2BJ.%26aulast%3DKeene%26aufirst%3DN.%26aulast%3DBerliner%26aufirst%3DM.%2BA.%26aulast%3DWessel%26aufirst%3DM.%2BD.%26atitle%3DSelective%2520addition%2520of%2520amines%2520to%25205-trifluoromethyl-2%252C4-dichloropyrimidine%2520induced%2520by%2520Lewis%2520acids%26jtitle%3DTetrahedron%2520Lett.%26date%3D2013%26volume%3D54%26spage%3D4610%26epage%3D4612%26doi%3D10.1016%2Fj.tetlet.2013.06.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lough, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, H. L.</span></span> <span> </span><span class="NLM_article-title">Equilibrium reactions of N-butanethiol with some conjugated heteroenoid compounds</span>. <i>Can. J. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1968</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">775</span>– <span class="NLM_lpage">781</span>, <span class="refDoi"> DOI: 10.1139/v68-128</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1139%2Fv68-128" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADyaF1cXpsFSluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=1968&pages=775-781&author=R.+B.+Pritchardauthor=C.+E.+Loughauthor=D.+J.+Currieauthor=H.+L.+Holmes&title=Equilibrium+reactions+of+N-butanethiol+with+some+conjugated+heteroenoid+compounds&doi=10.1139%2Fv68-128"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Equilibrium reactions of butanethiol with some conjugated heteroenoid compounds</span></div><div class="casAuthors">Pritchard, R. B.; Lough, C. E.; Currie, D. J.; Holmes, Henry L.</div><div class="citationInfo"><span class="NLM_cas:title">Canadian Journal of Chemistry</span>
        (<span class="NLM_cas:date">1968</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">775-81</span>CODEN:
                <span class="NLM_cas:coden">CJCHAG</span>;
        ISSN:<span class="NLM_cas:issn">0008-4042</span>.
    </div><div class="casAbstract">The reactions of 2-benzal-1,3-indandiones and the cyano-contg. benzalmalononitriles, ethyl benzalcyanoacetates, benzalcyanoacetamides, and benzalcycanoacetanilides with butanethiol at 25° in 20% ethanol-80% pH 7 buffer attain equil. at a rate too fast to measure by standard methods.  The equil. consts. were calcd. and these in turn related to Hammett σ and Taft σ* consts.  The differences in the reactions of these and other gem difunctional systems which react virtually completely with butanethiol under the same exptl. conditions and at a measurable rate, are attributed to participation of the functional group cis to the Ph group in the reverse reaction.  It is shown that butanethiol adds to cinnamalacetophenone by a 1,4-mechanism and the reactions of this nucleophile with similar compds. having extended conjugated systems are discussed.  22 references.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKmmPRTCc-9rVg90H21EOLACvtfcHk0lhGFEK3BGUaRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF1cXpsFSluw%253D%253D&md5=4d45492d65fe1f3ad785210a7c5e4be2</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1139%2Fv68-128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1139%252Fv68-128%26sid%3Dliteratum%253Aachs%26aulast%3DPritchard%26aufirst%3DR.%2BB.%26aulast%3DLough%26aufirst%3DC.%2BE.%26aulast%3DCurrie%26aufirst%3DD.%2BJ.%26aulast%3DHolmes%26aufirst%3DH.%2BL.%26atitle%3DEquilibrium%2520reactions%2520of%2520N-butanethiol%2520with%2520some%2520conjugated%2520heteroenoid%2520compounds%26jtitle%3DCan.%2520J.%2520Chem.%26date%3D1968%26volume%3D46%26spage%3D775%26epage%3D781%26doi%3D10.1139%2Fv68-128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flippot, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magné, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vignot, S.</span></span> <span> </span><span class="NLM_article-title">FGF/FGFR Signalling: implication in oncogenesis and perspectives</span>. <i>Bull. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">516</span>– <span class="NLM_lpage">526</span>, <span class="refDoi"> DOI: 10.1016/j.bulcan.2015.04.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1016%2Fj.bulcan.2015.04.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=25986739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A280%3ADC%252BC2MfltVOlsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2015&pages=516-526&author=R.+Flippotauthor=M.+Koneauthor=N.+Magn%C3%A9author=S.+Vignot&title=FGF%2FFGFR+Signalling%3A+implication+in+oncogenesis+and+perspectives&doi=10.1016%2Fj.bulcan.2015.04.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">FGF/FGFR signalling: Implication in oncogenesis and perspectives</span></div><div class="casAuthors">Flippot Ronan; Kone Moumini; Magne Nicolas; Vignot Stephane</div><div class="citationInfo"><span class="NLM_cas:title">Bulletin du cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">516-26</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Deregulation of FGF (fibroblast growth factor)/FGFR (fibroblast growth factor receptor) signalling leads to the promotion of several oncogenic mechanisms: proliferation, epithelial-mesenchymal transition, cytoskeleton modifications, migration and angiogenesis.  Deregulation of this pathway is reported in various cancers at early stages, and can therefore be responsible for the emergence of the hallmarks of cancer.  It is necessary to precise downstream pathways of FGFR signalling to understand its oncogenic potential.  We will then describe its implications in different cancer types.  Oncogenic mechanisms will be studied through the example of melanoma, in which deregulation of FGF/FGFR pathway is considered as a driver event and occurs in nearly 90% of cases.  The FGF/FGFR signalling pathway is a putative therapeutic target.  Numerous agents are in active development, operating through a selective or multi-targeted approach.  Recent studies have shown rather disappointing results in non-selected patients, but promising results in patients with FGF/FGFR pathway alterations.  A careful screening of patients is the key to a valuable evaluation of these new targeted molecular therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR6HPunjVlFNq-9TkgmBqTqfW6udTcc2ebIRAd6_G4-_7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MfltVOlsA%253D%253D&md5=b20bba3e85fa6601d18921e6bc344b08</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.bulcan.2015.04.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bulcan.2015.04.010%26sid%3Dliteratum%253Aachs%26aulast%3DFlippot%26aufirst%3DR.%26aulast%3DKone%26aufirst%3DM.%26aulast%3DMagn%25C3%25A9%26aufirst%3DN.%26aulast%3DVignot%26aufirst%3DS.%26atitle%3DFGF%252FFGFR%2520Signalling%253A%2520implication%2520in%2520oncogenesis%2520and%2520perspectives%26jtitle%3DBull.%2520Cancer%26date%3D2015%26volume%3D102%26spage%3D516%26epage%3D526%26doi%3D10.1016%2Fj.bulcan.2015.04.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chagoya, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwatra, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanni, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nullmeyergh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilmore, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spasojevic, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corcoran, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballman, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramakrishna, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markert, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesser, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwatra, M. M.</span></span> <span> </span><span class="NLM_article-title">Efficacy of osimertinib against EGFRvIII+ glioblastoma</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2074</span>– <span class="NLM_lpage">2082</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.27599</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.18632%2Foncotarget.27599" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=32547705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A280%3ADC%252BB38ngvVahsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=2074-2082&author=G.+Chagoyaauthor=S.+G.+Kwatraauthor=C.+W.+Nanniauthor=C.+M.+Robertsauthor=S.+M.+Phillipsauthor=S.+Nullmeyerghauthor=S.+P.+Gilmoreauthor=I.+Spasojevicauthor=D.+L.+Corcoranauthor=C.+C.+Youngauthor=K.+V.+Ballmanauthor=R.+Ramakrishnaauthor=D.+A.+Crossauthor=J.+M.+Markertauthor=M.+Limauthor=M.+R.+Gilbertauthor=G.+J.+Lesserauthor=M.+M.+Kwatra&title=Efficacy+of+osimertinib+against+EGFRvIII%2B+glioblastoma&doi=10.18632%2Foncotarget.27599"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of osimertinib against EGFRvIII+ glioblastoma</span></div><div class="casAuthors">Chagoya Gustavo; Markert James M; Kwatra Shawn G; Kwatra Shawn G; Nanni Cory W; Roberts Callie M; Gilmore Samuel P; Young Christopher C; Kwatra Madan M; Phillips Samantha M; Nullmeyergh Sarah; Kwatra Madan M; Spasojevic Ivan; Kwatra Madan M; Corcoran David L; Ballman Karla V; Ramakrishna Rohan; Cross Darren A; Lim Michael; Gilbert Mark R; Lesser Glenn J</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2074-2082</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Epidermal Growth Factor Receptor variant III (EGFRvIII) is an active mutant form of EGFR that drives tumor growth in a subset of glioblastoma (GBM).  It occurs in over 20% of GBMs, making it a promising receptor for small molecule targeted therapy.  We hypothesize that poor penetration of the blood-brain barrier by previously tested EGFR-tyrosine kinase inhibitors (EGFR-TKIs) such as afateninb, erlotinib, gefitinib, and lapatinib played a role in their limited efficacy.  The present study examined the effects of osimertinib (previously known as AZD9291) on EGFRvIII+ GBM models, both in vitro and in vivo.  Therefore, a panel of six GBM stem cells (GSCs) expressing EGFRvIII+ was evaluated.  The EGFRvIII+ GSC differed in the expression of EGFRvIII and other key genes.  The GSC line D317, which expresses high levels of EGFRvIII and has robust tyrosine kinase activity, was selected for assessing osimertinib's efficacy.  Herein, we report that osimertinib inhibits the constitutive activity of EGFRvIII tyrosine kinase with high potency (<100 nM) while also inhibiting its downstream signaling.  Further, osimertinib inhibited D317's growth in vitro and in both heterotopic and orthotopic xenograft models.  Additional preclinical studies are warranted to identify EGFRvIII+ GBM's molecular signature most responsive to osimertinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRPDwmlqQBUT8ve_zCu79I8fW6udTcc2ebIRAd6_G4-_7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38ngvVahsQ%253D%253D&md5=c9e989f0f9f2a3514b123017a3220ba5</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.27599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.27599%26sid%3Dliteratum%253Aachs%26aulast%3DChagoya%26aufirst%3DG.%26aulast%3DKwatra%26aufirst%3DS.%2BG.%26aulast%3DNanni%26aufirst%3DC.%2BW.%26aulast%3DRoberts%26aufirst%3DC.%2BM.%26aulast%3DPhillips%26aufirst%3DS.%2BM.%26aulast%3DNullmeyergh%26aufirst%3DS.%26aulast%3DGilmore%26aufirst%3DS.%2BP.%26aulast%3DSpasojevic%26aufirst%3DI.%26aulast%3DCorcoran%26aufirst%3DD.%2BL.%26aulast%3DYoung%26aufirst%3DC.%2BC.%26aulast%3DBallman%26aufirst%3DK.%2BV.%26aulast%3DRamakrishna%26aufirst%3DR.%26aulast%3DCross%26aufirst%3DD.%2BA.%26aulast%3DMarkert%26aufirst%3DJ.%2BM.%26aulast%3DLim%26aufirst%3DM.%26aulast%3DGilbert%26aufirst%3DM.%2BR.%26aulast%3DLesser%26aufirst%3DG.%2BJ.%26aulast%3DKwatra%26aufirst%3DM.%2BM.%26atitle%3DEfficacy%2520of%2520osimertinib%2520against%2520EGFRvIII%252B%2520glioblastoma%26jtitle%3DOncotarget%26date%3D2020%26volume%3D11%26spage%3D2074%26epage%3D2082%26doi%3D10.18632%2Foncotarget.27599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mobley, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkaria, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span> <span> </span><span class="NLM_article-title">InsR/IGF1R pathway mediates resistance to EGFR inhibitors in glioblastoma</span>. <i>Clin Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1767</span>– <span class="NLM_lpage">1776</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-15-1677</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1158%2F1078-0432.CCR-15-1677" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=26561558" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BC28Xls1Kjtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=1767-1776&author=Y.+Maauthor=N.+Tangauthor=R.+C.+Thompsonauthor=B.+C.+Mobleyauthor=S.+W.+Clarkauthor=J.+N.+Sarkariaauthor=J.+Wang&title=InsR%2FIGF1R+pathway+mediates+resistance+to+EGFR+inhibitors+in+glioblastoma&doi=10.1158%2F1078-0432.CCR-15-1677"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma</span></div><div class="casAuthors">Ma, Yufang; Tang, Nan; Thompson, Reid C.; Mobley, Bret C.; Clark, Steven W.; Sarkaria, Jann N.; Wang, Jialiang</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1767-1776</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Aberrant activation of EGFR is a hallmark of glioblastoma.  However, EGFR inhibitors exhibit at best modest efficacy in glioblastoma.  This is in sharp contrast with the observations in EGFR-mutant lung cancer.  We examd. whether activation of functionally redundant receptor tyrosine kinases (RTKs) conferred resistance to EGFR inhibitors in glioblastoma.  Exptl. Design: We collected a panel of patient-derived glioblastoma xenograft (PDX) lines that maintained expression of wild-type or mutant EGFR in serial xenotransplantation and tissue cultures.  Using this physiol. relevant platform, we tested the abilities of several RTK ligands to protect glioblastoma cells against an EGFR inhibitor, gefitinib.  Based on the screening results, we further developed a combination therapy cotargeting EGFR and insulin receptor (InsR)/insulin-like growth factor 1 receptor (IGF1R).  Results: Insulin and IGF1 induced significant protection against gefitinib in the majority of EGFR-dependent PDX lines with one exception that did not express InsR or IGF1R.  Blockade of the InsR/IGF1R pathway synergistically improved sensitivity to gefitinib or dacomitinib.  Gefitinib alone effectively attenuated EGFR activities and the downstream MEK/ERK pathway.  However, repression of AKT and induction of apoptosis required concurrent inhibition of both EGFR and InsR/IGF1R.  A combination of gefitinib and OSI-906, a dual InsR/IGF1R inhibitor, was more effective than either agent alone to treat s.c. glioblastoma xenograft tumors.  Conclusions: Our results suggest that activation of the InsR/IGF1R pathway confers resistance to EGFR inhibitors in EGFR-dependent glioblastoma through AKT regulation.  Concurrent blockade of these two pathways holds promise to treat EGFR-dependent glioblastoma.  Clin Cancer Res; 22(7); 1767-76. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfsp3VSZQ4n7Vg90H21EOLACvtfcHk0liw6d9Zuvo2Dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xls1Kjtbw%253D&md5=cc93f6a60329e0ad6a13dc711c5525ef</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-1677&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-1677%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DY.%26aulast%3DTang%26aufirst%3DN.%26aulast%3DThompson%26aufirst%3DR.%2BC.%26aulast%3DMobley%26aufirst%3DB.%2BC.%26aulast%3DClark%26aufirst%3DS.%2BW.%26aulast%3DSarkaria%26aufirst%3DJ.%2BN.%26aulast%3DWang%26aufirst%3DJ.%26atitle%3DInsR%252FIGF1R%2520pathway%2520mediates%2520resistance%2520to%2520EGFR%2520inhibitors%2520in%2520glioblastoma%26jtitle%3DClin%2520Cancer%2520Res.%26date%3D2016%26volume%3D22%26spage%3D1767%26epage%3D1776%26doi%3D10.1158%2F1078-0432.CCR-15-1677" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kurio, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukazawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takaoka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okui, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassan, N. M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honami, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatakeyama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naomoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, A.</span></span> <span> </span><span class="NLM_article-title">Anti-tumor effect in human breast cancer by TAE226, a dual inhibitor for FAK and IGF-IR in vitro and in vivo</span>. <i>Exp Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>317</i></span>,  <span class="NLM_fpage">1134</span>– <span class="NLM_lpage">1146</span>, <span class="refDoi"> DOI: 10.1016/j.yexcr.2011.02.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1016%2Fj.yexcr.2011.02.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=21338601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkt12ntr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=317&publication_year=2011&pages=1134-1146&author=N.+Kurioauthor=T.+Shimoauthor=T.+Fukazawaauthor=M.+Takaokaauthor=T.+Okuiauthor=N.+M.+M.+Hassanauthor=T.+Honamiauthor=S.+Hatakeyamaauthor=M.+Ikedaauthor=Y.+Naomotoauthor=A.+Sasaki&title=Anti-tumor+effect+in+human+breast+cancer+by+TAE226%2C+a+dual+inhibitor+for+FAK+and+IGF-IR+in+vitro+and+in+vivo&doi=10.1016%2Fj.yexcr.2011.02.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-tumor effect in human breast cancer by TAE226, a dual inhibitor for FAK and IGF-IR in vitro and in vivo</span></div><div class="casAuthors">Kurio, Naito; Shimo, Tsuyoshi; Fukazawa, Takuya; Takaoka, Munenori; Okui, Tatsuo; Hassan, Nur Mohammad Monsur; Honami, Tatsuki; Hatakeyama, Shinji; Ikeda, Masahiko; Naomoto, Yoshio; Sasaki, Akira</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Cell Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">317</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1134-1146</span>CODEN:
                <span class="NLM_cas:coden">ECREAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-4827</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Focal adhesion kinase (FAK) is a 125-kDa non-receptor type tyrosine kinase that localizes to focal adhesions.  FAK overexpression is frequently found in invasive and metastatic cancers of the breast, colon, thyroid, and prostate, but its role in osteolytic metastasis is not well understood.  In this study, we have analyzed antitumor effects of the novel FAK Tyr397 inhibitor TAE226 against bone metastasis in breast cancer by using TAE226.  Oral administration of TAE226 in mice significantly decreased bone metastasis and osteoclasts involved which were induced by MDA-MB-231 breast cancer cells and increased the survival rate of the mouse models of bone metastasis.  TAE226 also suppressed the growth of s.c. tumors in vivo and the proliferation and migration of MDA-MB-231 cells in vitro.  Significantly, TAE226 inhibited the osteoclast formation in murine pre-osteoclastic RAW264.7 cells, and actin ring and pit formation in mature osteoclasts.  Moreover, TAE226 inhibited the receptor activator for nuclear factor κ B Ligand (RANKL) gene expression induced by parathyroid hormone-related protein (PTHrP) in bone stromal ST2 cells and blood free calcium concn. induced by PTHrP administration in vivo.  These findings suggest that FAK was critically involved in osteolytic metastasis and activated in tumors, pre-osteoclasts, mature osteoclasts, and bone stromal cells and TAE226 can be effectively used for the treatment of cancer induced bone metastasis and other bone diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr55W5F5GlRfbVg90H21EOLACvtfcHk0liw6d9Zuvo2Dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkt12ntr0%253D&md5=1083838b4f36a4eaf62504d577b59ae5</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.yexcr.2011.02.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yexcr.2011.02.008%26sid%3Dliteratum%253Aachs%26aulast%3DKurio%26aufirst%3DN.%26aulast%3DShimo%26aufirst%3DT.%26aulast%3DFukazawa%26aufirst%3DT.%26aulast%3DTakaoka%26aufirst%3DM.%26aulast%3DOkui%26aufirst%3DT.%26aulast%3DHassan%26aufirst%3DN.%2BM.%2BM.%26aulast%3DHonami%26aufirst%3DT.%26aulast%3DHatakeyama%26aufirst%3DS.%26aulast%3DIkeda%26aufirst%3DM.%26aulast%3DNaomoto%26aufirst%3DY.%26aulast%3DSasaki%26aufirst%3DA.%26atitle%3DAnti-tumor%2520effect%2520in%2520human%2520breast%2520cancer%2520by%2520TAE226%252C%2520a%2520dual%2520inhibitor%2520for%2520FAK%2520and%2520IGF-IR%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DExp%2520Cell%2520Res.%26date%3D2011%26volume%3D317%26spage%3D1134%26epage%3D1146%26doi%3D10.1016%2Fj.yexcr.2011.02.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomkiewicz-Raule, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen-Pon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camacho-Artacho, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lietha, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbeuval, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coumoul, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbay, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and evaluation of novel imidazo[1,2-a][1,3,5]triazines and their derivatives as focal adhesion kinase inhibitors with antitumor activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">237</span>– <span class="NLM_lpage">251</span>, <span class="refDoi"> DOI: 10.1021/jm500784e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500784e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGhtLzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=237-251&author=P.+Daoauthor=N.+Smithauthor=C.+Tomkiewicz-Rauleauthor=E.+Yen-Ponauthor=M.+Camacho-Artachoauthor=D.+Liethaauthor=J.+P.+Herbeuvalauthor=X.+Coumoulauthor=C.+Garbayauthor=H.+Chen&title=Design%2C+Synthesis%2C+and+evaluation+of+novel+imidazo%5B1%2C2-a%5D%5B1%2C3%2C5%5Dtriazines+and+their+derivatives+as+focal+adhesion+kinase+inhibitors+with+antitumor+activity&doi=10.1021%2Fjm500784e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Evaluation of Novel Imidazo[1,2-a][1,3,5]triazines and Their Derivatives as Focal Adhesion Kinase Inhibitors with Antitumor Activity</span></div><div class="casAuthors">Dao, Pascal; Smith, Nikaia; Tomkiewicz-Raulet, Celine; Yen-Pon, Expedite; Camacho-Artacho, Marta; Lietha, Daniel; Herbeuval, Jean-Phillipe; Coumoul, Xavier; Garbay, Christiane; Chen, Huixiong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">237-251</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of triazinic inhibitors of focal adhesion kinase (FAK) have been recently shown to exert antiangiogenic activity against HUVEC cells and anticancer efficacy against several cancer cell lines.  We report herein that we further explored the heterocyclic core of these inhibitors by a fused imidazole ring with the triazine to provide imidazo[1,2-a][1,3,5]triazines, e.g., I.  Importantly, these new compds. displayed 10-7-10-8 M IC50 values, and the best inhibitor showed IC50 value of 50 nM against FAK enzymic activity.  Several inhibitors potently inhibited the proliferation of a panel of cancer cell lines expressing high levels of FAK.  Apoptosis anal. in U87-MG and HCT-116 cell lines suggested that these compds. delayed cell cycle progression by arresting cells in the G2/M phase of the cell cycle, retarding cell growth.  Further investigation demonstrated that these compds. strongly inhibited cell-matrix adhesion, migration, and invasion of U87-MG cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3lpXckaeVGrVg90H21EOLACvtfcHk0lg_mYqJaj6FiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGhtLzE&md5=0d2c7ef1b00e45bd462ea913b1bdc128</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm500784e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500784e%26sid%3Dliteratum%253Aachs%26aulast%3DDao%26aufirst%3DP.%26aulast%3DSmith%26aufirst%3DN.%26aulast%3DTomkiewicz-Raule%26aufirst%3DC.%26aulast%3DYen-Pon%26aufirst%3DE.%26aulast%3DCamacho-Artacho%26aufirst%3DM.%26aulast%3DLietha%26aufirst%3DD.%26aulast%3DHerbeuval%26aufirst%3DJ.%2BP.%26aulast%3DCoumoul%26aufirst%3DX.%26aulast%3DGarbay%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DH.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520evaluation%2520of%2520novel%2520imidazo%255B1%252C2-a%255D%255B1%252C3%252C5%255Dtriazines%2520and%2520their%2520derivatives%2520as%2520focal%2520adhesion%2520kinase%2520inhibitors%2520with%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D237%26epage%3D251%26doi%3D10.1021%2Fjm500784e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span> <span> </span><span class="NLM_article-title">FAK inhibitors induce cell multinucleation and dramatically increase pro-tumoral cytokine expression in RAW 264.7 macrophages</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>591</i></span>,  <span class="NLM_fpage">3861</span>– <span class="NLM_lpage">3871</span>, <span class="refDoi"> DOI: 10.1002/1873-3468.12895</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1002%2F1873-3468.12895" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=29090460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVKht7zJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=591&publication_year=2017&pages=3861-3871&author=X.+Heauthor=X.+Chenauthor=B.+Liauthor=J.+Jiauthor=S.+Chen&title=FAK+inhibitors+induce+cell+multinucleation+and+dramatically+increase+pro-tumoral+cytokine+expression+in+RAW+264.7+macrophages&doi=10.1002%2F1873-3468.12895"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">FAK inhibitors induce cell multinucleation and dramatically increase pro-tumoral cytokine expression in RAW 264.7 macrophages</span></div><div class="casAuthors">He, Xia; Chen, Xin; Li, Bogang; Ji, Jianxin; Chen, Shuang</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">591</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3861-3871</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Macrophages are abundant in the tumor microenvironment.  They are highly plastic and able to acquire pro-tumoral phenotypes in response to microenvironmental stimuli.  When we treated RAW 264.7 macrophages with inhibitors of various oncogenic pathways, we found that the focal adhesion kinase (FAK) inhibitors PF573228 and TAE226 could induce cell multi-nucleation by suppressing furrowing and cytokinesis.  This failure in cytokinesis involves Rac1, whose activity is elevated by FAK inhibitors, and the p21-activated kinases, comprising the downstream effectors of Rac.  We also investigated the influence of cell multi-nucleation on macrophage physiol. in RAW 264.7 cells.  This is the first study to report that FAK inhibitors suppress furrow ingression and early cytokinesis.  Of note, we found that FAK inhibitors caused a dramatic increase in pro-tumoral cytokines in multi-nuclear cells, suggesting the potential to convert macrophages into pro-tumoral phenotypes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrxjlS1jLRybVg90H21EOLACvtfcHk0lg_mYqJaj6FiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVKht7zJ&md5=c47e893ccd63810c06fd4cf2d399d09d</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1002%2F1873-3468.12895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1873-3468.12895%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DJi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DS.%26atitle%3DFAK%2520inhibitors%2520induce%2520cell%2520multinucleation%2520and%2520dramatically%2520increase%2520pro-tumoral%2520cytokine%2520expression%2520in%2520RAW%2520264.7%2520macrophages%26jtitle%3DFEBS%2520Lett.%26date%3D2017%26volume%3D591%26spage%3D3861%26epage%3D3871%26doi%3D10.1002%2F1873-3468.12895" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, J. A.</span></span> <span> </span><span class="NLM_article-title">Actin, a central player in cell shape and movement</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>326</i></span>,  <span class="NLM_fpage">1208</span>– <span class="NLM_lpage">1212</span>, <span class="refDoi"> DOI: 10.1126/science.1175862</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1126%2Fscience.1175862" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=19965462" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVKhur7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=326&publication_year=2009&pages=1208-1212&author=T.+D.+Pollardauthor=J.+A.+Cooper&title=Actin%2C+a+central+player+in+cell+shape+and+movement&doi=10.1126%2Fscience.1175862"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Actin, a central player in cell shape and movement</span></div><div class="casAuthors">Pollard, Thomas D.; Cooper, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">326</span>
        (<span class="NLM_cas:issue">5957</span>),
    <span class="NLM_cas:pages">1208-1212</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review.  Actin forms filaments that provide cells with mech. support and driving forces for movement.  Actin contributes to biol. processes such as sensing environmental forces, internalizing membrane vesicles, moving over surfaces, and dividing the cell in two.  These cellular activities are complex; they depend on interactions of actin monomers and filaments with numerous other proteins.  Here, the authors present a summary of the key questions in the field and suggest how those questions might be answered.  Understanding actin-based biol. phenomena will depend on identifying the participating mols. and defining their mol. mechanisms.  Comparisons of quant. measurements of reactions in live cells with computer simulations of math. models will also help generate meaningful insights.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvOwpGQVc49rVg90H21EOLACvtfcHk0lg_mYqJaj6FiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVKhur7L&md5=24c5374707cad687458434e5ee440f33</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1126%2Fscience.1175862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1175862%26sid%3Dliteratum%253Aachs%26aulast%3DPollard%26aufirst%3DT.%2BD.%26aulast%3DCooper%26aufirst%3DJ.%2BA.%26atitle%3DActin%252C%2520a%2520central%2520player%2520in%2520cell%2520shape%2520and%2520movement%26jtitle%3DScience%26date%3D2009%26volume%3D326%26spage%3D1208%26epage%3D1212%26doi%3D10.1126%2Fscience.1175862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tojkander, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gateva, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lappalainen, P.</span></span> <span> </span><span class="NLM_article-title">Actin stress fibers-assembly, dynamics and biological roles</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">1855</span>– <span class="NLM_lpage">1864</span>, <span class="refDoi"> DOI: 10.1242/jcs.098087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1242%2Fjcs.098087" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=22544950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVGltrzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2012&pages=1855-1864&author=S.+Tojkanderauthor=G.+Gatevaauthor=P.+Lappalainen&title=Actin+stress+fibers-assembly%2C+dynamics+and+biological+roles&doi=10.1242%2Fjcs.098087"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Actin stress fibers - assembly, dynamics and biological roles</span></div><div class="casAuthors">Tojkander, Sari; Gateva, Gergana; Lappalainen, Pekka</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1855-1864</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">A review.  Actin filaments assemble into diverse protrusive and contractile structures to provide force for a no. of vital cellular processes.  Stress fibers are contractile actomyosin bundles found in many cultured non-muscle cells, where they have a central role in cell adhesion and morphogenesis.  Focal-adhesion-anchored stress fibers also have an important role in mechanotransduction.  In animal tissues, stress fibers are esp. abundant in endothelial cells, myofibroblasts and epithelial cells.  Importantly, recent live-cell imaging studies have provided new information regarding the mechanisms of stress fiber assembly and how their contractility is regulated in cells.  In addn., these studies might elucidate the general mechanisms by which contractile actomyosin arrays, including muscle cell myofibrils and cytokinetic contractile ring, can be generated in cells.  In this Commentary, we discuss recent findings concerning the physiol. roles of stress fibers and the mechanism by which these structures are generated in cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4NnkBM0jRo7Vg90H21EOLACvtfcHk0lilePvm5zeQiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVGltrzF&md5=831f7cecfedc5bd7cd3bb3008c139607</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1242%2Fjcs.098087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.098087%26sid%3Dliteratum%253Aachs%26aulast%3DTojkander%26aufirst%3DS.%26aulast%3DGateva%26aufirst%3DG.%26aulast%3DLappalainen%26aufirst%3DP.%26atitle%3DActin%2520stress%2520fibers-assembly%252C%2520dynamics%2520and%2520biological%2520roles%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2012%26volume%3D125%26spage%3D1855%26epage%3D1864%26doi%3D10.1242%2Fjcs.098087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shannon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Entersz, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beelen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carcione, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carcione, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahtabfar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaca, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shreiber, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahn, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foty, R. A.</span></span> <span> </span><span class="NLM_article-title">Inhibition of glioblastoma dispersal by the MEK inhibitor PD0325901</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>, <span class="NLM_elocation-id">121</span> <span class="refDoi"> DOI: 10.1186/s12885-017-3107-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1186%2Fs12885-017-3107-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=28187762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjvVWhsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&author=S.+Shannonauthor=D.+Jiaauthor=I.+Enterszauthor=P.+Beelenauthor=M.+Yuauthor=C.+Carcioneauthor=J.+Carcioneauthor=A.+Mahtabfarauthor=C.+Vacaauthor=M.+Weaverauthor=D.+Shreiberauthor=J.+D.+Zahnauthor=L.+Liuauthor=H.+Linauthor=R.+A.+Foty&title=Inhibition+of+glioblastoma+dispersal+by+the+MEK+inhibitor+PD0325901&doi=10.1186%2Fs12885-017-3107-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of glioblastoma dispersal by the MEK inhibitor PD0325901</span></div><div class="casAuthors">Shannon, Stephen; Jia, Dongxuan; Entersz, Ildiko; Beelen, Paul; Yu, Miao; Carcione, Christian; Carcione, Jonathan; Mahtabfar, Aria; Vaca, Connan; Weaver, Michael; Shreiber, David; Zahn, Jeffrey D.; Liu, Liping; Lin, Hao; Foty, Ramsey A.</div><div class="citationInfo"><span class="NLM_cas:title">BMC Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">121/1-121/11</span>CODEN:
                <span class="NLM_cas:coden">BCMACL</span>;
        ISSN:<span class="NLM_cas:issn">1471-2407</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Dispersal of glioblastoma (GBM) cells leads to recurrence and poor prognosis.  Accordingly, mol. pathways involved in dispersal are potential therapeutic targets.  The mitogen activated protein kinase/extracellular signal regulated kinase (MAPK/ERK) pathway is commonly dysregulated in GBM, and targeting this pathway with MEK inhibitors has proven effective in controlling tumor growth.  Since this pathway also regulates ECM remodeling and actin organization - processes crucial to cell adhesion, substrate attachment, and cell motility - the aim of this study was to det. whether inhibiting this pathway could also impede dispersal.  Methods: A variety of methods were used to quantify the effects of the MEK inhibitor, PD0325901, on potential regulators of dispersal.  Cohesion, stiffness and viscosity were quantified using a method based on ellipsoid relaxation after removal of a deforming external force.  Attachment strength, cell motility, spheroid dispersal velocity, and 3D growth rate were quantified using previously described methods.  Results: We show that PD0325901 significantly increases aggregate cohesion, stiffness, and viscosity but only when tumor cells have access to high concns. of fibronectin.  Treatment also results in reorganization of actin from cortical into stress fibers, in both 2D and 3D culture.  Moreover, drug treatment localized pFAK at sites of cell-substratum adhesion.  Collectively, these changes resulted in increased strength of substrate attachment and decreased motility, a decrease in aggregate dispersal velocity, and in a marked decrease in growth rate of both 2D and 3D cultures.  Conclusions: Inhibition of the MAPK/ERK pathway by PD0325901 may be an effective therapy for reducing dispersal and growth of GBM cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdyWA292c227Vg90H21EOLACvtfcHk0lilePvm5zeQiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjvVWhsrs%253D&md5=ebc4d54360e6441d85e2bc6195a067b4</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1186%2Fs12885-017-3107-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12885-017-3107-x%26sid%3Dliteratum%253Aachs%26aulast%3DShannon%26aufirst%3DS.%26aulast%3DJia%26aufirst%3DD.%26aulast%3DEntersz%26aufirst%3DI.%26aulast%3DBeelen%26aufirst%3DP.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DCarcione%26aufirst%3DC.%26aulast%3DCarcione%26aufirst%3DJ.%26aulast%3DMahtabfar%26aufirst%3DA.%26aulast%3DVaca%26aufirst%3DC.%26aulast%3DWeaver%26aufirst%3DM.%26aulast%3DShreiber%26aufirst%3DD.%26aulast%3DZahn%26aufirst%3DJ.%2BD.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DFoty%26aufirst%3DR.%2BA.%26atitle%3DInhibition%2520of%2520glioblastoma%2520dispersal%2520by%2520the%2520MEK%2520inhibitor%2520PD0325901%26jtitle%3DBMC%2520Cancer%26date%3D2017%26volume%3D17%26doi%3D10.1186%2Fs12885-017-3107-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuller, G. N.</span></span> <span> </span><span class="NLM_article-title">Analysis of the activation status of Akt, NFkappaB, and Stat3 in human diffuse gliomas</span>. <i>Lab Invest.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">941</span>– <span class="NLM_lpage">951</span>, <span class="refDoi"> DOI: 10.1038/labinvest.3700123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1038%2Flabinvest.3700123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=15184909" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmvF2ksL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2004&pages=941-951&author=H.+Wangauthor=H.+Wangauthor=W.+Zhangauthor=H.+J.+Huangauthor=W.+S.+Liaoauthor=G.+N.+Fuller&title=Analysis+of+the+activation+status+of+Akt%2C+NFkappaB%2C+and+Stat3+in+human+diffuse+gliomas&doi=10.1038%2Flabinvest.3700123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of the activation status of Akt, NF.vkappa.B, and Stat3 in human diffuse gliomas</span></div><div class="casAuthors">Wang, Huamin; Wang, Hua; Zhang, Wei; Huang, Helen J.; Liao, Warren S. L.; Fuller, Gregory N.</div><div class="citationInfo"><span class="NLM_cas:title">Laboratory Investigation</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">941-951</span>CODEN:
                <span class="NLM_cas:coden">LAINAW</span>;
        ISSN:<span class="NLM_cas:issn">0023-6837</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Loss of phosphatase and tensin homolog (PTEN) and amplification of the epidermal growth factor receptor (EGFR) gene contribute to the progression of gliomas.  As downstream targets of the PTEN and EGFR signaling pathways, Akt, NF.vkappa.B, and signal transducer and activator of transcription-3 (Stat3) have been shown to play important roles in the control of cell proliferation, apoptosis, and oncogenesis.  The authors examd. the activation status of Akt, NF.vkappa.B, and Stat3 in 259 diffuse gliomas using tissue microarrays and immunohistochem., and evaluated their assocn. with glioma grade.  They obsd. significant pos. correlations between the activation status of Akt and NF.vkappa.B and glioma grade.  In contrast, only focal immunoreactivity for phospho-Stat3 was obsd. in <9% of high-grade gliomas.  In addn., they obsd. a significant correlation between the activation of Akt and NF.vkappa.B.  Functional correlation between Akt activation and the activation of NF.vkappa.B was confirmed in U251 MG GBM cells in which inhibition of Akt activation either by stable expression of PTEN or by the PI3-kinase inhibitors, wortmannin and LY294002, led to a concomitant decrease in NF.vkappa.B-binding activity.  Thus, the authors' results demonstrate that constitutive activation of Akt and NF.vkappa.B, but not Stat3, contributes significantly to the progression of diffuse gliomas, and activation of Akt may lead to NF.vkappa.B activation in high-grade gliomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCYk8nPy5DIrVg90H21EOLACvtfcHk0lilePvm5zeQiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmvF2ksL0%253D&md5=a7ac839b176336b8df970226fbe92e10</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Flabinvest.3700123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Flabinvest.3700123%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DH.%2BJ.%26aulast%3DLiao%26aufirst%3DW.%2BS.%26aulast%3DFuller%26aufirst%3DG.%2BN.%26atitle%3DAnalysis%2520of%2520the%2520activation%2520status%2520of%2520Akt%252C%2520NFkappaB%252C%2520and%2520Stat3%2520in%2520human%2520diffuse%2520gliomas%26jtitle%3DLab%2520Invest.%26date%3D2004%26volume%3D84%26spage%3D941%26epage%3D951%26doi%3D10.1038%2Flabinvest.3700123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sudheerkumar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiras, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jagtap, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shastry, P.</span></span> <span> </span><span class="NLM_article-title">Independent activation of Akt and NF-kappaB pathways and their role in resistance to TNF-alpha mediated cytotoxicity in gliomas</span>. <i>Mol. Carcinog.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">126</span>– <span class="NLM_lpage">136</span>, <span class="refDoi"> DOI: 10.1002/mc.20372</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1002%2Fmc.20372" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=17849421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A280%3ADC%252BD1c%252FlsFCqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2008&pages=126-136&author=P.+Sudheerkumarauthor=A.+Shirasauthor=G.+Dasauthor=J.+C.+Jagtapauthor=V.+Prasadauthor=P.+Shastry&title=Independent+activation+of+Akt+and+NF-kappaB+pathways+and+their+role+in+resistance+to+TNF-alpha+mediated+cytotoxicity+in+gliomas&doi=10.1002%2Fmc.20372"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Independent activation of Akt and NF-kappaB pathways and their role in resistance to TNF-alpha mediated cytotoxicity in gliomas</span></div><div class="casAuthors">Sudheerkumar P; Shiras Anjali; Das Gowry; Jagtap Jayashree C; Prasad Vandna; Shastry Padma</div><div class="citationInfo"><span class="NLM_cas:title">Molecular carcinogenesis</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">126-36</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Tumor associated macrophages (TAMs) constitute a substantial mass in gliomas.  The activated macrophages secrete various cytokines that affect diverse functions of tumors.  The aim of this study was to elucidate the role of Akt and NF-kappaB pathways in resistance to TNF-alpha mediated cell death in human gliomas using monolayers and multicellular spheroids (MCS) as in vitro models.  Akt and NF-kappaB are constitutively expressed and intimately involved in progression of gliomas.  The activation of these pathways also renders the tumors resistant to conventional treatments including chemotherapy.  While PI3K/Akt is shown to regulate the NF-kappaB activation in diverse systems, other studies place NF-kappaB upstream of Akt activation.  Using a stable IkappaBalpha mutant LN-18 cell line and pharmacological inhibitors to PI3K/Akt (LY294002) and Akt (Akt2), we provide evidence that Akt and NF-kappaB are activated independently on stimulation with TNF-alpha and both the pathways contribute towards resistance to TNF-alpha mediated cell death.  TNF-alpha-induced NF-kappaB activation independent of PI3K/Akt pathway was also confirmed in human glioma cell lines-LN-229 and U373MG.  We also show that NF-kappaB and Akt are activated during spheroidogenesis and their expression is further enhanced on stimulation with TNF-alpha implicating their involvement in resistance to cell death.  The findings thus underscore the relevance of spheroids as appropriate in vitro models for studying the signaling pathways in drug induced resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTAmbGdw5-hXax48Rj5GnGofW6udTcc2ebKH8ro6Cs2-Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c%252FlsFCqtw%253D%253D&md5=534540554597cd9be5a7bea5d680fa25</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1002%2Fmc.20372&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmc.20372%26sid%3Dliteratum%253Aachs%26aulast%3DSudheerkumar%26aufirst%3DP.%26aulast%3DShiras%26aufirst%3DA.%26aulast%3DDas%26aufirst%3DG.%26aulast%3DJagtap%26aufirst%3DJ.%2BC.%26aulast%3DPrasad%26aufirst%3DV.%26aulast%3DShastry%26aufirst%3DP.%26atitle%3DIndependent%2520activation%2520of%2520Akt%2520and%2520NF-kappaB%2520pathways%2520and%2520their%2520role%2520in%2520resistance%2520to%2520TNF-alpha%2520mediated%2520cytotoxicity%2520in%2520gliomas%26jtitle%3DMol.%2520Carcinog.%26date%3D2008%26volume%3D47%26spage%3D126%26epage%3D136%26doi%3D10.1002%2Fmc.20372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krippendorff, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuhaus, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lienau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huisinga, W. J.</span></span> <span> </span><span class="NLM_article-title">Mechanism-based inhibition: deriving KI and kinact directly from time-dependent IC50 values</span>. <i>J. Biomol. Screening</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">913</span>– <span class="NLM_lpage">919</span>, <span class="refDoi"> DOI: 10.1177/1087057109336751</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=10.1177%2F1087057109336751" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=19675314" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlSjtLjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=913-919&author=B.+F.+Krippendorffauthor=R.+Neuhausauthor=P.+Lienauauthor=A.+Reichelauthor=W.+J.+Huisinga&title=Mechanism-based+inhibition%3A+deriving+KI+and+kinact+directly+from+time-dependent+IC50+values&doi=10.1177%2F1087057109336751"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism-based inhibition: deriving KI and kinact directly from time-dependent IC50 values</span></div><div class="casAuthors">Krippendorff, Ben-Fillippo; Neuhaus, Roland; Lienau, Philip; Reichel, Andreas; Huisinga, Wilhelm</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">913-923</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">The potential of enzyme inhibition of a drug is frequently quantified in terms of IC50 values.  Although this is a suitable quantity for reversible inhibitors, concerns arise when dealing with irreversible or mechanism-based inhibitors (MBIs).  IC50 values of MBIs are time dependent, causing serious problems when aiming at ranking different compds. with respect to their inhibitory potential.  As a consequence, most studies and ranking schemes related to MBIs rely on the inhibition const. (KI) and the rate of enzyme inactivation (kinact) rather than on IC50 values.  In this article, the authors derive a novel relation between potentially time-dependent IC50 values and KI, kinact parameters for different types of inhibition.  This allows for direct estn. of KI and kinact values from time-dependent IC50 values, even without the need of addnl. preincubation expts.  The application of this approach is illustrated using a fluorimetric assay to access the drug-drug interaction potential assocd. with new chem. entities.  The approach can easily be implemented using std. software tools (e.g., XLfit) and may also be suitable for applications where mechanism-based inhibition is a desired mode of action (e.g., at particular pharmacol. drug targets).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSOIpe0vN8JLVg90H21EOLACvtfcHk0lizRKYd2ELY4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlSjtLjF&md5=93cb5f8644c7e1bdf872cf46756039cf</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1177%2F1087057109336751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057109336751%26sid%3Dliteratum%253Aachs%26aulast%3DKrippendorff%26aufirst%3DB.%2BF.%26aulast%3DNeuhaus%26aufirst%3DR.%26aulast%3DLienau%26aufirst%3DP.%26aulast%3DReichel%26aufirst%3DA.%26aulast%3DHuisinga%26aufirst%3DW.%2BJ.%26atitle%3DMechanism-based%2520inhibition%253A%2520deriving%2520KI%2520and%2520kinact%2520directly%2520from%2520time-dependent%2520IC50%2520values%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2009%26volume%3D14%26spage%3D913%26epage%3D919%26doi%3D10.1177%2F1087057109336751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6GCR" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6GCR','PDB','6GCR'); return false;">PDB: 6GCR</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i81"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01059">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_61188"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01059?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01059</a>.<ul class="NLM_list-list_type-label"><li><p class="inline">Kinetic mechanism for two-step covalent inhibition of FAK, molecular docking, intermediate synthesis, ion chromatograms obtained by QTRAP-MS, cell cycle distribution, HPLC purity of final compounds, and <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra of final compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01059/suppl_file/jm0c01059_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular string files for all of the final target compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01059/suppl_file/jm0c01059_si_002.csv">CSV</a>)</p></li></ul><ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">(<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01059/suppl_file/jm0c01059_si_001.pdf">PDF</a>)</p></li><li><p class="inline">(<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01059/suppl_file/jm0c01059_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01059/suppl_file/jm0c01059_si_001.pdf">jm0c01059_si_001.pdf (1.22 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01059/suppl_file/jm0c01059_si_002.csv">jm0c01059_si_002.csv (1.66 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01059&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01059%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-21" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01059" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677ae7ba78f421d6","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
